



(86) Date de dépôt PCT/PCT Filing Date: 2012/08/08

(87) Date publication PCT/PCT Publication Date: 2013/02/14

(45) Date de délivrance/Issue Date: 2021/10/05

(85) Entrée phase nationale/National Entry: 2014/01/29

(86) N° demande PCT/PCT Application No.: US 2012/050021

(87) N° publication PCT/PCT Publication No.: 2013/022989

(30) Priorités/Priorities: 2011/08/08 (US61/521,051);
2011/08/08 (US61/521,203); 2011/08/08 (US61/521,084);
2011/08/15 (US61/523,487); 2011/12/07 (US61/567,929);
2012/02/27 (US61/603,639)

(51) Cl.Int./Int.Cl. *C12N 15/82* (2006.01),
C12N 15/81 (2006.01), *C12N 9/00* (2006.01),
C12N 9/10 (2006.01), *C12N 9/90* (2006.01),
C12P 15/00 (2006.01)


(72) Inventeurs/Inventors:

HOUGHTON-LARSEN, JENS, DK;
HICKS, PAULA M., US;
NAESBY, MICHAEL, CH;
OSTERGAARD, TANGE THOMAS, CH;
HANSEN, JORGEN, DK;
DALGAARD MIKKELSEN, MICHAEL, DK;
...


(73) Propriétaire/Owner:

(54) Titre : PRODUCTION PAR RECOMBINAISON DE GLYCOSIDES DE STEVIOL


(54) Title: RECOMBINANT PRODUCTION OF STEVIOL GLYCOSIDES




Steviol




Steviolmonoside




Steviolbioside




Stevioside




Rebaudioside A




Rebaudioside B




Rebaudioside C




Rebaudioside D



Rebaudioside E



Rebaudioside F



Dulcoside A

(57) Abrégé/Abstract:

Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express recombinant genes encoding UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce steviol glycosides, e.g.,

(72) **Inventeurs(suite)/Inventors(continued):** HALKJAER HANSEN, ESBEN, DK; ERNESTO, SIMON, DK;
DE ANDRADE PEREIRA TAVARES, SABINA, CH

(73) **Propriétaires(suite)/Owners(continued):**EVOLVA SA, CH

(74) **Agent:** BENOIT & COTE INC.

(57) **Abrégé(suite)/Abstract(continued):**

Rebaudioside A and/or Rebaudioside D, which can be used as natural sweeteners in food products and dietary supplements.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2013/022989 A3

(43) International Publication Date
14 February 2013 (14.02.2013)

(51) International Patent Classification:

C12N 15/82 (2006.01) *C12N 9/00* (2006.01)
C12N 15/81 (2006.01) *C12P 15/00* (2006.01)
C12N 9/10 (2006.01) *C12N 9/90* (2006.01)

(21) International Application Number:

PCT/US2012/050021

(22) International Filing Date:

8 August 2012 (08.08.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/521,084	8 August 2011 (08.08.2011)	US
61/521,203	8 August 2011 (08.08.2011)	US
61/521,051	8 August 2011 (08.08.2011)	US
61/523,487	15 August 2011 (15.08.2011)	US
61/567,929	7 December 2011 (07.12.2011)	US
61/603,639	27 February 2012 (27.02.2012)	US

(71) Applicant (for all designated States except US): **EVOLVA SA** [CH/CH]; Duggingerstrasse 23, CH-4153 Reinach (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HOUGHTON-LARSEN, Jens** [DK/DK]; Jaegersborg Allé 27, A, 3 MF., DK-2920 Charlottenlund (DK). **HICKS, Paula, M.** [US/US]; 20161 Stonegate Drive, Bend, OR 97702 (US). **NAESBY, Michael** [DK/CH]; Stadthausgasse 18, CH-4051 Basel (CH). **OSTERGAARD, Tange, Thomas** [DK/CH]; Horburgstrasse 24, CH-4057 Basel (CH). **HANSEN, Jorgen** [DK/DK]; Peter Bangs Vej 122, 1th, DK-2000 Frederiksberg (DK). **DALGAARD MIKKELSEN, Michael** [DK/DK]; J.P.E. Hartmann's Alle 3, St, DK-2500 Valby (DK). **HALKJAER, Hansen, Esben** [DK/DK]; Worsaaesvej 20 3. Tv, DK-1972 Frederiks-

berg C (DK). **SIMON, Ernesto** [ES/DK]; Svaertegade 7, 2nd Floor, DK-1118 Copenhagen (DK).

(74) Agents: **MCCORMICK GRAHAM, Monica** et al.; Fish & Richardson, P.C., P. O. Box 1022, Minneapolis, MN 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

4 July 2013

(54) Title: RECOMBINANT PRODUCTION OF STEVIOL GLYCOSIDES

(57) Abstract: Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express recombinant genes encoding UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce steviol glycosides, e.g., Rebaudioside A and/or Rebaudioside D, which can be used as natural sweeteners in food products and dietary supplements.



WO 2013/022989 A3

Recombinant Production of Steviol Glycosides

5

TECHNICAL FIELD

10 This disclosure relates to the recombinant production of steviol glycosides. In particular, this disclosure relates to the production of steviol glycosides such as rebaudioside D by recombinant hosts such as recombinant microorganisms, plants, or plant cells. This disclosure also provides compositions containing steviol glycosides. The disclosure also relates to tools and methods for producing terpenoids by modulating the biosynthesis of terpenoid precursors of the squalene pathway.

15

BACKGROUND

Sweeteners are well known as ingredients used most commonly in the food, beverage, or confectionary industries. The sweetener can either be incorporated into a final food product during production or for stand-alone use, when appropriately diluted, as a tabletop sweetener or an at-home replacement for sugars in baking. Sweeteners
20 include natural sweeteners such as sucrose, high fructose corn syrup, molasses, maple syrup, and honey and artificial sweeteners such as aspartame, saccharine and sucralose. Stevia extract is a natural sweetener that can be isolated and extracted from a perennial shrub, *Stevia rebaudiana*. Stevia is commonly grown in South America and Asia for commercial production of stevia extract. Stevia extract, purified to various degrees, is
25 used commercially as a high intensity sweetener in foods and in blends or alone as a tabletop sweetener.

Extracts of the Stevia plant contain rebaudiosides and other steviol glycosides that contribute to the sweet flavor, although the amount of each glycoside often varies among different production batches. Existing commercial products are predominantly rebaudioside A with lesser amounts of other glycosides such as rebaudioside C, D, and F.

5 Stevia extracts may also contain contaminants such as plant-derived compounds that contribute to off-flavors. These off-flavors can be more or less problematic depending on the food system or application of choice. Potential contaminants include pigments, lipids, proteins, phenolics, saccharides, spathulenol and other sesquiterpenes, labdane diterpenes, monoterpenes, decanoic acid, 8,11,14-eicosatrienoic acid, 2-

10 methyl octadecane, pentacosane, octacosane, tetracosane, octadecanol, stigmasterol, β -sitosterol, α - and β -amyrin, lupeol, β -amryin acetate, pentacyclic triterpenes, centaureidin, quercitin, epi-alpha-cadinol, carophyllenes and derivatives, beta-pinene, beta-sitosterol, and gibberellin.

SUMMARY

15 Provided herein is a recombinant host, such as a microorganism, plant, or plant cell, comprising one or more biosynthesis genes whose expression results in production of steviol glycosides such as rebaudioside A, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, or dulcoside A. In particular, EUGT11, a uridine 5'-diphospho (UDP) glycosyl transferase described herein, can be used alone or in

20 combination with one or more other UDP glycosyl transferases such as UGT74G1, UGT76G1, UGT85C2, and UGT91D2c, to allow the production and accumulation of rebaudioside D in recombinant hosts or using *in vitro* systems. As described herein, EUGT11 has a strong 1,2-19-O-glucose glycosylation activity, which is an important step for rebaudioside D production.

25 Typically, stevioside and rebaudioside A are the primary compounds in commercially-produced stevia extracts. Stevioside is reported to have a more bitter and less sweet taste than rebaudioside A. The composition of stevia extract can vary from lot to lot depending on the soil and climate in which the plants are grown. Depending upon the sourced plant, the climate conditions, and the extraction process, the amount of

rebaudioside A in commercial preparations is reported to vary from 20 to 97% of the total steviol glycoside content. Other steviol glycosides are present in varying amounts in stevia extracts. For example, Rebaudioside B is typically present at less than 1-2%, whereas Rebaudioside C can be present at levels as high as 7-15%. Rebaudioside D is typically present in levels of 2% or less, and Rebaudioside F is typically present in compositions at 3.5% or less of the total steviol glycosides. The amount of the minor steviol glycosides affects the flavor profile of a Stevia extract. In addition, Rebaudioside D and other higher glycosylated steviol glycosides are thought to be higher quality sweeteners than Rebaudioside A. As such, the recombinant hosts and methods described herein are particularly useful for producing steviol glycoside compositions having an increased amount of Rebaudioside D for use, for example, as a non-caloric sweetener with functional and sensory properties superior to those of many high-potency sweeteners.

In one aspect, this document features a recombinant host that includes a recombinant gene encoding a polypeptide having at least 80% identity to the amino acid sequence set forth in SEQ ID NO:152.

This document also features a recombinant host that includes a recombinant gene encoding a polypeptide having the ability to transfer a second sugar moiety to the C-2' of a 19-O-glucose of rubusoside. This document also features a recombinant host that includes a recombinant gene encoding a polypeptide having the ability to transfer a second sugar moiety to the C-2' of a 19-O-glucose of stevioside.

In another aspect, this document features a recombinant host that includes a recombinant gene encoding a polypeptide having the ability to transfer a second sugar moiety to the C-2' of the 19-O-glucose of rubusoside and to the C-2' of the 13-O-glucose of rubusoside.

This document also features a recombinant host that includes a recombinant gene encoding a polypeptide having the ability to transfer a second sugar moiety to the C-2' of a 19-O-glucose of rebaudioside A to produce rebaudioside D, wherein the catalysis rate of the polypeptide is at least 20 times faster (e.g., 25 or 30 times faster) than a 91D2e

polypeptide having the amino acid sequence set forth in SEQ ID NO: 5 when the reactions are performed under corresponding conditions.

In any of the recombinant hosts described herein, the polypeptide can have at least 85% sequence identity (e.g., 90%, 95%, 98%, or 99% sequence identity) to the amino acid sequence set forth in SEQ ID NO:152. The polypeptide can have the amino acid sequence set forth in SEQ ID NO: 152.

Any of the hosts described herein further can include a recombinant gene encoding a UGT85C polypeptide having at least 90% identity to the amino acid sequence set forth in SEQ ID NO:3. The UGT85C polypeptide can include one or more amino acid substitutions at residues 9, 10, 13, 15, 21, 27, 60, 65, 71, 87, 91, 220, 243, 270, 289, 298, 334, 336, 350, 368, 389, 394, 397, 418, 420, 440, 441, 444, and 471 of SEQ ID NO:3.

Any of the hosts described herein further can include a recombinant gene encoding a UGT76G polypeptide having at least 90% identity to the amino acid sequence set forth in SEQ ID NO:7. The UGT76G polypeptide can have one or more amino acid substitutions at residues 29, 74, 87, 91, 116, 123, 125, 126, 130, 145, 192, 193, 194, 196, 198, 199, 200, 203, 204, 205, 206, 207, 208, 266, 273, 274, 284, 285, 291, 330, 331, and 346 of SEQ ID NO:7.

Any of the hosts described herein further can include a gene (e.g., a recombinant gene) encoding a UGT74G1 polypeptide.

Any of the hosts described herein further can include a gene (e.g., a recombinant gene) encoding a functional UGT91D2 polypeptide. The UGT91D2 polypeptide can have at least 80% sequence identity to the amino acid sequence set forth in SEQ ID NO:5. The UGT91D2 polypeptide can have a mutation at position 206, 207, or 343 of SEQ ID NO:5. The UGT91D2 polypeptide also can have a mutation at positions 211 and 286 of SEQ ID NO:5 (e.g., L211M and V286A, referred to as UGT91D2e-b). The UGT91D2 polypeptide can have the amino acid sequence set forth in SEQ ID NOs: 5, 10, 12, 76, 78, or 95.

Any of the hosts described herein further can include one or more of
(i) a gene encoding a geranylgeranyl diphosphate synthase;

(ii) a gene encoding a bifunctional copalyl diphosphate synthase and kaurene synthase, or a gene encoding a copalyl diphosphate synthase and a gene encoding a kaurene synthase;

(iii) a gene encoding a kaurene oxidase; and

5 (iv) a gene encoding a steviol synthetase. Each of the genes of (i), (ii), (iii), and (iv) can be a recombinant gene.

Any of the hosts described herein further can include one or more of

(v) a gene encoding a truncated HMG-CoA;

(vi) a gene encoding a CPR;

10 (vii) a gene encoding a rhamnose synthetase;

(viii) a gene encoding a UDP-glucose dehydrogenase; and

(ix) a gene encoding a UDP-glucuronic acid decarboxylase. At least one of the genes of (i), (ii), (iii), (iv), (v), (vi), (vii), (viii), or (ix) can be a recombinant gene.

The geranylgeranyl diphosphate synthase can have greater than 90 % sequence
15 identity to one of the amino acid sequences set forth in SEQ ID NOs: 121-128. The copalyl diphosphate synthase can have greater than 90 % sequence identity to the amino acid sequence set forth in SEQ ID NOs: 129-131. The kaurene synthase can have greater than 90 % sequence identity to one of the amino acid sequences set forth in SEQ ID NOs: 132-135. The kaurene oxidase can have greater than 90 % sequence identity to one of the
20 amino acid sequences set forth in SEQ ID NOs: 138-141. The steviol synthetase can have greater than 90 % sequence identity to one of the amino acid sequences set forth in SEQ ID NOs: 142-146.

Any of the recombinant hosts can produce at least one steviol glycoside when cultured under conditions in which each of the genes is expressed. The steviol glycoside
25 can be selected from the group consisting of rubusoside, rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, dulcoside A, stevioside, steviol-19-*O*-Glucoside, steviol-13-*O*-glucoside, steviol-1,2-bioside, steviol-1,3-bioside, 1,3-stevioside, as well as other rhamnosylated or xylosylated intermediates. The steviol glycoside (e.g., rebaudioside D) can accumulate to at least 1 mg/liter (e.g., at least 10
30 mg/liter, 20 mg/liter, 100 mg/liter, 200 mg/liter, 300 mg/liter, 400 mg/liter, 500 mg/liter,

600 mg/liter, or 700 mg/liter, or greater) of culture medium when cultured under said conditions.

This document also features a method of producing a steviol glycoside. The method includes growing any of the hosts described herein in a culture medium, under
5 conditions in which the genes are expressed; and recovering the steviol glycoside produced by the host. The growing step can include inducing expression of one or more of the genes. The steviol glycoside can be a 13-*O*-1,2-diglycosylated and/or a 19-*O*-1,2-diglycosylated steviol glycoside (e.g., stevioside, steviol 1,2 bioside, rebaudioside D, or rebaudioside E). For example, the steviol glycoside can be rebaudioside D or
10 rebaudioside E. Other examples of steviol glycosides can include rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside F, and dulcoside A.

This document also features a recombinant host. The host includes (i) a gene encoding a UGT74G1; (ii) a gene encoding a UGT85C2; (iii) a gene encoding a UGT76G1; (iv) a gene encoding a glycosyltransferase having the ability to transfer a
15 second sugar moiety to the C-2' of a 19-*O*-glucose of rubusoside or stevioside; and (v) optionally a gene encoding a UGT91D2e, wherein at least one of the genes is a recombinant gene. In some embodiments, each of the genes is a recombinant gene. The host can produce at least one steviol glycoside (e.g., rebaudioside D) when cultured under conditions in which each of the genes (e.g., recombinant genes) is expressed. The host
20 further can include (a) a gene encoding a bifunctional copalyl diphosphate synthase and kaurene synthase, or a gene encoding a copalyl diphosphate synthase and a gene encoding a kaurene synthase; (b) a gene encoding a kaurene oxidase; (c) a gene encoding a steviol synthetase; (d) a gene encoding a geranylgeranyl diphosphate synthase.

This document also features a steviol glycoside composition produced by any of
25 the hosts described herein. The composition has reduced levels of stevia plant-derived contaminants relative to a stevia extract.

In another aspect, this document features a steviol glycoside composition produced by any of the hosts described herein. The composition has a steviol glycoside composition enriched for rebaudioside D relative to the steviol glycoside composition of
30 a wild-type *Stevia* plant.

In yet another aspect, this document features a method of producing a steviol glycoside composition. The method includes growing a host described herein in a culture medium, under conditions in which each of the genes is expressed; and recovering the steviol glycoside composition produced by the host (e.g., a microorganism). The composition is enriched for rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F or dulcoside A relative to the steviol glycoside composition of a wild-type *Stevia* plant. The steviol glycoside composition produced by the host (e.g., microorganism) can have a reduced level of stevia plant-derived contaminants relative to a stevia extract.

This document also features a method for transferring a second sugar moiety to the C-2' of a 19-*O*-glucose or the C-2' of a 13-*O*-glucose in a steviol glycoside. The method includes contacting the steviol glycoside with a EUGT11 polypeptide described herein or UGT91D2 polypeptide described herein (e.g., UGT91D2e-b) and a UDP-sugar under suitable reaction conditions for the transfer of the second sugar moiety to the steviol glycoside. The steviol glycoside can be rubusoside, wherein the second sugar moiety is glucose, and stevioside is produced upon transfer of the second glucose moiety. The steviol glycoside can be stevioside, wherein the second sugar moiety is glucose, and Rebaudioside E is produced upon transfer of the second glucose moiety. The steviol glycoside can be Rebaudioside A, and Rebaudioside D is produced upon transfer of the second glucose moiety.

In another embodiment of an improved downstream steviol glycoside pathway as disclosed herein, materials and methods are provided for the recombinant production of sucrose synthase, and to materials and methods for increasing production of UDP-glucose in a host, specifically for increasing the availability of UDP-glucose *in vivo*, with the purpose of promoting glycosylation reactions in the cells, and methods for reducing UDP concentrations in the cells are provided.

The document also provides a recombinant host comprising one or more exogenous nucleic acids encoding a sucrose transporter and a sucrose synthase, wherein expression of the one or more exogenous nucleic acids with a glucosyltransferase results in increased levels of UDP-glucose in the host. Optionally, the one or more exogenous

nucleic acids comprise a SUS1 sequence. Optionally, the SUS1 sequence is from *Coffea arabica*, or encodes a functional homolog of the sucrose synthase encoded by the *Coffea arabica* SUS1 sequence, but equally an *Arabidopsis thaliana* or *Stevia rebaudiana* SUS1 may be used as described herein. In the recombinant host of the invention, the one or
5 more exogenous nucleic acids may comprise a sequence encoding a polypeptide having the sequence set forth in SEQ ID NO:180, or an amino acid sequence at least 90 percent identical thereto, and optionally the one or more exogenous nucleic acids comprise a SUC1 sequence. In one embodiment, the SUC1 sequence is from *Arabidopsis thaliana*, or the SUC1 sequence encodes a functional homolog of the sucrose transporter encoded
10 by the *Arabidopsis thaliana* SUC1 sequence. In the recombinant host, the one or more exogenous nucleic acids may comprise a sequence encoding a polypeptide having the sequence set forth in SEQ ID NO:179, or an amino acid sequence at least 90 percent identical thereto. The recombinant host has reduced ability to degrade external sucrose, as compared to a corresponding host that lacks the one or more exogenous nucleic acids.

15 The recombinant host may be a microorganism, such as a Saccharomycete, for example *Saccharomyces cerevisiae*. Alternatively, the microorganism is *Escherichia coli*. In an alternative embodiment, the recombinant host is a plant or plant cell.

The invention also provides a method for increasing the level of UDP-glucose and reducing the level of UDP in a cell, the method comprising expressing in the cell a
20 recombinant sucrose synthase sequence and a recombinant sucrose transporter sequence, in a medium comprising sucrose, wherein the cell is deficient in sucrose degradation.

The invention additionally provides a method for promoting a glycosylation reaction in a cell, comprising expressing in the cell a recombinant sucrose synthase sequence and a recombinant sucrose transporter sequence, in a medium comprising
25 sucrose, wherein the expressing results in a decreased level of UDP in the cell and an increased level of UDP-glucose in the cell, such that glycosylation in the cell is increased.

In either method for increasing the level of UDP-glucose or promoting glycosylation, the cell may produce vanillin glucoside, resulting in increased production of vanillin glucoside by the cell, or may produce steviol glucoside, resulting in increased
30 production of steviol glucoside by the cell. Optionally, the SUS1 sequence is a *A.*

thaliana, *S. rebaudiana*, or *Coffea arabica* SUS1 sequence (see e.g., FIG. 17, SEQ ID NOs. 175-177), or is a sequence that encodes a functional homolog of the sucrose synthase encoded by the *A. thaliana*, *S. rebaudiana*, or *Coffea arabica* SUS1 sequence. The recombinant sucrose synthase sequence optionally comprises a nucleic acid encoding a polypeptide having the sequence set forth in SEQ ID NO:180, or an amino acid sequence at least 90% identical thereto, wherein optionally the recombinant sucrose transporter sequence is a SUC1 sequence, or wherein optionally the SUC1 sequence is an *Arabidopsis thaliana* SUC1 sequence, or is a sequence that encodes a functional homolog of the sucrose transporter encoded by the *Arabidopsis thaliana* SUC1 sequence, or wherein optionally the recombinant sucrose transporter sequence comprises a nucleic acid encoding a polypeptide having the sequence set forth in SEQ ID NO:179, or an amino acid sequence at least 90 % identical thereto. In either method, the host is a microorganism, for example a Saccharomycete, optionally such as *Saccharomyces cerevisiae*. Or the host may be *Escherichia coli*. Or the host may be a plant cell.

Also provided herein is a recombinant host, such as a microorganism, comprising one or more biosynthesis genes whose expression results in production of diterpenoids. Such genes include a gene encoding an *ent*-copalyl diphosphate synthase (CDPS) (EC 5.5.1.13), a gene encoding an *ent*-kaurene synthase, a gene encoding an *ent*-kaurene oxidase; or a gene encoding a steviol synthetase. At least one of the genes is a recombinant gene. The host can also be a plant cell. Expression of these gene(s) in a Stevia plant can result in increased steviol glycoside levels in the plant. In some embodiments the recombinant host further comprises a plurality of copies of a recombinant gene encoding a CDPS polypeptide (EC 5.5.1.13) lacking a chloroplast transit peptide sequence. The CDPS polypeptide can have at least 90%, 95%, 99 %, or 100% identity to the truncated CDPS amino acid sequence set forth in FIG. 14. The host can further comprise a plurality of copies of a recombinant gene encoding a KAH polypeptide, e.g., a KAH polypeptide that has at least 90%, 95%, 99 %, or 100% identity to the KAH amino acid sequence set forth in FIG. 12. The host can further comprise one or more of: (i) a gene encoding a geranylgeranyl diphosphate synthase; (ii) a gene encoding a *ent*-kaurene oxidase; and (iii) a gene encoding a *ent*-kaurene synthase. The

host can further comprise one or more of (iv) a gene encoding a truncated HMG-CoA; (v) a gene encoding a CPR; (vi) a gene encoding a rhamnose synthetase; (vii) a gene encoding a UDP-glucose dehydrogenase; and (viii) a gene encoding a UDP-glucuronic acid decarboxylase. Two or more exogenous CPRs can be present, for example. The expression of one or more of such genes can be inducible. At least one of genes (i), (ii), (iii), (iv), (v), (vi), (vii), or (viii) can be a recombinant gene, and in some cases each of the genes of (i), (ii), (iii), (iv), (v), (vi), (vii), and (viii) is a recombinant gene. The geranylgeranyl diphosphate synthase can have greater than 90 % sequence identity to the amino acid sequence set forth in SEQ ID NO:127; the kaurene oxidase can have greater than 90 % sequence identity to the amino acid sequence set forth in SEQ ID NO:138; a CPR can have greater than 90 % sequence identity to the amino acid sequence set forth in SEQ ID NO:168; a CPR can have greater than 90 % sequence identity to the amino acid sequence set forth in SEQ ID NO:170, and a kaurene synthase can have greater than 90 % sequence identity to the amino acid sequence set forth in SEQ ID NO: 156.

In one aspect, this document features an isolated nucleic acid encoding a polypeptide having the amino acid sequence set forth in SEQ ID NO:5, wherein the polypeptide contains substitutions position 211 and 286 of SEQ ID NO:5. For example, the polypeptide can include a methionine at position 211 and an alanine at position 286.

In one aspect, this document features an isolated nucleic acid encoding a polypeptide having at least 80% identity (e.g., at least 85%, 90%, 95%, or 99% identity) to the amino acid sequence set forth in FIG. 12C (SEQ ID NO:164). The polypeptide can have the amino acid sequence set forth in FIG. 12C.

In another aspect, this document features a nucleic acid construct that included a regulatory region operably linked to a nucleic acid encoding a polypeptide having at least 80% identity (e.g., at least 85%, 90%, 95%, or 99% identity) to the amino acid sequence set forth in FIG. 12C (SEQ ID NO:164). The polypeptide can have the amino acid sequence set forth in FIG. 12C.

This document also features a recombinant host that includes a recombinant gene (e.g., a plurality of copies of a recombinant gene) encoding a KAH polypeptide having at least 80% identity (e.g., at least 85%, 90%, 95%, or 99% identity) to the amino acid

sequence set forth in FIG. 12C. The polypeptide can have the amino acid sequence set forth in FIG. 12C. The host can be a microorganism such as a saccharomycete (e.g., *Saccharomyces cerevisiae*) or *Escherichia coli*. The host can be a plant or plant cell (e.g., a *Stevia*, *Physcomitrella*, or tobacco plant or plant cell). The *Stevia* plant or plant cell is a *Stevia rebaudiana* plant or plant cell. The recombinant host can produce steviol when cultured under conditions in which each of the genes is expressed. The recombinant host can further comprise a gene encoding a UGT74G1 polypeptide; a gene encoding a UGT85C2 polypeptide; a gene encoding a UGT76G1 polypeptide; a gene encoding a UGT91D2 polypeptide; and/or a gene encoding a EUGT11 polypeptide.

Such a host can produce at least one steviol glycoside when cultured under conditions in which each of the genes is expressed. The steviol glycoside can be steviol-13-O-glucoside, steviol-19-O-glucoside, rubusoside, rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, and/or dulcoside A. The recombinant host can further comprise one or more of: a gene encoding a deoxyxylulose 5-phosphate synthase (DXS); a gene encoding a D-1-deoxyxylulose 5-phosphate reductoisomerase (DXR); a gene encoding a 4-diphosphocytidyl-2-C-methyl-D-erythritol synthase (CMS); a gene encoding a 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (CMK); a gene encoding a 4-diphosphocytidyl-2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (MCS); a gene encoding a 1-hydroxy-2-methyl-2(E)-butenyl 4-diphosphate synthase (HDS); and a gene encoding a 1-hydroxy-2-methyl-2(E)-butenyl 4-diphosphate reductase (HDR). The recombinant host can further comprise one or more of: a gene encoding an acetoacetyl-CoA thiolase; a gene encoding a truncated HMG-CoA reductase; a gene encoding a mevalonate kinase; a gene encoding a phosphomevalonate kinase; and a gene encoding a mevalonate pyrophosphate decarboxylase. In another aspect, this document features a recombinant host that further comprises a gene encoding an *ent*-kaurene synthase (EC 4.2.3.19) and/or a gene encoding a gibberellin 20-oxidase (EC 1.14.11.12). Such a host produces gibberellin GA3 when cultured under conditions in which each of the genes is expressed.

This document also features an isolated nucleic acid encoding a CPR polypeptide having at least 80% sequence identity (e.g., at least 85%, 90%, 95%, or 99% sequence

identity) to the *S. rebaudiana* CPR amino acid sequence set forth in FIG. 13. In some embodiments, the polypeptide has the *S. rebaudiana* CPR amino acid sequence set forth in FIG.13 (SEQ ID NOs: 169 and 170).

5 In any of the hosts described herein, expression of one or more of the genes can be inducible.

In any of the hosts described herein, one or more genes encoding endogenous phosphatases can be deleted or disrupted such that endogenous phosphatase activity is reduced. For example, the yeast gene *DPPI* and/or *LPPI* can be disrupted or deleted such that the degradation of farnesyl pyrophosphate (FPP) to farnesol is reduced and the
10 degradation of geranylgeranylpyrophosphate (GGPP)) to geranylgeraniol (GGOH) is reduced.

In another aspect, as described herein, *ERG9* can be modified as defined below, resulting in the decreased production of squalene synthase (SQS) and an accumulation of terpenoid precursors. The precursors may or may not be secreted into the culture medium
15 and can in turn be used as substrates to enzymes capable of metabolizing the terpenoid precursors into desired terpenoids.

Thus, in a main aspect the present invention relates to a cell comprising a nucleic acid sequence, said nucleic acid comprising

- i) a promoter sequence operably linked to
- 20 ii) a heterologous insert sequence operably linked to
- iii) an open reading frame operably linked to
- iv) a transcription termination signal,

wherein the heterologous insert sequence has the general formula (I):

25 $-X_1-X_2-X_3-X_4-X_5-$

wherein X_2 comprises at least 4 consecutive nucleotides being complementary to, and forming a hairpin secondary structure element with at least 4 consecutive nucleotides of X_4 , and
30

wherein X₃ is optional and if present comprises unpaired nucleotides involved in forming a hairpin loop between X₂ and X₄, and

wherein X₁ and X₅ individually and optionally comprises one or more nucleotides, and

5 wherein the open reading frame upon expression encodes a polypeptide sequence having at least 70% identity to a squalene synthase (EC 2.5.1.21) or a biologically active fragment thereof, said fragment having at least 70% sequence identity to said squalene synthase in a range of overlap of at least 100 amino acids.

The cell of the present invention is useful in enhancing yield of industrially
10 interesting terpenoids. Accordingly, in another aspect the present invention relates to a method for producing a terpenoid compound synthesized through the squalene pathway, in a cell culture, said method comprising the steps of

- (a) providing the cell as defined herein above,
- (b) culturing the cell of (a).
- 15 (c) recovering the terpenoid product compound.

By providing the cell comprising the genetically modified construct defined herein above, the accumulation of terpenoid precursors is enhanced (see e.g., FIG. 20).

Thus, in another aspect, the invention relates to a method for producing a terpenoid derived from a terpenoid precursor selected from the group consisting of
20 Farnesyl-pyrophosphate (FPP), Isopentenyl-pyrophosphate (IPP), Dimethylallyl-pyrophosphate (DMAPP), Geranyl-pyrophosphate (GPP) and/or Geranylgeranyl-pyrophosphate (GGPP), said method comprising:

- (a) contacting said precursor with an enzyme of the squalene synthase pathway,
- 25 (b) recovering the terpenoid product.

The present invention may operate by at least partly, sterically hindering binding of the ribosome to the RNA thus reducing the translation of squalene synthase.

Accordingly, in one aspect the present invention relates to a method for reducing the translation rate of a functional squalene synthase (EC 2.5.1.21) said method comprising:

- 30 (a) providing the cell defined herein above,

- (b) culturing the cell of (a).

Similarly, the invention in another aspect relates to a method for decreasing turnover of farnesyl-pp to squalene, said method comprising:

- (a) providing the cell defined herein above,

5

- (b) culturing the cell of (a).

As depicted in FIG. 20, the knocking down of the ERG9 results in build-up of precursors to squalene synthase. Thus in one aspect, the present invention relates to a method for enhancing accumulation of a compound selected from the group consisting of Farnesyl-pyrophosphate, Isopentenyl-pyrophosphate, Dimethylallyl-pyrophosphate, Geranyl-pyrophosphate and Geranylgeranyl-pyrophosphate, said method comprising the steps of:

10

- (a) providing the cell defined herein above, and

- (b) culturing the cell of (a).

In one embodiment the invention relates to the production of Geranylgeranyl Pyrophosphate (GGPP) as well as other terpenoids, which can be prepared from Geranylgeranyl Pyrophosphate (GGPP).

15

In this embodiment of the invention the above described decrease of production of squalene synthase (SQS) may be combined with an increase in activity of Geranylgeranyl Pyrophosphate Synthase (GGPPS), which converts FPP to Geranylgeranyl Pyrophosphate (GGPP), leading to increased production of GGPP.

20

Thus, in one embodiment the invention relates to a microbial cell comprising a nucleic acid sequence, said nucleic acid comprising

- i) a promoter sequence operably linked to
ii) a heterologous insert sequence operably linked to
iii) an open reading frame operably linked to
iv) a transcription termination signal,

25

wherein the heterologous insert sequence and the open reading frame are as defined herein above,

wherein said microbial cell furthermore comprises a heterologous nucleic acid encoding GGPPS operably linked to a nucleic acid sequence directing expression of GGPPS in said cell.

In addition, the document relates to a method for producing steviol or a steviol glycoside, wherein the method comprises use of any one of the above-mentioned microbial cells.

Any of the hosts described herein can be a microorganism (e.g., a Saccharomycete such as *Saccharomyces cerevisiae*, or *Escherichia coli*), or a plant or plant cell (e.g., a *Stevia* such as a *Stevia rebaudiana*, *Physcomitrella*, or tobacco plant or plant cell).

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below.

In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting. Other features and advantages of the invention will be apparent from the following detailed description. Applicants reserve the right to alternatively claim any disclosed invention using the transitional phrase “comprising,” “consisting essentially of,” or “consisting of,” according to standard practice in patent law.

DESCRIPTION OF DRAWINGS

FIG. 1 is the chemical structure of various steviol glycosides.

FIGS. 2A- D show representative pathways for the biosynthesis of steviol glycosides from steviol.

FIG. 3 is a schematic representation of 19-O-1,2-diglycosylation reactions by EUGT11 and UGT91D2e. The numbers are the average signal intensity for the substrates

or the products of the reaction, from liquid chromatography-mass spectrometry (LC-MS) chromatograms

FIG. 4 contains LC-MS chromatograms showing the production of rebaudioside D (RebD) from Rebaudioside A (RebA) using *in vitro* transcribed and translated
5 UGT91D2e (SEQ ID NO:5) (left panel) or EUGT11 (SEQ ID NO:152) (right panel). The LC-MS was set to detect certain masses corresponding to steviol + 5 glucoses (such as RebD), steviol + 4 glucoses (such as RebA) etc. Each 'lane' is scaled according to the highest peak.

FIG. 5 contains LC-MS chromatograms showing the conversion of rubusoside to
10 stevioside and compounds '2' and '3' (RebE) by UGT91D2e (left panel) and EUGT11 (right panel).

FIG. 6 is an alignment of the amino acid sequence of EUGT11 (SEQ ID NO:152, top line) with the amino acid sequence of UGT91D2e (SEQ ID NO:5, bottom line).

FIG. 7 contains the amino acid sequence of EUGT11 (SEQ ID NO:152), the
15 nucleotide sequence (SEQ ID NO:153) encoding EUGT11, and the nucleotide sequence encoding EUGT11 that has been codon optimized for expression in yeast (SEQ ID NO: 154).

FIG. 8 is an alignment of the secondary structure predictions of UGT91D2e with UGT85H2 and UGT71G1. Secondary structure predictions were made by subjecting the
20 amino acid sequences of the three UGTs to NetSurfP ver. 1.1 - Protein Surface Accessibility and Secondary Structure Predictions, at the world wide web at cbs.dtu.dk/services/NetSurfP/. This predicted the presence and location of alpha helices, beta sheets and coils in the proteins. These were subsequently labeled as shown for UGT91D2e. For example, the first N-terminal beta-sheet was labeled N β 1. The y-axis
25 represents the certainty of the prediction, the higher the more confident and the x-axis represents amino acid position. Although the primary sequence identity between these UGTs is very low, the secondary structures show a very high degree of conservation.

FIG. 9 is an alignment of the amino acid sequences of UGT91D1 and UGT91D2e (SEQ ID NO: 5).

FIG. 10 is a bar graph of the activity of double amino acid substitution mutants of UGT91D2e. The filled bars represent stevioside production and the open bars represent 1,2-bioside production.

FIG. 11 is a schematic representation of UDP-glucose regeneration for the biosynthesis of steviol glycosides. SUS = sucrose synthase; Steviol = steviol or steviol glycoside substrate; UGT = UDP glycosyl transferase.

FIG. 12A is the nucleotide sequence encoding the *Stevia rebaudiana* KAH (SEQ ID NO:163), designated SrKAHe1 herein.

FIG. 12B is the nucleotide sequence encoding the *Stevia rebaudiana* KAHe1 that has been codon-optimized for expression in yeast (SEQ ID NO:165).

FIG. 12C is the amino acid sequence of the *Stevia rebaudiana* KAHe1 (SEQ ID NO:164).

FIG. 13A contains the amino acid sequences of CPR polypeptides from *S. cerevisiae* (encoded by NCP1 gene) (SEQ ID NO:166), *A. thaliana* (encoded by ATR1 and encoded by ATR2) ((SEQ ID NOS: 148 and 168), and *S. rebaudiana* (encoded by CPR7 and encoded by CPR8) (SEQ ID NOS: 169 and 170).

FIG. 13B contains ATR1 nucleotide sequence (Accession No. CAA23011) that has been codon optimized for expression in yeast (SEQ ID NO:171); ATR2 nucleotide sequence that has been codon optimized for expression in yeast (SEQ ID NO:172); the *Stevia rebaudiana* CPR7 nucleotide sequence (SEQ ID NO:173); and the *Stevia rebaudiana* CPR8 nucleotide sequence (SEQ ID NO:174).

FIG. 14A contains the nucleotide sequence (SEQ ID NO:157) encoding a CDPS polypeptide (SEQ ID NO:158) from *Zea mays*. The sequence that is in bold and underlined can be deleted to remove the sequence encoding the chloroplast transit sequence.

FIG. 14B contains the amino acid sequence of the CDPS polypeptide (SEQ ID NO:158) from *Zea mays*. The sequence that is in bold and underlined can be deleted to remove the chloroplast transit sequence.

FIG. 15A contains a codon-optimized nucleotide sequence (SEQ ID NO:161) encoding a bifunctional CDPS-KS polypeptide (SEQ ID NO:162) from *Gibberella*

fujikuroi. FIG. 15B contains the amino acid sequence of the bifunctional CDPS-KS polypeptide (SEQ ID NO:162) from *Gibberella fujikuroi*.

FIG. 16 is a graph of the growth of two strains of *S. cerevisiae*, enhanced EFSC1972 (designated T2) and enhanced EFSC1972 with further overexpression of the Arabidopsis thaliana kaurene synthase (KS-5) (designated T7, squares). Numbers on the y-axis are OD600 values of the cell culture, while numbers on the x-axis represent hours of growth in synthetic complete based medium at 30°C.

FIG. 17 contains the nucleic acid sequences encoding the *A. thaliana*, *S. rebaudiana* (from contig10573 selection_ORF S11E, with the mutation that changes S11 to glutamate (E) in bold, lowercase letters), and coffee (*Coffea arabica*) sucrose synthases, SEQ ID NOs:175, 176, and 177, respectively.

FIG. 18 is a bar graph of rebD production in permeabilized *S. cerevisiae*, which had been transformed with EUGT11 or an empty plasmid ("Empty"). Cells were grown to exponential growth phase, washed in PBS buffer and subsequently treated with Triton X-100 (0.3% or 0.5% in PBS) 30°C, 30 min. After permeabilization cells were washed in PBS and resuspended in reaction mix containing 100 µM RebA and 300 µM UDP-glucose. Reactions proceeded for 20h, 30°C.

FIG. 19A is the amino acid sequence of the *A. thaliana* UDP-glycosyltransferase UGT72E2 (SEQ ID NO:178).

FIG. 19B is the amino acid sequence of the sucrose transporter SUC1 from *A. thaliana* (SEQ ID NO:179).

FIG. 19C is the amino acid sequence of the sucrose synthase from coffee (SEQ ID NO:180).

FIG. 20 is a schematic of the isoprenoid pathway in yeast, showing the position of ERG9.

FIG. 21 contains the nucleotide sequence of the *Saccharomyces cerevisiae* Cyc1 promoter (SEQ ID NO:185) and *Saccharomyces cerevisiae* Kex2 promoter (SEQ ID NO:186).

FIG. 22 is a schematic of the PCR product containing two regions, HR1 and HR2, which are homologous to parts of the genome sequence within the ERG9 promoter or 5'

end of the ERG9 open reading frame (ORF), respectively. Also, on the PCR product is an antibiotic marker, NatR, which can be embedded between two Lox sites (L) for subsequent excision with Cre recombinase. The PCR product further can include a promoter, such as either the wild type ScKex2, wild type ScCyc1, and the promoter further can include a heterologous insert such as a hairpin (SEQ ID NO: 181-184) at its 3'-end (See FIG. 23).

FIG. 23 is a schematic of promoter and ORF with a hairpin stemloop immediately upstream of the translation startsite (arrow) and an alignment of a portion of the wild-type *S. cerevisiae* Cyc1 promoter sequence and initial ATG of the ERG9 OPR without a heterologous insert (SEQ ID NO:187) and with four different heterologous inserts (SEQ ID NOs. 188-191). 75% refers to construct comprising the ScCyc1 promoter followed by SEQ ID NO: 184 (SEQ ID NO:191); 50% refers to construct comprising the ScCyc1 promoter followed by SEQ ID NO: 183 (SEQ ID NO:190); 20% refers to construct comprising the ScCyc1 promoter followed by SEQ ID NO: 182 (SEQ ID NO:189); 5% refers to construct comprising the ScCyc1 promoter followed by SEQ ID NO: 181 (SEQ ID NO:188).

FIG. 24 is a bar graph showing amorphaadiene produced in yeast strains with different promoter constructs inserted in front of the ERG9 gene of the host genome. CTRL-ADS refers to control strain with no modification; ERG9-CYC1-100% refers to construct comprising the ScCyc1 promoter and no insert; ERG9-CYC1-50% refers to construct comprising the ScCyc1 promoter followed by SEQ ID NO: 183 (SEQ ID NO:190); ERG9-CYC1-20% refers to construct comprising the ScCyc1 promoter followed by SEQ ID NO: 182 (SEQ ID NO:189); ERG9-CYC1-5% refers to construct comprising the ScCyc1 promoter followed by SEQ ID NO: 181 (SEQ ID NO:188); ERG9-KEX2-100% refers to construct comprising the ScKex2 promoter.

FIG. 25 contains the amino acid sequence of squalene synthase polypeptides from *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Yarrowia lipolytica*, *Candida glabrata*, *Ashbya gossypii*, *Cyberlindnera jadinii*, *Candida albicans*, *Saccharomyces cerevisiae*, *Homo sapiens*, *Mus musculus*, and *Rattus norvegicus* (SEQ ID NOs:192-202),

and the amino acid sequence of a geranylgeranyl diphosphate synthase (GGPPS) from *Aspergillus nidulans* and *S. cerevisiae* (SEQ ID NOs. 203 and 167).

FIG. 26 is a bar graph of geranylgeraniol (GGOH) accumulation in the ERG9-CYC1-5% strain and ERG9-KEX2 strain after 72 hours.

5 FIG. 27 is a representative chromatograph showing the conversion of rubusoside to xylosylated intermediates for RebF production by UGT91D2e and EUGT11.

Like reference symbols in the various drawings indicate like elements.

DETAILED DESCRIPTION

This document is based on the discovery that recombinant hosts such as plant
10 cells, plants, or microorganisms can be developed that express polypeptides useful for the biosynthesis of steviol glycosides such as rebaudioside A, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, or dulcoside A. The recombinant hosts described herein are particularly useful for producing Rebaudioside D. Such hosts can express one or more Uridine 5'-diphospho (UDP) glycosyl transferases suitable for producing steviol
15 glycosides. Expression of these biosynthetic polypeptides in various microbial chassis allows steviol glycosides to be produced in a consistent, reproducible manner from energy and carbon sources such as sugars, glycerol, CO₂, H₂, and sunlight. The proportion of each steviol glycoside produced by a recombinant host can be tailored by incorporating preselected biosynthetic enzymes into the hosts and expressing them at
20 appropriate levels, to produce a sweetener composition with a consistent taste profile. Furthermore, the concentrations of steviol glycosides produced by recombinant hosts are expected to be higher than the levels of steviol glycosides produced in the *Stevia* plant, which improves the efficiency of the downstream purification. Such sweetener compositions contain little or no plant based contaminants, relative to the amount of
25 contaminants present in *Stevia* extracts.

At least one of the genes is a recombinant gene, the particular recombinant gene(s) depending on the species or strain selected for use. Additional genes or biosynthetic modules can be included in order to increase steviol glycoside yield, improve efficiency with which energy and carbon sources are converted to steviol and its

glycosides, and/or to enhance productivity from the cell culture or plant. Such additional biosynthetic modules include genes involved in the synthesis of the terpenoid precursors, isopentenyl diphosphate and dimethylallyl diphosphate. Additional biosynthetic modules include terpene synthase and terpene cyclase genes, such as genes encoding
 5 geranylgeranyl diphosphate synthase and copalyl diphosphate synthase; these genes may be endogenous genes or recombinant genes.

I. Steviol and Steviol Glycoside Biosynthesis Polypeptides

A. Steviol Biosynthesis Polypeptides

10 Chemical structures for several of the compounds found in Stevia extracts are shown in FIG. 1, including the diterpene steviol and various steviol glycosides. CAS numbers are shown in Table A below. See also, Steviol Glycosides Chemical and Technical Assessment 69th JECFA, prepared by Harriet Wallin, Food Agric. Org. (2007).

15 **Table A.**

COMPOUND	CAS #
Steviol	471-80-7
Rebaudioside A	58543-16-1
Steviolbioside	41093-60-1
Stevioside	57817-89-7
Rebaudioside B	58543-17-2
Rebaudioside C	63550-99-2
Rebaudioside D	63279-13-0
Rebaudioside E	63279-14-1
Rebaudioside F	438045-89-7
Rubusoside	63849-39-4
Dulcoside A	64432-06-0

It has been discovered that expression of certain genes in a host such as a microorganism confers the ability to synthesize steviol glycosides upon that host. As discussed in more detail below, one or more of such genes may be present naturally in a
 20 host. Typically, however, one or more of such genes are recombinant genes that have been transformed into a host that does not naturally possess them.

The biochemical pathway to produce steviol involves formation of geranylgeranyl diphosphate, cyclization to (-) copalyl diphosphate, followed by oxidation and hydroxylation to form steviol. Thus, conversion of geranylgeranyl diphosphate to steviol in a recombinant microorganism involves the expression of a gene encoding a kaurene synthase (KS), a gene encoding a kaurene oxidase (KO), and a gene encoding a steviol synthetase (KAH). Steviol synthetase also is known as kaurenoic acid 13-hydroxylase.

Suitable KS polypeptides are known. For example, suitable KS enzymes include those made by *Stevia rebaudiana*, *Zea mays*, *Populus trichocarpa*, and *Arabidopsis thaliana*. See, Table 1 and SEQ ID NOs: 132-135 and 156. Nucleotide sequences encoding these polypeptides are set forth in SEQ ID NOs: 40-47 and 155. The nucleotide sequences set forth in SEQ ID NOs: 40-43 were modified for expression in yeast while the nucleotide sequences set forth in SEQ ID NOs: 44-47 are from the source organisms from which the KS polypeptides were identified.

Table 1. KS Clones

Enzyme Source Organism	gi Number	Accession Number	Construct Name	Length (nts)	SEQ ID (DNA)	SEQ ID (protein)
<i>Stevia rebaudiana</i>	4959241	AAD34295	MM-12	2355	40	132
<i>Stevia rebaudiana</i>	4959239	AAD34294	MM-13	2355	41	133
<i>Zea mays</i>	162458963	NP_001105097	MM-14	1773	42	134
<i>Populus trichocarpa</i>	224098838	XP_002311286	MM-15	2232	43	135
<i>Arabidopsis thaliana</i>	3056724	AF034774	EV-70	2358	155	156

Suitable KO polypeptides are known. For example, suitable KO enzymes include those made by *Stevia rebaudiana*, *Arabidopsis thaliana*, *Gibberella fujikuroi* and *Trametes versicolor*. See, Table 2 and SEQ ID NOs: 138-141. Nucleotide sequences encoding these polypeptides are set forth in in SEQ ID NOs: 52-59. The nucleotide sequences set forth in SEQ ID NOs: 52-55 were modified for expression in yeast. The nucleotide sequences set forth in SEQ ID NOs: 56-59 are from the source organisms from which the KO polypeptides were identified.

Table 2. KO Clones

Enzyme Source Organism	gi Number	Accession Number	Construct Name	Length (nts)	SEQ ID (DNA)	SEQ ID (protein)
<i>Stevia rebaudiana</i>	76446107	ABA42921	MM-18	1542	52	138
<i>Arabidopsis thaliana</i>	3342249	AAC39505	MM-19	1530	53	139
<i>Gibberella fujikuroi</i>	4127832	CAA76703	MM-20	1578	54	140
<i>Trametes versicolor</i>	14278967	BAB59027	MM-21	1500	55	141

Suitable KAH polypeptides are known. For example, suitable KAH enzymes include those made by *Stevia rebaudiana*, *Arabidopsis thaliana*, *Vitis vinifera* and *Medicago trunculata*. See, e.g., Table 3, SEQ ID NOs: 142-146; U.S. Patent Publication No. 2008-0271205; U.S. Patent Publication No. 2008-0064063 and Genbank Accession No. gi 189098312. The steviol synthetase from *Arabidopsis thaliana* is classified as a CYP714A2. Nucleotide sequences encoding these KAH enzymes are set forth in SEQ ID NOs: 60-69. The nucleotide sequences set forth in SEQ ID NOs: 60-64 were modified for expression in yeast while the nucleotide sequences from the source organisms from which the polypeptides were identified are set forth in SEQ ID NOs: 65-69.

Table 3. KAH Clones

Enzyme Source Organism	gi Number	Accession Number	Plasmid Name	Construct Name	Length (nts)	SEQ ID (DNA)	SEQ ID (protein)
<i>Stevia rebaudiana</i>		--*	pMUS35	MM-22	1578	60	142
<i>Stevia rebaudiana</i>	189418962	ACD93722	pMUS36	MM-23	1431	61	143
<i>Arabidopsis thaliana</i>	15238644	NP_197872	pMUS37	MM-24	1578	62	144
<i>Vitis vinifera</i>	225458454	XP_002282091	pMUS38	MM-25	1590	63	145
<i>Medicago trunculata</i>	84514135	ABC59076	pMUS39	MM-26	1440	64	146

* = Sequence is shown in U.S. Patent Publication No. 2008-0064063.

In addition, a KAH polypeptide from *Stevia rebaudiana* that was identified herein is particularly useful in a recombinant host. The nucleotide sequence (SEQ ID NO:163) encoding the *S. rebaudiana* KAH (SrKAHe1) (SEQ ID NO:164) is set forth in FIG. 12A. A nucleotide sequence encoding the *S. rebaudiana* KAH that has been codon-optimized for expression in yeast (SEQ ID NO:165) is set forth in FIG. 12B. The amino acid sequence of the *S. rebaudiana* KAH is set forth in FIG. 12C. The *S. rebaudiana* KAH shows significantly higher steviol synthase activity as compared to the *Arabidopsis thaliana* ent-kaurenoic acid hydroxylase described by Yamaguchi *et al.* (U.S. Patent Publication No. 2008/0271205 A1) when expressed in *S. cerevisiae*. The *S. rebaudiana* KAH polypeptide set forth in FIG. 12C has less than 20% identity to the KAH from U.S. Patent Publication No. 2008/0271205, and less than 35% identity to the KAH from U.S. Patent Publication No. 2008/0064063.

In some embodiments, a recombinant microorganism contains a recombinant gene encoding a KO and/or a KAH polypeptide. Such microorganisms also typically contain a recombinant gene encoding a cytochrome P450 reductase (CPR) polypeptide, since certain combinations of KO and/or KAH polypeptides require expression of an exogenous CPR polypeptide. In particular, the activity of a KO and/or a KAH polypeptide of plant origin can be significantly increased by the inclusion of a recombinant gene encoding an exogenous CPR polypeptide. Suitable CPR polypeptides are known. For example, suitable CPR enzymes include those made by *Stevia rebaudiana* and *Arabidopsis thaliana*. See, e.g., Table 4 and SEQ ID NOs: 147 and 148. Nucleotide sequences encoding these polypeptides are set forth in SEQ ID NOs: 70, 71, 73, and 74. The nucleotide sequences set forth in SEQ ID NOs: 70-72 were modified for expression in yeast. The nucleotide sequences from the source organisms from which the polypeptides were identified are set forth in SEQ ID NOs:73-75.

Table 4. CPR Clones

Enzyme Source Organism	gi Number	Accession Number	Plasmid Name	Construct Name	Length (nts)	SEQ ID (DNA)	SEQ ID (protein)
<i>Stevia rebaudiana</i>	93211213	ABB88839	pMUS40	MM-27	2133	70	147
<i>Arabidopsis</i>	15233853	NP_194183	pMUS41	MM-28	2079	71	148

<i>thaliana</i>							
<i>Giberella fujikuroi</i>	32562989	CAE09055	pMUS42	MM-29	2142	72	149

For example, the steviol synthase encoded by SrKAHe1 is activated by the *S. cerevisiae* CPR encoded by gene NCP1 (YHR042W). Even better activation of the steviol synthase encoded by SrKAHe1 is observed when the *Arabidopsis thaliana* CPR encoded by the gene *ATR2* or the *S. rebaudiana* CPR encoded by the gene *CPR8* are co-expressed. FIG. 13A contains the amino acid sequence of the *S. cerevisiae*, *A. thaliana* (from *ATR1* and *ATR2* genes) and *S. rebaudiana* CPR polypeptides (from *CPR7* and *CPR8* genes) (SEQ ID NOs: 166-170). FIG. 13 B contains the nucleotide sequence encoding the *A. thaliana* and *S. rebaudiana* CPR polypeptides (SEQ ID NOs:171-174).

For example, the yeast gene *DPPI* and/or the yeast gene *LPPI* can be disrupted or deleted such that the degradation of farnesyl pyrophosphate (FPP) to farnesol is reduced and the degradation of geranylgeranylpyrophosphate (GGPP) to geranylgeraniol (GGOH) is reduced. Alternatively, the promoter or enhancer elements of an endogenous gene encoding a phosphatase can be altered such that the expression of their encoded proteins is altered. Homologous recombination can be used to disrupt an endogenous gene. For example, a “gene replacement” vector can be constructed in such a way to include a selectable marker gene. The selectable marker gene can be operably linked, at both 5' and 3' end, to portions of the gene of sufficient length to mediate homologous recombination. The selectable marker can be one of any number of genes that complement host cell auxotrophy, provide antibiotic resistance, or result in a color change. Linearized DNA fragments of the gene replacement vector then are introduced into the cells using methods well known in the art (see below). Integration of the linear fragments into the genome and the disruption of the gene can be determined based on the selection marker and can be verified by, for example, Southern blot analysis. Subsequent to its use in selection, a selectable marker can be removed from the genome of the host cell by, e.g., Cre-loxP systems (see, e.g., Gossen et al. (2002) *Ann. Rev. Genetics* 36:153-173 and U.S. Application Publication No. 20060014264). Alternatively, a gene replacement vector can be constructed in such a way as to include a portion of the gene to

be disrupted, where the portion is devoid of any endogenous gene promoter sequence and encodes none, or an inactive fragment of, the coding sequence of the gene. An "inactive fragment" is a fragment of the gene that encodes a protein having, e.g., less than about 10% (e.g., less than about 9%, less than about 8%, less than about 7%, less than about 6%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, less than about 1%, or 0%) of the activity of the protein produced from the full-length coding sequence of the gene. Such a portion of the gene is inserted in a vector in such a way that no known promoter sequence is operably linked to the gene sequence, but that a stop codon and a transcription termination sequence are operably linked to the portion of the gene sequence. This vector can be subsequently linearized in the portion of the gene sequence and transformed into a cell. By way of single homologous recombination, this linearized vector is then integrated in the endogenous counterpart of the gene.

Expression in a recombinant microorganism of these genes results in the conversion of geranylgeranyl diphosphate to steviol.

B. Steviol Glycoside Biosynthesis Polypeptides

A recombinant host described herein can convert steviol to a steviol glycoside. Such a host (e.g., microorganism) contains genes encoding one or more UDP Glycosyl Transferases, also known as UGTs. UGTs transfer a monosaccharide unit from an activated nucleotide sugar to an acceptor moiety, in this case, an –OH or –COOH moiety on steviol or steviol derivative. UGTs have been classified into families and subfamilies based on sequence homology. Li et al. *J. Biol. Chem.* 276:4338-4343 (2001).

B. 1 Rubusoside Biosynthesis Polypeptides

The biosynthesis of rubusoside involves glycosylation of the 13-OH and the 19-COOH of steviol. See FIG. 2A. Conversion of steviol to rubusoside in a recombinant host such as a microorganism can be accomplished by the expression of gene(s) encoding UGTs 85C2 and 74G1, which transfer a glucose unit to the 13-OH or the 19-COOH, respectively, of steviol.

A suitable UGT85C2 functions as a uridine 5'-diphospho glucosyl:steviol 13-OH transferase, and a uridine 5'-diphospho glucosyl:steviol-19-*O*-glucoside 13-OH transferase. Functional UGT85C2 polypeptides also may catalyze glucosyl transferase reactions that utilize steviol glycoside substrates other than steviol and steviol-19-*O*-glucoside.

A suitable UGT74G1 polypeptide functions as a uridine 5'-diphospho glucosyl: steviol 19-COOH transferase and a uridine 5'-diphospho glucosyl: steviol-13-*O*-glucoside 19-COOH transferase. Functional UGT74G1 polypeptides also may catalyze glycosyl transferase reactions that utilize steviol glycoside substrates other than steviol and steviol-13-*O*-glucoside, or that transfer sugar moieties from donors other than uridine diphosphate glucose.

A recombinant microorganism expressing a functional UGT74G1 and a functional UGT85C2 can make rubusoside and both steviol monosides (i.e., steviol 13-*O*-monoglucoside and steviol 19-*O*-monoglucoside) when steviol is used as a feedstock in the medium. One or more of such genes may be present naturally in the host. Typically, however, such genes are recombinant genes that have been transformed into a host (e.g., microorganism) that does not naturally possess them.

As used herein, the term recombinant host is intended to refer to a host, the genome of which has been augmented by at least one incorporated DNA sequence. Such DNA sequences include but are not limited to genes that are not naturally present, DNA sequences that are not normally transcribed into RNA or translated into a protein ("expressed"), and other genes or DNA sequences which one desires to introduce into the non-recombinant host. It will be appreciated that typically the genome of a recombinant host described herein is augmented through the stable introduction of one or more recombinant genes. Generally, the introduced DNA is not originally resident in the host that is the recipient of the DNA, but it is within the scope of the invention to isolate a DNA segment from a given host, and to subsequently introduce one or more additional copies of that DNA into the same host, e.g., to enhance production of the product of a gene or alter the expression pattern of a gene. In some instances, the introduced DNA will modify or even replace an endogenous gene or DNA sequence by, e.g., homologous

recombination or site-directed mutagenesis. Suitable recombinant hosts include microorganisms, plant cells, and plants.

The term “recombinant gene” refers to a gene or DNA sequence that is introduced into a recipient host, regardless of whether the same or a similar gene or DNA sequence may already be present in such a host. “Introduced,” or “augmented” in this context, is known in the art to mean introduced or augmented by the hand of man. Thus, a recombinant gene may be a DNA sequence from another species, or may be a DNA sequence that originated from or is present in the same species, but has been incorporated into a host by recombinant methods to form a recombinant host. It will be appreciated that a recombinant gene that is introduced into a host can be identical to a DNA sequence that is normally present in the host being transformed, and is introduced to provide one or more additional copies of the DNA to thereby permit overexpression or modified expression of the gene product of that DNA.

Suitable UGT74G1 and UGT85C2 polypeptides include those made by *Stevia rebaudiana*. Genes encoding functional UGT74G1 and UGT85C2 polypeptides from *Stevia* are reported in Richman, et al. Plant J. 41: 56-67 (2005). Amino acid sequences of *S. rebaudiana* UGT74G1 and UGT85C2 polypeptides are set forth in SEQ ID NOs: 1 and 3, respectively. Nucleotide sequences encoding UGT74G1 and UGT85C2 that have been optimized for expression in yeast are set forth in SEQ ID NOs: 2 and 4, respectively. DNA 2.0 codon-optimized sequence for UGTs 85C2, 91D2e, 74G1 and 76G1 are set forth in SEQ ID NOs: 82, 84, 83, and 85, respectively. See also the UGT85C2 and UGT74G1 variants described below in the “Functional Homolog” section. For example, an UGT85C2 polypeptide containing substitutions at positions 65, 71, 270, 289, and 389 can be used (e.g., A65S, E71Q, T270M, Q289H, and A389V).

In some embodiments, the recombinant host is a microorganism. The recombinant microorganism can be grown on media containing steviol in order to produce rubusoside. In other embodiments, however, the recombinant microorganism expresses one or more recombinant genes involved in steviol biosynthesis, e.g., a CDPS gene, a KS gene, a KO gene and/or a KAH gene. Suitable CDPS polypeptides are known. For example, suitable CDPS enzymes include those made by *Stevia rebaudiana*,

Streptomyces clavuligerus, *Bradyrhizobium japonicum*, *Zea mays*, and *Arabidopsis*. See, e.g., Table 5 and SEQ ID NOs: 129-131, 158, and 160. Nucleotide sequences encoding these polypeptides are set forth in SEQ ID NOs: 34-39, 157, and 159. The nucleotide sequences set forth in SEQ ID NOs: 34-36 were modified for expression in yeast. The nucleotide sequences from the source organisms from which the polypeptides were identified are set forth in SEQ ID NOs: 37-39.

In some embodiments, CDPS polypeptides that lack a chloroplast transit peptide at the amino terminus of the unmodified polypeptide can be used. For example, the first 150 nucleotides from the 5' end of the *Zea mays* CDPS coding sequence shown in FIG. 14 (SEQ ID NO:157) can be removed. Doing so removes the amino terminal 50 residues of the amino acid sequence shown in FIG. 14 (SEQ ID NO:158), which encode a chloroplast transit peptide. The truncated CDPS gene can be fitted with a new ATG translation start site and operably linked to a promoter, typically a constitutive or highly expressing promoter. When a plurality of copies of the truncated coding sequence are introduced into a microorganism, expression of the CDPS polypeptide from the promoter results in an increased carbon flux towards *ent*-kaurene biosynthesis.

Table 5. CDPS Clones

Enzyme Source Organism	gi Number	Accession Number	Plasmid Name	Construct Name	Length (nts)	SEQ ID: (DNA)	SEQ ID (protein)
<i>Stevia rebaudiana</i>	2642661	AAB87091	pMUS22	MM-9	2364	34	129
<i>Streptomyces clavuligerus</i>	197705855	EDY51667	pMUS23	MM-10	1584	35	130
<i>Bradyrhizobium japonicum</i>	529968	AAC28895.1	pMUS24	MM-11	1551	36	131
<i>Zea mays</i>	50082774	AY562490		EV65	2484	157	158
<i>Arabidopsis thaliana</i>	18412041	NM_116512		EV64	2409	159	160

CDPS-KS bifunctional proteins (SEQ ID NOs: 136 and 137) also can be used. Nucleotide sequences encoding the CDPS-KS bifunctional enzymes shown in Table 6 were modified for expression in yeast (see SEQ ID NOs: 48 and 49). The nucleotide sequences from the source organisms from which the polypeptides were originally

identified are set forth in SEQ ID NOs: 50 and 51. A bifunctional enzyme from *Gibberella fujikuroi* (SEQ ID NO:162) also can be used. A nucleotide sequence encoding the *Gibberella fujikuroi* bifunctional CDPS-KS enzyme was modified for expression in yeast (see FIG. 15A, SEQ ID NO:161).

5

Table 6. CDPS-KS Clones

Enzyme Source Organism	gi Number	Accession Number	Construct Name	Length (nts)	SEQ ID (DNA)	SEQ ID (protein)
<i>Phomopsis amygdali</i>	186704306	BAG30962	MM-16	2952	48	136
<i>Physcomitrella patens</i>	146325986	BAF61135	MM-17	2646	49	137
<i>Gibberella fujikuroi</i>	62900107	Q9UVY5.1		2859	161	162

Thus, a microorganism containing a CDPS gene, a KS gene, a KO gene and a KAH gene in addition to a UGT74G1 and a UGT85C2 gene is capable of producing both steviol monosides and rubusoside without the necessity for using steviol as a feedstock.

10

In some embodiments, the recombinant microorganism further expresses a recombinant gene encoding a geranylgeranyl diphosphate synthase (GGPPS). Suitable GGPPS polypeptides are known. For example, suitable GGPPS enzymes include those made by *Stevia rebaudiana*, *Gibberella fujikuroi*, *Mus musculus*, *Thalassiosira pseudonana*, *Streptomyces clavuligerus*, *Sulfolobus acidocaldarius*, *Synechococcus* sp. and *Arabidopsis thaliana*. See, Table 7 and SEQ ID NOs: 121-128. Nucleotide sequences encoding these polypeptides are set forth in SEQ ID NOs:18-33. The nucleotide sequences set forth in SEQ ID NOs: 18-25 were modified for expression in yeast while the nucleotide sequences from the source organisms from which the polypeptides were identified are set forth in SEQ ID NOs: 26-33.

20

Table 7. GGPPS Clones

Enzyme Source Organism	gi Number	Accession Number	Plasmid Name	Construct Name	Length (nts)	SEQ ID (DNA)	SEQ ID (protein)
<i>Stevia rebaudiana</i>	90289577	ABD92926	pMUS14	MM-1	1086	18	121

<i>Gibberella fujikuroi</i>	3549881	CAA75568	pMUS15	MM-2	1029	19	122
<i>Mus musculus</i>	47124116	AAH69913	pMUS16	MM-3	903	20	123
<i>Thalassiosira pseudonana</i>	223997332	XP_002288339	pMUS17	MM-4	1020	21	124
<i>Streptomyces clavuligerus</i>	254389342	ZP_05004570	pMUS18	MM-5	1068	22	125
<i>Sulfolobus acidocaldarius</i>	506371	BAA43200	pMUS19	MM-6	993	23	126
<i>Synechococcus</i> sp.	86553638	ABC98596	pMUS20	MM-7	894	24	127
<i>Arabidopsis thaliana</i>	15234534	NP_195399	pMUS21	MM-8	1113	25	128

In some embodiments, the recombinant microorganism further can express recombinant genes involved in diterpene biosynthesis or production of terpenoid precursors, e.g., genes in the methylerythritol 4-phosphate (MEP) pathway or genes in the mevalonate (MEV) pathway discussed below, have reduced phosphatase activity, and/or express a sucrose synthase (SUS) as discussed herein.

B. 2 Rebaudioside A, Rebaudioside D, and Rebaudioside E Biosynthesis Polypeptides

The biosynthesis of rebaudioside A involves glucosylation of the aglycone steviol. Specifically, rebaudioside A can be formed by glucosylation of the 13-OH of steviol which forms the 13-*O*-steviolmonoside, glucosylation of the C-2' of the 13-*O*-glucose of steviolmonoside which forms steviol-1,2-bioside, glucosylation of the C-19 carboxyl of steviol-1,2-bioside which forms stevioside, and glucosylation of the C-3' of the C-13-*O*-glucose of stevioside. The order in which each glucosylation reaction occurs can vary. See FIG. 2A.

The biosynthesis of rebaudioside E and/or rebaudioside D involves glucosylation of the aglycone steviol. Specifically, rebaudioside E can be formed by glucosylation of the 13-OH of steviol which forms steviol-13-*O*-glucoside, glucosylation of the C-2' of the 13-*O*-glucose of steviol-13-*O*-glucoside which forms the steviol-1,2-bioside, glucosylation of the C-19 carboxyl of the 1,2-bioside to form 1,2-stevioside, and glucosylation of the C-2' of the 19-*O*-glucose of the 1,2-stevioside to form rebaudioside

E. Rebaudioside D can be formed by glucosylation of the C-3' of the C-13-O-glucose of rebaudioside E. The order in which each glycosylation reaction occurs can vary. For example, the glucosylation of the C-2' of the 19-O-glucose may be the last step in the pathway, wherein Rebaudioside A is an intermediate in the pathway. See FIG. 2C.

5 It has been discovered that conversion of steviol to rebaudioside A, rebaudioside D, and/or rebaudioside E in a recombinant host can be accomplished by expressing the following functional UGTs: EUGT11, 74G1, 85C2, and 76G1, and optionally 91D2. Thus, a recombinant microorganism expressing combinations of these four or five UGTs can make rebaudioside A and rebaudioside D when steviol is used as a feedstock.

10 Typically, one or more of these genes are recombinant genes that have been transformed into a microorganism that does not naturally possess them. It has also been discovered that UGTs designated herein as SM12UGT can be substituted for UGT91D2.

In some embodiments, less than five (e.g., one, two, three, or four) UGTs are expressed in a host. For example, a recombinant microorganism expressing a functional

15 EUGT11 can make rebaudioside D when rebaudioside A is used as a feedstock. A recombinant microorganism expressing two functional UGTs, EUGT11 and 76G1, and optionally a functional 91D12, can make rebaudioside D when rubusoside or 1,2-stevioside is used as a feedstock. As another alternative, a recombinant microorganism expressing three functional UGTs, EUGT11, 74G1, 76G1, and optionally 91D2, can

20 make rebaudioside D when fed the monoside, steviol-13-O-glucoside, in the medium. Similarly, conversion of steviol-19-O-glucoside to rebaudioside D in a recombinant microorganism can be accomplished by the expression of genes encoding UGTs EUGT11, 85C2, 76G1, and optionally 91D2, when fed steviol-19-O-glucoside. Typically, one or more of these genes are recombinant genes that have been transformed into a host

25 that does not naturally possess them.

Suitable UGT74G1 and UGT85C2 polypeptides include those discussed above. A suitable UGT76G1 adds a glucose moiety to the C-3' of the C-13-O-glucose of the acceptor molecule, a steviol 1,2 glycoside. Thus, UGT76G1 functions, for example, as a uridine 5'-diphospho glucosyl: steviol 13-O-1,2 glucoside C-3' glucosyl transferase and a

30 uridine 5'-diphospho glucosyl: steviol-19-O-glucose, 13-O-1,2 bioside C-3' glucosyl

transferase. Functional UGT76G1 polypeptides may also catalyze glucosyl transferase reactions that utilize steviol glycoside substrates that contain sugars other than glucose, e.g., steviol rhamnosides and steviol xylosides. See, FIGS 2A, 2B, 2C and 2D. Suitable UGT76G1 polypeptides include those made by *S. rebaudiana* and reported in Richman, et al. Plant J. 41: 56-67 (2005). The amino acid sequence of a *S. rebaudiana* UGT76G1 polypeptide is set forth in SEQ ID NO:7. The nucleotide sequence encoding the UGT76G1 polypeptide of SEQ ID NO:7 has been optimized for expression in yeast and is set forth in SEQ ID NO:8. See also the UGT76G1 variants set forth in the “Functional Homolog” section.

A suitable EUGT11 or UGT91D2 polypeptide functions as a uridine 5'-diphospho glucosyl: steviol-13-*O*-glucoside transferase (also referred to as a steviol-13-monoglucoside 1,2-glucosylase), transferring a glucose moiety to the C-2' of the 13-*O*-glucose of the acceptor molecule, steviol-13-*O*-glucoside.

A suitable EUGT11 or UGT91D2 polypeptide also functions as a uridine 5'-diphospho glucosyl: rubusoside transferase transferring a glucose moiety to the C-2' of the 13-*O*-glucose of the acceptor molecule, rubusoside, to produce stevioside. EUGT11 polypeptides also can transfer a glucose moiety to the C-2' of the 19-*O*-glucose of the acceptor molecule, rubusoside, to produce a 19-*O*-1,2-diglycosylated rubusoside (compound 2 in FIG. 3).

Functional EUGT11 or UGT91D2 polypeptides also can catalyze reactions that utilize steviol glycoside substrates other than steviol-13-*O*-glucoside and rubusoside. For example, a functional EUGT11 polypeptide may utilize stevioside as a substrate, transferring a glucose moiety to the C-2' of the 19-*O*-glucose residue to produce Rebaudioside E (see compound 3 in FIG. 3). Functional EUGT11 and UGT91D2 polypeptides may also utilize Rebaudioside A as a substrate, transferring a glucose moiety to the C-2' of the 19-*O*-glucose residue of Rebaudioside A to produce Rebaudioside D. As set forth in the Examples, EUGT11 can convert Rebaudioside A to Rebaudioside D at a rate that is least 20 times faster (e.g., as least 25 times or at least 30 times faster) than the corresponding rate of UGT91D2e (SEQ ID NO: 5) when the reactions are performed under similar conditions, i.e., similar time, temperature, purity,

and substrate concentration. As such, EUGT11 produces greater amounts of RebD than UGT91D2e when incubated under similar conditions.

In addition, a functional EUGT11 exhibits significant C-2' 19-O-diglycosylation activity with rubusoside or stevioside as substrates, whereas UGT91D2e has no
5 detectable diglycosylation activity with these substrates. Thus, a functional EUGT11 can be distinguished from UGT91D2e by the differences in steviol glycoside substrate-specificity. FIG. 3 provides a schematic overview of the 19-O-1,2 diglycosylation reactions that are performed by EUGT11 and UGT91D2e.

A functional EUGT11 or UGT91D2 polypeptide typically does not transfer a
10 glucose moiety to steviol compounds having a 1,3-bound glucose at the C-13 position, i.e., transfer of a glucose moiety to steviol 1,3-bioside and 1,3-stevioside does not occur.

Functional EUGT11 and UGT91D2 polypeptides can transfer sugar moieties from donors other than uridine diphosphate glucose. For example, a functional EUGT11 or UGT91D2 polypeptide can act as a uridine 5'-diphospho D-xylosyl: steviol-13-O-
15 glucoside transferase, transferring a xylose moiety to the C-2' of the 13-O-glucose of the acceptor molecule, steviol-13-O-glucoside. As another example, a functional EUGT11 or UGT91D2 polypeptide can act as a uridine 5'-diphospho L-rhamnosyl: steviol-13-O-glucoside transferase, transferring a rhamnose moiety to the C-2' of the 13-O-glucose of the acceptor molecule, steviol-13-O-glucoside

Suitable EUGT11 polypeptides are described herein and can include the EUGT11
20 polypeptide from *Oryza sativa* (GenBank Accession No. AC133334). For example, an EUGT11 polypeptide can have an amino acid sequence with at least 70% sequence identity (e.g., at least 75, 80, 85, 90, 95, 96, 97, 98, or 99% sequence identity) to the amino acid sequence set forth in SEQ ID NO: 152 (see FIG. 7). The nucleotide sequence
25 encoding the amino acid sequence of SEQ ID NO: 152 is set forth in SEQ ID NO: 153. SEQ ID NO: 154 is a nucleotide sequence encoding the polypeptide of SEQ ID NO: 152 that has been codon optimized for expression in yeast.

Suitable functional UGT91D2 polypeptides include those disclosed herein, e.g., the polypeptides designated UGT91D2e and UGT91D2m. The amino acid sequence of
30 an exemplary UGT91D2e polypeptide from *Stevia rebaudiana* is set forth in SEQ ID NO:

5. SEQ ID NO:6 is a nucleotide sequence encoding the polypeptide of SEQ ID NO:5 that has been codon optimized for expression in yeast. The *S. rebaudiana* nucleotide sequence encoding the polypeptide of SEQ ID NO:5 is set forth in SEQ ID NO:9. The amino acid sequences of exemplary UGT91D2m polypeptides from *S. rebaudiana* are set forth in SEQ ID NOs: 10 and 12, and are encoded by the nucleic acid sequences set forth in SEQ ID NOs: 11 and 13, respectively. In addition, UGT91D2 variants containing a substitution at amino acid residues 206, 207, and 343 of SEQ ID NO: 5 can be used. For example, the amino acid sequence set forth in SEQ ID NO:95 and having the following mutations with respect to wild-type UGT92D2e (SEQ ID NO:5) G206R, Y207C, and W343R can be used. In addition, a UGT91D2 variant containing substitutions at amino acid residues 211 and 286 can be used. For example, a UGT91D2 variant can include a substitution of a methionine for leucine at position 211 and a substitution of an alanine for valine at position 286 of SEQ ID NO:5 (UGT91D2e-b).

As indicated above, UGTs designated herein as SM12UGT can be substituted for UGT91D2. Suitable functional SM12UGT polypeptides include those made by *Ipomoea purpurea* (Japanese morning glory) and described in Morita et al. Plant J. 42, 353-363 (2005). The amino acid sequence encoding the *I. purpurea* IP3GGT polypeptide is set forth in SEQ ID NO:76. SEQ ID NO:77 is a nucleotide sequence encoding the polypeptide of SEQ ID NO:76 that has been codon optimized for expression in yeast. Another suitable SM12UGT polypeptide is a Bp94B1 polypeptide having an R25S mutation. See Osmani et al. Plant Phys. 148: 1295-1308 (2008) and Sawada et al. J. Biol. Chem. 280:899-906 (2005). The amino acid sequence of the *Bellis perennis* (red daisy) UGT94B1 polypeptide is set forth in SEQ ID NO:78. SEQ ID NO:79 is the nucleotide sequence encoding the polypeptide of SEQ ID NO:78 that has been codon optimized for expression in yeast.

In some embodiments, the recombinant microorganism is grown on media containing steviol-13-*O*-glucoside or steviol-19-*O*-glucoside in order to produce rebaudioside A and/or rebaudioside D. In such embodiments, the microorganism contains and expresses genes encoding a functional EUGT11, a functional UGT74G1, a functional UGT85C2, a functional UGT76G1, and an optional functional UGT91D2, and

is capable of accumulating rebaudioside A and rebaudioside D when steviol, one or both of the steviolmonosides, or rubusoside is used as feedstock.

In other embodiments, the recombinant microorganism is grown on media containing rubusoside in order to produce rebaudioside A and/or rebaudioside D. In such
5 embodiments, the microorganism contains and expresses genes encoding a functional EUGT11, a functional UGT76G1, and an optional functional UGT91D2, and is capable of producing rebaudioside A and/or rebaudioside D when rubusoside is used as feedstock.

In other embodiments the recombinant microorganism expresses one or more genes involved in steviol biosynthesis, e.g., a CDPS gene, a KS gene, a KO gene and/or a
10 KAH gene. Thus, for example, a microorganism containing a CDPS gene, a KS gene, a KO gene and a KAH gene, in addition to a EUGT11, a UGT74G1, a UGT85C2, a UGT76G1, and optionally a functional UGT91D2 (e.g., UGT91D2e), is capable of producing rebaudioside A, rebaudioside D, and/or rebaudioside E without the necessity for including steviol in the culture media.

15 In some embodiments, the recombinant host further contains and expresses a recombinant GGPPS gene in order to provide increased levels of the diterpene precursor geranylgeranyl diphosphate, for increased flux through the steviol biosynthetic pathway. In some embodiments, the recombinant host further contains a construct to silence the expression of non-steviol pathways consuming geranylgeranyl diphosphate, ent-
20 Kaurenoic acid or farnesyl pyrophosphate, thereby providing increased flux through the steviol and steviol glycosides biosynthetic pathways. For example, flux to sterol production pathways such as ergosterol may be reduced by downregulation of the *ERG9* gene. See, the *ERG9* section below and Examples 24-25. In cells that produce gibberellins, gibberellin synthesis may be downregulated to increase flux of ent-
25 kaurenoic acid to steviol. In carotenoid-producing organisms, flux to steviol may be increased by downregulation of one or more carotenoid biosynthetic genes. In some embodiments, the recombinant microorganism further can express recombinant genes involved in diterpene biosynthesis or production of terpenoid precursors, e.g., genes in the MEP or MEV) pathways discussed below, have reduced phosphatase activity, and/or
30 express a SUS as discussed herein.

One with skill in the art will recognize that by modulating relative expression levels of different UGT genes, a recombinant host can be tailored to specifically produce steviol glycoside products in a desired proportion. Transcriptional regulation of steviol biosynthesis genes and steviol glycoside biosynthesis genes can be achieved by a combination of transcriptional activation and repression using techniques known to those in the art. For *in vitro* reactions, one with skill in the art will recognize that addition of different levels of UGT enzymes in combination or under conditions which impact the relative activities of the different UGTs in combination will direct synthesis towards a desired proportion of each steviol glycoside. One with skill in the art will recognize that a higher proportion of rebaudioside D or E or more efficient conversion to rebaudioside D or E can be obtained with a diglycosylation enzyme that has a higher activity for the 19-*O*-glucoside reaction as compared to the 13-*O*-glucoside reaction (substrates rebaudioside A and stevioside).

In some embodiments, a recombinant host such as a microorganism produces rebaudioside D-enriched steviol glycoside compositions that have greater than at least 3% rebaudioside D by weight total steviol glycosides, e.g., at least 4% rebaudioside D at least 5% rebaudioside D, 10-20% rebaudioside D, 20-30% rebaudioside D, 30-40% rebaudioside D, 40-50% rebaudioside D, 50-60% rebaudioside D, 60-70% rebaudioside D, 70-80% rebaudioside D. In some embodiments, a recombinant host such as a microorganism produces steviol glycoside compositions that have at least 90% rebaudioside D, e.g., 90-99% rebaudioside D. Other steviol glycosides present may include those depicted in Figure 2 C such as steviol monosides, steviol glucobiosides, rebaudioside A, rebaudioside E, and stevioside. In some embodiments, the rebaudioside D-enriched composition produced by the host (e.g., microorganism) can be further purified and the rebaudioside D or rebaudioside E so purified can then be mixed with other steviol glycosides, flavors, or sweeteners to obtain a desired flavor system or sweetening composition. For instance, a rebaudioside D-enriched composition produced by a recombinant host can be combined with a rebaudioside A, C, or F-enriched composition produced by a different recombinant host, with rebaudioside A, F, or C purified from a Stevia extract, or with rebaudioside A, F, or C produced *in vitro*.

In some embodiments, rebaudioside A, rebaudioside D, rebaudioside B, steviol monoglucosides, steviol-1,2-bioside, rubusoside, stevioside, or rebaudioside E can be produced using *in vitro* methods while supplying the appropriate UDP-sugar and/or a cell-free system for regeneration of UDP-sugars. See, for example, Jewett MC, et al. *Molecular Systems Biology*, Vol. 4, article 220 (2008); Masada S et al. *FEBS Letters*, Vol. 581, 2562-2566 (2007). In some embodiments, sucrose and a sucrose synthase may be provided in the reaction vessel in order to regenerate UDP-glucose from the UDP generated during glycosylation reactions. See Figure 11. The sucrose synthase can be from any suitable organism. For example, a sucrose synthase coding sequence from *Arabidopsis thaliana*, *Stevia rebaudiana*, or *Coffea arabica* can be cloned into an expression plasmid under control of a suitable promoter, and expressed in a host such as a microorganism or a plant.

Conversions requiring multiple reactions may be carried out together, or stepwise. For example, rebaudioside D may be produced from rebaudioside A that is commercially available as an enriched extract or produced via biosynthesis, with the addition of stoichiometric or excess amounts of UDP-glucose and EUGT11. As an alternative, rebaudioside D may be produced from steviol glycoside extracts that are enriched for stevioside and rebaudioside A, using EUGT11 and a suitable UGT76G1 enzyme. In some embodiments, phosphatases are used to remove secondary products and improve the reaction yields. UGTs and other enzymes for *in vitro* reactions may be provided in soluble forms or in immobilized forms.

In some embodiments, rebaudioside A, rebaudioside D, or rebaudioside E can be produced using whole cells that are fed raw materials that contain precursor molecules such as steviol and/or steviol glycosides, including mixtures of steviol glycosides derived from plant extracts. The raw materials may be fed during cell growth or after cell growth. The whole cells may be in suspension or immobilized. The whole cells may be entrapped in beads, for example calcium or sodium alginate beads. The whole cells may be linked to a hollow fiber tube reactor system. The whole cells may be concentrated and entrapped within a membrane reactor system. The whole cells may be in fermentation broth or in a reaction buffer. In some embodiments, a permeabilizing agent is utilized for efficient

transfer of substrate into the cells. In some embodiments, the cells are permeabilized with a solvent such as toluene, or with a detergent such as Triton-X or Tween. In some embodiments, the cells are permeabilized with a surfactant, for example a cationic surfactant such as cetyltrimethylammonium bromide (CTAB). In some embodiments, the cells are permeabilized with periodic mechanical shock such as electroporation or a slight osmotic shock. The cells can contain one recombinant UGT or multiple recombinant UGTs. For example, the cells can contain UGT 76G1 and EUGT11 such that mixtures of stevioside and RebA are efficiently converted to RebD. In some embodiments, the whole cells are the host cells described in section III A. In some embodiments, the whole cells are a Gram-negative bacterium such as *E. coli*. In some embodiments, the whole cell is a Gram-positive bacterium such as *Bacillus*. In some embodiments, the whole cell is a fungal species such as *Aspergillus*, or a yeast such as *Saccharomyces*. In some embodiments, the term “whole cell biocatalysis” is used to refer to the process in which the whole cells are grown as described above (e.g., in a medium and optionally permeabilized) and a substrate such as rebA or stevioside is provided and converted to the end product using the enzymes from the cells. The cells may or may not be viable, and may or may not be growing during the bioconversion reactions. In contrast, in fermentation, the cells are cultured in a growth medium and fed a carbon and energy source such as glucose and the end product is produced with viable cells.

20

B. 3 Dulcoside A and Rebaudioside C Biosynthesis Polypeptides

The biosynthesis of rebaudioside C and/or dulcoside A involves glucosylation and rhamnosylation of the aglycone steviol. Specifically, dulcoside A can be formed by glucosylation of the 13-OH of steviol which forms steviol-13-*O*-glucoside, rhamnosylation of the C-2' of the 13-*O*-glucose of steviol-13-*O*-glucoside which forms the 1,2 rhamnobioside, and glucosylation of the C-19 carboxyl of the 1,2 rhamnobioside. Rebaudioside C can be formed by glucosylation of the C-3' of the C-13-*O*-glucose of dulcoside A. The order in which each glycosylation reaction occurs can vary. See FIG. 2B.

25

It has been discovered that conversion of steviol to dulcoside A in a recombinant host can be accomplished by the expression of gene(s) encoding the following functional UGTs: 85C2, EUGT11 and/or 91D2e, and 74G1. Thus, a recombinant microorganism expressing these three or four UGTs and a rhamnose synthetase can make dulcoside A when fed steviol in the medium. Alternatively, a recombinant microorganism expressing two UGTs, EUGT11 and 74G1, and rhamnose synthetase can make dulcoside A when fed the monoside, steviol-13-*O*-glucoside or steviol-19-*O*-glucoside, in the medium. Similarly, conversion of steviol to rebaudioside C in a recombinant microorganism can be accomplished by the expression of gene(s) encoding UGTs 85C2, EUGT11, 74G1, 76G1, optionally 91D2e, and rhamnose synthetase when fed steviol, by the expression of genes encoding UGTs EUGT11 and/or 91D2e, 74G1, and 76G1, and rhamnose synthetase when fed steviol-13-*O*-glucoside, by the expression of genes encoding UGTs 85C2, EUGT11 and/or 91D2e, 76G1, and rhamnose synthetase when fed steviol-19-*O*-glucoside, or by the expression of genes encoding UGTs EUGT11 and/or 91D2e, 76G1, and rhamnose synthetase when fed rubusoside. Typically, one or more of these genes are recombinant genes that have been transformed into a microorganism that does not naturally possess them.

Suitable EUGT11, UGT91D2, UGT74G1, UGT76G1 and UGT85C2 polypeptides include the functional UGT polypeptides discussed herein. Rhamnose synthetase provides increased amounts of the UDP-rhamnose donor for rhamnosylation of the steviol compound acceptor. Suitable rhamnose synthetases include those made by *Arabidopsis thaliana*, such as the product of the *A. thaliana* RHM2 gene.

In some embodiments, a UGT79B3 polypeptide is substituted for a UGT91D2 polypeptide. Suitable UGT79B3 polypeptides include those made by *Arabidopsis thaliana*, which are capable of rhamnosylation of steviol 13-*O*-monoside *in vitro*. *A. thaliana* UGT79B3 can rhamnosylate glucosylated compounds to form 1,2-rhamnosides. The amino acid sequence of an *Arabidopsis thaliana* UGT79B3 is set forth in SEQ ID NO:150. The nucleotide sequence encoding the amino acid sequence of SEQ ID NO:150 is set forth in SEQ ID NO:151.

In some embodiments rebaudioside C can be produced using *in vitro* methods while supplying the appropriate UDP-sugar and/or a cell-free system for regeneration of UDP-sugars. See, for example, “An integrated cell-free metabolic platform for protein production and synthetic biology” by Jewett MC, Calhoun KA, Voloshin A, Wu JJ and Swartz JR in Molecular Systems Biology, 4, article 220 (2008); Masada S et al. FEBS Letters, Vol. 581, 2562-2566 (2007). In some embodiments, sucrose and a sucrose synthase may be provided in the reaction vessel in order to regenerate UDP-glucose from UDP during the glycosylation reactions. See FIG. 11. The sucrose synthase can be from any suitable organism. For example, a sucrose synthase coding sequence from *Arabidopsis thaliana*, *Stevia rebaudiana*, or *Coffea arabica* can be cloned into an expression plasmid under control of a suitable promoter, and expressed in a host (e.g., a microorganism or a plant). In some embodiments a RHM2 enzyme (Rhamnose synthase) may also be provided, with NADPH, to generate UDP-rhamnose from UDP-glucose.

Reactions may be carried out together, or stepwise. For instance, rebaudioside C may be produced from rubusoside with the addition of stoichiometric amounts of UDP-rhamnose and EUGT11, followed by addition of UGT76G1 and an excess or stoichiometric supply of UDP-glucose. In some embodiments, phosphatases are used to remove secondary products and improve the reaction yields. UGTs and other enzymes for *in vitro* reactions may be provided in soluble forms or immobilized forms. In some embodiments, rebaudioside C, Dulcoside A, or other steviol rhamnosides can be produced using whole cells as discussed above. The cells can contain one recombinant UGT or multiple recombinant UGTs. For example, the cells can contain UGT 76G1 and EUGT11 such that mixtures of stevioside and RebA are efficiently converted to RebD. In some embodiments, the whole cells are the host cells described in section III A.

In other embodiments, the recombinant host expresses one or more genes involved in steviol biosynthesis, e.g., a CDPS gene, a KS gene, a KO gene and/or a KAH gene. Thus, for example, a microorganism containing a CDPS gene, a KS gene, a KO gene and a KAH gene, in addition to a UGT85C2, a UGT74G1, a EUGT11 gene, optionally a UGT91D2e gene, and a UGT76G1 gene, is capable of producing rebaudioside C without the necessity for including steviol in the culture media. In

addition, the recombinant host typically expresses an endogenous or a recombinant gene encoding a rhamnose synthetase. Such a gene is useful in order to provide increased amounts of the UDP-rhamnose donor for rhamnosylation of the steviol compound acceptor. Suitable rhamnose synthetases include those made by *Arabidopsis thaliana*,
5 such as the product of the *A. thaliana* RHM2 gene.

One with skill in the art will recognize that by modulating relative expression levels of different UGT genes as well as modulating the availability of UDP-rhamnose, a recombinant host can be tailored to specifically produce steviol and steviol glycoside products in a desired proportion. Transcriptional regulation of steviol biosynthesis genes,
10 and steviol glycoside biosynthesis genes can be achieved by a combination of transcriptional activation and repression using techniques known to those in the art. For *in vitro* reactions, one with skill in the art will recognize that addition of different levels of UGT enzymes in combination or under conditions which impact the relative activities of the different UGTs in combination will direct synthesis towards a desired proportion
15 of each steviol glycoside.

In some embodiments, the recombinant host further contains and expresses a recombinant GGPPS gene in order to provide increased levels of the diterpene precursor geranylgeranyl diphosphate, for increased flux through the rebaudioside A biosynthetic pathway. In some embodiments, the recombinant host further contains a construct to
20 silence or reduce the expression of non-steviol pathways consuming geranylgeranyl diphosphate, ent-Kaurenoic acid or farnesyl pyrophosphate, thereby providing increased flux through the steviol and steviol glycosides biosynthetic pathways. For example, flux to sterol production pathways such as ergosterol may be reduced by downregulation of the ERG9 gene. See, the ERG9 section below and Examples 24-25. In cells that produce
25 gibberellins, gibberellin synthesis may be downregulated to increase flux of ent-kaurenoic acid to steviol. In carotenoid-producing organisms, flux to steviol may be increased by downregulation of one or more carotenoid biosynthetic genes.

In some embodiments, the recombinant host further contains and expresses recombinant genes involved in diterpene biosynthesis or production of terpenoid

precursors, e.g., genes in the MEP or MEV pathway, have reduced phosphatase activity, and/or express a SUS as discussed herein.

In some embodiments, a recombinant host such as a microorganism produces steviol glycoside compositions that have greater than at least 15% rebaudioside C of the total steviol glycosides, e.g., at least 20% rebaudioside C, 30-40% rebaudioside C, 40-50% rebaudioside C, 50-60% rebaudioside C, 60-70% rebaudioside C, 70-80% rebaudioside C, 80-90% rebaudioside C. In some embodiments, a recombinant host such as a microorganism produces steviol glycoside compositions that have at least 90% rebaudioside C, e.g., 90-99% rebaudioside C. Other steviol glycosides present may include those depicted in Figures 2 A and B such as steviol monosides, steviol glucobiosides, steviol rhamnobiosides, rebaudioside A, and Dulcoside A. In some embodiments, the rebaudioside C-enriched composition produced by the host can be further purified and the rebaudioside C or Dulcoside A so purified may then be mixed with other steviol glycosides, flavors, or sweeteners to obtain a desired flavor system or sweetening composition. For instance, a rebaudioside C-enriched composition produced by a recombinant microorganism can be combined with a rebaudioside A, F, or D-enriched composition produced by a different recombinant microorganism, with rebaudioside A, F, or D purified from a Stevia extract, or with rebaudioside A, F, or D produced *in vitro*.

20

B. 4 Rebaudioside F Biosynthesis Polypeptides

The biosynthesis of rebaudioside F involves glucosylation and xylosylation of the aglycone steviol. Specifically, rebaudioside F can be formed by glucosylation of the 13-OH of steviol which forms steviol-13-O-glucoside, xylosylation of the C-2' of the 13-O-glucose of steviol-13-O-glucoside which forms steviol-1,2-xylobioside, glucosylation of the C-19 carboxyl of the 1,2-xylobioside to form 1,2-stevioxyloside, and glucosylation of the C-3' of the C-13-O-glucose of 1,2-stevioxyloside to form rebaudioside F. The order in which each glycosylation reaction occurs can vary. See FIG. 2D.

It has been discovered that conversion of steviol to rebaudioside F in a recombinant host can be accomplished by the expression of genes encoding the following

30

functional UGTs: 85C2, EUGT11 and/or 91D2e, 74G1, and 76G1, along with endogenous or recombinantly expressed UDP-glucose dehydrogenase and UDP-glucuronic acid decarboxylase. Thus, a recombinant microorganism expressing these four or five UGTs along with endogenous or recombinant UDP-glucose dehydrogenase and UDP-glucuronic acid decarboxylase can make rebaudioside F when fed steviol in the medium. Alternatively, a recombinant microorganism expressing two functional UGTs, EUGT11 or 91D2e, and 76G1, can make rebaudioside F when fed rubusoside in the medium. As another alternative, a recombinant microorganism expressing a functional UGT 76G1 can make rebaudioside F when fed 1,2 steviorhamnoside. As another alternative, a recombinant microorganism expressing 74G1, EUGT11 and/or 91D2e, 76G1, and can make rebaudioside F when fed the monoside, steviol-13-*O*-glucoside, in the medium. Similarly, conversion of steviol-19-*O*-glucoside to rebaudioside F in a recombinant microorganism can be accomplished by the expression of genes encoding UGTs 85C2, EUGT11 and/or 91D2e, and 76G1, when fed steviol-19-*O*-glucoside. Typically, one or more of these genes are recombinant genes that have been transformed into a host that does not naturally possess them.

Suitable EUGT11, UGT91D2, UGT74G1, UGT76G1 and UGT85C2 polypeptides include the functional UGT polypeptides discussed herein. In some embodiments, a UGT79B3 polypeptide is substituted for a UGT91, as discussed above. UDP-glucose dehydrogenase and UDP-glucuronic acid decarboxylase provide increased amounts of the UDP-xylose donor for xylosylation of the steviol compound acceptor. Suitable UDP-glucose dehydrogenases and UDP-glucuronic acid decarboxylases include those made by *Arabidopsis thaliana* or *Cryptococcus neoformans*. For example, suitable UDP-glucose dehydrogenase and UDP-glucuronic acid decarboxylases polypeptides can be encoded by the *A. thaliana* UGD1 gene and UXS3 gene, respectively. See, Oka and Jigami, FEBS J. 273:2645-2657 (2006).

In some embodiments rebaudioside F can be produced using *in vitro* methods while supplying the appropriate UDP-sugar and/or a cell-free system for regeneration of UDP-sugars. See, for example, Jewett MC, et al. Molecular Systems Biology, Vol. 4, article 220 (2008); Masada S et al. FEBS Letters, Vol. 581, 2562-2566 (2007). In some

embodiments, sucrose and a sucrose synthase are provided in the reaction vessel in order to regenerate UDP-glucose from UDP during the glycosylation reactions. See FIG. 11.

The sucrose synthase can be from any suitable organism. For example, a sucrose synthase coding sequence from *Arabidopsis thaliana*, *Stevia rebaudiana*, or *Coffea arabica* can be cloned into an expression plasmid under control of a suitable promoter, and expressed in a host, e.g., a microorganism or a plant. In some embodiments, UDP-xylose can be produced from UDP-glucose by supplying suitable enzymes, for example, the *Arabidopsis thaliana* UGD1 (UDP-glucose dehydrogenase) and UXS3 (UDP-glucuronic acid decarboxylase) enzymes along with NAD⁺ cofactor.

Reactions may be carried out together, or stepwise. For instance, rebaudioside F may be produced from rubusoside with the addition of stoichiometric amounts of UDP-xylose and EUGT11, followed by addition of UGT76G1 and an excess or stoichiometric supply of UDP-glucose. In some embodiments, phosphatases are used to remove secondary products and improve the reaction yields. UGTs and other enzymes for *in vitro* reactions may be provided in soluble forms or immobilized forms. In some embodiments, rebaudioside F or other steviol xylosides can be produced using whole cells as discussed above. For example, the cells may contain UGT 76G1 and EUGT11 such that mixtures of stevioside and RebA are efficiently converted to RebD. In some embodiments, the whole cells are the host cells described in section III A.

In other embodiments, the recombinant host expresses one or more genes involved in steviol biosynthesis, e.g., a CDPS gene, a KS gene, a KO gene and/or a KAH gene. Thus, for example, a microorganism containing a CDPS gene, a KS gene, a KO gene and a KAH gene, in addition to a EUGT11, UGT85C2, a UGT74G1, an optional UGT91D2 gene, and a UGT76G1 gene, is capable of producing rebaudioside F without the necessity for including steviol in the culture media. In addition, the recombinant host typically expresses an endogenous or a recombinant gene encoding a UDP-glucose dehydrogenase and a UDP-glucuronic acid decarboxylase. Such genes are useful in order to provide increased amounts of the UDP-xylose donor for xylosylation of the steviol compound acceptor. Suitable UDP-glucose dehydrogenases and UDP-glucuronic acid decarboxylases include those made by *Arabidopsis thaliana* or *Cryptococcus*

neoformans. For example, suitable UDP-glucose dehydrogenase and UDP-glucuronic acid decarboxylases polypeptides can be encoded by the *A. thaliana* UGD1 gene and UXS3 gene, respectively. See, Oka and Jigami, FEBS J. 273:2645-2657 (2006).

One with skill in the art will recognize that by modulating relative expression
5 levels of different UGT genes as well as modulating the availability of UDP-xylose, a recombinant microorganism can be tailored to specifically produce steviol and steviol glycoside products in a desired proportion. Transcriptional regulation of steviol biosynthesis genes can be achieved by a combination of transcriptional activation and repression using techniques known to those in the art. For *in vitro* reactions, one with
10 skill in the art will recognize that addition of different levels of UGT enzymes in combination or under conditions which impact the relative activities of the different UGTs in combination will direct synthesis towards a desired proportion of each steviol glycosides.

In some embodiments, the recombinant host further contains and expresses a
15 recombinant GGPPS gene in order to provide increased levels of the diterpene precursor geranylgeranyl diphosphate, for increased flux through the steviol biosynthetic pathway. In some embodiments, the recombinant host further contains a construct to silence the expression of non-steviol pathways consuming geranylgeranyl diphosphate, ent-Kaurenoic acid or farnesyl pyrophosphate, thereby providing increased flux through the
20 steviol and steviol glycosides biosynthetic pathways. For example, flux to sterol production pathways such as ergosterol may be reduced by downregulation of the ERG9 gene. See, the ERG9 section below and Examples 24-25. In cells that produce gibberellins, gibberellin synthesis may be downregulated to increase flux of ent-kaurenoic acid to steviol. In carotenoid-producing organisms, flux to steviol may be
25 increased by downregulation of one or more carotenoid biosynthetic genes. In some embodiments, the recombinant host further contains and expresses recombinant genes involved in diterpene biosynthesis, e.g., genes in the MEP pathway discussed below.

In some embodiments, a recombinant host such as a microorganism produces rebaudioside F-enriched steviol glycoside compositions that have greater than at least
30 4% rebaudioside F by weight total steviol glycosides, e.g., at least 5% rebaudioside F, at

least 6% of rebaudioside F, 10-20% rebaudioside F, 20-30% rebaudioside F, 30-40% rebaudioside F, 40-50% rebaudioside F, 50-60% rebaudioside F, 60-70% rebaudioside F, 70-80% rebaudioside F. In some embodiments, a recombinant host such as a microorganism produces steviol glycoside compositions that have at least 90% rebaudioside F, e.g., 90-99% rebaudioside F. Other steviol glycosides present may include those depicted in FIGs 2A and D such as steviol monosides, steviol glucobiosides, steviol xylobiosides, rebaudioside A, stevioxyloside, rubusoside and stevioside. In some embodiments, the rebaudioside F-enriched composition produced by the host can be mixed with other steviol glycosides, flavors, or sweeteners to obtain a desired flavor system or sweetening composition. For instance, a rebaudioside F-enriched composition produced by a recombinant microorganism can be combined with a rebaudioside A, C, or D-enriched composition produced by a different recombinant microorganism, with rebaudioside A, C, or D purified from a Stevia extract, or with rebaudioside A, C, or D produced *in vitro*.

15 C. Other Polypeptides

Genes for additional polypeptides whose expression facilitates more efficient or larger scale production of steviol or a steviol glycoside can also be introduced into a recombinant host. For example, a recombinant microorganism, plant, or plant cell can also contain one or more genes encoding a geranylgeranyl diphosphate synthase (GGPPS, also referred to as GGDPS). As another example, the recombinant host can contain one or more genes encoding a rhamnose synthetase, or one or more genes encoding a UDP-glucose dehydrogenase and/or a UDP-glucuronic acid decarboxylase. As another example, a recombinant host can also contain one or more genes encoding a cytochrome P450 reductase (CPR). Expression of a recombinant CPR facilitates the cycling of NADP⁺ to regenerate NADPH, which is utilized as a cofactor for terpenoid biosynthesis. Other methods can be used to regenerate NADHP levels as well. In circumstances where NADPH becomes limiting; strains can be further modified to include exogenous transhydrogenase genes. See, e.g., Sauer et al., J. Biol. Chem. 279: 6613–6619 (2004).

Other methods are known to those with skill in the art to reduce or otherwise modify the ratio of NADH/NADPH such that the desired cofactor level is increased.

As another example, the recombinant host can contain one or more genes encoding one or more enzymes in the MEP pathway or the mevalonate pathway. Such genes are useful because they can increase the flux of carbon into the diterpene biosynthesis pathway, producing geranylgeranyl diphosphate from isopentenyl diphosphate and dimethylallyl diphosphate generated by the pathway. The geranylgeranyl diphosphate so produced can be directed towards steviol and steviol glycoside biosynthesis due to expression of steviol biosynthesis polypeptides and steviol glycoside biosynthesis polypeptides.

As another example the recombinant host can contain one or more genes encoding a sucrose synthase, and additionally can contain sucrose uptake genes if desired. The sucrose synthase reaction can be used to increase the UDP-glucose pool in a fermentation host, or in a whole cell bioconversion process. This regenerates UDP-glucose from UDP produced during glycosylation and sucrose, allowing for efficient glycosylation. In some organisms, disruption of the endogenous invertase is advantageous to prevent degradation of sucrose. For example, the *S. cerevisiae* SUC2 invertase may be disrupted. The sucrose synthase (SUS) can be from any suitable organism. For example, a sucrose synthase coding sequence from, without limitation, *Arabidopsis thaliana*, *Stevia rebaudiana*, or *Coffea arabica* can be cloned into an expression plasmid under control of a suitable promoter, and expressed in a host (e.g., a microorganism or a plant). The sucrose synthase can be expressed in such a strain in combination with a sucrose transporter (e.g., the *A. thaliana* SUC1 transporter or a functional homolog thereof) and one or more UGTs (e.g., one or more of UGT85C2, UGT74G1, UGT76G1, and UGT91D2e, EUGT11 or functional homologs thereof). Culturing the host in a medium that contains sucrose can promote production of UDP-glucose, as well as one or more glucosides (e.g., steviol glycosides).

In addition, a recombinant host can have reduced phosphatase activity as discussed herein.

C. 1 MEP Biosynthesis Polypeptides

In some embodiments, a recombinant host contains one or more genes encoding enzymes involved in the methylerythritol 4-phosphate (MEP) pathway for isoprenoid biosynthesis. Enzymes in the MEP pathway include deoxyxylulose 5-phosphate synthase (DXS), D-1-deoxyxylulose 5-phosphate reductoisomerase (DXR), 4-diphosphocytidyl-2-C-methyl-D-erythritol synthase (CMS), 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (CMK), 4-diphosphocytidyl-2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (MCS), 1-hydroxy-2-methyl-2(E)-butenyl 4-diphosphate synthase (HDS) and 1-hydroxy-2-methyl-2(E)-butenyl 4-diphosphate reductase (HDR). One or more DXS genes, DXR genes, CMS genes, CMK genes, MCS genes, HDS genes and/or HDR genes can be incorporated into a recombinant microorganism. See, Rodríguez-Concepción and Boronat, Plant Phys. 130: 1079-1089 (2002).

Suitable genes encoding DXS, DXR, CMS, CMK, MCS, HDS and/or HDR polypeptides include those made by *E. coli*, *Arabidopsis thaliana* and *Synechococcus leopoliensis*. Nucleotide sequences encoding DXR polypeptides are described, for example, in U.S. Patent No. 7,335,815.

C. 2 Mevalonate Biosynthesis Polypeptides

In some embodiments, a recombinant host contains one or more genes encoding enzymes involved in the mevalonate pathway for isoprenoid biosynthesis. Genes suitable for transformation into a host encode enzymes in the mevalonate pathway such as a truncated 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase (tHMG), and/or a gene encoding a mevalonate kinase (MK), and/or a gene encoding a phosphomevalonate kinase (PMK), and/or a gene encoding a mevalonate pyrophosphate decarboxylase (MPPD). Thus, one or more HMG-CoA reductase genes, MK genes, PMK genes, and/or MPPD genes can be incorporated into a recombinant host such as a microorganism.

Suitable genes encoding mevalonate pathway polypeptides are known. For example, suitable polypeptides include those made by *E. coli*, *Paracoccus denitrificans*, *Saccharomyces cerevisiae*, *Arabidopsis thaliana*, *Kitasatospora griseola*, *Homo sapiens*, *Drosophila melanogaster*, *Gallus gallus*, *Streptomyces* sp. KO-3988, *Nicotiana attenuata*,

Kitasatospora griseola, *Hevea brasiliensis*, *Enterococcus faecium* and *Haematococcus pluvialis*. See, e.g., Table 8 and U.S. Patent Nos. 7,183,089, 5,460,949, and 5,306,862.

Table 8. Sources of HMG CoA Reductases and other Mevalonate Genes

Accession#	Organism	Enzyme	Size (nt)	Gene name	SEQ ID (codon optimized)	SEQ ID (protein)
XM_001467423	<i>Leishmania infantum</i>	Acetyl-CoA C-acetyltransferase	1323	MEV-4	103	104
YML075C	<i>Saccharomyces cerevisiae</i>	Truncated HMG (tHMG1)	1584	tHMG1	105	106
EU263989	<i>Ganoderma lucidum</i>	3-HMG-CoA reductase	3681	MEV-11	107	108
BC153262	<i>Bos taurus</i>	3-HMG-CoA reductase	2667	MEV-12	109	110
AAD47596	<i>Artemisia annua</i>	3-HMG-CoA reductase	1704	MEV-13	111	112
AAB62280	<i>Trypanosoma cruzi</i>	3-HMG-CoA reductase	1308	MEV-14	113	114
CAG41604	<i>Staph aureus</i>	3-HMG-CoA reductase	1281	MEV-15	115	116
DNA2.0 sequence	<i>Archaeoglobus fulgidus</i>	3-HMG-CoA reductase	1311	HMG reductase	117	118
DNA2.0 sequence	<i>Pseudomonas mevalonii</i>	3-HMG-CoA reductase	1287	HMG reductase	119	120

5 C.3 Sucrose Synthase Polypeptides

Sucrose synthase (SUS) can be used as a tool for generating UDP-sugar. SUS (EC 2.4.1.13) catalyzes the formation of UDP-glucose and fructose from sucrose and UDP (FIG. 11). UDP generated by the reaction of UGTs thus can be converted into UDP-glucose in the presence of sucrose. See, e.g., Chen et al. (2001) *J. Am. Chem. Soc.* 123:8866-8867; Shao et al. (2003) *Appl. Env. Microbiol.* 69:5238-5242; Masada et al. 10 (2007) *FEBS Lett.* 581:2562-2566; and Son et al. (2009) *J. Microbiol. Biotechnol.* 19:709-712.

Sucrose synthases can be used to generate UDP-glucose and remove UDP, facilitating efficient glycosylation of compounds in various systems. For example, yeast 15 deficient in the ability to utilize sucrose can be made to grow on sucrose by introducing a

sucrose transporter and a SUS. For example, *Saccharomyces cerevisiae* does not have an efficient sucrose uptake system, and relies on extracellular SUC2 to utilize sucrose. The combination of disrupting the endogenous *S. cerevisiae* SUC2 invertase and expressing recombinant SUS resulted in a yeast strain that was able to metabolize intracellular but
5 not extracellular sucrose (Riesmeier et al. ((1992) *EMBO J.* 11:4705-4713). The strain was used to isolate sucrose transporters by transformation with a cDNA expression library and selection of transformants that had gained the ability to take up sucrose.

As described herein, the combined expression of recombinant sucrose synthase and a sucrose transporter *in vivo* can lead to increased UDP-glucose availability and
10 removal of unwanted UDP. For example, functional expression of a recombinant sucrose synthase, a sucrose transporter, and a glycosyltransferase, in combination with knockout of the natural sucrose degradation system (SUC2 in the case of *S. cerevisiae*) can be used to generate a cell that is capable of producing increased amounts of glycosylated compounds such as steviol glycosides. This higher glycosylation capability is due to at
15 least (a) a higher capacity for producing UDP-glucose in a more energy efficient manner, and (b) removal of UDP from growth medium, as UDP can inhibit glycosylation reactions.

The sucrose synthase can be from any suitable organism. For example, a sucrose synthase coding sequence from, without limitation, *Arabidopsis thaliana*, *Stevia*
20 *rebaudiana*, or *Coffea arabica* (see, e.g., FIGs. 19A-19C, SEQ ID NOs:178, 179, and 180) can be cloned into an expression plasmid under control of a suitable promoter, and expressed in a host (e.g., a microorganism or a plant). As described in the Examples herein, a SUS coding sequence may be expressed in a *SUC2* (sucrose hydrolyzing enzyme) deficient *S. cerevisiae* strain, so as to avoid degradation of extracellular sucrose
25 by the yeast. The sucrose synthase can be expressed in such a strain in combination with a sucrose transporter (e.g., the *A. thaliana* SUC1 transporter or a functional homolog thereof) and one or more UGTs (e.g., one or more of UGT85C2, UGT74G1, UGT76G1, EUGT11, and UGT91D2e, or functional homologs thereof). Culturing the host in a medium that contains sucrose can promote production of UDP-glucose, as well as one or
30 more glucosides (e.g., steviol glucoside). It is to be noted that in some cases, a sucrose

synthase and a sucrose transporter can be expressed along with a UGT in a host cell that also is recombinant for production of a particular compound (e.g., steviol).

C. 4 Modulation of ERG9 activity

5 It is an object of the disclosure to produce terpenoids based on the concept of increasing the accumulation of terpenoid precursors of the squalene pathway. Non-limiting examples of terpenoids include Hemiterpenoids, 1 isoprene unit (5 carbons); Monoterpenoids, 2 isoprene units (10C); Sesquiterpenoids, 3 isoprene units (15C); Diterpenoids, 4 isoprene units (20C) (e.g. ginkgolides); Triterpenoids, 6 isoprene units
10 (30C); Tetraterpenoids, 8 isoprene units (40C) (e.g. carotenoids); and polyterpenoid with a larger number of isoprene units.

Hemiterpenoids include isoprene, prenol and isovaleric acid. Monoterpenoids include Geranyl pyrophosphate, Eucalyptol, Limonene and Pinene. Sesquiterpenoids include Farnesyl pyrophosphate, Artemisinin and Bisabolol. Diterpenoids include
15 Geranylgeranyl pyrophosphate, steviol, Retinol, Retinal, Phytol, Taxol, Forskolin and Aphidicolin. Triterpenoids include Squalene and Lanosterol. Tetraterpenoids include Lycopene and Carotene.

Terpenes are hydrocarbons resulting from the combination of several isoprene units. Terpenoids can be thought of as terpene derivatives. The term terpene is sometimes
20 used broadly to include the terpenoids. Just like terpenes, the terpenoids can be classified according to the number of isoprene units used. The present invention is focussed on terpenoids and in particular terpenoids derived through the squalene pathway from the precursors Farnesyl-pyrophosphate (FPP), Isopentenyl-pyrophosphate (IPP), Dimethylallyl-pyrophosphate (DMAPP), Geranyl-pyrophosphate (GPP) and/or
25 Geranylgeranyl-pyrophosphate (GGPP).

By terpenoids is understood terpenoids of the Hemiterpenoid class such as but not limited to isoprene, prenol and isovaleric acid; terpenoids of the Monoterpenoid class such as but not limited to geranyl pyrophosphate, eucalyptol, limonene and pinene; terpenoids of the Sesquiterpenoids class such as but not limited to farnesyl pyro-
30 phosphate, artemisinin and bisabolol; terpenoids of the diterpenoid class such as but not

limited to geranylgeranyl pyrophosphate, steviol, retinol, retinal, phytol, taxol, forskolin and aphidicolin; terpenoids of the Triterpenoid class such as but not limited to lanosterol; terpenoids of the Tetraterpenoid class such as but not limited to lycopene and carotene.

In one embodiment the invention relates to production of terpenoids, which are biosynthesized from Geranylgeranyl-pyrophosphate (GGPP). In particular such terpenoids may be steviol.


In one embodiment the invention relates to production of terpenoids, which are biosynthesized from Geranylgeranyl-pyrophosphate (GGPP). In particular such terpenoids may be steviol.

10 **The cell**

The present invention relates to a cell, such as any of the hosts described in section III, modified to comprise the construct depicted in FIG. 22. Accordingly, in a main aspect, the present invention relates to a cell comprising a nucleic acid, said nucleic acid comprising

- 15 i) a promoter sequence operably linked to
- ii) a heterologous insert sequence operably linked to
- iii) an open reading frame operably linked to
- iv) a transcription termination signal,

20 wherein the heterologous insert sequence has the general formula (I):



wherein X_2 comprises at least 4 consecutive nucleotides being complementary to, and forms a hairpin secondary structure element with at least 4 consecutive nucleotides of X_4 , and

25 wherein X_3 is optional and if present comprises nucleotides involved in forming a hairpin loop between X_2 and X_4 , and

wherein X_1 and X_5 individually and optionally comprise one or more nucleotides, and

30 wherein the open reading frame upon expression encodes a squalene synthase (EC 2.5.1.21), e.g., a polypeptide sequence having at least 70% identity to a squalene synthase

(EC 2.5.1.21) or a biologically active fragment thereof, said fragment having at least 70% sequence identity to said squalene synthase in a range of overlap of at least 100 amino acids.

In addition to above mentioned nucleic acid comprising a heterologous insert sequence, the cell may also comprise one or more additional heterologous nucleic acid sequences (e.g., nucleic acids encoding any of the steviol and steviol glycoside biosynthesis polypeptides of section I). In one preferred embodiment the cell comprises a heterologous nucleic acid encoding GGPPS operably linked to a nucleic acid sequence directing expression of GGPPS in said cell.

Heterologous insert sequence

The heterologous insert sequence can adapt the secondary structure element of a hairpin with a hairpin loop. The hairpin part comprises sections X_2 and X_4 which are complementary and hybridize to one another. Sections X_2 and X_4 flank section X_3 , which comprises nucleotides that form a loop – the hairpin loop. The term complementary is understood by the person skilled in the art as meaning two sequences compared to each other, nucleotide by nucleotide counting from the 5' end to the 3' end, or vice versa.

The heterologous insert sequence is long enough to allow a hairpin to be completed, but short enough to allow limited translation of an ORF that is present in-frame and immediately 3' to the heterologous insert sequence. Thus, in one embodiment, the heterologous insert sequence comprises 10-50 nucleotides, preferably 10-30 nucleotides, more preferably 15-25 nucleotides, more preferably 17-22 nucleotides, more preferably 18-21 nucleotides, more preferably 18-20 nucleotides, more preferably 19 nucleotides.

X_2 and X_4 may individually consist of any suitable number of nucleotides, so long as a consecutive sequence of at least 4 nucleotides of X_2 is complementary to a consecutive sequence of at least 4 nucleotides of X_4 . In a preferred embodiment X_2 and X_4 consist of the same number of nucleotides.

X_2 may for example consist of in the range of 4 to 25, such as in the range of 4 to 20, for example of in the range of 4 to 15, such as in the range of 6 to 12, for example in

the range of 8 to 12, such as in the range of 9 to 11 nucleotides.

X₄ may for example consist of in the range of 4 to 25, such as in the range of 4 to 20, for example of in the range of 4 to 15, such as in the range of 6 to 12, for example in the range of 8 to 12, such as in the range of 9 to 11 nucleotides.

5 In one preferred embodiment, X₂ consists of a nucleotide sequence, which is complementary to the nucleotide sequence of X₄, i.e. it is preferred that all nucleotides of X₂ are complementary to the nucleotide sequence of X₄.

In one preferred embodiment X₄ consists of a nucleotide sequence, which is complementary to the nucleotide sequence of X₂, i.e. it is preferred that all nucleotides of
10 X₄ are complementary to the nucleotide sequence of X₂. Very preferably, X₂ and X₄ consists of the same number of nucleotides, wherein X₂ is complementary to X₄ over the entire length of X₂ and X₄.

X₃ may be absent, i.e., X₃ may consist of zero nucleotides. It is also possible that X₃ consists of in the range of 1 to 5, such as in the range of 1 to 3 nucleotides.

15 X₁ may be absent, i.e., X₁ may consist of zero nucleotides. It is also possible that X₁ consists of in the range of 1 to 25, such as in the range of 1 to 20, for example in the range of 1 to 15, such as in the range of 1 to 10, for example in the range of 1 to 5, such as in the range of 1 to 3 nucleotides.

X₅ may be absent, i.e., X₅ may consist of zero nucleotides. It is also possible that
20 X₅ may consist of in the range 1 to 5, such as in the range of 1 to 3 nucleotides.

The sequence may be any suitable sequence fulfilling the requirements defined herein above. Thus, the heterologous insert sequence may comprise a sequence selected from the group consisting of SEQ ID NO: 181, SEQ ID NO:182, SEQ ID NO:183, and SEQ ID NO:184. In a preferred embodiment the insert sequence is selected from the
25 group consisting of SEQ ID NO: 181, SEQ ID NO:182, SEQ ID NO:183, and SEQ ID NO:184.

Squalene synthase

Squalene synthase (SQS) is the first committed enzyme of the biosynthesis pathway that leads to the production of sterols. It catalyzes the synthesis of squalene from
30 farnesyl pyrophosphate via the intermediate presqualene pyrophosphate. This enzyme is a

critical branch point enzyme in the biosynthesis of terpenoids/isoprenoids and is thought to regulate the flux of isoprene intermediates through the sterol pathway. The enzyme is sometimes referred to as farnesyl-diphosphate farnesyltransferase (FDFT1).

5 The mechanism of SQS is to convert two units of farnesyl pyrophosphate into squalene.

SQS is considered to be an enzyme of eukaryotes or advanced organisms, although at least one prokaryote has been shown to possess a functionally similar enzyme.

10 In terms of structure and mechanics, squalene synthase most closely resembles phytoene syntase, which serves a similar role in many plants in the elaboration of phytoene, a precursor of many carotenoid compounds.

A high level of sequence identity indicates likelihood that the first sequence is derived from the second sequence. Amino acid sequence identity requires identical amino acid sequences between two aligned sequences. Thus, a candidate sequence sharing 70% amino acid identity with a reference sequence requires that, following alignment, 70% of the amino acids in the candidate sequence are identical to the corresponding amino acids in the reference sequence. Identity may be determined by aid of computer analysis, such as, without limitations, the ClustalW computer alignment program as described in section D. Using this program with its default settings, the mature (bioactive) part of a query and a reference polypeptide are aligned. The number of fully conserved residues are counted and divided by the length of the reference polypeptide. The ClustalW algorithm may similarly be used to align nucleotide sequences. Sequence identities may be calculated in a similar way as indicated for amino acid sequences.

25 In one important embodiment, the cell of the present invention comprises a nucleic acid sequence coding, as defined herein, upon expression for a squalene synthase wherein the squalene synthase is at least 75%, such as at least 76%, such as at least 77%, such as at least 78%, such as at least 79%, such as at least 80%, such as at least 81%, such as at least 82%, such as at least 83%, such as at least 84%, such as at least 85%, such as at least 86%, such as at least 87%, such as at least 88%, such as at least 89%,
30 such as at least 90%, such as at least 91%, such as at least 92%, such as at least 93%,

such as at least 94%, such as at least 95%, such as at least 96%, such as at least 97%,
such as at least 98%, such as at least 99%, such as at least 99.5%, such as at least 99.6%,
such as at least 99.7%, such as at least 99.8%, such as at least 99.9%, such as 100%
identical to a squalene synthase wherein the squalene synthase is selected from the group
consisting of SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ
ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ
ID NO:201, and SEQ ID NO:202.

Promoter

A promoter is a region of DNA that facilitates the transcription of a particular
gene. Promoters are located near the genes they regulate, on the same strand and typically
upstream (towards the 5' region of the sense strand). In order for the transcription to take
place, the enzyme that synthesizes RNA, known as RNA polymerase, must attach to the
DNA near a gene. Promoters contain specific DNA sequences and response elements
which provide a secure initial binding site for RNA polymerase and for proteins called
transcription factors that recruit RNA polymerase. These transcription factors have
specific activator or repressor sequences of corresponding nucleotides that attach to
specific promoters and regulate gene expressions.

In bacteria, the promoter is recognized by RNA polymerase and an associated
sigma factor, which in turn are often brought to the promoter DNA by an activator
protein binding to its own DNA binding site nearby. In eukaryotes the process is more
complicated, and at least seven different factors are necessary for the binding of an RNA
polymerase II to the promoter. Promoters represent critical elements that can work in
concert with other regulatory regions (enhancers, silencers, boundary elements/insulators)
to direct the level of transcription of a given gene.

As promoters are normally immediately adjacent to the open reading frame (ORF)
in question, positions in the promoter are designated relative to the transcriptional start
site, where transcription of RNA begins for a particular gene (i.e., positions upstream are
negative numbers counting back from -1, for example -100 is a position 100 base pairs
upstream).

Promoter elements

- Core promoter - the minimal portion of the promoter required to properly initiate transcription
 - o Transcription Start Site (TSS)
 - o Approximately -35 bp upstream and/or downstream of the start site
 - 5 o A binding site for RNA polymerase
 - RNA polymerase I: transcribes genes encoding ribosomal RNA
 - RNA polymerase II: transcribes genes encoding messenger RNA and certain small nuclear RNAs
 - RNA polymerase III: transcribes genes encoding tRNAs and other
 10 small RNAs
 - o General transcription factor binding sites
 - Proximal promoter - the proximal sequence upstream of the gene that tends to contain primary regulatory elements
 - o Approximately -250 bp upstream of the start site
 - 15 o Specific transcription factor binding sites
 - Distal promoter - the distal sequence upstream of the gene that may contain additional regulatory elements, often with a weaker influence than the proximal promoter
 - o Anything further upstream (but not an enhancer or other regulatory region
 20 whose influence is positional/orientation independent)
 - o Specific transcription factor binding sites

Prokaryotic promoters

In prokaryotes, the promoter consists of two short sequences at -10 and -35 positions upstream from the transcription start site. Sigma factors not only help in enhancing RNAP binding to the promoter but also help RNAP target specific genes to transcribe.

The sequence at -10 is called the Pribnow box, or the -10 element, and usually consists of the six nucleotides TATAAT. The Pribnow box is essential to start transcription in prokaryotes.

30 The other sequence at -35 (the -35 element) usually consists of the seven

nucleotides TTGACAT. Its presence allows a very high transcription rate.

Both of the above consensus sequences, while conserved on average, are not found intact in most promoters. On average only 3 of the 6 base pairs in each consensus sequence is found in any given promoter. No promoter has been identified to date that has
5 intact consensus sequences at both the -10 and -35; artificial promoters with complete conservation of the -10/-35 hexamers has been found to promote RNA chain initiation at very high efficiencies.

Some promoters contain a UP element (consensus sequence 5'-
AAAWWTWTTTNNNAAANN-3'; W = A or T; N = any base) centered at -50; the
10 presence of the -35 element appears to be unimportant for transcription from the UP element-containing promoters.

Eukaryotic promoters

Eukaryotic promoters are typically located upstream of the gene (ORF) and can have regulatory elements several kilobases (kb) away from the transcriptional start site.
15 In eukaryotes, the transcriptional complex can cause the DNA to fold back on itself, which allows for placement of regulatory sequences far from the actual site of transcription. Many eukaryotic promoters, contain a TATA box (sequence TATAAA), which in turn binds a TATA binding protein which assists in the formation of the RNA polymerase transcriptional complex. The TATA box typically lies very close to the
20 transcriptional start site (often within 50 bases).

The cell of the present invention comprises a nucleic acid sequence which comprises a promoter sequence. The promoter sequence is not limiting for the invention and can be any promoter suitable for the host cell of choice.

In one embodiment of the present invention the promoter is a constitutive or
25 inducible promoter.

In a further embodiment of the invention, the promoter is selected from the group consisting of an endogenous promoter, PGK-1, GPD1, PGK1, ADH1, ADH2, PYK1, TPI1, PDC1, TEF1, TEF2, FBA1, GAL1-10, CUP1, MET2, MET14, MET25, CYC1, GAL1-S, GAL1-L, TEF1, ADH1, CAG, CMV, human UbiC, RSV, EF-1alpha, SV40,
30 Mt1, Tet-On, Tet-Off, Mo-MLV-LTR, Mx1, progesterone, RU486 and Rapamycin-

inducible promoter.

Post-transcriptional regulation

Post-transcriptional regulation is the control of gene expression at the RNA level, therefore between the transcription and the translation of the gene.

5 The first instance of regulation is at transcription (transcriptional regulation) where due to the chromatin arrangement and due to the activity of transcription factors, genes are differentially transcribed.

After being produced, the stability and distribution of the different transcripts is regulated (post-transcriptional regulation) by means of RNA binding protein (RBP) that control the various steps and rates of the transcripts: events such as alternative splicing, nuclear degradation (exosome), processing, nuclear export (three alternative pathways), sequestration in DCP2-bodies for storage or degradation, and ultimately translation. These proteins achieve these events thanks to a RNA recognition motif (RRM) that binds a specific sequence or secondary structure of the transcripts, typically at the 5' and 3' UTR of the transcript.

15 Modulating the capping, splicing, addition of a Poly(A) tail, the sequence-specific nuclear export rates and in several contexts sequestration of the RNA transcript occurs in eukaryotes but not in prokaryotes. This modulation is a result of a protein or transcript which in turn is regulated and may have an affinity for certain sequences.

20 *Capping*

Capping changes the five prime end of the mRNA to a three prime end by 5'-5' linkage, which protects the mRNA from 5' exonuclease, which degrades foreign RNA. The cap also helps in ribosomal binding.

Splicing

25 Splicing removes the introns, noncoding regions that are transcribed into RNA, in order to make the mRNA able to create proteins. Cells do this by spliceosomes binding on either side of an intron, looping the intron into a circle and then cleaving it off. The two ends of the exons are then joined together.

Polyadenylation

30 Polyadenylation is the addition of a poly(A) tail to the 3' end, i.e. the poly(A) tail

consists of multiple adenosine monophosphates. The poly-A sequence acts as a buffer to the 3' exonuclease and thus increases half-life of mRNA. In addition, a long poly(A) tail can increase translation. Thus the poly-A tail may be used to further modulate translation of the construct of the present invention, in order to arrive at the optimal translation rate.

5 In eukaryotes, polyadenylation is part of the process that produces mature messenger RNA (mRNA) for translation.

The poly(A) tail is also important for the nuclear export, translation, and stability of mRNA.

10 In one embodiment the nucleic acid sequence of the cell of the present invention, as defined herein above, further comprises a polyadenyl/polyadenylation sequence, preferably the 5' end of said polyadenyl l/polyadenylation sequence is operably linked to the 3' end of the open reading frame, such as to the open reading frame encoding squalene synthase.

RNA editing

15 RNA editing is a process which results in sequence variation in the RNA molecule, and is catalyzed by enzymes. These enzymes include the Adenosine Deaminase Acting on RNA (ADAR) enzymes, which convert specific adenosine residues to inosine in an mRNA molecule by hydrolytic deamination. Three ADAR enzymes have been cloned, ADAR1, ADAR2 and ADAR3, although only the first two subtypes have
20 been shown to have RNA editing activity. Many mRNAs are vulnerable to the effects of RNA editing, including the glutamate receptor subunits GluR2, GluR3, GluR4, GluR5 and GluR6 (which are components of the AMPA and kainate receptors), the serotonin_{2C} receptor, the GABA- α 3 receptor subunit, the tryptophan hydroxylase enzyme TPH2, the hepatitis delta virus and more than 16% of microRNAs. In addition to ADAR
25 enzymes, CDAR enzymes exist and these convert cytosines in specific RNA molecules, to uracil. These enzymes are termed 'APOBEC' and have genetic loci at 22q13, a region close to the chromosomal deletion which occurs in velocardiofacial syndrome (22q11) and which is linked to psychosis. RNA editing is extensively studied in relation to infectious diseases, because the editing process alters viral function.

30 *Post-transcriptional regulatory elements*

Use of a post-transcriptional regulatory elements (PRE) is often necessary to obtain vectors with sufficient performance for certain applications. Schambach et al in Gene Ther. (2006) 13(7):641-5 reports that introduction of a post-transcriptional regulatory element (PRE) of woodchuck hepatitis virus (WHV) into the 3' untranslated region of retroviral and lentiviral gene transfer vectors enhances both titer and transgene expression. The enhancing activity of the PRE depends on the precise configuration of its sequence and the context of the vector and cell into which it is introduced.

Thus use of a PRE such as a woodchuck hepatitis virus post-transcriptional regulatory elements (WPRE) may be useful in the preparation of the cell of the present invention when using a gene therapeutic approach.

Accordingly, in one embodiment the nucleic acid sequence of the cell defined herein further comprises a post-transcriptional regulatory element.

In a further embodiment, the post-transcriptional regulatory element is a Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE).

Terminal repeats

To insert genetic sequences into host DNA, viruses often use sequences of DNA that repeats up to thousands of times, so called repeats, or terminal repeats including long terminal repeats (LTR) and inverted terminal repeats (ITR), wherein said repeat sequences may be both 5' and 3' terminal repeats. ITRs aid in concatamer formation in the nucleus after the single-stranded vector DNA is converted by host cell DNA polymerase complexes into double-stranded DNA. ITR sequences may be derived from viral vectors, such as AAV, e.g. AAV2.

In one embodiment, the nucleic acid sequence or the vector of the cell defined herein comprises a 5' terminal repeat and a 3' terminal repeat.

In one embodiment said 5' and 3' terminal repeats are selected from Inverted Terminal Repeats [ITR] and Long Terminal Repeats [LTR].

In one embodiment of said 5' and 3' terminal repeats are AAV Inverted Terminal Repeats [ITR].

Geranylgeranyl Pyrophosphate Synthase

The microbial cells of the present invention may in preferred embodiments

contain a heterologous nucleic acid sequence encoding Geranylgeranyl Pyrophosphate Synthase (GGPPS). See, e.g., Table 7. GGPPS is an enzyme, which catalyzes the chemical reaction that turns one farnesyl pyrophosphate (FPP) molecule into one Geranylgeranyl Pyrophosphate (GGPP) molecule. Genes encoding GGPPS may for example be found in organisms that contain the mevalonate pathway.

The GGPPS to be used with the present invention may be any useful enzyme, which is capable of catalysing conversion of a farnesyl pyrophosphate (FPP) molecule into a Geranylgeranyl Pyrophosphate (GGPP) molecule. In particular, the GGPPS to be used with the present invention may be any enzyme capable of catalysing the following reaction:

(2E,6E)-farnesyl diphosphate + isopentenyl diphosphate $\rightarrow$ diphosphate + geranylgeranyl diphosphate.

It is preferred that the GGPPS used with the present invention is an enzyme categorised under EC 2.5.1.29.

The GGPPS may be GGPPS from a variety of sources, such as from bacteria, fungi or mammals. The GGPPS may be any kind of GGPPS, for example GGPPS-1, GGPPS-2, GGPPS-3 or GGPPS-4. The GGPPS may be wild type GGPPS or a functional homologue thereof.

For example, the GGPPS may be GGPPS-1 of *S. acidicaldarius* (SEQ ID NO: 126), GGPPS-2 of *A. nidulans* (SEQ ID NO: 203), GGPPS-3 of *S. cerevisiae* (SEQ ID NO: 167) or GGPPS-4 of *M. musculus* (SEQ ID NO: 123) or a functional homologue of any of the aforementioned.

The heterologous nucleic acid encoding said GGPPS may be any nucleic acid sequence encoding said GGPPS. Thus, in embodiments of the invention where GGPPS is a wild type protein, the nucleic acid sequence may for example be a wild type cDNA sequence encoding said protein. However, it is frequently the case that the heterologous nucleic acid is nucleic acid sequence encoding any particular GGPPS, where said nucleic acid has been codon optimised for the particular microbial cell. Thus, by way of example, if the microbial cell is *S. cerevisiae*, then the nucleic acid encoding GGPPS has preferably been codon optimised for optimal expression in *S. cerevisiae*.

Functional homologues of GGPPS are preferably protein having above-mentioned activity and sharing at least 70% amino acid identity with the sequence of a reference GGPPS. Methods for determining sequence identity are described herein above in the section "Squalene synthase" and in section D.

5 In one embodiment, the cell, such as the microbial of the present invention comprises a nucleic acid sequence coding a GGPPS or a functional homologue thereof, where said functional homologue is at least 75%, such as at least 76%, such as at least 77%, such as at least 78%, such as at least 79%, such as at least 80%, such as at least 81%, such as at least 82%, such as at least 83%, such as at least 84%, such as at least 10 85%, such as at least 86%, such as at least 87%, such as at least 88%, such as at least 89%, such as at least 90%, such as at least 91%, such as at least 92%, such as at least 93%, such as at least 94%, such as at least 95%, such as at least 96%, such as at least 97%, such as at least 98%, such as at least 99%, such as at least 99.5%, such as at least 99.6%, such as at least 99.7%, such as at least 99.8%, such as at least 99.9%, such as 15 100% identical to a GGPPS selected from the group consisting of SEQ ID NO:123, SEQ ID NO:126, SEQ ID NO:167 and SEQ ID NO:203.

Said heterologous nucleic acid sequence encoding a GGPPS is in general operably linked to a nucleic acid sequence directing expression of GGPPS in the microbial cell. The nucleic acid sequence directing expression of GGPPS in the microbial 20 cell may be a promoter sequence, and preferably said promoter sequence is selected according the particular microbial cell. The promoter may for example be any of the promoters described herein above in the section "Promoter"

Vectors

A vector is a DNA molecule used as a vehicle to transfer foreign genetic material 25 into another cell. The major types of vectors are plasmids, viruses, cosmids, and artificial chromosomes. Common to all engineered vectors is an origin of replication, a multicloning site, and a selectable marker.

The vector itself is generally a DNA sequence that consists of an insert (transgene) and a larger sequence that serves as the "backbone" of the vector. The 30 purpose of a vector which transfers genetic information to another cell is typically to

isolate, multiply, or express the insert in the target cell. Vectors called expression vectors (expression constructs) specifically are for the expression of the transgene in the target cell, and generally have a promoter sequence that drives expression of the transgene. Simpler vectors called transcription vectors are only capable of being transcribed but not translated: they can be replicated in a target cell but not expressed, unlike expression vectors. Transcription vectors are used to amplify their insert.

Insertion of a vector into the target cell is usually called transformation for bacterial cells, transfection for eukaryotic cells, although insertion of a viral vector is often called transduction.

Plasmids

Plasmid vectors are double-stranded generally circular DNA sequences that are capable of automatically replicating in a host cell. Plasmid vectors minimalistically consist of an origin of replication that allows for semi-independent replication of the plasmid in the host and also the transgene insert. Modern plasmids generally have many more features, notably including a "multiple cloning site" which includes nucleotide overhangs for insertion of an insert, and multiple restriction enzyme consensus sites to either side of the insert. In the case of plasmids utilized as transcription vectors, incubating bacteria with plasmids generates hundreds or thousands of copies of the vector within the bacteria in hours, and the vectors can be extracted from the bacteria, and the multiple cloning site can be cut by restriction enzymes to excise the hundredfold or thousandfold amplified insert. These plasmid transcription vectors characteristically lack crucial sequences that code for polyadenylation sequences and translation termination sequences in translated mRNAs, making protein expression from transcription vectors impossible. plasmids may be conjugative/transmissible and non-conjugative:

- conjugative: mediate DNA transfer through conjugation and therefore spread rapidly among the bacterial cells of a population; e.g., F plasmid, many R and some col plasmids.
- nonconjugative- do not mediate DNA through conjugation, e.g., many R and col plasmids.

Viral vectors

Viral vectors are generally genetically-engineered viruses carrying modified viral DNA or RNA that has been rendered noninfectious, but still contain viral promoters and also the transgene, thus allowing for translation of the transgene through a viral promoter. However, because viral vectors frequently are lacking infectious sequences, they require
5 helper viruses or packaging lines for large-scale transfection. Viral vectors are often designed for permanent incorporation of the insert into the host genome, and thus leave distinct genetic markers in the host genome after incorporating the transgene. For example, retroviruses leave a characteristic retroviral integration pattern after insertion that is detectable and indicates that the viral vector has incorporated into the host
10 genome.

In one embodiment the invention concerns a viral vector capable of transfecting a host cell, such as a cell that can be cultured, e.g. a yeast cell or any other suitable eukaryotic cell. The vector is then capable of transfecting said cell with a nucleic acid that includes the heterologous insert sequence as described herein.

15 The viral vector can be any suitable viral vector such as a viral vector selected from the group consisting of vectors derived from the Retroviridae family including lentivirus, HIV, SIV, FIV, EAIIV, CIV.

The viral vector may also be selected from the group consisting of alphavirus, adenovirus, adeno associated virus, baculovirus, HSV, coronavirus, Bovine papilloma
20 virus, Mo-MLV and adeno associated virus.

In embodiments of the invention wherein the microbial cell comprises a heterologous nucleic acid encoding GGPPS, then said heterologous nucleic acid may be positioned on the vector also containing the nucleic acid encoding squalene synthase, or the heterologous nucleic acid encoding GGPPS may be positioned on a different vector.
25 Said heterologous nucleic acid encoding GGPPS may be contained in any of the vectors described herein above.

In embodiments of the invention wherein the microbial cell comprises a heterologous nucleic acid encoding HMCR, then said heterologous nucleic acid may be positioned on the vector also containing the nucleic acid encoding squalene synthase, or
30 the heterologous nucleic acid encoding HMCR may be positioned on a different vector.

Said heterologous nucleic acid encoding HMCR may be contained in any of the vectors described herein above. It is also contained within the invention that the heterologous nucleic acid encoding GGPPS and the heterologous nucleic acid encoding HMCR may be positioned on the same or on individual vectors.

5 *Transcription*

Transcription is a necessary component in all vectors: the premise of a vector is to multiply the insert (although expression vectors later also drive the translation of the multiplied insert). Thus, even stable expression is determined by stable transcription, which generally depends on promoters in the vector. However, expression vectors have a variety of expression patterns: constitutive (consistent expression) or inducible (expression only under certain conditions or chemicals). This expression is based on different promoter activities, not post-transcriptional activities. Thus, these two different types of expression vectors depend on different types of promoters.

15 Viral promoters are often used for constitutive expression in plasmids and in viral vectors because they normally reliably force constant transcription in many cell lines and types.

Inducible expression depends on promoters that respond to the induction conditions: for example, the murine mammary tumor virus promoter only initiates transcription after dexamethasone application and the *Drosophila* heat shock promoter only initiates after high temperatures. transcription is the synthesis of mRNA. Genetic information is copied from DNA to RNA

20 *Expression*

Expression vectors require sequences that encode for e.g. polyadenylation tail (see herein above): Creates a polyadenylation tail at the end of the transcribed pre-mRNA that protects the mRNA from exonucleases and ensures transcriptional and translational termination: stabilizes mRNA production.

Minimal UTR length: UTRs contain specific characteristics that may impede transcription or translation, and thus the shortest UTRs or none at all are encoded for in optimal expression vectors.

Kozak sequence: Vectors should encode for a Kozak sequence in the mRNA, which assembles the ribosome for translation of the mRNA.

Above conditions are necessary for expression vectors in eukaryotes but not in prokaryotes.

5 Modern vectors may encompass additional features besides the transgene insert and a backbone such as a promoter (discussed above), genetic markers to e.g. allow for confirmation that the vector has integrated with the host genomic DNA, antibiotic resistance genes for antibiotic selection, and affinity tags for purification.

10 In one embodiment the cell of the present invention comprises a nucleic acid sequence integrated in a vector such as an expression vector.

 In one embodiment the the vector is selected from the group consisting of plasmid vectors, cosmids, artificial chromosomes and viral vectors.

 The plasmid vector should be able to be maintained and replicated in bacteria, fungi and yeast.

15 The present invention also concerns cells comprising plasmid and cosmid vectors as well as artificial chromosome vectors.

 The important factor is that the vector is functional and that the vector comprises at least the nucleic acid sequence comprising the heterologous insert sequence as described herein.

20 In one embodiment the vector is functional in fungi and in mammalian cells.

 In one embodiment the invention concerns a cell transformed or transduced with the vector as defined herein above.

Methods for producing terpenoids

25 As mentioned herein above, the cell of the present invention (e.g., recombinant host cells) is useful in enhancing yield of industrially relevant terpenoids.

 The cell of the invention may therefore be used in various set-ups in order to increase accumulation of terpenoid precursors and thus to increase yield of terpenoid products resulting from enzymatic conversion of said (upstream) terpenoid precursors.

Accordingly, in one aspect the present invention relates to a method for producing a terpenoid compound synthesized through the squalene pathway, in a cell culture, said method comprising the steps of

- (a) providing the cell as defined herein above,
- 5 (b) culturing the cell of (a).
- (c) recovering the terpenoid product compound.

By providing the cell comprising the genetically modified construct defined herein above, the accumulation of terpenoid precursors is enhanced (FIG. 20).

Thus, in another aspect, the invention relates to a method for producing a
10 terpenoid derived from a terpenoid precursor selected from the group consisting of Farnesyl-pyrophosphate (FPP), Isopentenyl-pyrophosphate (IPP), Dimethylallyl-pyrophosphate (DMAPP), Geranyl-pyrophosphate (GPP) and/or Geranylgeranyl-pyrophosphate (GGPP), said method comprising:

- (a) contacting said precursor with an enzyme of the squalene synthase
15 pathway,
- (b) recovering the terpenoid product.

In one embodiment the terpenoid (product) of the method of the present invention as defined herein above, is selected from the group consisting of hemiterpenoids, monoterpenes, sesquiterpenoids, diterpenoids, sesterpenes, triterpenoids, tetraterpenoids
20 and polyterpenoids.

In a further embodiment the terpenoid is selected from the group consisting of farnesyl phosphate, farnesol, geranylgeranyl, geranylgeraniol, isoprene, prenol, isovaleric acid, geranyl pyrophosphate, eucalyptol, limonene, pinene, farnesyl pyrophosphate, artemisinin, bisabolol, geranylgeranyl pyrophosphate, retinol, retinal, phytol, taxol ,
25 forskolin, aphidicolin, lanosterol, lycopene and carotene.

The terpenoid product can be used as starting point in an additional refining process. Thus, in one embodiment said method further comprises dephosphorylating the farnesyl phosphate to produce farnesol.

The enzyme or enzymes used in the process of preparing the target product
30 terpenoid compound is preferably an enzyme "located downstream" of the terpenoid

precursors Farnesyl-pyrophosphate, Isopentenyl-pyrophosphate, Dimethylallyl-pyrophosphate, Geranyl-pyrophosphate and Geranylgeranyl-pyrophosphate such as an enzyme located downstream of the terpenoid precursors Farnesyl-pyrophosphate, Isopentenyl-pyrophosphate, Dimethylallyl-pyrophosphate, Geranyl-pyrophosphate and Geranylgeranyl-pyrophosphate depicted in the squalene pathway of FIG. 20. The enzyme used in the process of preparing the target product terpenoid, based on the accumulation of precursors achieved through the present invention, may thus be selected from the group consisting of Dimethylallyltransferase (EC 2.5.1.1), Isoprene synthase (EC 4.2.3.27) and Geranyltranstransferase (EC 2.5.1.10).

The present invention may operate by at least partly, sterically hindering binding of the ribosome to the RNA thus reducing the translation of squalene synthase. Accordingly, in one aspect the present invention relates to a method for reducing the translation rate of a functional squalene synthase (EC 2.5.1.21) said method comprising:

- (a) providing the cell defined herein above,
- (b) culturing the cell of (a).

Similarly, the invention in another aspect relates to a method for decreasing turnover of farnesyl-pp to squalene, said method comprising:

- (a) providing the cell defined herein above,
- (b) culturing the cell of (a).

As depicted in FIG. 20, the knocking down of the ERG9 results in build-up of precursors to squalene synthase. Thus in one aspect, the present invention relates to a method for enhancing accumulation of a compound selected from the group consisting of Farnesyl-pyrophosphate, Isopentenyl-pyrophosphate, Dimethylallyl-pyrophosphate, Geranyl-pyrophosphate and Geranylgeranyl-pyrophosphate, said method comprising the steps of:

- (a) providing the cell defined herein above, and
- (b) culturing the cell of (a).

In one embodiment the method of the invention as define herein above further comprises recovering the Farnesyl-pyrophosphate, Isopentenyl-pyrophosphate, Dimethylallyl-pyrophosphate, Geranyl-pyrophosphate or Geranylgeranyl-pyrophosphate

compound. The recovered compound may be used in further processes for producing the desired terpenoid product compound. The further process may take place in the same cell culture as the process performed and defined herein above, such as the accumulation of the terpenoid precursors by the cell of the present invention. Alternatively, the recovered
5 precursors may be added to another cell culture, or a cell free system, to produce the desired products.

As the precursors are intermediates, however mainly stable intermediates, a certain endogenous production of terpenoid products may occur based on the terpenoid precursor substrates. Also, the cells of the invention may have additional genetic
10 modifications such that they are capable of performing both the accumulation of the terpenoid precursors (construct of the cell of the invention) and whole or substantially the whole subsequent biosynthesis process to the desired terpenoid product.

Thus, in one embodiment the method of the invention further comprises recovering a compound synthesized through the squalene pathway, said compound being
15 derived from said Farnesyl-pyrophosphate, Isopentenyl-pyrophosphate, Dimethylallyl-pyrophosphate, Geranyl-pyrophosphate and/or Geranylgeranyl-pyrophosphate. Occasionally it may be advantageous to include a squalene synthase inhibitor when culturing the cell of the present invention. Chemical inhibition of squalene synthase, e.g. by lapaquistat, is known in the art and is under investigation e.g. as a method of lowering
20 cholesterol levels in the prevention of cardiovascular disease. It has also been suggested that variants in this enzyme may be part of a genetic association with hypercholesterolemia. Other squalene synthase inhibitors include Zaragozic acid and RPR 107393.

Thus, in one embodiment the culturing step of the method(s) defined herein above
25 is performed in the presence of a squalene synthase inhibitor.

The cell of the invention may furthermore be genetically modified to further enhance production of certain key terpenoid precursors. In one embodiment the cell is additionally genetically modified to enhance activity of and/or overexpress one or more enzymes selected from the group consisting of Phosphomevalonate kinase (EC 2.7.4.2),
30 Diphosphomevalonate decarboxylase (EC 4.1.1.33), 4-hydroxy-3-methylbut-2-en-1-yl

diphosphate synthase (EC 1.17.7.1), 4-hydroxy-3-methylbut-2-enyl diphosphate reductase (EC 1.17.1.2), Isopentenyl-diphosphate Delta-isomerase 1 (EC 5.3.3.2), Short-chain Z-isoprenyl diphosphate synthase (EC 2.5.1.68), Dimethylallyltransferase (EC 2.5.1.1), Geranyltranstransferase (EC 2.5.1.10) and Geranylgeranyl pyrophosphate synthetase (EC 2.5.1.29).

As described herein above in one embodiment of the invention the microbial cell comprises both a nucleic acid encoding a squalene synthase as described herein above as well as a heterologous nucleic acid encoding a GGPPS. Such microbial cells are particularly useful for the preparation of GGPP as well as terpenoids, wherein GGPP is an intermediate in their biosynthesis.

Accordingly, in one aspect the invention relates to a method for preparing GGPP, wherein the method comprises the steps of

a. providing a microbial cell comprising a nucleic acid sequence, said nucleic acid comprising

- i) a promoter sequence operably linked to
- ii) a heterologous insert sequence operably linked to
- iii) an open reading frame operably linked to
- iv) a transcription termination signal,

wherein the heterologous insert sequence and the open reading

frame are as defined herein above,

wherein said microbial cell furthermore comprises a heterologous nucleic acid encoding GGPPS operably linked to a nucleic acid sequence directing expression of GGPPS in said cell;

b. Cultivating the microbial cell of a.;

c. Recovering the GGPP.

In another aspect the invention relates to a method for preparing a terpenoid of which GGPP is an intermediate in the biosynthesis pathway, wherein the method comprises the steps of

a. providing a microbial cell, wherein said microbial cell comprises a nucleic acid sequence, said nucleic acid comprising

- i) a promoter sequence operably linked to
- ii) a heterologous insert sequence operably linked to
- iii) an open reading frame operably linked to
- iv) a transcription termination signal,

5 wherein the heterologous insert sequence and the open reading frame are as defined herein above,

wherein said microbial cell furthermore comprises a heterologous nucleic acid encoding GGPPS operably linked to a nucleic acid sequence directing expression of GGPPS in said cell;

- 10 b. Cultivating the microbial cell of a; and
- c. Recovering the terpenoid,

wherein said terpenoid may be any terpenoid described herein above in the section “Terpenoids” having GGPP as intermediate in its biosyntheses; and said microbial cell may be any of the microbial cells described herein above in the section “The cell”; and
15 said promoter may be any promoter, such as any of the promoters described herein above in the section “Promoter”; and said heterologous insert sequence may be any of the heterologous insert sequences described herein above in the section “Heterologous insert sequence”; and said open reading frame encodes a squalene synthase, which may be any of the squalene synthases described herein above in the section “Squalene synthase”; and
20 said GGPPS may be any of the GGPPS described herein above in the section “Geranylgeranyl Pyrophosphate Synthase”.

In this embodiment said microbial cell may also optionally contain one or more additional heterologous nucleic acids encoding one or more enzymes involved in the biosynthesis pathway of said terpenoid.

25 In one particular aspect the invention relates to a method for preparing steviol, wherein the method comprises the steps of

- a. providing a microbial cell, wherein said microbial cell comprises a nucleic acid sequence, said nucleic acid comprising
 - i) a promoter sequence operably linked to
 - 30 ii) a heterologous insert sequence operably linked to

- iii) an open reading frame operably linked to
- iv) a transcription termination signal,

wherein the heterologous insert sequence and the open reading frame are as defined herein above,

5 wherein said microbial cell furthermore comprises a heterologous nucleic acid encoding GGPPS operably linked to a nucleic acid sequence directing expression of GGPPS in said cell;

b. Cultivating the microbial cell of a.;

c. Recovering steviol,

10 wherein said microbial cell may be any of the microbial cells described herein above in the section "The cell"; and said promoter may be any promoter, such as any of the promoters described herein above in the section "Promoter"; and said heterologous insert sequence may be any of the heterologous insert sequences described herein above in the section "Heterologous insert sequence"; and said open reading frame encodes a squalene
15 synthase, which may be any of the squalene synthases described herein above in the section "Squalene synthase"; and said GGPPS may be any of the GGPPS described herein above in the section "Geranylgeranyl Pyrophosphate Synthase".

In this embodiment said microbial cell may also optionally contain one or more additional heterologous nucleic acids encoding one or more enzymes involved in the
20 biosynthesis pathway of steviol.

In another aspect the invention relates to a method for preparing a terpenoid of which GGPP is an intermediate in the biosynthesis pathway, wherein the method comprises the steps of

a. providing a microbial cell, wherein said microbial cell comprises a nucleic
25 acid sequence, said nucleic acid comprising

- i) a promoter sequence operably linked to
- ii) a heterologous insert sequence operably linked to
- iii) an open reading frame operably linked to
- iv) a transcription termination signal,

wherein the heterologous insert sequence and the open reading frame are as defined herein above,

wherein said microbial cell furthermore comprises a heterologous nucleic acid encoding GGPPS operably linked to a nucleic acid sequence directing expression of GGPPS in said cell

and wherein said microbial cell furthermore comprises a heterologous nucleic acid encoding HMCR operably linked to a nucleic acid sequence directing expression of HMCR in said cell;

b. Cultivating the microbial cell of a.;

c. Recovering the terpenoid,

wherein said terpenoid may be any terpenoid described herein above in the section

“Terpenoids” having GGPP as intermediate in its biosyntheses; and said microbial cell may be any of the microbial cells described herein above in the section “The cell”; and

said promoter may be any promoter, such as any of the promoters described herein above

in the section “Promoter”; and said heterologous insert sequence may be any of the heterologous insert sequences described herein above in the section “Heterologous insert sequence”; and said open reading frame encodes a squalene synthase, which may be any of the squalene synthases described herein above in the section “Squalene synthase”; and said GGPPS may be any of the GGPPS described herein above in the section

“Geranylgeranyl Pyrophosphate Synthase”; and said HMCR may be any of the HMCR described herein above in the section “HMCR”.

In this embodiment said microbial cell may also optionally contain one or more additional heterologous nucleic acids encoding one or more enzymes involved in the biosynthesis pathway of said terpenoid.

In one particular aspect the invention relates to a method for preparing steviol, wherein the method comprises the steps of

a. providing a microbial cell, wherein said microbial cell comprises a nucleic acid sequence, said nucleic acid comprising

i) a promoter sequence operably linked to

ii) a heterologous insert sequence operably linked to

- iii) an open reading frame operably linked to
- iv) a transcription termination signal,

wherein the heterologous insert sequence and the open reading frame are as defined herein above,

5 wherein said microbial cell furthermore comprises a heterologous nucleic acid encoding GGPPS operably linked to a nucleic acid sequence directing expression of GGPPS in said cell;

b. Cultivating the microbial cell of a.;

c. Recovering steviol,

10 wherein said microbial cell may be any of the microbial cells described herein above in the section "The cell"; and said promoter may be any promoter, such as any of the promoters described herein above in the section "Promoter"; and said heterologous insert sequence may be any of the heterologous insert sequences described herein above in the section "Heterologous insert sequence"; and said open reading frame encodes a squalene
15 synthase, which may be any of the squalene synthases described herein above in the section "Squalene synthase"; and said GGPPS may be any of the GGPPS described herein above in the section "Geranylgeranyl Pyrophosphate Synthase" and said HMCR may be any of the HMCR described herein above in the section "HMCR".

In this embodiment said microbial cell may also optionally contain one or more
20 additional heterologous nucleic acids encoding one or more enzymes involved in the biosynthesis pathway of steviol.

In one embodiment the cell is additionally genetically modified to enhance activity of and/or overexpress one or more enzymes selected from the group consisting of acetoacetyl CoA thiolase, HMG-CoA reductase or the catalytic domain thereof, HMG-
25 CoA synthase, mevalonate kinase, phosphomevalonate kinase, phosphomevalonate decarboxylase, isopentenyl pyrophosphate isomerase, farnesyl pyrophosphate synthase, D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase and farnesyl pyrophosphate synthase.

In one embodiment of the method of the present invention, the cell comprises a
30 mutation in the ERG9 open reading frame.

In another embodiment of the method of the present invention the cell comprises an ERG9[Delta]::HIS3 deletion/insertion allele.

In yet another embodiment the step of recovering the compound in the method of the present invention further comprises purification of said compound from the cell
5 culture media.

D. Functional Homologs

Functional homologs of the polypeptides described above are also suitable for use in producing steviol or steviol glycosides in a recombinant host. A functional homolog is
10 a polypeptide that has sequence similarity to a reference polypeptide, and that carries out one or more of the biochemical or physiological function(s) of the reference polypeptide. A functional homolog and the reference polypeptide may be natural occurring polypeptides, and the sequence similarity may be due to convergent or divergent evolutionary events. As such, functional homologs are sometimes designated in the
15 literature as homologs, or orthologs, or paralogs. Variants of a naturally occurring functional homolog, such as polypeptides encoded by mutants of a wild type coding sequence, may themselves be functional homologs. Functional homologs can also be created via site-directed mutagenesis of the coding sequence for a polypeptide, or by combining domains from the coding sequences for different naturally-occurring
20 polypeptides (“domain swapping”). Techniques for modifying genes encoding functional UGT polypeptides described herein are known and include, *inter alia*, directed evolution techniques, site-directed mutagenesis techniques and random mutagenesis techniques, and can be useful to increase specific activity of a polypeptide, alter substrate specificity, alter expression levels, alter subcellular location, or modify polypeptide:polypeptide
25 interactions in a desired manner. Such modified polypeptides are considered functional homologs. The term “functional homolog” is sometimes applied to the nucleic acid that encodes a functionally homologous polypeptide.

Functional homologs can be identified by analysis of nucleotide and polypeptide sequence alignments. For example, performing a query on a database of nucleotide or
30 polypeptide sequences can identify homologs of steviol or steviol glycoside biosynthesis

polypeptides. Sequence analysis can involve BLAST, Reciprocal BLAST, or PSI-BLAST analysis of nonredundant databases using a GGPPS, a CDPS, a KS, a KO or a KAH amino acid sequence as the reference sequence. Amino acid sequence is, in some instances, deduced from the nucleotide sequence. Those polypeptides in the database that have greater than 40% sequence identity are candidates for further evaluation for suitability as a steviol or steviol glycoside biosynthesis polypeptide. Amino acid sequence similarity allows for conservative amino acid substitutions, such as substitution of one hydrophobic residue for another or substitution of one polar residue for another. If desired, manual inspection of such candidates can be carried out in order to narrow the number of candidates to be further evaluated. Manual inspection can be performed by selecting those candidates that appear to have domains present in steviol biosynthesis polypeptides, *e.g.*, conserved functional domains.

Conserved regions can be identified by locating a region within the primary amino acid sequence of a steviol or a steviol glycoside biosynthesis polypeptide that is a repeated sequence, forms some secondary structure (*e.g.*, helices and beta sheets), establishes positively or negatively charged domains, or represents a protein motif or domain. See, *e.g.*, the Pfam web site describing consensus sequences for a variety of protein motifs and domains on the World Wide Web at sanger.ac.uk/Software/Pfam/ and pfam.janelia.org/. The information included at the Pfam database is described in Sonnhammer *et al.*, Nucl. Acids Res., 26:320-322 (1998); Sonnhammer *et al.*, Proteins, 28:405-420 (1997); and Bateman *et al.*, Nucl. Acids Res., 27:260-262 (1999). Conserved regions also can be determined by aligning sequences of the same or related polypeptides from closely related species. Closely related species preferably are from the same family. In some embodiments, alignment of sequences from two different species is adequate.

Typically, polypeptides that exhibit at least about 40% amino acid sequence identity are useful to identify conserved regions. Conserved regions of related polypeptides exhibit at least 45% amino acid sequence identity (*e.g.*, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% amino acid sequence identity). In some embodiments, a conserved region exhibits at least 92%, 94%, 96%, 98%, or 99% amino acid sequence identity.

For example, polypeptides suitable for producing steviol glycosides in a recombinant host include functional homologs of EUGT11, UGT91D2e, UGT91D2m, UGT85C, and UGT76G. Such homologs have greater than 90% (e.g., at least 95% or 99%) sequence identity to the amino acid sequence of EUGT11 (SEQ ID NO: 152),
5 UGT91D2e (SEQ ID NO:5), UGT91D2m (SEQ ID NO:10), UGT85C (SEQ ID NO:3), or UGT76G (SEQ ID NO:7). Variants of EUGT11, UGT91D2, UGT85C, and UGT76G polypeptides typically have 10 or fewer amino acid substitutions within the primary amino acid sequence, e.g., 7 or fewer amino acid substitutions, 5 or conservative amino acid substitutions, or between 1 and 5 substitutions. However, in some embodiments,
10 variants of EUGT11, UGT91D2, UGT85C, and UGT76G polypeptides can have 10 or more amino acid substitutions (e.g., 10, 15, 20, 25, 30, 35, 10-20, 10-35, 20-30, or 25-35 amino acid substitutions). The substitutions may be conservative, or in some embodiments, non-conservative. Non-limiting examples of non-conservative changes in UGT91D2e polypeptides include glycine to arginine and tryptophan to arginine. Non-
15 limiting examples of non-conservative substitutions in UGT76G polypeptides include valine to glutamic acid, glycine to glutamic acid, glutamine to alanine, and serine to proline. Non-limiting examples of changes to UGT85C polypeptides include histidine to aspartic acid, proline to serine, lysine to threonine, and threonine to arginine.

In some embodiments, a useful UGT91D2 homolog can have amino acid
20 substitutions (e.g., conservative amino acid substitutions) in regions of the polypeptide that are outside of predicted loops, e.g., residues 20-26, 39-43, 88-95, 121-124, 142-158, 185-198, and 203-214 are predicted loops in the N-terminal domain and residues 381-386 are predicted loops in the C-terminal domain of SEQ ID NO:5. For example, a useful UGT91D2 homolog can include at least one amino acid substitution at residues 1-19, 27-
25 38, 44-87, 96-120, 125-141, 159-184, 199-202, 215-380, or 387-473 of SEQ ID NO:5. In some embodiments, a UGT91D2 homolog can have an amino acid substitution at one or more residues selected from the group consisting of residues 30, 93, 99, 122, 140, 142, 148, 153, 156, 195, 196, 199, 206, 207, 211, 221, 286, 343, 427, and 438 of SEQ ID NO:5. For example, a UGT91D2 functional homolog can have an amino acid
30 substitution at one or more of residues 206, 207, and 343, such as an arginine at residue

206, a cysteine at residue 207, and an arginine at residue 343 of SEQ ID NO:5. See, SEQ ID NO:95. Other functional homologs of UGT91D2 can have one or more of the following: a tyrosine or phenylalanine at residue 30, a proline or glutamine at residue 93, a serine or valine at residue 99, a tyrosine or a phenylalanine at residue 122, a histidine or tyrosine at residue 140, a serine or cysteine at residue 142, an alanine or threonine at residue 148, a methionine at residue 152, an alanine at residue 153, an alanine or serine at residue 156, a glycine at residue 162, a leucine or methionine at residue 195, a glutamic acid at residue 196, a lysine or glutamic acid at residue 199, a leucine or methionine at residue 211, a leucine at residue 213, a serine or phenylalanine at residue 221, a valine or isoleucine at residue 253, a valine or alanine at residue 286, a lysine or asparagine at residue 427, an alanine at residue 438, and either an alanine or threonine at residue 462 of SEQ ID NO:5. In another embodiment, a UGT91D2 functional homolog contains a methionine at residue 211 and an alanine at residue 286.

In some embodiments, a useful UGT85C homolog can have one or more amino acid substitutions at residues 9, 10, 13, 15, 21, 27, 60, 65, 71, 87, 91, 220, 243, 270, 289, 298, 334, 336, 350, 368, 389, 394, 397, 418, 420, 440, 441, 444, and 471 of SEQ ID NO:3. Non-limiting examples of useful UGT85C homologs include polypeptides having substitutions (with respect to SEQ ID NO:3) at residue 65 (e.g., a serine at residue 65), at residue 65 in combination with residue 15 (a leucine at residue 15), 270 (e.g., a methionine, arginine, or alanine at residue 270), 418 (e.g., a valine at residue 418), 440 (e.g., an aspartic acid at residue at residue 440), or 441 (e.g., an asparagine at residue 441); residues 13 (e.g., a phenylalanine at residue 13), 15, 60 (e.g., an aspartic acid at residue 60), 270, 289 (e.g., a histidine at residue 289), and 418; substitutions at residues 13, 60, and 270; substitutions at residues 60 and 87 (e.g., a phenylalanine at residue 87); substitutions at residues 65, 71 (e.g., a glutamine at residue 71), 220 (e.g., a threonine at residue 220), 243 (e.g., a tryptophan at residue 243), and 270; substitutions at residues 65, 71, 220, 243, 270, and 441; substitutions at residues 65, 71, 220, 389 (e.g., a valine at residue 389), and 394 (e.g., a valine at residue 394); substitutions at residues 65, 71, 270, and 289; substitutions at residues 220, 243, 270, and 334 (e.g., a serine at residue 334); or substitutions at residues 270 and 289. The following amino acid mutations did not result

in a loss of activity in 85C2 polypeptides: V13F, F15L, H60D, A65S, E71Q, I87F, K220T, R243W, T270M, T270R, Q289H, L334S, A389V, I394V, P397S, E418V, G440D, and H441N. Additional mutations that were seen in active clones include K9E, K10R, Q21H, M27V, L91P, Y298C, K350T, H368R, G420R, L431P, R444G, and
 5 M471T. In some embodiments, an UGT85C2 contains substitutions at positions 65 (e.g., a serine), 71 (a glutamine), 270 (a methionine), 289 (a histidine), and 389 (a valine).

The amino acid sequence of *Stevia rebaudiana* UGTs 74G1, 76G1 and 91D2c with N-terminal, in-frame fusions of the first 158 amino acids of human MDM2 protein, and *Stevia rebaudiana* UGT85C2 with an N-terminal in-frame fusion of 4 repeats of the
 10 synthetic PMI peptide (4 X TSFAEYWNLLSP, SEQ ID NO:86) are set forth in SEQ ID NOs: 90, 88, 94, and 92, respectively; see SEQ ID NOs: 89, 92, 93, and 95 for the nucleotide sequences encoding the fusion proteins.

In some embodiments, a useful UGT76G homolog can have one or more amino acid substitutions at residues 29, 74, 87, 91, 116, 123, 125, 126, 130, 145, 192, 193, 194,
 15 196, 198, 199, 200, 203, 204, 205, 206, 207, 208, 266, 273, 274, 284, 285, 291, 330, 331, and 346 of SEQ ID NO:7. Non-limiting examples of useful UGT76G homologs include polypeptides having substitutions (with respect to SEQ ID NO:7) at residues 74, 87, 91, 116, 123, 125, 126, 130, 145, 192, 193, 194, 196, 198, 199, 200, 203, 204, 205, 206, 207,
 20 208, and 291; residues 74, 87, 91, 116, 123, 125, 126, 130, 145, 192, 193, 194, 196, 198, 199, 200, 203, 204, 205, 206, 207, 208, 266, 273, 274, 284, 285, and 291; or residues 74, 87, 91, 116, 123, 125, 126, 130, 145, 192, 193, 194, 196, 198, 199, 200, 203, 204, 205,
 206, 207, 208, 266, 273, 274, 284, 285, 291, 330, 331, and 346. See, Table 9.

Table 9

Clone	Mutations
76G_G7	M29I, V74E, V87G, L91P, G116E, A123T, Q125A, I126L, T130A, V145M, C192S, S193A, F194Y, M196N, K198Q, K199I, Y200L, Y203I, F204L, E205G, N206K, I207M, T208I, P266Q, S273P, R274S, G284T, T285S, 287-3 bp deletion, L330V, G331A, L346I
76G_H12	M29I, V74E, V87G, L91P, G116E, A123T, Q125A, I126L, T130A, V145M, C192S, S193A, F194Y, M196N, K198Q, K199I, Y200L,

	Y203I, F204L, E205G, N206K, I207M, T208I, P266Q, S273P, R274S, G284T, T285S, 287-3 bp deletion
76G_C4	M29I, V74E, V87G, L91P, G116E, A123T, Q125A, I126L, T130A, V145M, C192S, S193A, F194Y, M196N, K198Q, K199I, Y200L, Y203I, F204L, E205G, N206K, I207M, T208I

Methods to modify the substrate specificity of, for example, EUGT11 or UGT91D2e, are known to those skilled in the art, and include without limitation site-directed/rational mutagenesis approaches, random directed evolution approaches and combinations in which random mutagenesis/saturation techniques are performed near the active site of the enzyme. For example see Sarah A. Osmani, et al. *Phytochemistry* 70 (2009) 325–347.

A candidate sequence typically has a length that is from 80 percent to 200 percent of the length of the reference sequence, *e.g.*, 82, 85, 87, 89, 90, 93, 95, 97, 99, 100, 105, 110, 115, 120, 130, 140, 150, 160, 170, 180, 190, or 200 percent of the length of the reference sequence. A functional homolog polypeptide typically has a length that is from 95 percent to 105 percent of the length of the reference sequence, *e.g.*, 90, 93, 95, 97, 99, 100, 105, 110, 115, or 120 percent of the length of the reference sequence, or any range between. A percent identity for any candidate nucleic acid or polypeptide relative to a reference nucleic acid or polypeptide can be determined as follows. A reference sequence (*e.g.*, a nucleic acid sequence or an amino acid sequence) is aligned to one or more candidate sequences using the computer program ClustalW (version 1.83, default parameters), which allows alignments of nucleic acid or polypeptide sequences to be carried out across their entire length (global alignment). Chenna *et al.*, *Nucleic Acids Res.*, 31(13):3497-500 (2003).

ClustalW calculates the best match between a reference and one or more candidate sequences, and aligns them so that identities, similarities and differences can be determined. Gaps of one or more residues can be inserted into a reference sequence, a candidate sequence, or both, to maximize sequence alignments. For fast pairwise alignment of nucleic acid sequences, the following default parameters are used: word

size: 2; window size: 4; scoring method: percentage; number of top diagonals: 4; and gap penalty: 5. For multiple alignment of nucleic acid sequences, the following parameters are used: gap opening penalty: 10.0; gap extension penalty: 5.0; and weight transitions: yes. For fast pairwise alignment of protein sequences, the following parameters are used:

5 word size: 1; window size: 5; scoring method: percentage; number of top diagonals: 5; gap penalty: 3. For multiple alignment of protein sequences, the following parameters are used: weight matrix: blosum; gap opening penalty: 10.0; gap extension penalty: 0.05; hydrophilic gaps: on; hydrophilic residues: Gly, Pro, Ser, Asn, Asp, Gln, Glu, Arg, and Lys; residue-specific gap penalties: on. The ClustalW output is a sequence alignment

10 that reflects the relationship between sequences. ClustalW can be run, for example, at the Baylor College of Medicine Search Launcher site on the World Wide Web (searchlauncher.bcm.tmc.edu/multi-align/multi-align.html) and at the European Bioinformatics Institute site on the World Wide Web (ebi.ac.uk/clustalw).

To determine percent identity of a candidate nucleic acid or amino acid sequence

15 to a reference sequence, the sequences are aligned using ClustalW, the number of identical matches in the alignment is divided by the length of the reference sequence, and the result is multiplied by 100. It is noted that the percent identity value can be rounded to the nearest tenth. For example, 78.11, 78.12, 78.13, and 78.14 are rounded down to 78.1, while 78.15, 78.16, 78.17, 78.18, and 78.19 are rounded up to 78.2.

20 It will be appreciated that functional UGTs can include additional amino acids that are not involved in glucosylation or other enzymatic activities carried out by the enzyme, and thus such a polypeptide can be longer than would otherwise be the case. For example, a EUGT11 polypeptide can include a purification tag (e.g., HIS tag or GST tag), a chloroplast transit peptide, a mitochondrial transit peptide, an amyloplast peptide,

25 signal peptide, or a secretion tag added to the amino or carboxy terminus. In some embodiments, a EUGT11 polypeptide includes an amino acid sequence that functions as a reporter, e.g., a green fluorescent protein or yellow fluorescent protein.

II. Steviol and Steviol Glycoside Biosynthesis Nucleic Acids

30 A recombinant gene encoding a polypeptide described herein comprises the

coding sequence for that polypeptide, operably linked in sense orientation to one or more regulatory regions suitable for expressing the polypeptide. Because many microorganisms are capable of expressing multiple gene products from a polycistronic mRNA, multiple polypeptides can be expressed under the control of a single regulatory
5 region for those microorganisms, if desired. A coding sequence and a regulatory region are considered to be operably linked when the regulatory region and coding sequence are positioned so that the regulatory region is effective for regulating transcription or translation of the sequence. Typically, the translation initiation site of the translational reading frame of the coding sequence is positioned between one and about fifty
10 nucleotides downstream of the regulatory region for a monocistronic gene.

In many cases, the coding sequence for a polypeptide described herein is identified in a species other than the recombinant host, *i.e.*, is a heterologous nucleic acid. Thus, if the recombinant host is a microorganism, the coding sequence can be from other prokaryotic or eukaryotic microorganisms, from plants or from animals. In some case,
15 however, the coding sequence is a sequence that is native to the host and is being reintroduced into that organism. A native sequence can often be distinguished from the naturally occurring sequence by the presence of non-natural sequences linked to the exogenous nucleic acid, *e.g.*, non-native regulatory sequences flanking a native sequence in a recombinant nucleic acid construct. In addition, stably transformed exogenous
20 nucleic acids typically are integrated at positions other than the position where the native sequence is found.

“Regulatory region” refers to a nucleic acid having nucleotide sequences that influence transcription or translation initiation and rate, and stability and/or mobility of a transcription or translation product. Regulatory regions include, without limitation,
25 promoter sequences, enhancer sequences, response elements, protein recognition sites, inducible elements, protein binding sequences, 5′ and 3′ untranslated regions (UTRs), transcriptional start sites, termination sequences, polyadenylation sequences, introns, and combinations thereof. A regulatory region typically comprises at least a core (basal) promoter. A regulatory region also may include at least one control element, such as an
30 enhancer sequence, an upstream element or an upstream activation region (UAR). A

regulatory region is operably linked to a coding sequence by positioning the regulatory region and the coding sequence so that the regulatory region is effective for regulating transcription or translation of the sequence. For example, to operably link a coding sequence and a promoter sequence, the translation initiation site of the translational
5 reading frame of the coding sequence is typically positioned between one and about fifty nucleotides downstream of the promoter. A regulatory region can, however, be positioned as much as about 5,000 nucleotides upstream of the translation initiation site, or about 2,000 nucleotides upstream of the transcription start site.

The choice of regulatory regions to be included depends upon several factors,
10 including, but not limited to, efficiency, selectability, inducibility, desired expression level, and preferential expression during certain culture stages. It is a routine matter for one of skill in the art to modulate the expression of a coding sequence by appropriately selecting and positioning regulatory regions relative to the coding sequence. It will be understood that more than one regulatory region may be present, *e.g.*, introns, enhancers,
15 upstream activation regions, transcription terminators, and inducible elements.

One or more genes can be combined in a recombinant nucleic acid construct in “modules” useful for a discrete aspect of steviol and/or steviol glycoside production. Combining a plurality of genes in a module, particularly a polycistronic module, facilitates the use of the module in a variety of species. For example, a steviol
20 biosynthesis gene cluster, or a UGT gene cluster, can be combined in a polycistronic module such that, after insertion of a suitable regulatory region, the module can be introduced into a wide variety of species. As another example, a UGT gene cluster can be combined such that each UGT coding sequence is operably linked to a separate regulatory region, to form a UGT module. Such a module can be used in those species
25 for which monocistronic expression is necessary or desirable. In addition to genes useful for steviol or steviol glycoside production, a recombinant construct typically also contains an origin of replication, and one or more selectable markers for maintenance of the construct in appropriate species.

It will be appreciated that because of the degeneracy of the genetic code, a
30 number of nucleic acids can encode a particular polypeptide; *i.e.*, for many amino acids,

there is more than one nucleotide triplet that serves as the codon for the amino acid. Thus, codons in the coding sequence for a given polypeptide can be modified such that optimal expression in a particular host is obtained, using appropriate codon bias tables for that host (e.g., microorganism). SEQ ID NOs:18-25, 34-36, 40-43, 48-49, 52-55, 60-64, 5 70-72, and 154 set forth nucleotide sequences encoding certain enzymes for steviol and steviol glycoside biosynthesis, modified for increased expression in yeast. As isolated nucleic acids, these modified sequences can exist as purified molecules and can be incorporated into a vector or a virus for use in constructing modules for recombinant nucleic acid constructs.

10 In some cases, it is desirable to inhibit one or more functions of an endogenous polypeptide in order to divert metabolic intermediates towards steviol or steviol glycoside biosynthesis. For example, it may be desirable to downregulate synthesis of sterols in a yeast strain in order to further increase steviol or steviol glycoside production, e.g., by downregulating squalene epoxidase. As another example, it may be desirable to inhibit 15 degradative functions of certain endogenous gene products, e.g., glycohydrolases that remove glucose moieties from secondary metabolites or phosphatases as discussed herein. As another example, expression of membrane transporters involved in transport of steviol glycosides can be inhibited, such that secretion of glycosylated steviosides is inhibited. Such regulation can be beneficial in that secretion of steviol glycosides can be 20 inhibited for a desired period of time during culture of the microorganism, thereby increasing the yield of glycoside product(s) at harvest. In such cases, a nucleic acid that inhibits expression of the polypeptide or gene product may be included in a recombinant construct that is transformed into the strain. Alternatively, mutagenesis can be used to generate mutants in genes for which it is desired to inhibit function.

25 **III. Hosts**

A. Microorganisms

A number of prokaryotes and eukaryotes are suitable for use in constructing the recombinant microorganisms described herein, e.g., gram-negative bacteria, yeast and fungi. A species and strain selected for use as a steviol or steviol glycoside production

strain is first analyzed to determine which production genes are endogenous to the strain and which genes are not present. Genes for which an endogenous counterpart is not present in the strain are assembled in one or more recombinant constructs, which are then transformed into the strain in order to supply the missing function(s).

5 Exemplary prokaryotic and eukaryotic species are described in more detail below. However, it will be appreciated that other species may be suitable. For example, suitable species may be in a genus selected from the group consisting of *Agaricus*, *Aspergillus*, *Bacillus*, *Candida*, *Corynebacterium*, *Escherichia*, *Fusarium*/*Gibberella*, *Kluyveromyces*, *Laetiporus*, *Lentinus*, *Phaffia*, *Phanerochaete*, *Pichia*, *Physcomitrella*, *Rhodoturula*,
10 *Saccharomyces*, *Schizosaccharomyces*, *Sphaceloma*, *Xanthophyllomyces* and *Yarrowia*. Exemplary species from such genera include *Lentinus tigrinus*, *Laetiporus sulphureus*, *Phanerochaete chrysosporium*, *Pichia pastoris*, *Physcomitrella patens*, *Rhodoturula glutinis* 32, *Rhodoturula mucilaginosa*, *Phaffia rhodozyma* UBV-AX, *Xanthophyllomyces dendrorhous*, *Fusarium fujikuroi*/*Gibberella fujikuroi*, *Candida utilis*
15 and *Yarrowia lipolytica*. In some embodiments, a microorganism can be an Ascomycete such as *Gibberella fujikuroi*, *Kluyveromyces lactis*, *Schizosaccharomyces pombe*, *Aspergillus niger*, or *Saccharomyces cerevisiae*. In some embodiments, a microorganism can be a prokaryote such as *Escherichia coli*, *Rhodobacter sphaeroides*, or *Rhodobacter capsulatus*. It will be appreciated that certain microorganisms can be used to screen and
20 test genes of interest in a high throughput manner, while other microorganisms with desired productivity or growth characteristics can be used for large-scale production of steviol glycosides.

Saccharomyces cerevisiae

Saccharomyces cerevisiae is a widely used chassis organism in synthetic biology,
25 and can be used as the recombinant microorganism platform. There are libraries of mutants, plasmids, detailed computer models of metabolism and other information available for *S. cerevisiae*, allowing for rational design of various modules to enhance product yield. Methods are known for making recombinant microorganisms.

A steviol biosynthesis gene cluster can be expressed in yeast using any of a
30 number of known promoters. Strains that overproduce terpenes are known and can be

used to increase the amount of geranylgeranyl diphosphate available for steviol and steviol glycoside production.

Aspergillus spp.

Aspergillus species such as *A. oryzae*, *A. niger* and *A. sojae* are widely used
5 microorganisms in food production, and can also be used as the recombinant
microorganism platform. Nucleotide sequences are available for genomes of *A. nidulans*,
A. fumigatus, *A. oryzae*, *A. clavatus*, *A. flavus*, *A. niger*, and *A. terreus*, allowing rational
design and modification of endogenous pathways to enhance flux and increase product
yield. Metabolic models have been developed for *Aspergillus*, as well as transcriptomic
10 studies and proteomics studies. *A. niger* is cultured for the industrial production of a
number of food ingredients such as citric acid and gluconic acid, and thus species such as
A. niger are generally suitable for the production of food ingredients such as steviol and
steviol glycosides.

Escherichia coli

15 *Escherichia coli*, another widely used platform organism in synthetic biology, can
also be used as the recombinant microorganism platform. Similar to *Saccharomyces*,
there are libraries of mutants, plasmids, detailed computer models of metabolism and
other information available for *E. coli*, allowing for rational design of various modules to
enhance product yield. Methods similar to those described above for *Saccharomyces* can
20 be used to make recombinant *E. coli* microorganisms.

Agaricus, *Gibberella*, and *Phanerochaete* spp.

Agaricus, *Gibberella*, and *Phanerochaete* spp. can be useful because they are
known to produce large amounts of gibberellin in culture. Thus, the terpene precursors
for producing large amounts of steviol and steviol glycosides are already produced by
25 endogenous genes. Thus, modules containing recombinant genes for steviol or steviol
glycoside biosynthesis polypeptides can be introduced into species from such genera
without the necessity of introducing mevalonate or MEP pathway genes.

Arxula adeninivorans (*Blastobotrys adeninivorans*)

Arxula adeninivorans is a dimorphic yeast (it grows as a budding yeast like the
30 baker's yeast up to a temperature of 42 °C, above this threshold it grows in a filamentous

form) with unusual biochemical characteristics. It can grow on a wide range of substrates and can assimilate nitrate. It has successfully been applied to the generation of strains that can produce natural plastics or the development of a biosensor for estrogens in environmental samples.

5 *Yarrowia lipolytica*

Yarrowia lipolytica is a dimorphic yeast (see *Arxula adeninivorans*) that can grow on a wide range of substrates. It has a high potential for industrial applications but there are no recombinant products commercially available yet.

Rhodobacter spp.

10 *Rhodobacter* can be used as the recombinant microorganism platform. Similar to *E. coli*, there are libraries of mutants available as well as suitable plasmid vectors, allowing for rational design of various modules to enhance product yield. Isoprenoid pathways have been engineered in membranous bacterial species of *Rhodobacter* for increased production of carotenoid and CoQ10. See, U.S. Patent Publication Nos.
15 20050003474 and 20040078846. Methods similar to those described above for *E. coli* can be used to make recombinant *Rhodobacter* microorganisms.

Candida boidinii

Candida boidinii is a methylotrophic yeast (it can grow on methanol). Like other methylotrophic species such as *Hansenula polymorpha* and *Pichia pastoris*, it provides
20 an excellent platform for the production of heterologous proteins. Yields in a multigram range of a secreted foreign protein have been reported. A computational method, IPRO, recently predicted mutations that experimentally switched the cofactor specificity of *Candida boidinii* xylose reductase from NADPH to NADH.

Hansenula polymorpha (*Pichia angusta*)

25 *Hansenula polymorpha* is another methylotrophic yeast (see *Candida boidinii*). It can furthermore grow on a wide range of other substrates; it is thermo-tolerant and can assimilate nitrate (see also *Kluyveromyces lactis*). It has been applied to the production of hepatitis B vaccines, insulin and interferon alpha-2a for the treatment of hepatitis C, furthermore to a range of technical enzymes.

30 *Kluyveromyces lactis*

Kluyveromyces lactis is a yeast regularly applied to the production of kefir. It can grow on several sugars, most importantly on lactose which is present in milk and whey. It has successfully been applied among others to the production of chymosin (an enzyme that is usually present in the stomach of calves) for the production of cheese. Production takes place in fermenters on a 40,000 L scale.

Pichia pastoris

Pichia pastoris is a methylotrophic yeast (see *Candida boidinii* and *Hansenula polymorpha*). It provides an efficient platform for the production of foreign proteins. Platform elements are available as a kit and it is worldwide used in academia for the production of proteins. Strains have been engineered that can produce complex human N-glycan (yeast glycans are similar but not identical to those found in humans).

Physcomitrella spp.

Physcomitrella mosses, when grown in suspension culture, have characteristics similar to yeast or other fungal cultures. This genera is becoming an important type of cell for production of plant secondary metabolites, which can be difficult to produce in other types of cells.

B. Plant Cells or Plants

In some embodiments, the nucleic acids and polypeptides described herein are introduced into plants or plant cells to increase overall steviol glycoside production or enrich for the production of specific steviol glycosides in proportion to others. Thus, a host can be a plant or a plant cell that includes at least one recombinant gene described herein. A plant or plant cell can be transformed by having a recombinant gene integrated into its genome, *i.e.*, can be stably transformed. Stably transformed cells typically retain the introduced nucleic acid with each cell division. A plant or plant cell can also be transiently transformed such that the recombinant gene is not integrated into its genome. Transiently transformed cells typically lose all or some portion of the introduced nucleic acid with each cell division such that the introduced nucleic acid cannot be detected in daughter cells after a sufficient number of cell divisions. Both transiently transformed

and stably transformed transgenic plants and plant cells can be useful in the methods described herein.

Transgenic plant cells used in methods described herein can constitute part or all of a whole plant. Such plants can be grown in a manner suitable for the species under
5 consideration, either in a growth chamber, a greenhouse, or in a field. Transgenic plants can be bred as desired for a particular purpose, *e.g.*, to introduce a recombinant nucleic acid into other lines, to transfer a recombinant nucleic acid to other species, or for further selection of other desirable traits. Alternatively, transgenic plants can be propagated vegetatively for those species amenable to such techniques. As used herein, a transgenic
10 plant also refers to progeny of an initial transgenic plant provided the progeny inherits the transgene. Seeds produced by a transgenic plant can be grown and then selfed (or outcrossed and selfed) to obtain seeds homozygous for the nucleic acid construct.

Transgenic plants can be grown in suspension culture, or tissue or organ culture. For the purposes of this invention, solid and/or liquid tissue culture techniques can be
15 used. When using solid medium, transgenic plant cells can be placed directly onto the medium or can be placed onto a filter that is then placed in contact with the medium. When using liquid medium, transgenic plant cells can be placed onto a flotation device, *e.g.*, a porous membrane that contacts the liquid medium.

When transiently transformed plant cells are used, a reporter sequence encoding a
20 reporter polypeptide having a reporter activity can be included in the transformation procedure and an assay for reporter activity or expression can be performed at a suitable time after transformation. A suitable time for conducting the assay typically is about 1-21 days after transformation, *e.g.*, about 1-14 days, about 1-7 days, or about 1-3 days. The use of transient assays is particularly convenient for rapid analysis in different
25 species, or to confirm expression of a heterologous polypeptide whose expression has not previously been confirmed in particular recipient cells.

Techniques for introducing nucleic acids into monocotyledonous and dicotyledonous plants are known in the art, and include, without limitation, *Agrobacterium*-mediated transformation, viral vector-mediated transformation,
30 electroporation and particle gun transformation, U.S. Patent Nos 5,538,880; 5,204,253;

6,329,571; and 6,013,863. If a cell or cultured tissue is used as the recipient tissue for transformation, plants can be regenerated from transformed cultures if desired, by techniques known to those skilled in the art.

A population of transgenic plants can be screened and/or selected for those members of the population that have a trait or phenotype conferred by expression of the transgene. For example, a population of progeny of a single transformation event can be screened for those plants having a desired level of expression of a steviol or steviol glycoside biosynthesis polypeptide or nucleic acid. Physical and biochemical methods can be used to identify expression levels. These include Southern analysis or PCR amplification for detection of a polynucleotide; Northern blots, S1 RNase protection, primer-extension, or RT-PCR amplification for detecting RNA transcripts; enzymatic assays for detecting enzyme or ribozyme activity of polypeptides and polynucleotides; and protein gel electrophoresis, Western blots, immunoprecipitation, and enzyme-linked immunoassays to detect polypeptides. Other techniques such as *in situ* hybridization, enzyme staining, and immunostaining also can be used to detect the presence or expression of polypeptides and/or nucleic acids. Methods for performing all of the referenced techniques are known. As an alternative, a population of plants comprising independent transformation events can be screened for those plants having a desired trait, such as production of a steviol glycoside or modulated biosynthesis of a steviol glycoside. Selection and/or screening can be carried out over one or more generations, and/or in more than one geographic location. In some cases, transgenic plants can be grown and selected under conditions which induce a desired phenotype or are otherwise necessary to produce a desired phenotype in a transgenic plant. In addition, selection and/or screening can be applied during a particular developmental stage in which the phenotype is expected to be exhibited by the plant. Selection and/or screening can be carried out to choose those transgenic plants having a statistically significant difference in a steviol glycoside level relative to a control plant that lacks the transgene.

The nucleic acids, recombinant genes, and constructs described herein can be used to transform a number of monocotyledonous and dicotyledonous plants and plant cell systems. Non-limiting examples of suitable monocots include, for example, cereal

crops such as rice, rye, sorghum, millet, wheat, maize, and barley. The plant may be a non-cereal monocot such as asparagus, banana, or onion. The plant also may be a dicot such as stevia (*Stevia rebaudiana*), soybean, cotton, sunflower, pea, geranium, spinach, or tobacco. In some cases, the plant may contain the precursor pathways for phenyl
5 phosphate production such as the mevalonate pathway, typically found in the cytoplasm and mitochondria. The non-mevalonate pathway is more often found in plant plastids [Dubey, et al., 2003 *J. Biosci.* **28** 637–646]. One with skill in the art may target expression of steviol glycoside biosynthesis polypeptides to the appropriate organelle through the use of leader sequences, such that steviol glycoside biosynthesis occurs in the
10 desired location of the plant cell. One with skill in the art will use appropriate promoters to direct synthesis, e.g., to the leaf of a plant, if so desired. Expression may also occur in tissue cultures such as callus culture or hairy root culture, if so desired.

In one embodiment, one or more nucleic acid or polypeptides described herein are introduced into *Stevia* (e.g., *Stevia rebaudiana*) such that overall steviol glycoside
15 biosynthesis is increased or that the overall steviol glycoside composition is selectively enriched for one or more specific steviol glycosides (e.g., rebaudioside D). For example, one or more recombinant genes can be introduced into *Stevia* such that a EUGT11 enzyme (e.g., SEQ ID NO: 152 or a functional homolog thereof) is expressed alone or in combination with one or more of: a UGT91D enzyme such as UGT91D2e (e.g., SEQ ID
20 NO:5 or a functional homolog thereof), UGT91D2m (e.g., SEQ ID NO:10); a UGT85C enzyme such as a variant described in the “Functional Homolog” section, a UGT76G1 enzyme such as a variant described in the “Functional Homolog” section, or a UGT74G1 enzyme. Nucleic acid constructs typically include a suitable promoter (e.g., 35S, e35S, or ssRUBISCO promoters) operably linked to a nucleic acid encoding the UGT
25 polypeptide. Nucleic acids can be introduced into *Stevia* by *Agrobacterium*-mediated transformation; electroporation-mediated gene transfer to protoplasts; or by particle bombardment. See, e.g., Singh, et al., *Compendium of Transgenic Crop Plants: Transgenic Sugar, Tuber and Fiber*, Edited by Chittaranjan Kole and Timothy C. Hall, Blackwell Publishing Ltd. (2008), pp. 97-115. For particle bombardment of stevia leaf

derived callus, the parameters can be as follows: 6 cm distance, 1100 psi He pressure, gold particles, and one bombardment.

Stevia plants can be regenerated by somatic embryogenesis as described by Singh et al., 2008, *supra*. In particular, leaf segments (approximately 1-2cm long) can be removed from 5 to 6-week-old *in vitro* raised plants and incubated (adaxial side down) on MS medium supplemented with B5 vitamins, 30 g sucrose and 3 g Gelrite. 2,4-dichlorophenoxyacetic acid (2,4-D) can be used in combination with 6-benzyl adenine (BA), kinetin (KN), or zeatin. Proembryogenic masses appear after 8 weeks of subculture. Within 2-3 weeks of subcultures, somatic embryos will appear on the surface of cultures. Embryos can be matured in medium containing BA in combination with 2,4-D, α -naphthaleneacetic acid (NAA), or indolbutyric acid (IBA). Mature somatic embryos that germinate and form plantlets can be excised from calli. After plantlets reach 3-4 weeks, the plantlets can be transferred to pots with vermiculite and grown for 6-8 weeks in growth chambers for acclimatization and transferred to greenhouses.

In one embodiment, steviol glycosides are produced in rice. Rice and maize are readily transformable using techniques such as *Agrobacterium*-mediated transformation. Binary vector systems are commonly utilized for *Agrobacterium* exogenous gene introduction to monocots. See, for example, U.S. Patent Nos. 6,215,051 and 6,329,571. In a binary vector system, one vector contains the T-DNA region, which includes a gene of interest (e.g., a UGT described herein) and the other vector is a disarmed Ti plasmid containing the *vir* region. Co-integrated vectors and mobilizable vectors also can be used. The types and pretreatment of tissues to be transformed, the strain of *Agrobacterium* used, the duration of the inoculation, the prevention of overgrowth and necrosis by the *Agrobacterium*, can be readily adjusted by one of skill in the art. Immature embryo cells of rice can be prepared for transformation with *Agrobacterium* using binary vectors. The culture medium used is supplemented with phenolic compounds. Alternatively, the transformation can be done *in planta* using vacuum infiltration. See, for example, WO 2000037663, WO 2000063400, and WO 2001012828.

IV. Methods of Producing Steviol Glycosides

Recombinant hosts described herein can be used in methods to produce steviol or steviol glycosides. For example, if the recombinant host is a microorganism, the method can include growing the recombinant microorganism in a culture medium under conditions in which steviol and/or steviol glycoside biosynthesis genes are expressed. The recombinant microorganism may be grown in a fed batch or continuous process. Typically, the recombinant microorganism is grown in a fermentor at a defined temperature(s) for a desired period of time. Depending on the particular microorganism used in the method, other recombinant genes such as isopentenyl biosynthesis genes and terpene synthase and cyclase genes may also be present and expressed. Levels of substrates and intermediates, e.g., isopentenyl diphosphate, dimethylallyl diphosphate, geranylgeranyl diphosphate, kaurene and kaurenoic acid, can be determined by extracting samples from culture media for analysis according to published methods.

After the recombinant microorganism has been grown in culture for the desired period of time, steviol and/or one or more steviol glycosides can then be recovered from the culture using various techniques known in the art. In some embodiments, a permeabilizing agent can be added to aid the feedstock entering into the host and product getting out. If the recombinant host is a plant or plant cells, steviol or steviol glycosides can be extracted from the plant tissue using various techniques known in the art. For example, a crude lysate of the cultured microorganism or plant tissue can be centrifuged to obtain a supernatant. The resulting supernatant can then be applied to a chromatography column, e.g., a C-18 column, and washed with water to remove hydrophilic compounds, followed by elution of the compound(s) of interest with a solvent such as methanol. The compound(s) can then be further purified by preparative HPLC. See also WO 2009/140394.

The amount of steviol glycoside (e.g., rebaudioside D) produced can be from about 1 mg/L to about 1500 mg/L, e.g., about 1 to about 10 mg/L, about 3 to about 10 mg/L, about 5 to about 20 mg/L, about 10 to about 50 mg/L, about 10 to about 100 mg/L, about 25 to about 500 mg/L, about 100 to about 1,500 mg/L, or about 200 to about 1,000 mg/L. In general, longer culture times will lead to greater amounts of product. Thus, the

recombinant microorganism can be cultured for from 1 day to 7 days, from 1 day to 5 days, from 3 days to 5 days, about 3 days, about 4 days, or about 5 days.

It will be appreciated that the various genes and modules discussed herein can be present in two or more recombinant microorganisms rather than a single microorganism. When a plurality of recombinant microorganisms is used, they can be grown in a mixed culture to produce steviol and/or steviol glycosides. For example, a first microorganism can comprise one or more biosynthesis genes for producing steviol while a second microorganism comprises steviol glycoside biosynthesis genes. Alternatively, the two or more microorganisms each can be grown in a separate culture medium and the product of the first culture medium, e.g., steviol, can be introduced into second culture medium to be converted into a subsequent intermediate, or into an end product such as rebaudioside A. The product produced by the second, or final microorganism is then recovered. It will also be appreciated that in some embodiments, a recombinant microorganism is grown using nutrient sources other than a culture medium and utilizing a system other than a fermentor.

Steviol glycosides do not necessarily have equivalent performance in different food systems. It is therefore desirable to have the ability to direct the synthesis to steviol glycoside compositions of choice. Recombinant hosts described herein can produce compositions that are selectively enriched for specific steviol glycosides (e.g., rebaudioside D) and have a consistent taste profile. Thus, the recombinant microorganisms, plants, and plant cells described herein can facilitate the production of compositions that are tailored to meet the sweetening profile desired for a given food product and that have a proportion of each steviol glycoside that is consistent from batch to batch. Microorganisms described herein do not produce the undesired plant byproducts found in Stevia extracts. Thus, steviol glycoside compositions produced by the recombinant microorganisms described herein are distinguishable from compositions derived from Stevia plants.

V. Food Products

The steviol glycosides obtained by the methods disclosed herein can be used to make food products, dietary supplements and sweetener compositions. For example, substantially pure steviol or steviol glycoside such as rebaudioside A or rebaudioside D
5 can be included in food products such as ice cream, carbonated beverages, fruit juices, yogurts, baked goods, chewing gums, hard and soft candies, and sauces. Substantially pure steviol or steviol glycoside can also be included in non-food products such as pharmaceutical products, medicinal products, dietary supplements and nutritional supplements. Substantially pure steviol or steviol glycosides may also be included in
10 animal feed products for both the agriculture industry and the companion animal industry. Alternatively, a mixture of steviol and/or steviol glycosides can be made by culturing recombinant microorganisms separately or growing different plants/plant cells, each producing a specific steviol or steviol glycoside, recovering the steviol or steviol glycoside in substantially pure form from each microorganism or plant/plant cells and
15 then combining the compounds to obtain a mixture containing each compound in the desired proportion. The recombinant microorganisms, plants, and plant cells described herein permit more precise and consistent mixtures to be obtained compared to current Stevia products. In another alternative, a substantially pure steviol or steviol glycoside can be incorporated into a food product along with other sweeteners, e.g. saccharin,
20 dextrose, sucrose, fructose, erythritol, aspartame, sucralose, monatin, or acesulfame potassium. The weight ratio of steviol or steviol glycoside relative to other sweeteners can be varied as desired to achieve a satisfactory taste in the final food product. See, e.g., U.S. Patent Publication No. 2007/0128311. In some embodiments, the steviol or steviol glycoside may be provided with a flavor (e.g., citrus) as a flavor modulator. For
25 example, Rebaudioside C can be used as a sweetness enhancer or sweetness modulator, in particular for carbohydrate based sweeteners, such that the amount of sugar can be reduced in the food product.

Compositions produced by a recombinant microorganism, plant, or plant cell described herein can be incorporated into food products. For example, a steviol
30 glycoside composition produced by a recombinant microorganism, plant, or plant cell can

be incorporated into a food product in an amount ranging from about 20 mg steviol glycoside/kg food product to about 1800 mg steviol glycoside/kg food product on a dry weight basis, depending on the type of steviol glycoside and food product. For example, a steviol glycoside composition produced by a recombinant microorganism, plant, or plant cell can be incorporated into a dessert, cold confectionary (e.g., ice cream), dairy product (e.g., yogurt), or beverage (e.g., a carbonated beverage) such that the food product has a maximum of 500 mg steviol glycoside/kg food on a dry weight basis. A steviol glycoside composition produced by a recombinant microorganism, plant, or plant cell can be incorporated into a baked good (e.g., a biscuit) such that the food product has a maximum of 300 mg steviol glycoside/kg food on a dry weight basis. A steviol glycoside composition produced by a recombinant microorganism, plant, or plant cell can be incorporated into a sauce (e.g., chocolate syrup) or vegetable product (e.g., pickles) such that the food product has a maximum of 1000 mg steviol glycoside/kg food on a dry weight basis. A steviol glycoside composition produced by a recombinant microorganism, plant, or plant cell can be incorporated into a bread such that the food product has a maximum of 160 mg steviol glycoside/kg food on a dry weight basis. A steviol glycoside composition produced by a recombinant microorganism, plant, or plant cell can be incorporated into a hard or soft candy such that the food product has a maximum of 1600 mg steviol glycoside/kg food on a dry weight basis. A steviol glycoside composition produced by a recombinant microorganism, plant, or plant cell can be incorporated into a processed fruit product (e.g., fruit juices, fruit filling, jams, and jellies) such that the food product has a maximum of 1000 mg steviol glycoside/kg food on a dry weight basis.

For example, such a steviol glycoside composition can have from 90-99% rebaudioside A and an undetectable amount of stevia plant-derived contaminants, and be incorporated into a food product at from 25-1600 mg/kg, e.g., 100-500 mg/kg, 25-100 mg/kg, 250-1000 mg/kg, 50-500 mg/kg or 500-1000 mg/kg on a dry weight basis.

Such a steviol glycoside composition can be a rebaudioside B-enriched composition having greater than 3% rebaudioside B and be incorporated into the food product such that the amount of rebaudioside B in the product is from 25-1600 mg/kg,

e.g., 100-500 mg/kg, 25-100 mg/kg, 250-1000 mg/kg, 50-500 mg/kg or 500-1000 mg/kg on a dry weight basis. Typically, the rebaudioside B-enriched composition has an undetectable amount of stevia plant-derived contaminants.

Such a steviol glycoside composition can be a rebaudioside C-enriched composition having greater than 15% rebaudioside C and be incorporated into the food product such that the amount of rebaudioside C in the product is from 20-600 mg/kg, e.g., 100-600 mg/kg, 20-100 mg/kg, 20-95 mg/kg, 20-250 mg/kg, 50-75 mg/kg or 50-95 mg/kg on a dry weight basis. Typically, the rebaudioside C-enriched composition has an undetectable amount of stevia plant-derived contaminants.

Such a steviol glycoside composition can be a rebaudioside D-enriched composition having greater than 3% rebaudioside D and be incorporated into the food product such that the amount of rebaudioside D in the product is from 25-1600 mg/kg, e.g., 100-500 mg/kg, 25-100 mg/kg, 250-1000 mg/kg, 50-500 mg/kg or 500-1000 mg/kg on a dry weight basis. Typically, the rebaudioside D-enriched composition has an undetectable amount of stevia plant-derived contaminants.

Such a steviol glycoside composition can be a rebaudioside E-enriched composition having greater than 3% rebaudioside E and be incorporated into the food product such that the amount of rebaudioside E in the product is from 25-1600 mg/kg, e.g., 100-500 mg/kg, 25-100 mg/kg, 250-1000 mg/kg, 50-500 mg/kg or 500-1000 mg/kg on a dry weight basis. Typically, the rebaudioside E-enriched composition has an undetectable amount of stevia plant-derived contaminants.

Such a steviol glycoside composition can be a rebaudioside F-enriched composition having greater than 4% rebaudioside F and be incorporated into the food product such that the amount of rebaudioside F in the product is from 25-1000 mg/kg, e.g., 100-600 mg/kg, 25-100 mg/kg, 25-95 mg/kg, 50-75 mg/kg or 50-95 mg/kg on a dry weight basis. Typically, the rebaudioside F-enriched composition has an undetectable amount of stevia plant-derived contaminants.

Such a steviol glycoside composition can be a dulcoside A-enriched composition having greater than 4% dulcoside A and be incorporated into the food product such that the amount of dulcoside A in the product is from 25-1000 mg/kg, e.g., 100-600 mg/kg,

25-100 mg/kg, 25-95 mg/kg, 50-75 mg/kg or 50-95 mg/kg on a dry weight basis.

Typically, the dulcoside A-enriched composition has an undetectable amount of stevia plant-derived contaminants.


Such a steviol glycoside composition can be a composition enriched for
5 rubusoside xylosylated on either of the two positions--the 13-O-glucose or the 19-O-glucose. Such a composition can have greater than 4% of the xylosylated rubusoside compound, and can be incorporated into the food product such that the amount of xylosylated rubusoside compound in the product is from 25-1000 mg/kg, e.g., 100-600 mg/kg, 25-100 mg/kg, 25-95 mg/kg, 50-75 mg/kg or 50-95 mg/kg on a dry weight basis.
10 Typically, the xylosylated rubusoside enriched composition has an undetectable amount of stevia plant-derived contaminants.

Such a steviol glycoside composition can be a composition enriched for compounds rhamnosylated on either of the two positions--the 13-O-glucose or the 19-O-glucose, or compounds containing one rhamnose and multiple glucoses (e.g., steviol 13-O-1,3-diglycoside-1,2-rhamnoside). Such a composition can have greater than 4% of the
15 rhamnosylated compound, and can be incorporated into the food product such that the amount of rhamnosylated compound in the product is from 25-1000 mg/kg, e.g., 100-600 mg/kg, 25-100 mg/kg, 25-95 mg/kg, 50-75 mg/kg or 50-95 mg/kg on a dry weight basis. Typically, the composition enriched for rhamnosylated compounds has as an
20 undetectable amount of stevia plant-derived contaminants.

In some embodiments, a substantially pure steviol or steviol glycoside is incorporated into a tabletop sweetener or "cup-for-cup" product. Such products typically are diluted to the appropriate sweetness level with one or more bulking agents, e.g., maltodextrins, known to those skilled in the art. Steviol glycoside compositions enriched
25 for rebaudioside A, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, dulcoside A, or rhamnosylated or xylosylated compounds, can be package in a sachet, for example, at from 10,000 to 30,000 mg steviol glycoside/kg product on a dry weight basis, for tabletop use.

In some embodiments, this disclosure relates to the following items:

1. A recombinant host cell comprising a nucleic acid sequence, said nucleic acid comprising a heterologous insert sequence operably linked to an open reading frame, wherein the heterologous insert sequence has the general formula (I):



5 wherein X_2 comprises at least 4 consecutive nucleotides complementary to at least 4 consecutive nucleotides of X_4 ,

wherein X_3 comprises zero nucleotides, or one or more nucleotides forming a hairpin loop,

wherein X_1 and X_5 each individually consists of zero nucleotides, or one or more
10 nucleotides,


wherein the open reading frame encodes a squalene synthase (EC 2.5.1.21).

2. The recombinant cell according to item 1, said nucleic acid comprises in 5' to 3' order, a promoter sequence operably linked to a heterologous insert sequence operably linked to an open reading frame, wherein the heterologous insert sequence and
15 the open reading frame are as defined in item 1.

3. A cell comprising a nucleic acid sequence, said nucleic acid comprising

- i) a promoter sequence operably linked to
- ii) a heterologous insert sequence operably linked to
- iii) an open reading frame operably linked to
- 20 iv) a transcription termination signal,

wherein the heterologous insert sequence has the general formula (I):



wherein X_2 comprises at least 4 consecutive nucleic acids being complementary to, and forms a hairpin secondary structure element with at least 4 consecutive nucleic
25 acids of X_4 , and

wherein X_3 comprises unpaired nucleic acids thus forming a hairpin loop between X_2 and X_4 , and

wherein X_1 and X_5 individually and optionally comprises one or more nucleic
30 acids, and

wherein the open reading frame upon expression encodes a polypeptide sequence having at least 70% identity to a squalene synthase (EC 2.5.1.21) or a biologically active fragment thereof, said fragment having at least 70% sequence identity to said squalene synthase in a range of overlap of at least 100 amino acids.

5 4. The cell according to any one of items 1 to 3, wherein the heterologous insert sequence comprises 10-50 nucleotides, preferably 10-30 nucleotides, more preferably 15-25 nucleotides, more preferably 17-22 nucleotides, more preferably 18-21 nucleotides, more preferably 18-20 nucleotides, more preferably 19 nucleotides.

 5. The cell according to any one of items 1 to 4, wherein X_2 and X_4 consists of the
10 same number of nucleotides.

 6. The cell according to any one of items 1 to 5, wherein all X_2 consists of in the range of 4 to 25, such as in the range of 4 to 20, for example of in the range of 4 to 15, such as in the range of 6 to 12, for example in the range of 8 to 12, such as in the range of 9 to 11 nucleotides.

15 7. The cell according to any one of items 1 to 6, wherein all X_4 consists of in the range of 4 to 25, such as in the range of 4 to 20, for example of in the range of 4 to 15, such as in the range of 6 to 12, for example in the range of 8 to 12, such as in the range of 9 to 11 nucleotides.

 8. The cell according to any one of items 1 to 7, wherein X_2 consists of a
20 nucleotide sequence, which is complementary to the nucleotide sequence of X_4 .

 9. The cell according to any one of items 1 to 8, wherein X_4 consists of a nucleotide sequence, which is complementary to the nucleotide sequence of X_2 .

 10. The cell according to any one of items 1 to 9, wherein X_3 is absent, i.e. X_3 consists of zero nucleotides.

25 11. The cell according to any one of items 1 to 9, wherein X_3 consists of in the range of 1 to 5, such as in the range of 1 to 3 nucleotides.

 12. The cell according to any one of items 1 to 11, wherein X_1 is absent, i.e. X_1 consists of zero nucleotides.

 13. The cell according to any one of items 1 to 11, wherein X_1 consists of in the
30 range of 1 to 25, such as in the range of 1 to 20, for example in the range of 1 to 15, such

as in the range of 1 to 10, for example in the range of 1 to 5, such as in the range of 1 to 3 nucleotides.

14. The cell according to any one items 1 to 13, wherein X_5 is absent, i.e. X_5 consists of zero nucleotides.

5 15. The cell according to any one of items 1 to 11, wherein X_5 consists of in the range 1 to 5, such as in the range of 1 to 3 nucleotides.

16. The cell according to any one of items 1 to 15, wherein the heterologous insert sequence comprises a sequence selected from the group consisting of SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 183 and SEQ ID NO: 184.

10 17. The cell according to any one of items 1 to 16, wherein the heterologous insert sequence is selected from the group consisting of SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 183 and SEQ ID NO: 184.

18. The cell according to any one of items 1 to 17, wherein the squalene synthase is at least 75%, such as at least 80%, such as at least 85%, such as at least 87%, such as at
15 least 90%, such as at least 91%, such as at least 92%, such as at least 93%, such as at least 94%, such as at least 95%, such as at least 96%, such as at least 97%, such as at least 98%, such as at least 99%, such as 100% identical to a squalene synthase selected from the group consisting of SEQ ID NO: 192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ
20 ID NO:199, SEQ ID NO:200, SEQ ID NO:201, and SEQ ID NO:202.

19. The cell according to any one of items 1 to 18, wherein said promoter is a constitutive or inducible promoter.

20. The cell according to any one of items 1 to 19, wherein said promoter is selected from the group consisting of an endogenous promoter, GPD1, PGK1, ADH1,
25 ADH2, PYK1, TPI1, PDC1, TEF1, TEF2, FBA1, GAL1-10, CUP1, MET2, MET14, MET25, CYC1, GAL1-S, GAL1-L, TEF1, ADH1, CAG, CMV, human UbiC, RSV, EF-1alpha, SV40, Mt1, Tet-On, Tet-Off, Mo-MLV-LTR, Mx1, progesterone, RU486 and Rapamycin-inducible promoter.

21. The cell according to any one of items 1 to 20, wherein the nucleic acid
30 sequence further comprises a polyadenyl sequence.

22. The cell according to item 21, wherein the 5' end of said polyadenyl sequence is operably linked to the 3' end of the nucleic acid of item 1.

23. The cell according to any one of items 1 to 22, wherein the nucleic acid sequence further comprises a post-transcriptional regulatory element.

5 24. The cell of item 23, wherein said post-transcriptional regulatory element is a Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE).

25. The cell of any of items 1 to 24, wherein the nucleic acid comprises a 5' terminal repeat and a 3' terminal repeat.

10 26. The cell of item 25, wherein the 5' and 3' terminal repeats are selected from Inverted Terminal Repeats [ITR] and Long Terminal Repeats [LTR].

27. The cell according to any one of items 1 to 26, wherein the nucleic acid sequence is integrated in a vector.

28. The cell of item 27, wherein the vector is an expression vector.

15 29. The cell of item 27, wherein the vector is selected from the group consisting of plasmid vectors, cosmids, artificial chromosomes and viral vectors.

30. The cell of item 29 wherein the plasmid vector can be maintained and replicated in bacteria, fungi and yeast.

20 31. The cell of item 29, wherein the viral vector is selected from the group consisting of vectors derived from the Retroviridae family including lentivirus, HIV, SIV, FIV, EAIV, CIV.

32. The cell of item 31, wherein the viral vector is selected from the group consisting of alphavirus, adenovirus, adeno associated virus, baculovirus, HSV, coronavirus, Bovine papilloma virus, Mo-MLV and adeno associated virus.

25 33. The cell of any of items 27 to 32, wherein said vector is functional in mammalian cells.

34. The cell of any of the preceding items wherein the cell is transformed or transduced with the vector of any of the items 27 to 33.

35. The cell of any of items 1 to 34, wherein said cell is a eukaryotic cell.

36. The cell of any of items 1 to 34, wherein said cell is a prokaryotic cell.

37. The cell of item 35, wherein said cell is selected from the group consisting of fungi cells such as yeast and aspergillus; microalgae such as Chlorella and Prototheca; plant cells; and mammalian cells, such as human, feline, porcine, simian, canine, murine, rat, mouse and rabbit cells.

5 38. The cell of item 37, wherein the yeast is selected from the group consisting of *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Yarrowia lipolytica*, *Candida glabrata*, *Ashbya gossypii*, *Cyberlindnera jadinii*, and *Candida albicans*.

39. The cell of item 37, wherein the cell is selected from the group consisting of CHO, CHO-K1, HEI193T, HEK293, COS, PC12, HiB5, RN33b, BHK cells.

10 40. The cell of item 36, wherein said cell is *E. coli*, *Corynebacterium*, *Bacillus*, *Pseudomonas* or *Streptomyces*.

41. The cell of any of items 35 to 40, wherein said prokaryotic cell, or said fungi cell, has been genetically modified to express at least a portion of the enzymes of the mevalonate independent pathway.

15 42. The cell according to any one of items 1 to 41, wherein the cell furthermore comprises a heterologous nucleic acid encoding GGPPS operably linked to a nucleic acid sequence directing expression of GGPPS in said cell.

43. The cell according to item 42, wherein said GGPPS is selected from the groups consisting of SEQ ID NO: 126, SEQ ID NO:123, SEQ ID NO:203, SEQ ID
20 NO:167, and functional homologues thereof sharing at least 75% sequence identity with any of the aforementioned.

43. A method for producing a terpenoid compound synthesized through the squalene pathway, in a cell culture, said method comprising the steps of

- 25 (a) providing the cell of any one of items 1 to 42,
 (b) culturing the cell of (a).
 (c) recovering the terpenoid product compound.

44. A method for producing a terpenoid derived from a terpenoid precursor selected from the group consisting of Farnesyl-pyrophosphate (FPP), Isopentenyl-pyrophosphate (IPP), Dimethylallyl-pyrophosphate (DMAPP), Geranyl-pyrophosphate

(GPP) and/or Geranylgeranyl-pyrophosphate (GGPP),
said method comprising:

(a) contacting said precursor with an enzyme of the squalene synthase pathway,

5 (b) recovering the terpenoid product.

45. The method of any of items 44 and 45, wherein the terpenoid product is selected from the group consisting of hemiterpenoids, monoterpenes, sesquiterpenoids, diterpenoids, sesterpenes, triterpenoids, tetraterpenoids and polyterpenoids.

46. The method of item 44, wherein the terpenoid is selected from the group
10 consisting of farnesyl phosphate, farnesol, geranylgeranyl, geranylgeraniol, isoprene, prenol, isovaleric acid, geranyl pyrophosphate, eucalyptol, limonene, pinene, farnesyl pyrophosphate, artemisinin, bisabolol, geranylgeranyl pyrophosphate, retinol, retinal, phytol, taxol, forskolin, aphidicolin, lanosterol, lycopene and carotene.

47. The method of item 46, wherein said method further comprises
15 dephosphorylating the farnesyl phosphate to produce farnesol.

48. The method of item 44, wherein the enzyme of the squalene synthase pathway is selected from the group consisting of Dimethylallyltransferase (EC 2.5.1.1), Isoprene synthase (EC 4.2.3.27) and Geranyltranstransferase (EC 2.5.1.10).

49. A method for reducing the translation rate of a functional squalene synthase
20 (EC 2.5.1.21) said method comprising:

- (a) providing the cell of any one of items 1 to 42,
- (b) culturing the cell of (a).

50. A method for decreasing turnover of farnesyl-pp to squalene, said method comprising:

- 25
- (d) providing the cell of any one of items 1 to 42,
 - (e) culturing the cell of (a).

51. A method for enhancing accumulation of a compound selected from the group consisting of Farnesyl-pyrophosphate, Isopentenyl-pyrophosphate, Dimethylallyl-pyrophosphate, Geranyl-pyrophosphate and Geranylgeranyl-pyrophosphate, said method
30 comprising the steps of:

- (a) providing the cell of any one of items 1 to 42, and
- (b) culturing the cell of (a).

52. The method of item 51, further comprising recovering the Farnesyl-pyrophosphate, Isopentenyl-pyrophosphate, Dimethylallyl-pyrophosphate, Geranyl-pyrophosphate or Geranylgeranyl-pyrophosphate compound.

53. The method of any one of items 51 and 52, further comprising recovering a compound synthesized through the squalene pathway, said compound being derived from said Farnesyl-pyrophosphate, Isopentenyl-pyrophosphate, Dimethylallyl-pyrophosphate, Geranyl-pyrophosphate and/or Geranylgeranyl-pyrophosphate.

54. The method of any of items 43 to 53, wherein the step of culturing the cell is performed in the presence of a squalene synthase inhibitor.

55. The method of any of items 43 to 54, wherein the cell additionally is genetically modified to enhance activity of and/or overexpress one or more enzymes selected from the group consisting of Phosphomevalonate kinase (EC 2.7.4.2), Diphosphomevalonate decarboxylase (EC 4.1.1.33), 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase (EC 1.17.7.1), 4-hydroxy-3-methylbut-2-enyl diphosphate reductase (EC 1.17.1.2), Isopentenyl-diphosphate Delta-isomerase 1 (EC 5.3.3.2), Short-chain Z-isoprenyl diphosphate synthase (EC 2.5.1.68), Dimethylallyltransferase (EC 2.5.1.1), Geranyltransferase (EC 2.5.1.10) and Geranylgeranyl pyrophosphate synthetase (EC 2.5.1.29).

56. The method of any of items 43 to 55, wherein the cell additionally is genetically modified to enhance activity of and/or overexpress one or more enzymes selected from the group consisting of acetoacetyl CoA thiolase, HMG-CoA reductase or the catalytic domain thereof, HMG-CoA synthase, mevalonate kinase, phosphomevalonate kinase, phosphomevalonate decarboxylase, isopentenyl pyrophosphate isomerase, farnesyl pyrophosphate synthase, D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase and farnesyl pyrophosphate synthase.

57. The method of any of items 43 to 56, wherein the cell comprises a mutation in the ERG9 open reading frame.

58. The method of any of items 43 to 57, wherein the cell comprises an ERG9[Delta]::HIS3 deletion/insertion allele.

59. The method of any of items 43 to 58, wherein the step of recovering the compound comprises purification of said compound from the cell culture media.

5

VI. Examples

The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims. In the examples described herein, the following LC-MS methodology was used to analyze steviol glycosides and steviol pathway intermediates unless otherwise indicated.

10

1) Analyses of steviol glycosides

LC-MS analyses were performed using an Agilent 1200 Series HPLC system (Agilent Technologies, Wilmington, DE, USA) fitted with a Phenomenex® kinetex C18 column (150 x 2.1 mm, 2.6 μ m particles, 100 Å pore size) connected to a TSQ Quantum Access (ThermoFisher Scientific) triple quadrupole mass spectrometer with a heated electrospray ion (HESI) source. Elution was carried out using a mobile phase of eluent B (MeCN with 0.1% Formic acid) and eluent A (water with 0.1% Formic acid) by increasing the gradient from 10->40 % B from min 0.0 to 1.0, increasing 40 -> 50% B in min 1.0 to 6.5, 50->100% B from min 6.5 to 7.0 and finally washing and re-equilibration.

The flow rate was 0.4ml/min and the column temperature 30°C. The steviol glycosides were detected using SIM (Single Ion Monitoring) in positive mode with the following m/z-traces.

20

Description	Exact Mass	m/z trace	compound (typical t_R in min)
Steviol + 1 Glucose	[M+H] ⁺ 481.2796	481.2± 0.5	19-SMG (6.1), 13-SMG (6.4)
	[M+Na] ⁺ 503.2615	503.1± 0.5	
Steviol + 2 Glucose	[M+Na] ⁺ 665.3149	665± 0.5	Rubusoside (4.7) Steviol-1,2-bioside (5.2) Steviol-1,3-bioside (5.8)
Steviol + 3 Glucose	[M+Na] ⁺ 827.3677	827.4 ± 0.5	1,2-Stevioside (4.0) 1,3-Stevioside (4.4) Rebaudioside B (5.0)
Steviol + 4 Glucose	[M+Na] ⁺ 989.4200	989.4 ± 0.5	Rebaudioside A (3.9)

Steviol + 5 Glucose	[M+Na] ⁺ 1151.4728	1151.4 ± 0.5	Rebaudioside D (3.3)
---------------------	-------------------------------	--------------	----------------------

The level of steviol glycosides were quantified by comparing with calibration curves obtained with authentic standards from LGC Standards. For example, standard solutions of 0.5 to 100 µM Rebaudioside A were typically utilized to construct a calibration curve.

2) Analyses of Steviol and *ent*-kaurenoic acid

LC-MS analyses of steviol and *ent*-kaurenoic acid were performed on the system described above. For the separation, a Thermo Science Hypersil Gold (C-18, 3µm, 100x2.1mm) column was used and a 20mM ammonium acetate aqueous solution was used as eluent A and acetonitrile as eluent B. The gradient conditions were: 20->55% B in min 0.0 to 1.0, 55->100 in min 1.0-7.0 and finally washing and re-equilibration. The flow rate was 0.5 mL/min and the column temperature 30°C. Steviol and *ent*-kaurenoic acid were detected using SIM (Single Ion Monitoring) in negative mode with the following m/z-traces.

Description	Exact Mass	m/z trace	typical t_R in min
Steviol	[M-H] ⁻ 317.2122	317.4 ± 0.5	3.3
Ent-kaurenoic acid	[M-H] ⁻ 301.2173	301.4 ± 0.5	5.5

3) HPLC quantification of UDP-Glucose

For the quantification of UDP-glucose, an Agilent 1200 Series HPLC system was used, with a Waters XBridge BEH amide (2.5µm, 3.0x50mm) column. Eluent A was a 10 mM ammonium acetate aqueous solution (pH 9.0) and Eluent B acetonitrile. The gradient conditions were: 95% B holding from min 0.0-0.5, decreasing from 95-50% B in min 0.5-4.5, holding 50% B from min 4.5-6.8 and finally re-equilibrating to 95% B. The flow rate was 0.9 mL/min and the column temperature 20°C. UDP-glucose was detected by UV_{262nm} absorbance.

The amount of UDP-glucose was quantified by comparing with a calibration curve obtained with a commercially available standard (e.g., from Sigma Aldrich).

Example 1 –Identification of EUGT11

Fifteen genes were tested for RebA 1,2-glycosylation activity. See Table 10.

Table 10

Name	Source	GenBank Accession No.
EUGT2	Oryza sativa UGT91 homolog	AP003270
EUGT3	Oryza sativa UGT91 homolog	AP005171
EUGT4	Oryza sativa UGT91 homolog	AP005643
EUGT6	Oryza sativa UGT91 homolog	AP005259
EUGT7	Oryza sativa UGT91 homolog	AP005171
EUGT8	Oryza sativa UGT91 homolog	XM 470006
EUGT9	Oryza sativa UGT91 homolog	AP005643
EUGT10	Oryza sativa UGT91 homolog	AC133334
EUGT11	Oryza sativa UGT91 homolog	AC133334
EUGT12	Oryza sativa UGT91 homolog	AC133334
EUGT15	Petunia x hybrid UGT79 homolog	Z25802
EUGT16	Arabidopsis thaliana UGT79 homolog	AC004786
EUGT17	Dianthus caryophyllus UGT79 homolog	AB294391
EUGT18	Ipomoea nil UGT79 homolog	AB192314
EUGT19	Oryza sativa UGT79 homolog	NM_001074394

5

In vitro transcription and translation of these genes was performed, and the resulting UGTs incubated with RebA and UDP-glucose. Following incubation, the reactions were analyzed by LC-MS. The reaction mixture containing EUGT11 (Rice, AC133334, SEQ ID NO:152) was shown to convert significant quantities of RebA to RebD. See LC-MS chromatograms in FIG. 4. As shown in the left panel of FIG. 4, UGT91D2e produced a trace amount of RebD when RebA was used as the feedstock. As shown in the right panel of FIG. 4, EUGT11 produced a significant amount of RebD when RebA was used as the feedstock. Preliminary quantification of the amount of RebD that was produced indicated that EUGT11 was approximately 30 times more efficient than UGT91D2e at converting RebA to RebD.

15

To further characterize EUGT11 and for quantitative comparison to UGT91D2e, the nucleotide sequence encoding EUGT11 (SEQ ID NO: 153, non-codon optimized, FIG. 7) was cloned into two *E. coli* expression vectors, one containing an *N*-terminal

HIS-tag and one containing an *N*-terminal GST-tag. EUGT11 was expressed using both systems and purified. When the purified enzymes were incubated with UDP-glucose and RebA, RebD was produced.

5 **Example 2 –Identification of EUGT11 Reactions**

EUGT11 was produced by *in vitro* transcription and translation, and incubated with various substrates in the RebD pathway. Similar experiments were carried out using *in vitro* transcribed and translated UGT91D2e. FIG. 3 shows a schematic overview of 19-O-1,2-diglycosylation reactions performed by EUGT11 and UGT91D2e. Compounds 1-10 3 were identified solely by mass and expected retention time. The numbers shown in FIG. 3 are the average peak height of the indicated steviol glycoside obtained from a LC-MS chromatogram, and, although not quantitative, can be used to compare the activity of the two enzymes. EUGT11 and UGT91D2e were not able to use steviol as a substrate. Both enzymes were able to convert steviol 19-*O*-monoglucoside (SMG) to compound 1, with15 EUGT11 being about ten times more efficient than UGT91D2e at converting 19-SMG to compound 1.

Both enzymes were able to convert rubusoside to stevioside with comparable activity but only EUGT11 was able to convert rubusoside to compound 2 and compound 3 (RebE). See FIG. 5. The left panel of FIG. 5 contains LC-MS chromatograms of the20 conversion of rubusoside to stevioside. The right panel of FIG. 5 contains chromatograms of the conversion of rubusoside to stevioside, to compound 2, and to compound 3 (RebE). Conversion of rubusoside to compound 3 requires two consecutive 1, 2-*O*-glycosylations at the 19- and 13-positions of steviol. UGT91D2e was able to produce a trace amount of compound 3 (RebE) in one experiment whereas EUGT1125 produced a significant amount of compound 3.

Both enzymes were able to convert RebA to RebD. However, EUGT11 was approximately 30 times better at converting RebA to RebD. Overall, it appears that EUGT11 produces more product than UGT91D2e in all reactions (with similar time, concentrations, temperature, and purity of enzyme) except the conversion of rubusoside30 to stevioside.

Example 3 –Expression of EUGT11 in Yeast

The nucleotide sequence encoding EUGT11 was codon-optimized (SEQ ID NO:154) and transformed into yeast along with nucleic acids encoding all four UGTs (UGT91D2e, UGT74G1, UGT76G1, and UGT85C2). The resulting yeast strain was grown in medium containing steviol and steviol glycosides that accumulated were analyzed by LC-MS. EUGT11 was required for the production of RebD. In other experiments, RebD production has been observed with UGT91D2e, UGT74G1, UGT76G1, and UGT85C2.

Example 4 –UGT Activity on 19-O-1,2-diglycosylated steviol glycosides

The 19-O-1,2-diglycosylated steviol glycosides produced by EUGT11 need further glycosylation to be converted to RebD. The following experiments were performed to determine if other UGTs could use these intermediates as substrates.

In one experiment, compound 1 was produced *in vitro* from 19-SMG by either EUGT11 or UGT91D2e in the presence of UDP-glucose. After boiling the sample, UGT85C2 and UDP-glucose were added. The sample was analyzed by LC-MS and compound 2 was detected. This experiment indicated that UGT85C2 can use compound 1 as a substrate.

In another experiment, compound 2 was incubated with UGT91D2e and UDP-glucose. The reaction was analyzed by LC-MS. UGT91D2e was not able to convert compound 2 to compound 3 (RebE). Incubation of compound 2 with EUGT11 and UDP-glucose results in the production of compound 3. UGT76G1 was able to use RebE as a substrate to produce RebD.

This shows that the 19-O-1,2-diglycosylation of the steviol glycosides is able to take place at any time during production of RebD as the downstream enzymes are able to metabolize the 19-O-1,2-diglycosylated intermediates.

Example 5 – Comparison of EUGT11 and UGT91D2e Sequence

The amino acid sequence of EUGT11 (SEQ ID NO:152, FIG. 7) and the amino acid sequence of UGT91D2e (SEQ ID NO:5) were aligned using the FASTA algorithm (Pearson and Lipman, Proc. Natl. Acad. Sci., 85:2444-2448 (1998)). See FIG. 6.

5 EUGT11 and UGT91D2e are 42.7% identical over 457 amino acids.

Example 6 –Modification of 19-1,2-diglycosylating activity of UGT91D2e

Crystal structures are available for a number of UGTs. Generally, the N-terminal half of a UGT is primarily involved with substrate binding whereas the C-terminal half is
10 involved in binding the UDP-sugar donor.

Modeling the secondary structure of UGT91D2e onto the secondary structure of the UGTs that have been crystalized revealed a conserved pattern of secondary structure, despite a highly diverged primary sequence as shown in FIG. 8. The crystal structures of UGT71G1 and UGT85H2 (see, for example H. Shao *et al*, The Plant Cell November
15 2005 vol. 17 no 11 3141-3154 and L. Li *et al.*, J Mol Biol. 2007 370(5):951-63) have been reported. Known loops, alpha-helices and beta-sheets are indicated on UGT91D2e in FIG. 8. Although the homology at the primary structure level of these UGTs is fairly low, the secondary structure appears to be conserved, allowing predictions regarding the locations of amino acids involved in substrate binding on UGT91D2e based on the
20 location of such amino acids in UGT85H2 and UGT71G1.

Regions commonly involved in substrate binding were superimposed on UGT91D2e and largely shown to coincide with the 22 amino acid differences from UGT91D1 (GenBank Accession No. Protein Accession number AAR06918, GI:37993665). UGT91D1 is highly expressed in *Stevia* and thought to be a functional
25 UGT. However, its substrate is not a steviol glycoside. This suggests that UGT91D1 has a different substrate, which may be defined by the 22 amino acids with which it differs from UGT91D2e. FIG. 9 is an alignment of the amino acid sequences of UGT91D1 and UGT91D2e. The boxes represent areas that are reported to be involved in substrate binding. The amino acids highlighted in dark grey show the 22 amino acid differences
30 between UGT91D1 and UGT91D2e. Stars denote amino acids that have been shown to

be involved in substrate binding in UGTs that have had their crystal structure resolved (more stars under one particular amino acids means substrate binding has been shown with more than one structure-resolved UGTs). There is a strong correlation between the 22 amino acid differences between the two UGT91s, the regions known to be involved in substrate binding, and the actual amino acids involved in substrate binding in the crystal structure-resolved UGTs. This suggests that the 22 amino acid differences between the two UGT91s are involved in substrate binding.

All 22 altered 91D2es were expressed in a XJb Autolysis *E. coli* strain from a pGEX-4T1 vector. In order to assess the activity of the enzymes, two substrate feeding experiments were performed - *in vivo* and *in vitro*. Most mutants had lower activity than wild type, however, 5 mutants showed increased activity. This was reproduced by *in vitro* transcription and translation (IVT) and showed that C583A, C631A and T857C have approximately 3-fold higher stevioside-forming activity than the wild-type UGT91D2e, whereas C662t and A1313C had approximately twice the stevioside-forming activity (nucleotide numbering). These changes result in amino acid mutations corresponding to L195M, L211M, V286A; and S221F and E438A, respectively. The increased activity differed depending on substrate, with C583A and C631A showing almost a 10-fold increase using 13-SMG as substrate and about a 3-fold increase using rubusoside as substrate, whereas T857C showed a 3-fold increase when using either 13-SMG or rubusoside as substrate.

To investigate if these mutations were additive, a range of double mutants were made and analyzed for activity (FIG. 10). In this particular experiment, a higher wild type level of activity was observed than the previous four experiments; however, the relative activities of the mutations remain the same. As rubusoside accumulates in many of the *S. cerevisiae* strains expressing the 4 UGTs (UGT74G1, UGT85C2, UGT76G1, and UGT91D2e), the stevioside-forming activity may be more important for increasing steviol glycoside production. As such, the double mutant C631A/T857C (nucleotide numbering) may be useful. This mutant has been named UGT91D2e-b, which contains the amino acid modifications L211M and V286A. The experiments have been reproduced *in vitro* using *S. cerevisiae*-expressed UGT91D2e-mutants.

To improve 19-1,2-diglycosylating activity of UGT91D2e, a directed saturated mutagenic screen of UGT91D2e of the 22 amino acid differences between UGT91D2e and UGT91D1 was performed. GeneArt's® (Life Technologies, Carlsbad, CA) site-saturation mutagenesis was used to obtain a library containing each of the mutations.

5 The library was cloned into the BamHI and NotI sites of pGEX4T1 bacterial expression plasmid expressing the mutated versions of 91D2e as GST fusion proteins, resulting in a new library (Lib#116). Lib#116 was transformed into XJbAutolysis *E. coli* strain (ZymoResearch, Orange, CA) to produce approximately 1600 clones containing the 418 expected mutations (i.e., 22 positions with 19 different amino acids at each position).
10 Other plasmids expressing GST-tagged versions of 91D2e (EPCS1314), 91D2e-b (EPSC1888) or EUGT11 (EPSC1744) as well as the empty pGEX4T1 (PSB12) were transformed as well.

Screening by LC-MS

To analyze the approximately 1600 mutant clones of UGT91D2e, the *E. coli*
15 transformants were grown overnight at 30°C in 1 ml of NZCYM containing ampicillin (100 mg/l) and chloramphenicol (33 mg/l), in 96-well format. The next day, 150 µl of each culture was inoculated into 3 ml NZCYM containing ampicillin (100 mg/l), chloramphenicol (33 mg/l), arabinose 3 mM, IPTG 0.1 mM and ethanol 2% v/v, in 24-well format, and incubated at 20°C and 200 rpm for ~20h. The following day, cells were
20 spun down and pellets were resuspended in 100 µl of lysis buffer containing 10mM Tris-HCl pH 8, 5 mM MgCl₂, 1 mM CaCl₂ and complete mini protease inhibitor EDTA-free (3 tablets/100 ml) (Hoffmann-La Roche, Basel, Switzerland) and frozen -80°C for at least 15 minutes to promote cell lysis. Pellets were thawed at room temperature and 50 µl of DNase mix (1 µl of 1.4 mg/ml DNase in H₂O (~80000u/ml), 1.2 µl of MgCl₂ 500 mM
25 and 47.8 µl of 4x PBS buffer solution) was added to each well. Plates were shaken at 500 rpm for 5 min at room temperature to allow degradation of genomic DNA. Plates were spun down at 4000 rpm for 30 min at 4°C and six µl of the lysates were used in UGT *in vitro* reactions as described for GST-91D2e-b, using rubusoside or rebaudioside A as substrates. In each case, the resulting compounds, stevioside or rebaudioside D (rebD),
30 were measured by LC-MS. Results were analyzed in comparison with the stevioside or

rebD produced by the lysates expressing the corresponding controls (91D2e, 91D2e-b, EUGT11 and the empty plasmid). Clones showing activity similar to or higher than the ones expressing 91D2e-b were selected as primary hits.

Half of the 1600 clones and the corresponding controls were assayed for their capacity to glycosylate rubusoside and rebaudiosideA. Stevioside and RebD were quantified by LC-MS. Under the conditions used, lysates from clones expressing the native UGT91D2e show activity just around background with both substrates (approximately 0.5 μ M stevioside and 1 μ M RebD), while clones expressing UGT91D2e-b show consistently improved product formation (>10 μ M Stevioside; > 1.5 μ M RebD). Clones expressing EUGT11 consistently display a higher level of activity, especially using RebA as substrate. Cutoff for considering clones as *primary hits* in the screening was generally set at 1.5 μ M for both products, but in some cases was adjusted for each independent assay.

Example 7 –EUGT11 Homologs

A Blastp search of the NCBI nr database using the EUGT11 protein sequence revealed approximately 79 potential UGT homologs from 14 plant species (one of which is the Stevia UGT91D1, approximately 67% identical to EUGT11 in conserved UGT regions but less than 45% overall). Homologs with greater than 90% identity in conserved regions were identified from corn, soybean, *Arabidopsis*, grape, and *Sorghum*. The overall homology of the full-length EUGT11 homologs, at the amino acid level, was only 28-68%.

RNA was extracted from plant material by the method described by Iandolino *et al.* (Iandolino et al., *Plant Mol Biol Reporter* 22, 269-278, 2004), the RNeasy Plant mini Kit (Qiagen) according to the manufacturer's instructions, or using the Fast RNA Pro Green Kit (MP Biomedicals) according to the manufacturer's instructions. cDNA was produced by AffinityScript QPCR cDNA Synthesis Kit (Agilent) according to the manufacturer's instructions. Genomic DNA was extracted using the FastDNA kit (MP Biomedicals) according to the manufacturer's instructions. PCR was performed on cDNA

using either the Dream Taq polymerase (Fermentas) or the Phusion polymerase (New England Biolabs) and a series of primers designed to amplify the homologs.

PCR-reactions were analyzed by electrophoresis in SyberSafe-containing agarose-TAE gels. DNA was visualized by UV-irradiation in a trans illuminator. Bands of the correct size were cut out, purified through spin columns according to the manufacturer's specifications, and cloned into TOPO-Zero blunt (for Phusion polymerase-generated products) or TOPO-TA (for Dream Taq-generated products). The TOPO-vectors containing the PCR-products were transformed into *E. coli* DH5Ba and plated on LB-agar plates containing the appropriate selective antibiotics. DNA was extracted from surviving colonies and sequenced. The genes with the correct sequence were cut out by restriction digest with SbfI and AscI, cloned into similarly digested IVT8 vector and transformed into *E. coli*. PCRs were performed on all cloned genes to amplify the gene and flanking regions required for *in vitro* transcription and translation. Proteins were produced from the PCR products by *in vitro* transcription and translation using the Promega L5540, TNT T7 Quick for PCR DNA Kit according to the manufacturer's instructions. Production of protein was evaluated by incorporation of ³⁵S-methionine followed by separation by SDS-PAGE and visualization on a Typhoon phosphor-imager.

Activity assays were set up totaling 20% (by volume) of each *in vitro* reaction, 0.1 mM rubusoside or RebA, 5% DMSO, 100 mM Tris-HCl pH 7.0, 0.01 units Fast alkaline phosphatase (Fermentas), and 0.3 mM UDP-glucose (final concentrations). Following incubation at 30°C for one hour, the samples were analyzed by LC-MS for production of stevioside and RebD as described above. The UGT91D2c and UGT91D2c-b (double mutant described in Example 6) were used as positive controls, along with EUGT11. Under the initial assay conditions, clone P 64B (see Table 11) produced a trace amount of product using rubusoside and RebA. Table 11 lists the percent identity at the amino acid level compared to EUGT11 for the whole length of the UGTs, which ranges from 28-58%. High amounts of homology (96-100%) were observed over shorter stretches of sequences, which may indicate highly conserved domains of plant UGTs.

Table 11.

List of cloned EUGT11 homologs and their amino acid percent identity to EUGT11.

UGT	Accession	% identity to EUGT11
P44G	XP_002297733.1	32.16
P54A	XP_002532392.1	34.20
P51H	XP_002325254.1	32.53
P55D	XP_002533517.1	31.90
P5F	AAM12787.1	31.73
P48G	XP_002318358.1	33.20
P52F	XP_002334090.1	32.80
P48F	XP_002318358.1	33.00
T4B-b	NP_565540.4	31.19
P56C	XP_002533518.1	32.60
T67H	XP_002270294.1	34.06
T65E	CAN80742.1	34.98
T74G	XP_002270331.1	35.48
T65D	CAN80742.1	34.98
T69F1	XP_003635103.1	34.69
P6B	Q66PF2.1	33.20
P6D variant	Q66PF2.1	33.60
P64B	ACE87855.1	34.64
T3F	AT5G65550	34.94
P53H	XP_002527371.1	33.40
P53F	XP_002527371.1	33.40
P46H	XP_002303861.1	32.40
2-b	NP_199780.1	35.79
T70F	XP_002275802.1	36.67
T72A	XP_002275850.1	36.42
T71G	XP_002275824.1	37.25
P49G	XP_002320817.1	35.15
P57H	XP_002511902.1	36.23
45 Pop	XP_002302598.1	34.21
P50G	XP_002323718.1	32.86
P50H	XP_002323718.1	32.66
T73G	XP_002281094.1	32.05
63	XP_002458816.1	37.25
P78B	NP_001147674.1	35.33
62	XP_002458815.1	34.06
P9F	BAJ84800.1	37.92
T7H	NP_001240857.1	31.30
16-1	BAJ93155.1	58.03
T16H	BAJ93155.1	58.03
31TA	BAD35324.1	51.81

P41G	NP_001174664.1	35.40
P37G	NP_001051010.1	56.71
P60aH	XP_002466606.1	57.35
12	BAJ89368.1	44.35
P12A	BAJ89368.1	44.35
P12H	BAJ89368.1	44.35
P10B	BAJ86656.1	45.16
P58aF	XP_002463702.1	43.71
P59aG	XP_002463705.1	43.51
P76H	NP_001140711.1	28.81

Example 8 - Cell-free Biocatalytic Production of Reb-D

The cell-free approach is an *in vitro* system where RebA, stevioside or a steviol glycoside mixture is enzymatically converted to RebD. The system requires stoichiometric amounts of UDP-glucose and therefore UDP-glucose regeneration from UDP and sucrose using sucrose synthase can be used. Additionally, sucrose synthase removes UDP produced during the reaction, which improves conversion to glycosylated products by alleviated product inhibition observed for glycosylation reactions. See, WO 2011/153378.

Enzyme expression and purification

UGT91D2e-b (described in Example 6) and EUGT11 are key enzymes that catalyze the glycosylation of RebA yielding RebD. These UGTs were expressed in bacteria (*E. coli*) but one of ordinary skill in the art will appreciate that such proteins also can be prepared using different methods and hosts (e.g., other bacteria such as *Bacillus* *sp.*, yeast such as *Pichia* *sp.* or *Saccharomyces* *sp.*, other fungi (e.g., *Aspergillus*), or other organisms). For example, the proteins can be produced by *in vitro* transcription and translation or by protein synthesis.

The UGT91D2e-b and EUGT11 genes were cloned in pET30a or pGEX4T1 plasmids. Resulting vectors were transformed into an XJb (DE3) Autolysis *E. coli* strain (ZymoResearch, Orange, CA). Initially, *E. coli* transformants were grown overnight at 30°C in NZCYM medium, followed by induction with 3 mM arabinose and 0.1 mM IPTG, and further incubation overnight at 30°C. The corresponding fusion proteins were purified by affinity chromatography using included 6HIS- or GST- tags and standard

methods. One skilled in the art will appreciate that other protein purification methods such as gel filtration or other chromatography techniques also can be used, along with precipitation/crystallization or fractionation with e.g., ammonium sulfate. While EUGT11 was expressed well using the initial conditions, UGT91D2e-b required several
5 modifications to the base protocol to increase protein solubility, including lowering the temperature of the overnight expression from 30°C to 20°C and adding 2% ethanol to the expression medium. Generally 2-4 mg/L of soluble GST-EUGT11 and 400-800 µg/l of GST-UGT91D2e-b were purified with this method.

Stability of EUGT11

10 Reactions were conducted to explore the stability of EUGT11 under various RebA to RebD reaction conditions. Omitting the substrate from the reaction mixture, EUGT11 was pre-incubated for various periods of time before substrate was added. Following a pre-incubation of the enzyme in 100 mM Tris-HCl buffer, substrate (100 µM RebA) and other reaction components (300 µM UDP-glucose, and 10 U/mL Alkaline
15 Phosphatase (Fermentas/Thermo Fisher, Waltham, MA)) were added (0, 1, 4 or 24 hours after the incubation was started). The reaction was then allowed to proceed for 20h, after which the reactions were stopped and RebD product-formation measured. Experiments were repeated at different temperatures: 30°C, 32.7°C, 35.8°C and 37°C.

The activity of EUGT11 was reduced rapidly when the enzyme was pre-incubated
20 at 37°C, reaching approximately half activity after 1 hour, and having almost no activity after 4 hours. At 30°C, the activity was not significantly reduced after 4 hours and after 24 hours, approximately one-third of the activity remained. This suggests that EUGT11 is heat-labile.

To assess the thermal stability of EUGT11 and to compare it with the other UGTs
25 in the steviol glycosylation pathway, denaturation temperatures of the proteins were determined using differential scanning calorimetry (DSC). Use of DSC thermograms to estimate denaturation temperatures, T_D , is described, for example, by E. Freire in *Methods in Molecular Biology* 1995, Vol. 40 191-218. DSC was performed (using 6HIS-purified EUGT11, yielding an apparent T_D of 39°C; while when GST-purified 91D2e-b was used,
30 the measured T_D was 79°C. For reference, the measured T_D when using 6HIS-purified

UGT74G1, UGT76G1 and UGT85C2 was 86°C in all cases. One of skill in the art will recognize that enzyme immobilization or addition of thermal protectants can be added to the reactions to improve stability of the protein. Non-limiting examples of thermal protectants include trehalose, glycerol, ammonium sulphate, betaine, trimethylamine oxide, and proteins.

Enzyme kinetics

A series of experiments were performed to determine kinetic parameters of EUGT11 and 91D2e-b. For both enzymes, 100 µM RebA, 300 µM UDP-glucose, and 10 U/mL Alkaline Phosphatase (Fermentas/Thermo Fisher, Waltham, MA) were used in the reactions. For EUGT11, the reactions were performed at 37°C using 100 mM Tris-HCl, pH 7, and 2% enzyme. For 91D2e-b, the reactions were performed at 30°C using 20 mM Hepes-NaOH, pH 7.6, 20% (by volume) enzyme. The initial velocities (V_0) were calculated in the linear range of a product versus time plot.

To first investigate the linearity intervals, initial time-courses were done for each enzyme. EUGT11 was assayed at 37°C for 48h at initial concentrations of 100 µM RebA and 300 µM UDP-glucose. UGT91D2e-b was assayed at 37°C for 24h at initial concentrations of 200 µM RebA and 600 µM UDP-glucose. Based on these range-finding studies, it was determined that the initial 10 minutes in the case of EUGT11, and the initial 20 minutes in UGT91D2e-b would be in the linear range with respect to product formation, and therefore initial velocities of each reaction were calculated in those intervals. In the case of EUGT11, RebA concentrations assayed were 30 µM, 50 µM, 100 µM, 200 µM, 300 µM and 500 µM. Concentration of UDP-glucose was always three times the concentration of RebA and incubation was performed at 37°C. By plotting the calculated V_0 as a function of the substrate concentrations, Michaelis-Menten curves were generated. By plotting the reciprocal of V_0 and the reciprocal of $[S]$, a Lineweaver-Burk graphic was obtained, with $y = 339.85x + 1.8644$; $R^2 = 0.9759$.

$V_{\max}$ and K_M parameters were determined from the curve-fit Lineweaver-Burk data, calculated from the x- and y intercepts ($x=0$, $y=1/V_{\max}$) and ($y=0$, $x=-1/K_M$). Additionally, the same parameters also were calculated by a non-linear least squares regression, using the SOLVER function in Excel. The results obtained with both methods

for EUGT11 and RebA are presented in Table 12, along with all the kinetic parameters of this example. Results from both Nonlinear Least Square Fit method and Lineweaver-Burk plot are presented in Table 12. K_{cat} is calculated based on V_{max} divided by the approximate amount of protein in the assay.

Table 12
Comparison of kinetic parameters for EUGT11 and UGT 91D2e-b, with RebA or UDP-glucose as substrate.

	Nonlinear Least Square Fit				Lineweaver-Burk plot			
	Reb A		UDP-glucose		Reb A		UDP-glucose	
	EUGT11	91D2e-b	EUGT11	91D2e-b	EUGT11	91D2e-b	EUGT11	91D2e-b
$V_{\max}$ ($\mu\text{M} \cdot \text{min}^{-1}$)	0.52	0.34	0.79	0.19	0.54	0.44	0.78	0.18
K_{cat} (min^{-1})	8.11	0.32	12.32	0.2	8.42	0.41	12.1	0.19
K_M (μM)	162.5	1150	130	45.1	182.3	1580	118	41.9
K_{cat}/K_M ($\text{min}^{-1} \cdot \mu\text{M}^{-1}$)	0.05	0.000275	0.095	0.00454	0.046	0.000258	0.102	0.00463

In order to investigate the influence of UDP-glucose concentration in the glycosylation reaction, as well as the affinity of EUGT11 for UDP-glucose, similar kinetics analysis were performed. EUGT11 was incubated with increasing amounts of UDP-glucose (20 μ M, 50 μ M, 100 μ M, and 200 μ M), maintaining an excess of RebA (500 μ M). The kinetic parameters were calculated as described above, and shown in Table 12.

In the case of UGT91D2e-b, RebA concentrations assayed were 50 μ M, 100 μ M, 200 μ M, 300 μ M, 400 μ M and 500 μ M. Concentration of UDP-glucose was always three times the concentration of RebA and incubation was performed at 30°C, in the reaction conditions described above for UGT91D2e-b. The kinetic parameters were calculated as previously described; and the resulting kinetic parameters are shown in Table 12.

Additionally, kinetic parameters of UGT91D2e-b towards UDP-glucose were determined. UGT91D2e-b was incubated with increasing amounts of UDP-glucose (30 μ M, 50 μ M, 100 μ M, and 200 μ M), maintaining an excess of RebA (1500 μ M). incubation was performed at 30°C, in optimal conditions for UGT91D2e-b. The kinetic parameters were calculated as previously described and results are presented in Table 12.

By comparison of the kinetics parameters for EUGT11 and 91D2e-b, it was concluded that 91D2e-b has a lower K_{cat} and has lower affinity for RebA (higher K_M) although the K_M for UDP-glucose of 91D2e-b is lower than EUGT11. UGT91D2e-b has a lower K_{cat}/K_M which is a measure of catalytic efficiency, combining information on rate of catalysis with a particular substrate (K_{cat}) and the strength of enzyme-substrate binding (K_M).

Determining the limiting factor in reactions

Under the conditions described above for EUGT11, approximately 25% of the RebA administered was converted to RebD. The limiting factor in these conditions could be either the enzyme, UDP-glucose or RebA. Experiments were set up to distinguish between these possibilities. A standard assay was allowed to run its course during 4 hours. This was followed by addition of either extra RebA substrate, extra enzyme, extra UDP-glucose or extra enzyme and UDP-glucose. Addition of extra enzyme resulted in a relative increase of the conversion of around 50%, adding extra RebA or UDP-glucose

alone did not increase the conversion significantly, but the simultaneous addition of enzyme and UDP-glucose increased the conversion approximately 2-fold.

Experiments were conducted to examine the limit to this benefit of adding bolus amounts of UDP-glucose and fresh enzyme in the conversion of RebA to RebD reaction. Additional enzyme or enzyme and UDP-glucose were added after 1, 6, 24 and 28 hours. In the case of the addition of both extra EUGT11 and UDP-glucose, a conversion of more than 70% was achieved. No other components had a significant effect on the conversion. This indicates that EUGT11 is a primary limiting factor for the reaction but UDP-glucose also is limiting. As UDP-glucose is present at 3-fold higher concentration than RebA, this indicates that UDP-glucose may be somewhat unstable in the reaction mixture, at least in the presence of EUGT11. Alternatively, as explained below, EUGT11 may be metabolizing the UDP-glucose.

Inhibition studies

Experiments were conducted to determine if factors such as sucrose, fructose, UDP, product (RebD) and impurities in the less pure Stevia extracts raw materials inhibited the extent of the conversion of steviol glycoside substrates to RebD. In a standard reaction mixture, excess of the potential inhibitors (sucrose, fructose, UDP, RebD, or a commercial blend of steviol glycosides (*Steviva*, Steviva Brands, Inc., Portland, OR)) were added. Following incubation, RebD-production was quantified. Addition of 500 µg/ml of the commercial *Steviva* mix (approximately 60% 1,2-stevioside, 30% RebA, 5% Rubusoside, 2% 1,2-bioside, less than 1% of RebD, RebC and others, as evaluated by LC-MS) was not found to be inhibitory, but rather increased the overall RebD production (to around 60 µM from around 30 µM without any addition) well beyond the RebD originally added with the blend (around 5 µM). From the molecules tested, only UDP was shown to have an inhibitory effect on RebD-production at the concentration used (500 µM), as measured by LC-MS. The RebD that was produced was less than 7 µM. This inhibition can be alleviated in the *in vivo* or *in vitro* reactions for RebD production, by including an UDP recycling system to UDP-glucose, either by yeast or by an added SUS (sucrose synthase enzyme) in conjunction with sucrose. Moreover, when working with lower amounts of UDP-glucose (300 µM), the

addition of alkaline phosphatase to remove UDP-G does not increase the amount of RebD produced in the *in vitro* glycosylations substantially, suggesting that the UDP produced may not be inhibitory at these concentrations.

RebA vs crude steviol glycoside mix

5 In some experiments, a crude steviol glycoside mix was used as a source of RebA instead of purified RebA. As such a crude steviol glycoside mix contains a high percentage of stevioside along with RebA, UGT76G1 was included in the reactions. *In vitro* reactions were performed as described above using 0.5 g/l of the *Steviva*[®] mix as substrate and enzyme (UGT76G1 and/or EUGT11) and incubated at 30°C. The presence
10 of steviol glycosides was analyzed by LC-MS.

 When only UGT76G1 was added to the reactions, stevioside was converted to RebA quite efficiently. An unknown penta-glycoside (with a retention time peak at 4.02 min) also was detected. When only EUTG11 was added to the reaction, large amounts of RebE, RebA, RebD and an unknown steviol-pentaglycoside (with a retention time peak at
15 3.15 min) were found. When both EUGT11 and UGT76G1 were added to the reactions, the stevioside peak was reduced, and almost entirely converted to RebA and RebD. There were trace amounts of the unknown steviol-pentaglycoside (peak at 4.02 min). No RebE was detected nor was the second unknown steviol-pentaglycoside (peak at 3.15 min). This result indicated that the use of stevia extracts as a substrate to produce RebD *in vitro*
20 is possible when EUGT11 and UGT76G1 are used in combination.

Non-specific UDP-glucose metabolism

 To determine if EUGT11 can metabolize UDP-glucose independently of the conversion of RebA to RebD, GST-purified EUGT11 was incubated in the presence or absence of RebA substrate, and UDP-glucose usage was measured as UDP-release, using
25 the TR-FRET Transcreener[®] kit (BellBrook Labs). The Transcreener[®] kit is based on a tracer molecule bound to an antibody. The tracer molecule is displaced by UDP or ADP in a highly sensitive and quantitative manner. The FP kit includes an Alexa633 tracer bound to an antibody. The tracer is displaced by UDP/ADP. The displaced tracer freely rotates leading to a decrease in fluorescence polarization. Therefore, UDP production is
30 proportional to a decrease in polarization. The FI kit includes a quenched Alexa594

Tracer bound to an antibody, which is conjugated to an IRDye® QC-1 quencher. The tracer is displaced by UDP/ADP, whereby the displaced tracer is un-quenched, leading to a positive increase in fluorescence intensity. Therefore, UDP production is proportional to an increase in fluorescence. A TR-FRET kit includes a HiLyte647 Tracer bound to an
5 Antibody-Tb conjugate. Excitation of the terbium complex in the UV range (ca. 330 nm) results in energy transfer to the tracer and emission at a higher wavelength (665nm) after a time delay. The tracer is displaced by UDP/ADP causing a decrease in TR-FRET.

It was observed that UDP-glucose measured was the same independent of the presence of RebA substrate. UDP release was not detectable in the absence of enzyme.
10 This indicates a non-specific degradation of UDP-glucose by EUGT11. Nevertheless, RebD was still produced when RebA was added, suggesting that EUGT11 would preferentially catalyze RebA glycosylation over the non-specific UDP-glucose degradation.

Experiments were set up to find out the destiny of the glucose molecule in the
15 absence of RebA or other obvious glycosylation substrates. One common factor in all previous reactions was the presence of Tris buffer and/or trace amounts of glutathione, which both contain potential glycosylation sites. The effect of these molecules on the non-specific UDP-glucose consumption was assayed using GST-purified EUGT11 (with glutathione) and HIS-purified enzyme (without glutathione) in *in vitro* reactions, in the
20 presence or absence of RebA. UDP-glucose usage was measured as UDP-release, using the TR-FRET Transcencer® kit. UDP release occurred in all cases and was independent of the presence of RebA. UDP release was slower when the HIS-purified enzyme was used, but the overall catalytic activity of the enzyme in conversion of RebA to RebD was also lower, suggesting a lower amount of active soluble enzyme present in the assay.
25 Therefore, it appears that the UDP-glucose metabolism by EUGT11 is independent of the presence of substrate and independent of the presence of glutathione in the reaction, under the conditions tested.

To test the effect of Tris on the metabolism of UDP-glucose by EUGT11, GST-EUGT11 was purified using a Tris- or a PBS-based buffer for the elution, obtaining
30 similar amounts of protein in both cases. Tris- and PBS-purified enzymes were used in *in*

vitro reactions using Tris and HEPES as buffers respectively, in the presence or absence of RebA in a similar manner as above. In both conditions, the UDP release was the same in the reactions whether RebA was added or not, indicating that the metabolism of UDP-glucose by EUGT11 is independent of both the presence of RebA and Tris in the
5 reaction. This suggests that the UDP-release detected may somehow be an artifact caused by a property of EUGT11 or, alternatively, EUGT11 may be hydrolyzing UDP-glucose. EUGT11 is still efficient at converting RebA to RebD preferentially and the loss of UDP-G can be compensated by addition of the sucrose synthase recycling system described below.

10 **RebA solubility**

The solubility of RebA determines the concentration that can be used both for the whole-cell approach and for the cell-free approach. Several different solutions of RebA in water were made and left at room temperature for several days. After 24 hours of storage, RebA precipitated at concentrations of 50 mM or higher. Twenty-five mM RebA started
15 to precipitate after 4-5 days, while 10 mM or lower concentrations remained in solution, even when stored at 4°C.

RebD solubility

The solubility of RebD was assessed by making several different solutions of RebD in water were made and incubated at 30°C for 72 hours. RebD was found to be
20 soluble in water initially in concentrations of 1 mM or lower while concentrations of 0.5 mM or less were found to be stable for longer periods of time. One with skill in the art will recognize that the solubility can be influenced by any number of conditions such as pH, temperature, or different matrices.

Sucrose synthase

Sucrose synthase (SUS) has been used to regenerate UDP-glucose from UDP and sucrose (FIG. 11) for other small molecule glycosylations (Masada Sayaka *et al. FEBS Letters* 581 (2007) 2562–2566.). Three SUS1 genes from *A. thaliana*, *S. rebaudiana* and coffee (*Coffea arabica*) were cloned into pGEX4T1 *E. coli* expression vectors (see FIG.
25 17 for the sequences). Using methods similar to those described for EUGT11, around 0.8 mg/l of GST-AtSUS1 (*A. thaliana* SUS1) was purified. Initial expression of CaSUS1
30

(*Coffea arabica* SUS1) and SrSUS1 (*S. rebaudiana* SUS1) followed by GST-purification did not produce significant amounts of protein although, when analyzed by western blot, the presence of GST-SrSUS1 was verified. When GST-SrSUS1 was expressed at 20°C in the presence of 2% ethanol, approximately 50 µg/l of enzyme was produced.

5 Experiments were performed to evaluate the UDP-glucose regenerating activity of the purified GST-AtSUS1 and GST-SrSUS1. *In vitro* assays were conducted in 100 mM Tris-HCl pH=7.5 and 1 mM UDP (final concentration). Either ~2.4 µg of purified GST-AtSUS1, ~0.15 µg of GST-SrSUS1, or ~1.5 µg commercial BSA (New England Biolabs, Ipswich, MA) were also added. Reactions were done in presence or absence of ~200 mM
10 sucrose and incubated at 37°C for 24h. Product UDP-glucose was measured by HPLC as described in the analytical section. AtSUS1 produced ~0.8 mM UDP-glucose when sucrose was present. No UDP-glucose was observed when SrSUS1 or the negative control (BSA) was used. The lack of activity observed for SrSUS1 could be explained by the poor quality and concentration of the purified enzyme. UDP-glucose production by
15 AtSUS1 was sucrose dependent and, therefore, it was concluded that AtSUS1 can be used in a coupled reaction to regenerate the UDP-glucose used by EUGT1 or other UGTs for small molecule glycosylation (FIG. 11, above).

SUS catalyzes the formation of UDP-glucose and fructose from sucrose and from UDP as depicted in FIG. 11. This UDP-glucose then can be used by EUGT11 for
20 glycosylation of RebA to produce RebD. *In vitro* assays as described above were performed, adding ~200 mM sucrose, 1 mM UDP, 100 µM RebA, ~1.6 µg purified GST-AtSUS1 and ~0.8 µg GST-EUGT11. Formation of product, RebD, was evaluated by LC-MS. When AtSUS, EUGT11, sucrose and UDP were mixed with RebA, 81±5 µM of RebD was formed. The reaction was dependent on the presence of AtSUS, EUGT11 and
25 sucrose. The conversion rate was similar to what has been observed previously using UDP-glucose provided extraneously. This shows that AtSUS can be used to regenerate UDP-glucose for RebD-formation by EUGT11.

Example 9: Whole-cell Biocatalytic Production of RebD

In this example, several parameters were studied that are factors for using whole cell biocatalytic systems in the production of RebD from RebA or other steviol glycosides. The ability of raw materials to cross the cell membrane and availability of UDP-glucose are two such factors. Permeabilizing agents were studied as well as
5 different cell types to ascertain which systems may be the most beneficial for RebD production.

Permeabilizing agents

Several different permeabilization agents have previously been shown to allow intracellular enzymatic conversion of various compounds that are normally not able to
10 cross a cell membrane (Chow and Palecek, *Biotechnol Prog.* 2004 Mar-Apr;20(2):449-56). In several cases, the approaches resemble a partial lysis of the cells and, in yeast, often rely on the removal of the cell membrane by a detergent and the encapsulation of the enzymes inside of the remaining cell wall, which is permeable to smaller molecules. Common to these methods is the exposure to the permeabilizing agent followed by a
15 centrifugation step to pellet cells before the addition of the substrate. See, for example, Flores *et al.*, *Enzyme Microb. Technol.*, 16, pp. 340-346 (1994); Presecki & Vasic-Racki, *Biotechnology Letters*, 27, pp. 1835-1839 (2005); . Yu *et al.*, *J Ind Microbiol Biotechnol*, 34, 151-156 (2007); Chow and Palecek, *Cells. Biotechnol. Prog.*, 20, pp. 449-456 (2004); Fernandez *et al.*, *Journal of Bacteriology*, 152, pp. 1255-1264 (1982); Kondo *et al.*,
20 *Enzyme and microbial technology*, 27, pp. 806-811 (2000); Abraham and Bhat, *J Ind Microbiol Biotechnol*, 35, pp. 799-804 (2008); Liu *et al.*, *Journal of bioscience and bioengineering*, 89, pp. 554-558 (2000); and Gietz and Schiestl, *Nature Protocols*, 2, pp. 31-34 (2007) regarding permeabilization of yeast. See, Naglak and Wang, *Biotechnology and Bioengineering*, 39, pp. 732-740 (1991); Alakomi *et al.*, *Applied and environmental*
25 *Microbiology*, 66, pp. 2001-2005 (2000); and Fowler and Zabin, *Journal of bacteriology*, 92, pp. 353-357 (1966) regarding permeabilization of bacteria. As described in this example, it was determined if cells could remain viable and therefore could retain *de novo* UDP-glucose biosynthesis.

Experiments were done to establish conditions for permeabilization in *E. coli* and
30 in yeast. Growing cells (*S. cerevisiae* or *E. coli*) were treated with different

concentrations/combinations of permeabilization agents: toluene, chloroform and ethanol for permeabilization of *S. cerevisiae*, and guanidine, lactic acid, DMSO and/or Triton X-100TM for permeabilization of *E. coli*. Tolerance of both model organisms to high concentrations of RebA and other potential substrates also was evaluated. The permeabilization was measured by the amount of RebD produced from a EUGT11-expressing organism after incubation in a RebA containing medium (feeding experiment). Enzyme activity was monitored before and after exposure to the permeabilizing agents by lysing the cells and analyzing the activity of the released UGTs in an *in vitro* assay.

In yeast, none of the permeabilization conditions tested resulted in an increase on RebD above the detected background (i.e., contaminating RebD levels present in the RebA stock used for feeding). This indicates that, under the tested conditions, yeast cells remain impermeable to RebA and/or the reduced cell viability caused by the solvents results in a decrease of EUGT11 activity as well.

In *E. coli*, none of the conditions tested resulted in permeabilization of the cells and subsequent production of RebD above background levels. Detectable levels of RebD were measured when lysates from strains expressing EUGT11 were used in the *in vitro* reactions (data not shown), indicating that EUGT11 enzyme is present and active even after all permeabilization treatments (though the level of activity varies). The permeabilization treatments had little or no effect on cell viability, except treating cultures with 0.2 M guanidine and 0.5% TritonX-100TM, which severely decreased viability.

S. cerevisiae also was subjected to permeabilization assays not allowing further growth of the cells using Triton X-100TM, N-lauryl sarcosine (LS), or Lithium acetate + polyethylene glycol (LiAc+PEG). That is, under these conditions, permeabilization renders the cells unviable by removing the cell membrane altogether while retaining the cell-wall as a barrier to keep enzymes and gDNA inside. In such methods, UDP-glucose can be supplemental or recycled as described above. The advantage of permeabilization versus the purely *in vitro* approach is that individual enzymes do not need to be separately produced and isolated.

N-Lauryl sarcosine treatment resulted in inactivation of EUGT11 and only a minor increase in RebD was detected when LiAc/PEG was applied (data not shown). Treatment with Triton X-100TM 0.3% or 0.5%, however, increased the amount of RebD above background levels (see Figure 18) while sustaining the activity of EUGT11. For Triton X-100TM assays, overnight cultures were washed three times in PBS buffer. Cells corresponding to 6 OD₆₀₀ units were resuspended in PBS containing 0.3% or 0.5% Triton X-100TM respectively. Treated cells were vortexed and incubated 30 minutes at 30°C. After treatment, cells were washed in PBS buffer. Cells corresponding to 5 OD₆₀₀ units were used in an *in vitro* assay, as described for GST-EUGT11 and 0.6 OD₆₀₀ units were resuspended in reaction buffer and incubated overnight at 30°C as described for the LS treated samples. Untreated samples were used as controls.

Lysates from transformants expressing EUGT11 were able to convert some RebA into RebD (8 to 50 µM were measured in the reactions) when cells were untreated or after treatment with LiAc/PEG or Triton X100TM. However, no RebD was measured in lysates of cell pellets treated with LS. Permeabilized but non-lysed cells were able to produce some RebD (1.4 to 1.5 µM measured) when treated with 0.3% or 0.5% Triton X100TM (Figure 18) while no RebD was found on the samples treated with LS or LiAc/PEG. These results show that RebD can be produced from RebA biocatalytically using whole cells and using Triton X100TM as the permeabilizing agent.

20 **Example 10 – Assessment of codon optimized UGT sequences**

Optimal coding sequences for UGT 91d2e, 74G1, 76G1, and 85C2 were designed and synthesized for yeast expression using two methodologies, supplied by GeneArt (Regensburg, Germany) (SEQ ID NOs: 6, 2, 8, and 4, respectively) or DNA 2.0 (Menlo Park, CA) (SEQ ID NOs: 84, 83, 85, and 82, respectively). The amino acid sequences of UGT 91d2e, 74G1, 76G1, and 85C2 (SEQ ID NOs: 5, 1, 7, and 3, respectively) were not changed.

The wild-type, DNA 2.0, and GeneArt sequences were assayed for *in vitro* activity to compare reactivity on substrates in the steviol glycosides pathway. UGTs were inserted in high copy (2µ) vectors and expressed from a strong constitutive

promoter (GPD1) (vectors P423-GPD, P424-GPD, P425-GPD, and P426-GPD). The plasmids were transformed individually into the universal Watchmaker strain, EFSC301 (described in Example 3 of WO2011/153378) and assays were carried out using cell lysates prepared from equal amount of cells (8 OD units). For the enzymatic reactions, 6
5 μ L of each cell lysate were incubated in a 30 μ L reaction with 0.25 mM steviol (final concentration) to test UGT74G1 and UGT85C2 clones, and with 0.25 mM 13-SMG (13SMG) (final concentration) to test 76G1 and 91D2e UGTs. Assays were carried out for 24 hours at 30°C. Prior to LC-MS analysis, one volume of 100% DMSO was added to each reaction, samples were centrifuged at 16000g, and the supernatants analysed.

10 The lysates expressing the GeneArt-optimized genes provided higher levels of UGT activity under the conditions tested. Expressed as a percentage of the wild-type enzyme, the GeneArt lysates showed equivalent activity to the wild-type for UGT74G1, 170% activity for UGT76G1, 340% activity for UGT85C2 and 130% activity for UGT91D2e. Using UGT85C2 may improve the overall flux and productivity of cells for
15 production of Reb-A and Reb-D when expressed in *S. cerevisiae*.

Further experiments were conducted to determine if the codon-optimized UGT85C2 could reduce 19-SMG accumulation and increase rubusoside and higher glycosylated steviol glycosides production. The production of 19-SMG and rubusoside were analysed in a steviol-feeding experiment of *S. cerevisiae* strain BY4741 expressing
20 the wild type UGT74G1 as well as the codon-optimized UGT85C2 from high copy (2 μ) vectors under strong constitutive promoter (GPD1) (vectors P426-GPD and P423-GPD, respectively). Whole culture samples (without cell removal) were taken and boiled in an equal volume of DMSO for total glycosides levels. Intracellular concentrations reported were obtained by pelleting cells, and resuspending in 50% DMSO to the volume of the
25 original culture sample taken, followed by boiling. The “total” glycosides level and the normalized intracellular level then were measured using LC-MS. Using wild type UGT74G1 and wild type UGT85C2, approximately 13.5 μ M rubusoside was produced in total with a maximum normalized intracellular concentration of about 7 μ M. In contrast, when wild type UGT74G1 and codon-optimized UGT85C2 were used, a maximum of 26
30 μ M rubusoside was produced, or approximately double of what was produced using the

wild type UGT85C2. Additionally, the maximum normalized intracellular concentration of rubusoside was 13 μ M, again an approximate doubling of what was produced using wild type UGT85C2. Intracellular concentration of 19-SMG was significantly reduced from a maximum of 35 μ M using the wild type UGT85C2 to 19 μ M using the codon-
5 optimized UGT85C2. Consequently, about 10 μ M less total 19-SMG was measured for the codon-optimized UGT85C2. This shows that more 19-SMG is converted into rubusoside and confirms that the wild type UGT85C2 is a bottleneck.

During diversity screening, another homolog of UGT85C2 was discovered during *Stevia rebaudiana* cDNA cloning. The homolog has the following combination of
10 conserved amino acid polymorphisms (with respect to the amino acid numbering of the wild-type *S. rebaudiana* UGT85C coding sequence set forth in Accession No. AY345978.1): A65S, E71Q, T270M, Q289H, and A389V. This clone, termed UGT85C2 D37, was expressed through coupled *in vitro* transcription-translation of PCR products (TNT[®]T7 Quick for PCR DNA kit, Promega). The expression product was
15 assayed for glycosylation activity using steviol (0.5 mM) as the sugar acceptor, as described in WO/2011/153378 with the exception that assays were allowed to incubate for 24 hours. As compared to the wildtype UGT85C2 control assay, the D37 enzyme appears to have approximately 30% higher glycosylation activity.

20 **Example 11 - Identification of a novel *S. rebaudiana* KAH**

A partial sequence (GenBank Accession No. BG521726) was identified in the *Stevia rebaudiana* EST data base that had some homology to a *Stevia* KAH. The partial sequence was blasted against raw *Stevia rebaudiana* pyrosequencing reads using CLC main workbench software. Reads that partially overlapped with the ends of the partial
25 sequence were identified and used to increase the length of the partial sequence. This was done several times until the sequence encompassed both the start- and the stop codons. The complete sequence was analyzed for frameshift mutations and nucleotide substitutions that may have been introduced by blasting the complete sequence against the raw pyrosequencing reads. The resulting sequence was designated SrKAHe1. See
30 FIG. 12.

Activity of the KAH encoded by SrKAHe1 was assessed *in vivo* in *S. cerevisiae* background strain CEN.PK 111-61A, which expresses genes encoding enzymes constituting the entire biosynthetic pathway from the yeast secondary metabolites isopentenyl pyrophosphate (IPP) and farnesyl pyrophosphate (FPP) to steviol-19-O-monoside, except the steviol synthase enzyme that converts *ent*-kaurenoic acid to steviol.

Briefly, the *S. cerevisiae* strain CEN.PK 111-61A was modified to express an *Aspergillus nidulans* GGPPS, a 150 nt truncated *Zea mays* CDPS (with a new start codon, see below), a *S. rebaudiana* KS, a *S. rebaudiana* KO and the *S. rebaudiana* UGT74G1 from chromosomally integrated gene copies, with TPI1 and GPD1 yeast promoters driving transcription. The CEN.PK 111-61A yeast strain that expresses all of these genes was designated EFSC2386. Thus, strain EFSC2386 contained the following integrated genes: *Aspergillus nidulans* Geranyl geranyl pyrophosphate synthase (GGPPS); *Zea mays* *ent*-Copalyl diphosphate synthase (CDPS); *Stevia rebaudiana ent*-Kaurene synthase (KS); *Stevia rebaudiana ent*-kaurene oxidase (KO); and *Stevia rebaudiana* UGT74G1; in combination with the pathway from IPP and FPP to steviol-19-O-monoside, without a steviol synthase (KAH).

Expression of different steviol synthases (from episomal expression plasmids) was tested in strain EFSC2386 in combination with the expression of various CPRs (from episomal expression plasmids), and production of steviol-19-O-monoside was detected by LC-MS analysis of culture sample extracts. The nucleic acids encoding the CPRs were inserted in the multi cloning site of the p426 GPD basic plasmid while the nucleic acids encoding the steviol synthases were inserted in the multi cloning site the p415 TEF basic plasmid (p4XX basic plasmid series by Mumberg *et al.*, *Gene* 156 (1995), 119-122). Production of steviol-19-O-monoside occurs when a functional steviol synthase enzyme is present.

The KAHs that were expressed from episomal expression plasmids in strain EFSC2386 were “indKAH” (Kumar *et al.*, Accession no. DQ398871; Reeja *et al.*, Accession No. EU722415); “KAH1” (*S. rebaudiana* steviol synthase from Brandle *et al.*, U.S. Patent Publication No. 2008/0064063 A1); “KAH3” (*A. thaliana* steviol synthase from Yamaguchi *et al.*, U.S. Patent Publication No. 2008/0271205 A1); “SrKAHe1” (*S.*

rebaudiana steviol synthase cloned from *S. rebaudiana* cDNA as described above); and “DNA2.0.SrKAHe1” (codon optimized sequence (DNA2.0) encoding *S. rebaudiana* steviol synthase, see FIG. 12B).

The CPRs that were expressed from episomal expression plasmids in strain EFSC2386 were “CPR1” (*S. rebaudiana* NADPH dependent cytochrome P450 reductase (Kumar *et al.*, Accession no. DQ269454); “ATR1” (*A. thaliana* CPR, Accession No. CAA23011, see also FIG. 13); “ATR2” (*A. thaliana* CPR, Accession No. CAA46815, see also FIG. 13); “CPR7” (*S. rebaudiana* CPR, see FIG. 13, CPR7 is similar to “CPR1”); “CPR8” (*S. rebaudiana* CPR, similar to *Artemisia annua* CPR, see FIG. 13); and “CPR4” (*S. cerevisiae* NCP1 (Accession No. YHR042W, see also FIG. 13).

Table 13 provides the levels of steviol-19-O-monoside (μM) in strain EFSC2386 with the various combination of steviol synthases and CPRs.

Table 13
19-SMG Production

Strain	19-SMG production (μM)
"indKAH" CPR1	0.000
"indKAH" ATR1	0.000
"indKAH" ATR2	0.000
"indKAH" CPR7	0.000
"indKAH" CPR8	0.000
"indKAH" CPR4	0.000
"KAH1" CPR1	0.000
"KAH1" ATR1	0.000
"KAH1" ATR2	0.000
"KAH1" CPR7	0.000
"KAH1" CPR8	0.000
"KAH1" CPR4	0.000
"KAH3" CPR1	5.300
"KAH3" ATR1	5.921
"KAH3" ATR2	0.000
"KAH3" CPR7	5.693
"KAH3" CPR8	0.000

"KAH3" CPR4	0.000
"SrKAHe1" CPR1	20.129
"SrKAHe1" ATR1	15.613
"SrKAHe1" ATR2	40.407
"SrKAHe1" CPR7	33.724
"SrKAHe1" CPR8	41.695
"SrKAHe1" CPR4	28.949
"DNA2.0.SrKAHe1" CPR1	26.065
"DNA2.0.SrKAHe1" ATR1	26.974
"DNA2.0.SrKAHe1" ATR2	54.354
"DNA2.0.SrKAHe1" CPR7	30.797
"DNA2.0.SrKAHe1" CPR8	50.956
"DNA2.0.SrKAHe1" CPR4	30.368

Only KAH3 and the steviol synthase encoded by SrKAHe1 had activity when expressed in *S. cerevisiae*. The DNA 2.0. codon optimized SrKAHe1 sequence encoding steviol synthase resulted in a level of steviol-19-O-monoside accumulation that was approximately one order of magnitude higher as compared with a codon optimized KAH3 when each were co-expressed with optimal CPRs. In the experiments presented in this example, the combination of KAH1 and ATR2 CPR did not result in the production of steviol-19-O-monoside.

Example 12 - Pairings of CPRs and KO

The CEN.PK *S. Cerevisiae* EFSC2386 strain and the CPRs referred to in this Example are described in the Example 11 ("Identification of *S. rebaudiana* KAH"). EFSC2386 contained the following integrated genes: *Aspergillus nidulans* Geranyl geranyl pyrophosphate synthase (GGPPS); *Zea mays* ent-copalyl diphosphate synthase (CDPS); *Stevia rebaudiana* ent-kaurene synthase (KS); and *Stevia rebaudiana* ent-kaurene oxidase (KO). This strain produces ent-kaurenoic acid that was detected by LC-MS analysis.

A collection of cytochrome P450 reductases (CPRs) were expressed and tested in strain EFSC2386; "CPR1" (*S. rebaudiana* NADPH dependent cytochrome P450 reductase, Kumar *et al.*, Accession no. DQ269454); "ATR1" (*A. thaliana* CPR, Accession

No. CAA23011); “ATR2” (*A. thaliana* CPR, Accession No. CAA46815); “CPR7” (*S. rebaudiana* CPR, CPR7 is similar to “CPR1”); “CPR8” (*S. rebaudiana* CPR, similar to *Artemisia annua* CPR; and “CPR4” (*S. cerevisiae* NCP1, Accession No. YHR042W).

Overexpression of the *S. cerevisiae* endogenous native CPR (referred to as CPR4 in Table 14), and especially overexpression of one of the *A. thaliana* CPRs namely ATR2, gives good activation of the *Stevia rebaudiana* kaurene oxidase (the latter called KO1 in Table 14) and results in increased accumulation of *ent*-kaurenoic acid. See Table 14, which presents the area under curve (AUC) of the *ent*-kaurenoic acid peak in the LC-MS chromatograms. KO1 is an *ent*-kaurenoic acid producing yeast control strain without additional overexpression of CPRs.

Table 14 - Effect of Different Cytochrome P450 Reductase Enzymes with KO-1

Cytochrome P450 Reductase	Ent-Kaurenoic Acid (AUC)
CPR-1	14113
ATR-1	13558
ATR-2	29412
CPR-7	18918
CPR-8	12590
CPR-4	25103
Control	16593

Example 13 - Evaluating KS-5 and KS-1 in steviol pathways

The yeast strain EFSC1972 is a CEN.PK 111-61A *S. cerevisiae* strain that has the biosynthetic pathway from IPP/FPP to rubusoside expressed by integrated gene copies encoding the *Aspergillus nidulans* GGPPS (internal name GGPPS-10), the *Stevia rebaudiana* KS (KS1, SEQ ID NO:133), the *Arabidopsis thaliana* KAH (KAH-3, SEQ ID NO:144), the *Stevia rebaudiana* KO (KO1, SEQ ID NO:138), the *Stevia rebaudiana* CPR (CPR-1, SEQ ID NO:147), the full length *Zea mays* CDPS (CDPS-5, SEQ ID NO:158), the *Stevia rebaudiana* UGT74G1 (SEQ ID NO:1) and *Stevia rebaudiana* UGT85C2 (SEQ ID NO:3). Furthermore EFSC1972 has down regulation of the ERG9 gene expression by displacement of the endogenous promoter with the copper inducible promoter CUP1.

When EFSC1972 is transformed with a CEN/ARS-based plasmid that expresses the *Stevia rebaudiana* SrKAHe1 from a TEF1 promoter, and simultaneously transformed with 2 μ -based plasmids that express the *Synechococcus sp* GGPPS (GGPPS-7) and a truncated version of the *Zea mays* CDPS (truncated CDPS-5) from a GPD promoter, the result is growth-impaired *S. cerevisiae* producer of rubusoside (and 19-SMG). This strain is referred to as the “enhanced EFSC1972” in the following text. To determine whether the slow growth rate is caused by accumulation of the toxic pathway intermediate ent-copalyl diphosphate, a collection of kaurene synthase (KS) genes was expressed in the “enhanced EFSC1972” strain then growth and steviol glycoside production was assessed.

Expression of the *A. thaliana* KS (KS5) results in improved growth and steviol glycoside production of the “enhanced EFSC1972” strain. See FIG. 16. The same positive effect on growth cannot be achieved by further overexpression of the *Stevia rebaudiana* kaurene synthase (KS-1) in the enhanced EFSC1972 (data not shown).

Example 14 -- Yeast Strain EFSC1859

Saccharomyces cerevisiae strain EFSC1859 contains GGPPS-10, CDPS-5, KS-1, KO-1, KAH-3, CPR-1 and UGT74G1 coding sequences integrated into the genome and expressed from the strong constitutive GPD1 and TPI1 promoters. See Table 15. In addition, the endogenous promoter for the yeast ERG9 gene was replaced with the copper inducible promoter CUP1 for downregulation of the ERG9 squalene synthase. In standard yeast growth medium, the *ERG9* gene is transcribed at very low levels, since the concentration of copper in such medium is low. The decrease in ergosterol production in this strain results in increased amounts of isoprene units available for isoprenoid biosynthesis. In addition, strain EFSC1859 also expresses UGT85C2 from a 2 micron multicopy vector using a GPD1 promoter. EFSC1859 produces rubusoside and steviol 19-O-glycoside.

Zea mays CDPS DNA, with and without the chloroplast signal peptide, was expressed from a 2 micron multicopy plasmid using the GPD promoter. The nucleotide sequence and amino acid sequence of the *Zea mays* CDPS are forth in FIG. 14. The

chloroplast signal peptide is encoded by nucleotides 1-150 and corresponds to residues 1 to 50 of the amino acid sequence.

Table 15

Gene Source	Enzyme	Designation	gi Number	Accession No.
<i>Aspergillus nidulans</i>	GGPP synthase	GGPPS-10 (C301)	29468175	AF479566
<i>Zea mays</i>	CDP synthase	CDPS-5 (EV65)	50082774	AY562490
<i>Stevia rebaudiana</i>	Kaurene synthase	KS-1	4959241	AAD34295
<i>Stevia rebaudiana</i>	KO	KO-1	76446107	ABA42921
<i>Arabidopsis thaliana</i>	KAH	KAH-3	15238644	NP_197872
<i>Stevia rebaudiana</i>	UGT74G1			
<i>Stevia rebaudiana</i>	UGT85C2			
<i>Stevia rebaudiana</i>	CPR	CPR-1	93211213	ABB88839

5

EFSC1859 + maize full-length CDPS plasmid, and EFSC + maize truncated CDPS plasmid were grown in selective yeast medium with 4% glucose. Rubusoside and 19-SMG production were measured by LC-MS to estimate the production level. The removal of the plastid leader sequence did not appear to increase steviol glycoside production as compared to the wild-type sequence, and demonstrates that the CDPS transit peptide can be removed without causing a loss of steviol glycoside biosynthesis.

10

Example 15 -- Yeast Strain EFSC1923

Saccharomyces cerevisiae strain CEN.PK 111-61A was modified to produce steviol glycosides by introduction of steviol glycoside pathway enzymes from various organisms. The modified strain was designated EFSC1923.

15

Strain EFSC1923 contains an *Aspergillus nidulans* GGPP synthase gene expression cassette in the *S. cerevisiae* *PRP5-YBR238C* intergenic region, a *Zea mays* full-length CDPS and *Stevia rebaudiana* CPR gene expression cassette in the *MPT5-*

YGL176C intergenic region, a *Stevia rebaudiana* kaurene synthase and CDPS-1 gene expression cassette in the *ECM3-YOR093C* intergenic region, an *Arabidopsis thaliana* KAH and *Stevia rebaudiana* KO gene expression cassette in the *KINI-INO2* intergenic region, a *Stevia rebaudiana* UGT74G1 gene expression cassette in the MGA1-YGR250C intergenic region and a *Stevia rebaudiana* UGT85C2 gene expression cassette integrated by displacing the *TRP1* gene ORF. See Table 15. In addition, the endogenous promoter for the yeast ERG9 gene was replaced with the copper inducible promoter CUP1.

Strain EFSC1923 produced approximately 5 μ M of the steviol glycoside, steviol 19-*O*-monoside, on selective yeast medium with 4% glucose.

Example 16 – Expression of a Truncated Maize CDPS in Yeast Strain EFSC1923

The 150 nucleotides at the 5' end of the *Zea mays* CDP synthase coding sequence in Table 15 (SEQ ID NO:157, see FIG. 14) was deleted, the remainder of the coding sequence was provided with a new translation start ATG, and the truncated sequence was operably linked to the GPD1 promoter in the multicopy plasmid p423GPD in *Saccharomyces cerevisiae* EFSC1923. Plasmid p423GPD is described in Mumberg, D et al, Gene, **156** : 119-122 (1995). EFSC1923 and EFSC1923 plus p423GPD-Z.m.tCDPS were grown in for 96 hours in selective yeast medium containing 4% glucose. The amount of steviol 19-*O*-monoside produced by EFSC1923 + p423GPD-Z.m.tCDPS (the truncated *Zea mays* CDPS) under these conditions was approximately 2.5 fold more than that produced by EFSC1923 without the plasmid.

The *Arabidopsis thaliana* KAH coding sequence from Table 15 was inserted in a multicopy plasmid designated p426GPD, under the control of the GPD1 promoter. Plasmid p426GPD is described in Mumberg, D et al, Gene, **156** : 119-122 (1995). No significant difference was observed between the amount of steviol 19-*O*-monoside produced by EFSC1923 + p426GPD-A.t.KAH, and EFSC1923 lacking the plasmid.

EFSC1923 was transformed with both p423GPD-Z.m.tCDPS and p426GPD-A.t.KAH. Surprisingly, the amount of steviol 19-*O*-monoside produced under these conditions by EFSC1923 harboring both plasmids (i.e., the truncated *Zea mays*

CDPS and *Arabidopsis* KAH) was more than 6 fold greater than the amount produced by EFSC1923 alone.

A bifunctional CDPS-KS from *Gibberella fujikuroi* (NCBI Accession no: Q9UVY5.1, FIG. 15) was cloned and compared to the truncated CDPS-5. The
5 bifunctional *Gibberella* CDPS-KS was cloned into a 2 μ plasmid with a GPD promoter and transformed with a plasmid expressing the *Arabidopsis thaliana* KAH-3 from a 2 μ based-plasmid from a GPD promoter into EFSC1923. In shake flask studies, this bi-functional CDPS-KS was about 5.8 times more active in producing steviol 19-O-monoside than strain EFSC1923 with the KAH-3 alone. However, it was found to be less
10 optimal than the KAH-3 and truncated CDPS combination under the conditions tested. Therefore, further strains were constructed with KS-5 and truncated CDPS.

Example 17 - Toxicity of Intermediates

The effect on *S. cerevisiae* vitality of geranyl geranyl pyrophosphate (GGPP), *ent*-
15 copalyl diphosphate (CDP) or *ent*-kaurene production was investigated by expression of *Synechococcus sp* GGPPS alone (GGPP production), the GGPPS and the 50 amino acid N-terminally truncated *Zea mays* CDPS (see Example 16) together (CDP production), or the GGPPS, truncated CDPS and the *Arabidopsis thaliana* kaurene synthase (KS5) together (*ent* kaurene production) in the laboratory *S. cerevisiae* strain CEN.PK
20 background. Genes were expressed from 2 μ plasmids with GPD promoters driving transcription of truncated CDPS and KS5, while transcription of the GGPPS was driven by the ADH1 promoter. The growth of *S. cerevisiae* CEN.PK transformed with various combinations of these plasmids (GGPPS alone; GGPPS + truncated CDPS; or GGPPS + truncated CDPS + KS5) or plasmids without gene insertions was observed. GGPP
25 production, and especially CDP production, was toxic to *S. cerevisiae* when produced as end products. Interestingly, *ent*-kaurene appeared to not be toxic to yeast in the amounts produced in this experiment.

Example 18 - Disruption of endogenous phosphatase activity

The yeast genes *DPPI* and *LPPI* encode phosphatases that can degrade FPP and GGPP to farnesol and geranylgeraniol, respectively. The gene-encoding *DPPI* was deleted in strain EFSC1923 (described in Example 15) to determine if there was an effect on steviol glycoside production. When this *dpp1* mutant strain was further transformed with a plasmid expressing the *Z. mays* CDPS lacking the chloroplast transit sequence (Example 16), both small and large transformants emerged. Strains of the “large colony” type produced ~40% more 19-SMG as compared to “small colony” type and the non-*DPPI* deleted strain, under the conditions tested. These results indicate that deletion of *DPPI* can have a positive effect on steviol glycoside production and that the degradation of prenyl pyrophosphates in yeast therefore could influence steviol glycoside production negatively.

Example 19 - Construction of a genetically stable yeast reporter strain producing vanillin glucoside from glucose with a disrupted SUC2 gene

A yeast strain producing vanillin glucoside from glucose was created basically as described in Brochado et al. ((2010) *Microbial Cell Factories* 9:84-98) (strain VG4), but with additional integration into the ECM3 inter-locus region in the yeast genome of an expression cassette with *E. coli* EntD PPTase controlled by the yeast TPI1 promoter (as described in Hansen et al. (2009) *Appl. Environ. Microbiol.* 75(9):2765–2774), disruption of SUC2 by replacing coding sequence with a MET15 expression cassette, and disruption of LEU2 by replacing coding sequence with a Tn5ble expression cassette conferring resistance to phlcomycin. The resulting yeast strain was called V28. This strain also encodes a recombinant *A. thaliana* UDP-glycosyltransferase (UGT72E2, GenBank Accession No. Q9LVR1) having the amino acid sequence set forth in FIG. 19 (SEQ ID NO:178).

Example 20 - Expression of sucrose transporter and sucrose synthase in yeast already biosynthesizing vanillin glucoside

A sucrose transporter SUC1 from *Arabidopsis thaliana* was isolated by PCR amplification from cDNA prepared from *A. thaliana*, using proof-reading PCR

polymerase. The resulting PCR fragment was transferred by restriction digestion with *SpeI* and *EcoRI* and inserted into the corresponding in the low copy number yeast expression vector p416-TEF (a CEN-ARS based vector), from which the gene can be expressed from the strong TEF promoter. The resulting plasmid was named pVAN192.

5 The sequence of the encoded sucrose transporter is set forth in FIG. 19B (GenBank Accession No. AEE35247, SEQ ID NO:179).

A sucrose synthase SUS1 from *Coffea arabica* (Accession No. CAJ32596) from was isolated by PCR amplification from cDNA prepared from *C. arabica*, using proof-reading PCR polymerase. The PCR fragment was transferred by restriction digestion with *SpeI* and *SalI* and inserted into the corresponding position in the high copy number yeast expression vector p425-GPD (a 2 μ m based vector), from which the gene can be expressed from the strong GPD promoter. The resulting plasmid was named pMUS55. The sequence of the encoded sucrose synthase is set forth in FIG. 19C (GenBank Accession No. CAJ32596; SEQ ID NO:180).

15 pVAN192 and pMUS55 were introduced into the yeast strain V28 by genetic transformation, using a lithium acetate transformation protocol, creating the yeast strain V28::pVAN192::pMUS55. A control strain was made by transforming V28 with the empty plasmids P146-TEF and P425-GPD.

These two yeast strains were grown in 200 ml cultures in 500 ml Erlenmeyer shake flasks using SC (synthetic complete) growth medium without aromatic amino acids supplemented with 2% glucose and 2% sucrose and adjusted to pH 5.0. Cultures were incubated at moderate revolution (150 rpm), at 30°C for 72 hours. Samples were taken at 72 hours, and the content of vanillin glucoside determined. As can be seen from the table below, VG production in the control strain (containing empty plasmids p416-TEF and p425-GPD) was 330 mg/L VG, while the yeast strain V28::pVAN192::pMUS55 expressing sucrose synthase and sucrose transporter produced 445 mg/l VG, corresponding to a 34.8% increase in VG production.

Strain	Vanillin glucoside (g/L after 72 h)
V28 (p416-TEF + P425-GPD)	330
V28::pVAN192::pMUS55	445

This indicates that co-expression of a sucrose synthase and a sucrose transporter together with a glucosyltransferase increased the ability to glycosylate a small molecule aglycon, and concentration of the glycosylated aglycon was significantly increased. In this case, a significant improvement in vanillin glucosylation was achieved, resulting in a significant increase in titer of the end product, vanillin-O- β -glucoside.

Example 21 - Improved Steviol Glycoside Producing Strains

Strain construction of Saccharomyces cerevisiae EFSC2763

EFSC2763 yeast strain is derived from a wild type *Saccharomyces cerevisiae* strain containing three auxotrophic modifications, namely the deletions of *URA3*, *LEU2* and *HIS3*. The genetics of the strain have been stabilized and can be used as a regular diploid or haploid yeast strain. EFSC2763 has been converted to a steviol glycoside producing yeast by genomic-integration of four DNA constructs. Each construct contains multiple genes that were introduced into the yeast genome by homologous recombination. Furthermore, construct one and two were assembled by homologous recombination.

The first construct contains eight genes and is inserted in the *DPPI* locus and disrupts and partially deletes *DPPI* (see Example 18). The DNA inserted contains: the *A. gossypii* TEF promoter expressing the NatMX gene (selectable marker) followed by the TEF terminator from *A. gossypii*; Gene Art codon optimized *S. rebaudiana* *UGT85C2* (see Example 10) expressed from the native yeast GPD1 promoter and followed by the native yeast CYC1 terminator; *S. rebaudiana* *CPR-8* (see FIG. 13) expressed using the TPI1 promoter followed by the native yeast TDH1 terminator; *A. thaliana* Kaurene synthase (KS-5, see Example 13, SEQ ID NO:156) expressed from the PDC1 promoter and followed by the native yeast FBA1 terminator; *Synechococcus* sp. GGPPS (GGPPS-7) expressed using the TEF2 promoter and followed by the native yeast PFI1 terminator;

DNA2.0 codon-optimized *S. rebaudiana* KAHc1 (see Example 11, SEQ ID NO:165), expressed from the TEF1 promoter and followed by the ENO2 terminator; *S. rebaudiana* KO-1 expressed using the FBA1 promoter and followed by the native yeast TDH2 terminator; and *Zea mays* truncated CDPS (see Example 14) expressed using the PGK1 promoter and followed by the native yeast ADH2 terminator.

The second construct was inserted at the *YPRCΔ15* locus and contains the native yeast TEF promoter from *A. gossypii* in front expressing the KanMX gene (selectable marker) followed by the TEF terminator from *A. gossypii*, the Gene Art codon optimized *A. thaliana* ATR2 (see FIG. 13B) expressed from the PGK1 promoter followed by the yeast ADH2 terminator, *S. rebaudiana* UGT74G1 expressed from the TPI1 promoter followed by the yeast TDH1 terminator, Gene Art codon-optimized *S. rebaudiana* UGT76G1 expressed from the TEF1 promoter followed by the yeast ENO2 terminator, and GeneArt codon-optimized *S. rebaudiana* UGT91D2e-b (see Example 6) expressed from the GPD1 promoter and followed by the yeast CYC1 terminator.

The first and the second construct were combined in the same spore clone by mating and dissection. This yeast strain was subsequently transformed with construct three and four in two successive events.

Construct three was integrated between genes *PRP5* and *YBR238C* and contained the TEF promoter from *A. gossypii* in expressing the *K. lactis* LEU2 gene followed by the TEF terminator from *A. gossypii*, the GPD1 promoter expressing the DNA2.0-optimized *S. rebaudiana* KAHc1 followed by the CYC1 terminator, and the TPI1 promoter expressing the *Zea mays* truncated CDPS. Construct four was integrated in the genome between genes *ECM3* and *YOR093C* with an expression cassette containing the TEF promoter from *A. gossypii* expressing the *K. pneumoniae* hph gene followed by the TEF terminator from *A. gossypii*, *Synechococcus* sp. GGPPS expressed from the GPD1 promoter followed by the CYC1 terminator, and the TPI1 promoter expressing the *A. thaliana* Kaurene synthase. The four utilized genetic markers were subsequently removed.

As analyzed by LC-MS following the DMSO-extraction of total steviol glycosides from cells and broth, EFSC2772 produces between 40-50 μ M or 2-3

μM/OD600 Rebaudioside A, after growth for four days in 3 ml SC (Synthetic Complete) media at 30°C with 320 RPM shaking in deep-well plates.

Strain construction of Saccharomyces cerevisiae EFSC2772

5 EFSC2772 is very similar to strain 2763 with the exception that the genetic markers were not removed, and the strain was made prototrophic by introduction of the two plasmids p413TEF (public domain CEN/ARS shuttle plasmid with *HIS3* marker) and p416-TEF (public domain CEN/ARS shuttle plasmid with *URA3* marker) by transformation, and designated EFSC2772.

10 As analyzed by LC-MS following the DMSO-extraction of total steviol glycosides from cells and broth, EFSC2772 produces similar levels of Rebaudioside A as 2763, after growth in deep-well plates. Higher optical densities and higher titers were obtained through aerobic fed-batch growth in 2L (working volume) fermentors which included a ~16 hour growth phase in the base medium (Synthetic Complete media)
15 followed by ~100 hours of feeding with glucose utilized as the carbon and energy source combined with trace metals, vitamins, salts, and Yeast Nitrogen Base (YNB) and/or amino acid supplementation. The pH was kept near pH 5 and the temperature setpoint was 30°C. As evidenced by LC-MS, combined cellular and extracellular product concentrations were between 920-1660 mg/L of Reb-A and approximately 300-320 mg/L
20 of Reb-D in the two different experiments, approximately 700 mg/L of Reb-A was detected in the broth when the higher titer results were obtained. Additionally a large peak was seen for Reb-B, and one skilled in the art will recognize that additional copies of UGT74G1 or upregulation of UGT74G1 will further increase the conversion of RebB to RebA.

25 Strain EFSC2743 was made in a similar manner as above, but without the two plasmids conferring prototrophy and with the addition of a p416 (CEN/ARS)-based plasmid expressing EUGT11 from the TEF promoter. This strain was grown in a fed-batch fermentation as above. This strain produced a total amount of RebD of 920 mg/L and furthermore approximately a 9:1 ratio of RebD to RebA was seen. Approximately
30 360 mg/L of RebD was found in the broth.

Example 22 - UDP-glucose capacity

In Example 21, it was shown that yeast can fully glycosylate over 1 mM steviol e.g., to RebD, RebB, and RebA. Similarly, *Saccharomyces* strains are able to glycosylate as much as 60 mM of other small molecule products (data not shown). However, the glycosylation limit of the yeast native UDP-glucose regenerating system is unknown, or the rate at which it replenishes the UDP-glucose pool needed for cell wall synthesis. Therefore, experiments were designed to investigate if an increase in UDP-glucose production would increase the glycosylation rate in yeast. A *suc2* deletion mutant was transformed with plasmids harboring the *A. thaliana suc1* gene encoding a sucrose transporter, UGT74G1 and *A. thaliana* SUS. UGT74G1 can rapidly glycosylate steviol to steviol 19-O-monoglucoside (19-SMG). Transformants were pre-grown overnight in 13-ml culture tubes containing 4 ml of SC medium lacking leucine, histidine and uracil. The next day, cells corresponding to 2 OD₆₀₀ units were spun down and resuspended in 2 ml of fresh media was containing 2% sucrose and or 100 μ M steviol. Cultures were shaken at 30°C for 3 days in culture tubes. After 1h, 3h, 6h, 21h and 46h, aliquots were taken. Aliquots of 100 μ l of culture were spun down and an equal volume of DMSO was added. Samples were vortexed, heated at 80°C for 15 minutes, centrifuged, and the 19-SMG content analyzed by LC-MS. No difference in the rate of glycosylation of steviol was observed between wild-type and SUS1-augmented strains at the time points tested. This suggests that glycosylation of steviol by UGT74G1 proceeds at a slower rate than UDP-glucose is regenerated by the yeast and that extra UDP-glucose may not be needed to achieve high titers of small molecule glycosylation *in vivo*. Nevertheless, the use of a SUS to recycle UDP-glucose *in vitro* is shown in Example 8 and therefore its use in an *in vivo* system is expected to increase the rate of production of steviol glycosides, if UDP-glucose should become limiting.

Example 23 - Reb-C and Reb-F production *in vivo* from glucose

Production of RebC from steviol

Previous experiments (Publication No. WO/2011/153378) have shown that recombinantly expressed *Arabidopsis thaliana* RHM2 (rhamnose synthetase, locus tag AT1G53500) is able to convert UDP-glucose to UDP-rhamnose. This UDP-rhamnose can be used to produce steviol-13-*O*-glucopyranosyl-1,2-rhamnoside, when incubated with UGT91D2e and steviol-13-*O*-monoglucoside *in vitro*.

Further experiments were conducted to confirm production of RebC from steviol by expressing all 4 UGTs and the RHM2 in yeast *in vivo*, followed by steviol feeding. EFSC301 strain (MAT alpha, *lys2ADE8 his3ura3leu2trp1*) was transformed with the following plasmids expressing wild type gene sequences: p424GPD expressing wild type UGT74G1 (Accession no: AY345982); p423GPD expressing wild type 85C2 (Accession no.: AY345978.1); and a p426GPD derived-plasmid expressing wildtype UGT76G1 (Accession no: AY345974) and UGT91D2e under GPD promoters. Plasmid p425GPD expressing either RHM2 or an empty p425GPD control plasmid was cotransformed with the UGTs. Transformants were pre-grown overnight in 13 mL culture tubes containing 2-3 ml of SC medium lacking leucine, histidine, tryptophan and uracil. The next day, after growth had reached 0.4 OD₆₀₀ units, cells were spun down, resuspended in fresh medium containing 25 µM steviol and shaken at 30°C for 3 days in culture tubes. An aliquot of 100 µL of culture was spun down. An equal volume of DMSO was added to the supernatant of this sample while 200 µL of 50% DMSO was added to the pellet. Samples were vortexed, heated at 80°C for 15 minutes, centrifuged, and the steviol glycoside content analyzed by LC-MS. RebC was detected in growth media and cellular extracts only when the RHM2 gene was coexpressed with the UGTs. Quantification showed that approximately equal amounts of RebA and RebC were produced. This shows that RHM2 is able to produce significant quantities of UDP-rhamnose *in vivo* and that UGT91D2e is capable of efficient rhamnosylation *in vivo*. Two other compounds were observed via LC-MS with retention times of 5.64 and 5.33 minutes and m/z ratios corresponding to steviol with 1 glucose- and 1 rhamnose (steviol-1,2 rhamnobioside), and 2 glucoses- and 1 rhamnose (Dulcoside A), respectively. This suggests that the remaining UGTs in the steviol glycoside pathway are capable of accepting rhamnosylated intermediates, i.e, the rhamnosylation step does not need to occur last.

In addition, a series of sequential *in vitro* experiments were conducted to determine whether any dead-end reactions occur in the rebaudioside C pathway. See FIG.2B. For example, the rhamnosylation activity of UGT91D2e on rubusoside and subsequent conversion of the product to RebC by UGT76G1 was demonstrated using *in vitro* reactions. In this experiment, UGT91D2e and RHM2 recombinantly expressed in *E. coli* and purified were incubated overnight with rubusoside, NADPH, NAD⁺ and UDP-glucose. The reaction mixture was subsequently boiled to denature the enzymes. An aliquot of the reaction was added to an enzyme preparation of UGT76G1 with UDP-glucose. The rubusoside was converted in the presence of UGT91D2e and RHM2 to a compound with m/z corresponding to steviol with 2-glucoses and 1-rhamnose. Subsequently, this compound was converted in the presence of UGT76G1 to RebC, which indicates that the intermediate is Dulcoside A. This experiment therefore demonstrates that UGT91D2e is able to rhamnosylate rubusoside and that UGT76G1 is able to convert the product to RebC.

Similarly, it was shown through *in vitro* reactions that rhamnosylation of 13-SMG by UGT91D2e (forming a steviol compound with one glucose and one rhamnose) and subsequent formation of a compound with 2 glucoses and 1 rhamnose by UGT76G1. This compound has a unique retention time (4.56 min) and is thought to be steviol 13-*O*-1,3-diglycoside-1,2-rhamnoside. This compound also was observed when steviol was fed to yeast expressing the four UGTs and RHM2.

From the current data, it is shown that UGT91D2e is able to rhamnosylate 13-SMG and rubusoside. It is also shown that UGT74G1 and UGT76G1 are able to metabolize the rhamnosylated compound produced by UGT91D2e from 13-SMG. When these compounds are incubated with the remaining UGT (UGT74G1 or UGT76G1 depending on which UGT was used for the previous step), RebC is formed. This indicates that the order of glycosylation is of little importance as UGT74G1 and UGT76G1 are able to glycosylate rhamnosylated substrates.

Production of RebC from glucose

Plasmids expressing RHM2 and UGTs 76G1 and 91D2e were transformed into a stable rubusoside producer, the EFSC1923 strain (see Example 15). This yeast is a *Saccharomyces cerevisiae* CEN.PK 111-61A derivative with the UGTs 85C2 (Accession no.: AY345978.1) and 74G1 (Accession no: AY345982) integrated into the genome as well as auxotrophic modifications. In strain EFSC1923 (see Example 15), expression of squalene synthase, which is encoded by ERG9, was downregulated by displacement of the endogenous promoter with the CUP1 copper-inducible promoter. Strain EFSC1923 also contains an *Aspergillus nidulans* GGPP synthase (GGPPS-10) expression cassette in the *S. cerevisiae* PRP5-YBR238C intergenic region, a *Zea mays* full-length CDPS (CDPS-5) and *Stevia rebaudiana* CPR (CPR-1) gene expression cassette in the *MPT5-YGL176C* intergenic region, a *Stevia rebaudiana* Kaurene synthase and CDPS (KS-1/CDPS-1) gene expression cassette in the *ECM3-YOR093C* intergenic region, an *Arabidopsis thaliana* KAH (KAH-3) and *Stevia rebaudiana* KO (KO-1) gene expression cassette in the *KINI-INO2* intergenic region, a *Stevia rebaudiana* UGT74G1 gene expression cassette in the MGA1-YGR250C intergenic region and a *Stevia rebaudiana* UGT85C2 gene expression cassette integrated by displacing the *TRP1* gene ORF20. Inserted steviol pathway genes are described in Table 11 of published PCT WO/2011/153378.

EFSC1923 strain was transformed with a p423GPD-derived plasmid expressing wildtype UGT74G1 and UGT85C2 sequences using GPD promoters and a p426GPD-derived plasmid expressing wildtype UGT76G1 (Accession no: AY345974) and UGT91D2e (see SEQ ID NO:5) under the control of GPD promoters. Plasmid p425GPD expressing *Arabidopsis thaliana* RHM2 (enzyme locus tag AT1G53500) or an empty p425GPD control plasmid was co-transformed. Transformants were pre-grown overnight in 13-ml culture tubes containing 2-3 ml of SC medium lacking leucine, histidine and uracil. The next day, when the culture reached an OD₆₀₀ of 0.4 units it was centrifuged, resuspended in fresh medium, and shaken at 30°C for 3 days in culture tubes. One hundred µL of culture were spun down; to this an equivalent volume of DMSO was added to the supernatant while 200 µL of 50% DMSO was added to the pellet. Samples

were vortexed, heated at 80°C for 15 minutes, spun down and the steviol glycoside content analyzed by LC-MS.

Analyses of the medium and normalized intracellular content of this strain showed production of RebC. Approximately 8 μ M RebC and 4 μ M RebA was produced as determined by LC-MS. Furthermore, the intermediates produced following steviol feeding were not detected in this experiment. Accumulation of RebC was strictly dependent on expression of RHM2. This example demonstrates *de novo* biosynthesis of RebC from glucose.

Production of additional Steviol glycosides from steviol and glucose

Using the same GPD-based plasmids described above, the stable steviol-producing strain EFSC1923 containing UGT74G1 and UGT85C2 was transformed with the UGTs required to produce RebB (UGT76G1 and UGT91D2e/EUGT11), RebE (UGT91D2e/EUGT11) and dulcoside A (RHM2, UGT91D2e/EUGT11). Wildtype EUGT11 (NCBI: NP_001051007), which was found to have higher diglycosylation activity, was cloned into p424GPD for this experiment. Transformants were pre-grown overnight in 13-ml culture tubes containing 2-3 ml of SC medium lacking leucine, histidine, tryptophan and uracil. The next day, after growth had reached 0.4 OD₆₀₀ units, cells were spun down, resuspended in fresh medium containing 25 μ M steviol (except for glucose experiments) and shaken at 30°C for 3 days in culture tubes. An aliquot of 100 μ L of culture was spun down. An equal volume of DMSO was added to the supernatant of this sample while 200 μ L of 50% DMSO was added to the pellet. Samples were vortexed, heated at 80°C for 15 minutes, centrifuged, and the steviol glycoside content analyzed by LC-MS. LC-MS analyses confirmed *in vivo* production of RebB, RebE, and Dulcoside A in *S. cerevisiae* from glucose or steviol. See, e.g., FIGs. 2A and 2B. A higher concentration of steviol-glycosides was observed following steviol-feeding (as judged by chromatograms).

Characterization of RebF pathway intermediates using EUGT11.

The xylosylating properties of UGT91D2e and EUGT11 were compared *in vitro*. By using UDP-xylose as the sugar-donor, UGT91D2e was previously shown to xylosylate steviol-13-O-monoglucoside forming a key intermediate in RebF biosynthesis

(Publication No. WO/2011/153378). Similar *in vitro* experiments using EUGT11 and UGT91D2e have shown that these UGTs are capable of xylosylating rubusoside. When UGT91D2e is used, the LC-MS analysis shows a new peak with an m/z ratio corresponding to steviol with 2 glucose molecules and 1 xylose. See, FIG. 26. Because
5 of the shift in the retention time this peak is thought to correspond to rubusoside xylosylated on the 13-O-glucose. When EUGT11 is used, the LC-MS analysis shows two new, similar sized peaks at retention time 3.99 and 4.39 minutes with m/z ratios corresponding to steviol with 2 glucoses and 1 xylose. These products most likely correspond to rubusoside xylosylated on either of the two positions--the 13-O-glucose or
10 the 19-O-glucose.

Production of RebF from glucose

In vivo production of RebF requires cloning of UGD1 (UDP-glucose dehydrogenase) and USX3 (UDP-glucuronic acid decarboxylase) from *Arabidopsis* for
15 production of UDP-xylose. UGD1 and UXS3 were inserted in a high copy (2 μ) vector, derived from P425-GPD, containing two expression cassettes, and expressed from strong constitutive promoters (*TPII* and *GPD1*, respectively). The plasmid was transformed into the RebA producer strain EFSC2763 (described in Example 21) and cultivated during 3 days in selection medium (SC -leu). The LC-MS results clearly show the appearance of a
20 new peak at retention time 4.13 minutes with m/z ratios corresponding to steviol with 3 glucoses and 1 xylose and identified as RebF (based on a commercial RebF standard), as well as other new peaks with m/z ratios corresponding to steviol with 2 glucoses and 1 xylose (as above), indicating that UGT91D2e was capable of carrying out xylosylation *in vivo*. These peaks were not seen in the negative controls.

25

Example 24 - Effect of squalene synthase (ERG9) down regulation using a heterologous insert

In yeast such as *Saccharomyces cerevisiae*, the mevalonate pathway produces a number of isoprenoid phosphate intermediates in the biosynthetic pathway to squalene
30 (See FIG. 20). The squalene synthase in yeast is *ERG9*. See GenBank Accession No.

P29704.2 for the *Saccharomyces cerevisiae* squalene synthase; P36596 for the *Schizosaccharomyces pombe* squalene synthase; Q9Y753 for the *Yarrowia lipolytica* squalene synthase; Q9HGZ6 for the *Candida glabrata* squalene synthase; Q752X9 for the *Ashbya gossypii* squalene synthase; O74165 for the *Cyberlindnera jadinii* squalene synthase; P78589 for the *Candida albicans* squalene synthase; P38604 for the *Saccharomyces cerevisiae* lanosterol synthase; P37268 for the *Homo sapiens* squalene synthase; P53798 for the *Mus musculus* squalene synthase; and Q02769 for the *Rattus norvegicus* squalene synthase. See FIG. 25 (SEQ ID NOs:192-202).

Introduction of stemloop structure in 5'UTR of ERG9 gene

The wild-type *ERG9* promoter region was replaced with the *CYC1* promoter sequence and a 5'UTR sequence by homologous recombination. The 5'UTR region contains a sequence that can form a stemloop structure. See SEQ ID NOs. 181-183. SEQ ID NO:184 is another sequence that also can be used.

SEQ ID NO: 181 (heterologous insert 1): TGAATTCGTTAACGAATTC
 SEQ ID NO: 182 (heterologous insert 2): TGAATTCGTTAACGAACTC
 SEQ ID NO: 183 (heterologous insert 3): TGAATTCGTTAACGAAGTC
 SEQ ID NO: 184 (heterologous insert 4): TGAATTCGTTAACGAAATT

Without being bound to a particular mechanism, the stemloop may partially block the 5'-3' directed ribosomal scanning for the AUG and reduce the translation of the transcript. Stemloops with different degree of basepairing were tested to find stemloops that reduced the *ERG9* transcript translation sufficiently to boost FPP levels without affecting the growth of the yeast strain.

DNA fragments encompassing an *ERG9* promoter upstream sequence (for homologous recombination), an expression cassette for the gene (*NatR*) that confers resistance to Nourseothricin, a *CYC1* promoter (SEQ ID NO: 185, FIG. 21), a 5' UTR sequence with a stemloop structure, and an *ERG9* ORF sequence (for homologous recombination) were generated by PCR. DNA fragments that contained either the *CYC1*

promoter or the KEX2 promoter (SEQ ID NO: 186) but no stemloops were also generated as controls. The flanking ERG9 sequences for recombination as well as the stemloop structure were introduced via the PCR oligos. An overview of the construct for homologous recombination is shown in FIG. 22. The DNA fragments were transformed
5 into an *S.cerevisiae* host strain that subsequently was selected on nourseothricin containing growth plates. Clones with successful exchange of the native ERG9 promoter with the CYC1 promoter and stemloop-containing 5'UTR sequence were identified. Overview and sequence of the stem-loop region is provided in FIG. 23. The sequence identified as 5% corresponds with the heterologous insert having SEQ ID NO:181; the
10 sequence identified as 20% corresponds with the heterologous insert having SEQ ID NO:182; and the sequence identified as 50% corresponds with the heterologous insert having SEQ ID NO:183.

Assessment of FPP accumulation (boosting effect)

The Amorpha-4,11-diene Synthase (ADS) gene catalyzes the chemical reaction
15 that turns one FPP molecule into Amorpha-4,11-diene in the plant *Artemisia annua*. The gene is functional and efficient in *S.cerevisiae* and can be used to indirectly assess the accumulation of FPP in the strains with the stemloop structure introduced in the heterologous 5'UTR of the ERG9 gene. An *S.cerevisiae* codon optimized nucleic acid encoding ADS (GenBank Accession No. AAF61439) was cloned on a multicopy plasmid
20 (2 μ) under the control of the PGK1 promoter and transformed in the wild type and engineered *S. cerevisiae* strains. Amorpha-4,11-diene production was measured and compared to the standard compound caryophyllene, as described by (Ro *et al.* 2006. *Nature* 440(7086):940–943; Paradise *et al. Biotechnol Bioeng.* 2008 Jun 1;100(2):371-8; Newman *et al. Biotechnol Bioeng* 95(4):684–691).

25 Chemicals

Dodecane and caryophyllene were purchased from Sigma-Aldrich (St.Louis, MO). Complete Supplement Mixtures for formulation of Synthetic Complete (SC) media were purchased from Formedium (UK). All others chemical were purchased from Sigma-Aldrich.

30 Yeast cultivation

Engineered yeast strains were grown in SC 2% glucose with uracil dropped out. Cultures were grown at 30°C overnight and then used to inoculate main cultures in 250 mL shake flasks containing 25 mL SC medium, and grown to an optical density of 0.1 at 600nm. The main cultures were grown for 72h at 30°C. Because amorphadiene at very low concentrations is volatile from aqueous cultures, 2.5 mL dodecane was added to each culture flask in order to trap and retain the amorphadiene produced. 10 µl of the dodecane layer was sampled and diluted 100 fold in ethyl acetate for quantification by GC-MS

GC-MS analysis of amorphadiene

GC-MS was used to measure amorphadiene production from yeast cultures. Samples were analysed using the method as follow: The GC oven temperature program used 80°C for 2 min, followed by a ramping of 30°C/min to 160°C, then 3°C/min up to 170°C, and finally 30°C/min up to 300°C with a 2 min final hold. Injector and MS quadrupole detector temperatures were 250°C and 150°C, respectively. 1µL was injected in split less mode. The MS was operated in full scan mode. Amorphadiene concentration was calculated in (-)-tran-caryophyllene equivalents using a caryophyllene standard curve using the total ions.

The analysis of the different strains, including the different promoter constructs, showed an increased production of amorphadiene ((2.5 x) when using the heterologous insert having the nucleotide sequence set forth in SEQ ID NO: 181 compared to either no insert or the inserts having the nucleotide sequences set forth in SEQ ID NO:182 and 183. See FIG. 24. The heterologous insert set forth in SEQ ID NO:181 has the most stable secondary structure. For comparison the wild type yeast, with unmodified ERG9, was also analyzed (FIG. 24: CTRL-ADS) and this strain showed even lower production of amorphadiene. Conversely, the construct that comprised the very weak promoter ScKex2 showed an even higher level of amorphadiene (6 x).

Example 25 - Analysis of the effect of Squalene Synthase (ERG9) down regulation and GGPPS overexpression on GGPP production.

Assessment of GGPP accumulation

S.cerevisiae contains a GGPPS (BTS1). In addition to BTS1 there are several heterologous GGPPS enzymes that are functional and efficient in *S. cerevisiae*. When a functional GGPPS is overexpressed in *S.cerevisiae*, it leads to accumulation of GGPP, which may be converted to geranylgeraniol (GGOH) by the *S. cerevisiae* enzymes DPP1 and LPP1. The GGOH is partly exported to the yeast culture medium. GGOH can be measured by GC-MS and its accumulation can indirectly be used to assess the potential pool of GGPP that is available for enzymes that use GGPP as substrate.

Four different GGPPSs (GGPPS-1 (*S.acidicaldarius*, see Table 7), GGPPS-2 (*A. nidulans*, FIG. 25, SEQ ID NO:203), GGPPS-3 (*S.cerevisiae*, BTS1, FIG. 25, SEQ ID NO:167), and GGPPS-4 (*M. musculus*, see Table 7)) were assessed. The nucleotide sequences encoding GGPPS-1, GGPPS-2, and GGPPS-4 were *S. cerevisiae* codon optimized. All nucleic acids encoding the GGPPS polypeptides were cloned on a multicopy plasmid (2 μ) under the control of the PGK1 promoter and transformed in two different ERG9 down regulated strains: KEX2-ERG9 and CYC1(5%)-ERG9 (see Example 24).

Engineered yeast strains were grown in SC 2% glucose with uracil dropped out. Complete Supplement Mixtures for formulation of Synthetic Complete (SC) media were purchased from Formedium (UK). All others chemical were purchased from Sigma-Aldrich (St.Louis, MO). All optical density measurements were done at OD 600nm. Cultures were grown at 30°C overnight and then used to inoculate 250 ml unbaffled culture flasks containing 25ml SC medium at an OD600 of 0.1. The main cultures were grown for 72h at 30°C.

To measure GGOH accumulation, yeast cells (pellet) and yeast culture medium (supernatant) were extracted separately and then combined before analysis by GC-MS. The supernatant was extracted with Hexane in a 1:1 ratio. The pellet was first subjected to a saponification in solution containing 20% KOH and 50% Ethanol and the lysed cells were finally extracted with Hexane in a 1:1 ratio. The GC oven temperature program used was 80°C for 2 min, followed by a ramp to 160°C at 30°C/min, then to 170°C at 3°C/min and finally to 300°C at 30°C/min with a 2 min hold. Injector and MS quadrupole

detector temperatures were 250°C and 150°C, respectively. 2ul was injected in split less mode. The MS was operated in full scan mode.

When the GGPPS were overexpressed in the CYC1(5%)-ERG9 strain or KEX2-ERG9 strain, there was a significant increase in GGOH (GGPP) production observed
5 with all four GGPPS polypeptides compared to the control where no GGPPS was expressed. Notably, the CYC1(5%)-ERG9 strain showed a 2-4 fold higher GGOH (GGPP) accumulation than the KEX2-ERG9 strain. The results are shown in FIG. 26.

OTHER EMBODIMENTS

It is to be understood that while the invention has been described in conjunction
10 with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

CLAIMS:

1. A method for producing a target steviol glycoside composition, comprising contacting a starting composition comprising a steviol, a precursor steviol glycoside, and/or a mixture thereof with a first polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:152; and one or more polypeptides selected from a group consisting of:
 - (a) a second polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:5;
 - (b) a polypeptide operable for rhamnosylation of steviol 13-O-glucoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:150;
 - (c) a polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT74 family, comprising a UGT74G1 polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-19 carboxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:1;
 - (d) a polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT85 family, comprising a UGT85C2 polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-13 hydroxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:3; and
 - (e) a polypeptide operable for beta 1,3 glycosylation of the C3' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80%

sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:7;

wherein at least one of the polypeptides is a recombinant polypeptide;

and one or more UDP-sugar, under suitable reaction conditions for the transfer of one or more sugar moieties from the one or more UDP-sugar to the steviol, the precursor steviol glycoside, and/or the mixture thereof,

thereby producing the target steviol glycoside composition;

wherein the target steviol glycoside is or the target steviol glycoside composition comprises one or more of steviol-1,2-bioside, stevioside, rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, dulcoside A, steviol-1,2-rhamnobioside, steviol-1,2-xylobioside, or 1,2 stevioxyloside and/or a combination thereof; and

wherein the precursor steviol glycoside is steviol-13-O-glucoside, steviol-19-O-glucoside, rubusoside, steviol-1,2-bioside, stevioside, rebaudioside A, rebaudioside B, or rebaudioside E, or a mixture thereof.

2. The method of claim 1, wherein the one or more UDP-sugar is UDP-glucose, UDP-rhamnose, fructose, and/or UDP-xylose.
3. The method of claim 1, wherein:
 - (a) the precursor steviol glycoside is steviol-13-O-glucoside, steviol-19-O-glucoside, rubusoside, steviol-1,2-bioside, or stevioside, or a mixture thereof, the one or more UDP-sugar is UDP-glucose, the steviol, the precursor steviol glycoside or the mixture thereof is contacted with one or more polypeptides comprising the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:152 and one or more polypeptides selected from a group consisting of the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT85 family, comprising a UGT85C2 polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-13

hydroxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:3, the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT74 family, comprising a UGT74G1 polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-19 carboxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:1; the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:5; and the polypeptide operable for beta 1,3 glycosylation of the C3' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:7; and

- rebaudioside A is produced upon transfer of the one or more sugar moieties from the one or more UDP-glucose to steviol, the precursor steviol glycoside, or the mixture thereof; or
- (b) the precursor steviol glycoside is steviol-13-O-glucoside or steviol-1,2-bioside or a mixture thereof, the one or more UDP-sugar is UDP-glucose,

the steviol, the precursor steviol glycoside or the mixture thereof is contacted with one or more polypeptides comprising the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:152 and one or more polypeptides selected from a group consisting of the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT85 family, comprising a UGT85C2 polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-13

hydroxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:3, the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:5; and the polypeptide operable for beta 1,3 glycosylation of the C3' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:7; and

- rebaudioside B is produced upon transfer of the one or more sugar moieties from the one or more UDP-glucose to steviol, the precursor steviol glycoside, or the mixture thereof; or
- (c) the precursor steviol glycoside is steviol-13-O-glucoside, steviol-19-O-glucoside, rubusoside, steviol-1,2-bioside, or stevioside or a mixture thereof, the one or more UDP-sugar is UDP-glucose,

the steviol, the precursor steviol glycoside or the mixture thereof is contacted with one or more polypeptides comprising the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:152 and one or more polypeptides selected from a group consisting of the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT85 family, comprising a UGT85C2 polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-13 hydroxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:3, the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT74 family, comprising a UGT74G1 polypeptide operable for glycosylating steviol or the precursor

steviol glycoside at its C-19 carboxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:1; the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:5; and the polypeptide operable for beta 1,3 glycosylation of the C3' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:7; and

- rebaudioside E is produced upon transfer of the one or more sugar moieties from the one or more UDP-glucose to steviol, the precursor steviol glycoside, or the mixture thereof; or
- (d) the precursor steviol glycoside is steviol-13-O-glucoside, steviol-19-O-glucoside, rubusoside, steviol-1,2-bioside, stevioside, rebaudioside A, rebaudioside B, or rebaudioside E, or a mixture thereof, the one or more UDP-sugar is UDP-glucose,

the steviol, the precursor steviol glycoside or the mixture thereof is contacted with one or more polypeptides comprising the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:152 and one or more polypeptides selected from a group consisting of the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT85 family, comprising a UGT85C2 polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-13 hydroxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:3, the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT74 family, comprising a UGT74G1

polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-19 carboxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:1; the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:5; and the polypeptide operable for beta 1,3 glycosylation of the C3' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:7; and

- rebaudioside D is produced upon transfer of the one or more sugar moieties from the one or more UDP-glucose to steviol, the precursor steviol glycoside, or the mixture thereof; or
- (e) the precursor steviol glycoside is steviol-13-O-glucoside, steviol-19-O-glucoside, or rubusoside, or a mixture thereof, the one or more UDP-sugar is UDP-glucose and UDP-rhamnose,

the steviol, the precursor steviol glycoside or the mixture thereof is contacted with one or more polypeptides comprising the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:152 and one or more polypeptides selected from a group consisting of the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT85 family, comprising a UGT85C2 polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-13 hydroxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:3, the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT74 family, comprising a UGT74G1

polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-19 carboxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:1; the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:5; and the polypeptide operable for rhamnosylation of steviol 13-O-monoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:150; and

dulcoside A is produced upon transfer of the one or more sugar moieties from the one or more UDP-glucose and UDP-rhamnose to steviol, the precursor steviol glycoside, or the mixture thereof; or

- (f) the precursor steviol glycoside is steviol-13-O-glucoside, steviol-19-O-glucoside, or rubusoside, or a mixture thereof, the one or more UDP-sugar is UDP-glucose and UDP-rhamnose,

the steviol, the precursor steviol glycoside or the mixture thereof is contacted with one or more polypeptides comprising the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:152 and one or more polypeptides selected from a group consisting of the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT85 family, comprising a UGT85C2 polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-13 hydroxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:3, the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT74 family, comprising a UGT74G1

polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-19 carboxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:1; the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:5; the polypeptide operable for rhamnosylation of steviol 13-O-monoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:150; and the polypeptide operable for beta 1,3 glycosylation of the C3' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:7; and

rebaudioside C is produced upon transfer of the one or more sugar moieties from the one or more UDP-glucose and UDP-rhamnose to steviol, the precursor steviol glycoside, or the mixture thereof; or

- (g) the precursor steviol glycoside is steviol-13-O-glucoside, steviol-19-O-glucoside, or rubusoside, or a mixture thereof, the one or more UDP-sugar is UDP-glucose and UDP-xylose,

the steviol, the precursor steviol glycoside or the mixture thereof is contacted with one or more polypeptides comprising the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:152 and one or more polypeptides selected from a group consisting of the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT85 family, comprising a UGT85C2 polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-13

hydroxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:3, the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT74 family, comprising a UGT74G1 polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-19 carboxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:1; the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:5; or the polypeptide operable for beta 1,3 glycosylation of the C3' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:7; and

rebaudioside F is produced upon transfer of the one or more sugar moieties from the one or more UDP-glucose and UDP-xylose to steviol, the precursor steviol glycoside, or the mixture thereof; or

- (h) the precursor steviol glycoside is steviol-13-O-glucoside, the one or more UDP-sugar is UDP-glucose,

the steviol, the precursor steviol glycoside or the mixture thereof is contacted with one or more polypeptides comprising the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:152 and one or more polypeptides selected from a group consisting of the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT85 family, comprising a UGT85C2 polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-13

hydroxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:3, the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT74 family, comprising a UGT74G1 polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-19 carboxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:1; and the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:5; and

- steviol-1,2-bioside is produced upon transfer of the one or more sugar moieties from the one or more UDP-glucose to steviol, the precursor steviol glycoside, or the mixture thereof; or
- (i) the precursor steviol glycoside is steviol-13-O-glucoside, steviol-19-O-glucoside, or rubusoside, or a mixture thereof, the one or more UDP-sugar is UDP-glucose,

the steviol, the precursor steviol glycoside or the mixture thereof is contacted with one or more polypeptides comprising the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:152 and one or more polypeptides selected from a group consisting of the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT85 family, comprising a UGT85C2 polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-13 hydroxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:3, the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT74 family, comprising a UGT74G1

polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-19 carboxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:1; the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:5; and the polypeptide operable for beta 1,3 glycosylation of the C3' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:7; and

stevioside is produced upon transfer of the one or more sugar moieties from the one or more UDP-glucose to steviol, the precursor steviol glycoside, or the mixture thereof; or

- (j) the precursor steviol glycoside is steviol-13-O-glucoside, steviol-19-O-glucoside, or rubusoside, or a mixture thereof, the one or more UDP-sugar is UDP-glucose and UDP-xylose,

the steviol, the precursor steviol glycoside or the mixture thereof is contacted with one or more polypeptides comprising the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:152 and one or more polypeptides selected from a group consisting of the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT85 family, comprising a UGT85C2 polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-13 hydroxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:3, the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT74 family, comprising a UGT74G1

polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-19 carboxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:1; the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:5; or the polypeptide operable for beta 1,3 glycosylation of the C3' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:7; and

1,2 stevioxyloside is produced upon transfer of the one or more sugar moieties from the one or more UDP-glucose and UDP-xylose to steviol, the precursor steviol glycoside, or the mixture thereof; or

- (k) the precursor steviol glycoside is steviol-13-O-glucoside, the one or more UDP-sugar is UDP-glucose and UDP-xylose,

the steviol, the precursor steviol glycoside or the mixture thereof is contacted with one or more polypeptides comprising the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:152 and one or more polypeptides selected from a group consisting of the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT85 family, comprising a UGT85C2 polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-13 hydroxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:3, the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT74 family, comprising a UGT74G1

polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-19 carboxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:1; the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:5; or the polypeptide operable for beta 1,3 glycosylation of the C3' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:7; and

steviol-1,2-xylobioside is produced upon transfer of the one or more sugar moieties from the one or more UDP-glucose and UDP-xylose to steviol, the precursor steviol glycoside, or the mixture thereof; and

- (l) the precursor steviol glycoside is steviol-13-O-glucoside, the one or more UDP-sugar is UDP-glucose and UDP-rhamnose,

the steviol, the precursor steviol glycoside or the mixture thereof is contacted with one or more polypeptides comprising the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:152 and one or more polypeptides selected from a group consisting of the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT85 family, comprising a UGT85C2 polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-13 hydroxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:3, the polypeptide of uridine 5'-diphospho (UDP) glycosyl transferase (UGT) UGT74 family, comprising a UGT74G1

polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-19 carboxyl group having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:1; the polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:5; and the polypeptide operable for rhamnosylation of steviol 13-O-monoside having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:150; and

 steviol-1,2-rhamnobiocide is produced upon transfer of the one or more sugar moieties from the one or more UDP-glucose and UDP-rhamnose to steviol, the precursor steviol glycoside, or the mixture thereof.

4. The method of any one of claims 1-3, wherein the method is an *in vitro* method, further comprising supplying the one or more UDP-sugars or supplying a cell-free system for regeneration of the one or more UDP-sugars.
5. The method of claim 4, wherein the *in vitro* method is an enzymatic *in vitro* method or a whole cell *in vitro* method.
6. The method of claim 5, wherein the whole cell *in vitro* method comprises feeding raw materials comprising Stevia extracts, wherein the extracts comprise the one or more UDP-sugars and one or more of a steviol, a precursor steviol glycoside and a mixture thereof to a whole cell.
7. The method of any one of claims 5-6, wherein the whole cell used in the whole cell *in vitro* method comprises one or more recombinant genes encoding a sucrose synthase (SUS) polypeptide encoded by a nucleotide sequence having at least 80% sequence identity relative to the full length of the nucleotide sequence set forth in any one of SEQ ID NOs:175-177 or having at least 80%

sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:180 or a sucrose transporter polypeptide having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:179.

8. The method of claim 7, wherein:
 - (a) the sucrose transporter polypeptide is produced in a permeabilized recombinant host cell that has been transformed with a gene encoding an *Arabidopsis thaliana* sucrose transporter polypeptide having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:179; and
 - (b) the SUS polypeptide is produced in a permeabilized recombinant host cell that has been transformed with a gene having at least 80% sequence identity relative to the full length of the nucleotide sequence set forth in any one of SEQ ID NOs:175-177 or encoding a polypeptide having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in SEQ ID NO:180.
9. The method of any one of claims 5-8, wherein an endogenous sucrose invertase of the whole cell comprising the *in vitro* method is disrupted.
10. The method of any one of claims 5-9, further comprising feeding raw materials during or after cell growth.
11. The method of any one of claims 5-10, wherein the whole cell used in the whole cell *in vitro* method is:
 - (a) in suspension or immobilized;
 - (b) entrapped in a calcium or sodium alginate bead;
 - (c) linked to a hollow fiber tube reactor system;
 - (d) concentrated and entrapped within a membrane reactor system; or
 - (e) in fermentation broth or in a reaction buffer.

12. The method of any one of claims 5-11, further comprising permeabilizing the whole cell by using a permeabilizing agent, wherein the permeabilizing agent is a solvent, a detergent, or a surfactant, or by a mechanical shock, an electroporation, or an osmotic shock.
13. The method of any one of claims 5-12, wherein the whole cell used in the whole cell *in vitro* method is a plant cell, a mammalian cell, an insect cell, a fungal cell from *Aspergillus* genus or a yeast cell from *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Yarrowia lipolytica*, *Candida glabrata*, *Ashbya gossypii*, *Cyberlindnera jadinii*, *Pichia pastoris*, *Kluyveromyces lactis*, *Hansenula polymorpha*, *Candida boidinii*, *Arxula adeninivorans*, *Xanthophyllomyces dendrorhous*, or *Candida albicans* species, an algal cell or a bacterial cell from *Escherichia coli* species or *Bacillus* genus.
14. The method of any one of claims 5-13, wherein the whole cell used in the whole cell *in vitro* method is a yeast cell from *Yarrowia lipolytica* species.
15. The method of any one of claims 1-14, further comprising use of a phosphatase.
16. The method of any one of claims 1-15, wherein:
 - (a) the second polypeptide operable for beta 1,2 glycosylation of the C2' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside comprises:
 - (i) a polypeptide having an arginine at residue 206, a cysteine at residue 207, and an arginine at residue 343 of SEQ ID NO:5;
 - (ii) a polypeptide having a tyrosine or phenylalanine at residue 30, a proline or glutamine at residue 93, a serine or valine at residue 99, a tyrosine or a phenylalanine at residue 122, a histidine or tyrosine at residue 140, a serine or cysteine at residue 142, an alanine or threonine at residue 148, a methionine at residue 152, an alanine at residue 153, an alanine or serine at residue 156, a glycine

at residue 162, a leucine or methionine at residue 195, a glutamic acid at residue 196, a lysine or glutamic acid at residue 199, a leucine or methionine at residue 211, a leucine at residue 213, a serine or phenylalanine at residue 221, a valine or isoleucine at residue 253, a valine or alanine at residue 286, a lysine or asparagine at residue 427, an alanine at residue 438, and either an alanine or threonine at residue 462 of SEQ ID NO:5;

- (iii) a polypeptide having a methionine at residue 211 and an alanine at residue 286 of SEQ ID NO:5; or
 - (iv) a polypeptide having at least 80% sequence identity relative to the full length of the amino acid sequence set forth in any one of SEQ ID NOs:10, 12, 76, 78, or 95;
- (b) the polypeptide operable for glycosylating steviol or the precursor steviol glycoside at its C-13 hydroxyl group comprises
- a polypeptide having one or more amino acid substitutions at residues K9E, K10R, V13F, F15L, Q21H, M27V, H60D, A65S, E71Q, I87F, L91P, K220T, R243W, T270M, T270R, Q289H, Y298C, L334S, K350T, H368R, A389V, I394V, P397S, E418V, G420R, L431P, G440D, H441N, R444G, and M471T of SEQ ID NO:3;

and

- (c) the polypeptide operable for beta 1,3 glycosylation of the C3' of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside comprises
- a polypeptide having one or more amino acid substitutions at residues M29I, V74E, V87G, L91P, G116E, A123T, Q125A, I126L, T130A, V145M, C192S, S193A, F194Y, M196N, K198Q, K199I, Y200L, Y203I, F204L, E205G, N206K, I207M, T208I,

P266Q, S273P, R274S, G284T, T285S, L330V,
G331A, and L346I of SEQ ID NO:7.

17. The method of any one of claims 1-16, further comprising isolating the target steviol glycoside composition.
18. The method of claim 17, wherein the isolating step comprises:
 - (a) providing the target steviol glycoside composition;
 - (b) separating a liquid phase of the target steviol glycoside composition from a solid phase of the target steviol glycoside composition to obtain a supernatant comprising a produced target steviol glycoside composition;
 - (c) providing one or more adsorbent resins, comprising providing the adsorbent resins in a packed column; and
 - (d) contacting the supernatant of step (b) with the one or more adsorbent resins in order to obtain at least a portion of the produced target steviol glycoside composition, thereby isolating the portion of the produced target steviol glycoside composition;or
 - (a) providing the target steviol glycoside composition;
 - (b) separating a liquid phase of the target steviol glycoside composition from a solid phase of the target steviol glycoside composition to obtain a supernatant comprising a produced target steviol glycoside composition;
 - (c) providing one or more ion exchange or reversed-phase chromatography columns; and
 - (d) contacting the supernatant of step (b) with the one or more ion exchange or reversed-phase chromatography columns in order to obtain at least a portion of the produced target steviol glycoside composition, thereby isolating the portion of the produced target steviol glycoside composition;or
 - (a) providing the target steviol glycoside composition;

- (b) separating a liquid phase of the target steviol glycoside composition from a solid phase of the target steviol glycoside composition to obtain a supernatant comprising a produced target steviol glycoside composition;
 - (c) crystallizing or extracting the produced target steviol glycoside composition, thereby isolating a crystallized or extracted target steviol glycoside composition.
- 19. The method of any one of claims 1-18, further comprising recovering the target steviol glycoside composition.
- 20. The method of claim 19, wherein the target steviol glycoside composition is enriched for the produced target steviol glycoside relative to a steviol glycoside composition from a Stevia plant and has a reduced level of Stevia plant-derived components relative to a plant-derived Stevia extract.
- 21. The method of any one of claims 1-20, wherein the steviol is a plant-derived or synthetic steviol.

Figure 1




Figure 2A






Figure 2B



[illegible]

Figure 2D



91D2e EUGT11

6.1E7 5.9E7

4.8E5 1.3E6

91D2e EUGT11

4E6 3.9E6

ND 3.5E6

5.9E7 5.8E5

91D2e EUGT11

6.1E7 5.9E7

ND 1.2E6

91D2e EUGT11

3.5E7 3.2E7

1E6 2E7

91D2e EUGT11

91D2e EUGT11

250μM 250μM

0.23yM 7,0yM

Steviol

Steviol-19-O-Glucoside

Rubusoside

Stevioside

Reb A

Reb D

'1'

'2'

'3'

EUGT11 RebA feeding






FIGURE 5

UGT91D2e Rubusoside feeding



EUGT11 Rubusoside feeding




```

463 residues in 1 query sequences
473 residues in 1 library sequences
Tcomplib [36.3.5a Jun, 2011(preload8)] (16 proc in memory [03])
start: Thu Jul 7 13:19:40 2011 done: Thu Jul 7 13:19:40 2011
Scan time: 0.030 Display time: 0.010
Function used was FASTA [36.3.5a Jun, 2011(preload8)]

```


Figure 8




FIGURE 9

UGT91D1	MATSDSIVDD	RKQLHVATFP	WLAFGHILPF	LQLSKLIAEK	GHKVSFLSTT	RNIQRLSSHI	60
UGT91D2e	MATSDSIVDD	RKQLHVATFP	WLAFGHILPY	LQLSKLIAEK	GHKVSFLSTT	RNIQRLSSHI	60
			loopN1	loopN2			
UGT91D1	SPLINVVQLT	LPRVQELPED	AEATTDVHPE	DIQYLKKAVD	GLOPEVTRFL	EQHSPDWIYY	120
UGT91D2e	SPLINVVQLT	LPRVQELPED	AEATTDVHPE	DIQYLKKAAD	GLOPEVTRFL	EQHSPDWIYY	120
			loopN3/Na3				
UGT91D1	DFTHWLPSI	AASLGISRAH	FCVITPWTIA	YLA PSSDAMI	NDSGRTTVE	DLTTPPKWFFP	180
UGT91D2e	DFTHWLPSI	AASLGISRAH	FSVITPWAIA	YMGPSADAMI	NDSGRTTVE	DLTTPPKWFFP	180
			loopN4	loopN5			
UGT91D1	FPTKVCWRKH	DLARMEPYEA	PGISDGYRMG	MVFKGSDCLL	EKCYHEFGTQ	WLPLETLHQ	240
UGT91D2e	FPTKVCWRKH	DLARMEPYEA	PGISDGYRMG	LVLKGS DCLL	EKCYHEFGTQ	WLPLETLHQ	240
			Na5a	Na5b	loopC1		
UGT91D1	VPVVPVGLLP	PEIPGDEKDE	TWVS IKKWLD	GKQKGSVVYV	ALGSEALVSD	TEVVELALGL	300
UGT91D2e	VPVVPVGLLP	PEIPGDEKDE	TWVS IKKWLD	GKQKGSVVYV	ALGSEALVSD	TEVVELALGL	300
					**		
UGT91D1	ELSGLPFVWA	YRKPKGPAKS	DSVELPDGFV	ERTDRGLVW	TSWAPQLRIL	SHESVCGFLT	360
UGT91D2e	ELSGLPFVWA	YRKPKGPAKS	DSVELPDGFV	ERTDRGLVW	TSWAPQLRIL	SHESVCGFLT	360
			loopC5				
UGT91D1	HCGSGSIVEG	LMFGHPLIML	PIFGDQPLNA	RLLEDKQVGI	EIPRNEEDGC	LTKESVARSL	420
UGT91D2e	HCGSGSIVEG	LMFGHPLIML	PIFGDQPLNA	RLLEDKQVGI	EIPRNEEDGC	LTKESVARSL	420
					**		
UGT91D1	RSVVVENEGE	IYKANARELS	KIYNDTKVEK	EYVSQFVDYL	EKNARAVAID	HES	474
UGT91D2e	RSVVVENEGE	IYKANARELS	KIYNDTKVEK	EYVSQFVDYL	EKNARAVAID	HES	474

FIGURE 10




FIGURE 11




FIG. 12A

Stevia rebaudiana KAH nucleotide (SEQ ID NO: 163)

ATGGAGGCTTCATATCATATACATTTCCATTCTTCTGCTTCTAGCTTCGTACCTCTTCACCAACCCAACTTCGTCGTAAATCAGCCCAATCT
ACCGCCGACGGTGTCCCATCCATCCCATTAATCGGTTCATCTCTACCTCCTCAAAAACCACTCTATAGAACACTAGCCAAAATTGCCG
CCAAATACGGCCCTATCCTCCAACTCCAACTAGGTACCGCGGTCTCGTAATCTCCTCCCTTCCGCGCCGCGAAGAAATGCTTCACC
ACAACGACGTTATCTTCGCCAACCGTCCGAAGACGCTATTCCGAAAAAATTGTAGGGGTACCAAGCTTTCACGACATACGTTGTGACGAAA
CCAGTGGCGCAACCTCCGCGCGGTTCGATCCATCGAGATTCTATCAGTCCACCGGCTCAACGAGTTTCACGACATACGTTGTGACGAAA
ACCGGCTTCTGATCCGTAAACTAAGATCCAGTTCTTCTCCGTCACCTGTATAAAGGTGTTTACGCACTAACGTTAAATGTGATTATG
AGAATGATCTCCGGAAGAGGATTTTCGACTCGGGTGATCGGGAATTGGAGGAGGAAGGAAAGCGAATTCGGGAGATACTCGATGAGAC
ACTTTTGCTCGCGGTGCTTCTAATGTTGGGGATTACTTGCAGATTCTGAAATTGTTGGGGTGAAGAGCTTGGAGAAAGGAAAGGAAAG
CATTGCAGAAAAAGAGAGATGATTTCTTTCAGGGACTGATCGAGCAAGTTCCGAAATCTAGAGGGGCTAAAGTGGGAAAAAGGAAAGGAA
ACGATGATCGAGTTGTTATCCCTACAAGAATCTGAACCTGAGTATTACACTGACGCCATGATCCGATCATTTGTGCTGGGTTTATT
AGCAGCAGGGAGTGATACATCGGCTGGAACATAGGAATGGCGATGTCTCTTTTGGTAAACCAACCCACGATATACCTTACATTGGTGCATCAATAACGAG
CTGAAATTGATCGAGTCATCGGCAACAACCGTCTAATTGATGAGTCCGACATAGGGAATATACCTTACATTGGTGCATCAATAACGAG
ACGCTCAGATTGTACCTGCGGCGCGTGTCTATTTCCCATGAGTCATCAGCGGACTGTGTTATCAGCGGTACAAACATCCCTCGTGG
GACGATGCTTATTGTCAACCAATGGCGGATACATCATGACCCAAAGGTGTGGACGACCCCTGAGACATTCAACCGGAAGATTCCAAG
GGCTTGAAGGACACGAGACGGGTTTAAGCTGATGCCCTTTGGTCCGGAAGGAGGGGTTGTCCAGGGGAGGGATTGGCGGATTCTGTTG
CTTGGGATGACTCTCGGGTCGGTTATCCAATGCTTTGATTGGGAACGAGTCGGTGACGAGATGGTTGATATGACCGAAGGCTCTTGGGGT
CACGTTGCCTAAAGCTGTACCATTAGTCGCCAAAGTCAAGCCCGGTTCCGAAATGACGAAATCTACTCTCTGAGCTATGA

FIGURE 12

FIG. 12B

Stevia rebaudiana KAHel nucleotide (SEQ ID NO: 165)

ATGGAAGCCCTCTTACCTATACATTTCTATTTTGCCTTTTACTGGCATCATACCTGTTCACCACTCAACTTAGAAGGAAGAGCGCTAATCT
ACCACCAACCGTGTTCATCAATACCAATCATATTGGACACTTATACTTACTCAAAAAGCCTCTTTATAGAACTTTAGCAAAAATTGCCG
CTAAGTACGGACCAATACTGCAATTACAACTCGGCTACAGACGTTGTTCTGGTGAATTCCTCACCATCAGCAGCAGAAGAGTGCTTTACC
AATAACGATGTAATCTTCGCAATAGACCTAAGACATTGTTTGGCAAAATAGTGGGTGGAACATCCCTTGGCAGTTTATCTCTACGGCGA

TCAATGGCGTAATCTAAGGAGAGTAGCTTCTATCGAAATCCTATCAGTTTCATGATATCAGAGTGGATGAGA
 ACAGATTGTTAATTAGAAAACTTAGAAGTTTCATCTTCTCCTGTIACCTIATAACAGTCTTTTATGCTCTAACATTGAAACGTCATTATG
 AGAATGATCTCTGGCAAAAGATAATTTCGACAGTGGGATAGAGAAATTGGAGGAGGAAGGTAAGAGATTTCGACAGAAATCTTAGACGAAAC
 GTTGCTTCTAGCCGGTGCTTCTAATGTTGGCGACTACTTACCAATATTTGAACCTGGTGGGAGTTAAGTCTCTTGAAGAAATTTGATCG
 CTTTGCAGAAAAAGAGAGATGACTTTTTCCAGGGTTTGATTGAACAGGTTAGAAAACTCTCGTGGTCTAAAGTAGGCAAGGTAGAAAA
 ACGATGATCGAACTCTTATTATCTTTTGAAGAGTTCAGAACCTGAGTACTATACAGATGCTATGATAAGATCTTTTGTCTTAGGTCTGCT
 GGCTGCAGGTAGTGATACTTCAGCGGCACTATGGAATGGCCATCAGCTTACTGGTCAATCACCCACATGTATTGAAGAAAGCTCAAG
 CTGAAATCGATAGAGTTATCGGTAATAACAGATTGATTGACGAGTCAGACATTTGGAATATCCCTTACATCGGCTGATTATCAATGAA
 ACTCTAAGACTCTATCCAGCAGGGCCATTGTTGTTCCACATGAAAGTTCTGCCGACTGCGTTATTTCGGTTACAAATATACCTAGAGG
 TACAAATGTTAATCGTAACCAATGGGCGATTTCATCAGATCCTAAAGTCTGGGATGATCCTGAAACCTTTAAACCTGAAAGATTCAAG
 GATTAGAAGAACTAGAGATGGTTTCAAACTTATGCCATTTCGGTTCTGGGAGAAAGAGATGTCCAGGTGAAGGTTTGGCAATAAGGCTG
 TTAGGATGACACTAGGCTCAGTGATCCAATGTTTGTGATTGGGAGAGATGAGATGGTTGCACATGACAGAGGTTTGGGTGT
 CACACTTCTAAGGCCGTTCCATTAGTTGCCAAATGTAAAGCCACGTTCCGAAATGACTAATCTCCTATCCGAACTTTAA

FIG. 12C

Stevia rebaudiana KAHel polypeptide (SEQ ID NO:164)
 MEASYLYISILLLLASYLFTIQLRRKKSANLPPTVFPSIPIIGHLYLLKKPLYRTLAKIAA
 KYGPILQLQLGYRRVLVISSPSAAEECFNNNDVIFANRPKTLFCKIVGGTSLGSLSYGDQ
 WRNLRVASIEILSVHRLNEFHDIRVDENRLLIRKLSSSSPVTLITVFYALTILNVIMRM
 ISGKRYFDSGDRELEEEGKRPREILDETLILLAGASNVGDYLPILNWI,GVKSLEKKLIALQ
 KKRDDFFQGLIEQVRKSRGAKVGKGRKTMIELLLSLQESEPEYYTDAMIRSFVLGLLAAG
 SDTSAGTMEWAMSLLVNHPHVLKKAQAEIDRVIGNNRLIDESDLGNIPYIGCIINETLRL
 YPAGPLLPFHESADCVISSYNIPRGTMILVNQWAIHHDPKVWDDPETFKPERFQGLEGT
 RDGFKLMPFPGSGRRGCPGEGLAIRLLGMTLGSVIQCDFDWERVGDENVDMTEGLGVTLPKA
 VPLVAKCKPRSEMTNLLSEL

FIGURE 13A

S. cerevisiae CPR polypeptide encoded by NCP1 (SEQ ID NO: 166)
 MPFGIDNTDFTVLAGLVAVLLYVKRNSIKELMSDDGDITAVSSGNRDIAQVVTENNKNYLVLVYASQTGTAEDYAKFSKELVAKFNL
 NVMCADVENYDFESLNDVPVIVSIFISTYGEEDFPDGAVNFEFICNAEAGALSNLRNMFGLGNSTYEFFNGAAKKAEEKHLAAGAIR
 LGKLGEADDGAGTTDEDYMAWKDSILEVLKDELHLDEQEAFTSQFYTVLNEITDSMSLGEPSAHYLPSSHQNLNRNADGIQLGPFDLNQ
 PYTAPIVKSRELFSSNDRNCHSEFDLSGNIKYSTGDHLAVWPSNPLEKVEQFLSIFNLDPETIFDLKPLDPTVKVPFPTTTIGAAI
 KHYLEITGPVSRQLFSSLIQFAPNADVKEKITLLSKDKDQFAVEITSKYFNIAADALKYLSGAKWDTVPMQFIVESVPQMTPRYYSISS
 SSLSEKQTVHVTIVENFPNPELPDAPPVVGVTNLLRNQLAQNNVNIAETNLPVHYDLNGPRKLFANYKLPVHVRNFRNFRNPNPST
 PVMIGPGTGVAPFRGFIRERVAFLSQKGGNNVSLGKHILFYGSRNTDDFLYQDEWPEYAKKLDGSEFEMVVAHSRLPNTKKVYVQDK
 LKDYEDQVFEMINNGAFIYVCGDAKGMAGVSTALVGILSRGKSITTTDEATELIKMLKTSGRYQEDVW

Arabidopsis thaliana CPR polypeptide encoded by ATR1 (SEQ ID NO: 148)

1 mtsalyasdl fkqlksimgt dslsddvvlv iattslalva gfvvllwkt tadrsgelkp
 61 lmipkslmak dedddldlgs gktrvsiiff tqtgtaegfa kalseeikar yekaaavkvid
 121 lddyaadddq yeeklkktl affcvatygd geptdnaarf ykwfteener diklqqlayg
 181 vfallgnrqye hfnkigivld eelckkgakr lievglgddd qsieddfnaw keslwseidk
 241 llkdeddksv atpytavipe yrvvthdprf ttqksmesnv angnttidih hpcrvdvavq
 301 kelhthesdr scihlefdis rtgityetgd hvgvyaenhv eiveeagkl ghsldlvfsi
 361 hadkedgspl esavppfpfg pctltgtglar yadllnpprk salvalaaya tepseaeek
 421 hltspdgkde ysqwivasqr sllevmaafp sakpplgvff aaiaprlqpr yysissprl
 481 apsrvhvtsa lvygptptgr ihkgvcstwm knavpaecksh ecsgapifir asnfklpsnp
 541 stpivmvpgp tglapfrgfl qermalkedg eelgssllff gcrnrqmdfi yedelnnfvd
 601 qgviselima fsregaqkey vqhkmmekaa qvwdlikcog ylyvcgdakg mardvhrtlh
 661 tivqegeqvs sseaaaiykk lqtegrylrd vw

A. thaliana CPR polypeptide encoded by ATR2 (SEQ ID NO: 168)

1 msssssssts midlmaaiik gepvivsdpa nasayesvaa elssmlienr qfamivttsi
 61 avligciavl vwrsgsgns krveplkplv ikpreeeidd grkkvtiffg tqtgtaegfa

121 kalgeeakar yektrfkivd lddyaaddde yeeklkkedv afflatygd geptdnaarf
181 ykwftegndr gewlknkyg vfglqnrqye hfnkvakvvd dilveggaqr lvqvglgddd
241 qcieddftaw realwpeldt ilreegdtav atpytaavle yrvsihdsed akfnditlan
301 gngytvfdag hpykanvavk relhtpesdr scihlefdia gsgltmkldg hvglvcdnls
361 etvdealrl1 dmspdtyfsl haekedgtpi ssslpppfpp cnlrrtaltry acilsspkks
421 alvalaahas dpteaerlkh laspagkdey skwvvesqrs llevmaefps akpplgvffa
481 gvaprlqprf ysissspkia etrihvtcal vyekmptgri hkgvcstwmk navpyeksek
541 lflgrpifvr qsnfklpsds kvpiimigpg tglapfrgfl qerlalvesg velgpsvlff
601 gcrnrmdfi yeelqrfev sgalaelsva fsregptkey vqhkmmdkas diwnmisqga
661 ylyvcgdakg mardvhrslh tiaqeqgsmd stkaegfvkn lqtsgrylrd vw

Stevia rebaudiana CPR7 (SEQ ID NO: 169)

MQSEVEASTIDLMTAVLKDTVIDTANASDNGDSKMPPALAMFEIRDLLILTTSAVLVGCFFVVLVWKRSSGKKSGKELEPPKIVVP
KRRLEQEVDDGKKKVT1FFGTQGTAEQFAKALFEEAKARYEKAFAKVIDLDDYAADDDEYAEKLLKKETYAFFFLATYGDGEPTDNAAK
FYKWFTEGDEKGVWLQKLQYGVFGLGNRQYEHFNKIGIVVDDGLTEQGAKRIVPVGLGDDQSIEDDFSANKELVWPELDLLRDEDDK
AAATPYTAAIPEYRVVFDKPDAPSDDDHTQTNHGAHVDAQHPCRSNVAVKKELHTPESDRSCSTHLEFDISHTGLSYETGDHVGVCENL
IEVVEEAGKLLGLSTDITYFSLHIDNEDGSLGSPSLQPPFPCTLRKALTNYADLLSSPKKSTLLALAAHASDPTADRLRFLASREGK
DEYAEWVVANQSRSLLEVMEAFPSARPPGLGVFFAAVAPRLQPRYYSISSSPKMEPNRIHVTCAIVYEKTPAGRIHKGICSTWMKNAVPLT
ESQDCSWAPIFVRTSNFRLPIDPKVPVIMIGPGTGLAPFRGFLQERLALKESGTELGSILFFGCRNRKVDYIYENELNNFVENGALSE
LDVAFSRDGPTEKEYVQHKMTQKASEIWNMLSEGAYLYVCGDAKGMAKDVRHTLHTIVQEQQSLDSSKAELYVKNLQMSGRYL RDVW

Stevia rebaudiana CPR8 (SEQ ID NO: 170)

MQSNSVKISPLDLVTALFSGKVLDTSNASESGESAMLP TIAMIMENRELIMILTTSAVLIGCVVVLVWRRSSTKKSALPPVIVPKR
VQEEEVDDGKKKVTVEFGTQGTAEQFAKALVEEAKARYEKAFAKVIDLDDYAADDDEYEEKLKKESLAFFFLATYGDGEPTDNAARFY
KWFTEGDAKGEWLNKLQYGVFGLGNRQYEHFNKIAKVDDGLVEQGAKRIVPVGLGDDQCIEDDFTAWKELVWPELDQLRDEDDTTV
ATPYTAAVAEYRVVFHEKPDALSEDYSYTNHGAHVDAQHPCRSNVAVKKELHSPESDRSCSTHLEFDISNTGLSYETGDHVGVCENLSE
VVNDAERLVGLPPDTYSSIHTDSEDGSLGGASLPPFPCTLRKALTCYADVLSPPKKSALLALAAHATDPSEADRLKFLASPAKDE
YSQWIVASQRSLLLEVMEAFPSAKPSLGVFFASVAPRLQPRYYSISSSPKMAPDRIHVTCAIVYEKTPAGRIHKGVCSTWMKNAVPMTF
QDCSWAPIYVRTSNFRLPSDPKVPVIMIGPGTGLAPFRGFLQERLALKEAGTDLGSLILFFGCRNRKVDYIYENELNNFVETGALS
VAFSREGPTKEYVQHKMSEKASDIWNLLSEGAYLYVCGDAKGMAKDVRHTLHTIVQEQQSLDSSKAELYVKNLQMSGRYL RDVW

FIGURE 13B

```

>ATR1 codon optimized by DNA2.0. (SEQ ID NO: 171)
ATGACTTCTGCACCTTATGCGCTCCGATCTTTTCAAAACAATTGAAAAGTATCATGGAACGGATTCTTTGTCCGATGA'TGTTGTATTAGT
TATTGCTACAAACTTCTCTGGCACTGGTTGCTGGTTTTCGTTGTCTTATTGTGGAAGAACACCGCAGATCGTTCCGGCGAGCTAAAGC
CACTAATGATCCCTAAGTCTCTGATGGCGAAAGATGAGGATGATGACTTAGATCTAGGTTCTGGAAGAACGAGAGTCTCTATCTTCTTC
GGCACAAACCCGGAACAGCCGGAAGGATTCGCTAAAGCACTTTCAGAAGAGATCAAGCAAGATACGAAAGAGCGGCTGTAAAGATAAT
CGATTTGGATGATTACCGTCCCGATGATGACCAATATGAGGAAAAGTTGAAAAAGGAAACATTGGCTTTCTTTGTGTAGCCACGTATG
GTGATGGTGAACCAACCGATAACGCCGCAAGATTCTACAAGTGGTTTACTGAAGAGAACGAAAGAGATATCAAGTTGACAGCAACTTGCT
TACGGCGTTTTTGCCTTAGGTAAACAGACAAATACGAGCACTTTAAACAAGATAGGTATTGCTCTTAGATGAAGAGTTATGCAAAAAGGGTGC
GAAGAGATTGATTGAAGTCGGTTTAGGAGATGATGATCAATCTATCCAGGATGACTTTAATGCATGGAAGGAATCTTTGTGGTCTGAAT
TAGATAAGTTACTTAAGGACCAAGATGATAAATCCGTTGCCACTCCATACACAGCCGTCATTCAGAAATATAGAGTAGTTACTCATGAT
CCAAGATTCACAACAACAGAAATCAATGGAAGATAATGTGGCTAATGGTAATACATCCATCGATATTTCATCATCCATGTAGAGTAGACGT
TGCAGTTCAAAAAGGAATTGCACACTCATGAATCAGACAGATCTTGCAATACATCTTGAATTTGATATATACGTACTGGTATCACTTACG
AACAGGTGATCACGTGGGTGTCTACGCTGAAAACCATGTTGAAATTTGTAGAGGAAGCTGCCACCATTTCCAGGACCATGCCCTAGGTAC
GTTTTCTCAATTTCATGCCGATAAAGAGGATGGCTCACCACTAGAAAATCAGCTCTAGTGGCTTGGCTGCGTACGCCACAGAACCTTCTGAGG
CGGTTTAGCTCGTTACGGGATCTGTTAAATCCTCCACGTAATCAGCTCTAGTGGCTTGGCTGCGTACGCCACAGAACCTTCTGAGG
CAGAAAAACTGAAACATCTAACTTCACCAGATGGTAAGGATGAATACTCACAATGGATAGTAGCTAGTCAACGTTCTTTACTAGAAGTT
ATGGCTGCTTTCCCATCCGCTAAACCTCCTTTGGGTGTTTCTTCGCCGCAATAGCGCTAGACTGCAACCAAGATACTATTCAATTC
ATCCTCACCTAGACTGGCACCATCAAGAGTTTCAATCAGATCCGCTTTAGTGTACGGTCCAACTCCTACTGTAGAAATCCATAAGGGCG
TTTGTTCACATGGATGAAAAACGCGGTTCAGCAGAGAGTCTCACGAATGTTCTGTGTGCTCCAAATCTTTATCAGAGCCTCCAACCTC
AAACTGCCTTCCAATCCTTCTACTCCTATTGTCTATGGTCCGTCCGTACAGGTCTTGCTCCATTTCAGAGGTTTCTTACAAGAGAGAAAT
GGCCTTAAAGGAGGATGGTGAAGAGTTGGGATCTTCTTTGTTGTTTTTCGGCTGTAGAAAACAGACAAAATGGATTTTCATCTACGAAGATG
AACTGAATAACTTTGTAGATCAAGGAGTTATTTTCAGAGTTGATAATGGCTTTTTCAGAGAGGAGTCTCAGAAAGGAGTACGTCCCAACAC
AAAATGATGGAAAAGGCCGCACAAAGTTTGGGACTTAATCAAAAGAGGAAGGCTATCTATATGCTGTGTGATGCAAAAGGATGGCAAG
AGATGTTCAAGAACACTTCATATACTATAGTCCAGGAACAGGAAGCGTTAGTTCTTCTGAAGCGGAAGCAATTGTGAAAAAGTTACAAA
CAGACGGAAGATACTTGAGAGATGTGTGGTAA

```

>ATR2 codon optimized by Genscript (SEQ ID NO: 172)

ATGTCTTCTCTCTCTCCAGTACCTCTATGATTGATGGCTGCTATTATTAAGGTGAACCAAGTTATCGTCTCCGACCCAGC
AAATGCCCTCTGCTTATGAATCAGTTGCTGCAGAAATTGCTTCAATGTTGATCGAAAACAGACAAATTCGCCATGATCGTAACATACATCAA
TCGCTGTTTTCGATCGGTGATTGTCATGTTGGTATGGAGAAGATCCGGTAGTGGTAATTTAAAGAGTCGAACCTTTTGAAACCATTA
GTAATTAAAGCCAAAGAGAAGAATAAGATGACGGTAGAAAAGAAAGTTACAAATATTTTTCGGTACCCAACTGGTACAGCTGAAGGTTT
TGCAAAAGCCTTAGGTGAAGAAGCTAAGCAAGATACGAAAAGACTAGATTCAGATAGTCGATTTGGATGACTATGCCGCTGATGACG
ATGAATACGAAGAAAAGTTGAAGAAAGAAAGATGTTGTCATTTTCTTTTGGCAACCTATGGTGACGGTGAACCAACTGACAAATGCAGCC
AGATTCACAAATGGTTTACAGAGGGTAAATGATCGTGGTGAATGGTTGAAAACCTTAAAGTACGGTGTTCGGTTTGGGTAAACAGACA
ATACGAACATTTCAACAAAAGTTGCAAAAGGTTCTCGACGATATTTTGGTTCGAACAAGGTGCTCAAAGATTAGTCCAAAGTAGGTTTGGGTG
ACGATGACCAATGTATAGAAAGATGACTTTACTGCCTGGAGAGAAAGCTTTGTGGCTGAATTAGACACAATCTTGAGAGAAGAAGGTGAC
ACCGCCGTTGCTACCCCATATACAGTATACAGTTCGATGCACAACACCTTACAAAGCTAACGTTGCAGTCAAGAGAGAAATTAACATGATATCAC
TTTGGCCAAATGGTAACGGTTATACAGTTTCGATGCACAACACCTTACAAAGCTAACGTTGCAGTCAAGAGAGAAATTAACATGATATCAC
AATCCGACAGAAAGTTGTATACACTTGGAAATTTGATATCGCTGGTTCCCGGTTTAAACCATGAAGTTGGGTGACCATGTAGGTGTTTATGC
GACAAATTGCTGAAAACGTGTGATGAAGCATTGAGATTGTTGGATATGTCCCTGACACTTATTTAGTTTGCACGCTGAAAAGAAAGA
TGGTACACCAATTTCCAGTTCTTTACCACCTCCATTCCCTCCATGTAACTTAAGAACACGCTTGACCAGATACGCTTGCTTGTATCAT
CCCCTAAAAAGTCCGCTTGGTTGCTTTAGCCGCTCATGCTAGTATCCTACTGATCCTACTGAAGCAGAAAGATTGAAACACTTAGCATCTCCAGCC
GGTAAAGATGAATATCAAAGTGGTAGTGAATCTCAAAGATCATTTGTTAGAAAGTTATGGCAGAAATTTCCCATCTGCCAAGCCTCCATT
AGGTGCTCTTCTTGTGCTAGCACCTAGATTGCCAACCAAGATTCTACTCAATCAGTTCTTCACCTAAGATCGCTGAAACTAGAAATTC
ATGTTACATGTGCATTAGTCTACGAAAAGATGCCAACCGGTAGAAATTCACAAGGGTGTATGCTCTACTTGGATGAAAAATGCTGTTCCT
TACGAAAAATCAGAAAAGTTGTTCTTAGGTAGACCAATCTTCGTAAGACAATCAAACCTTCAAGTTGCCCTTCTGATTCAAAGGTTCCAAAT
AATCATGATAGGTCCTGTACAGGTTTAGCCCCATTCAGAGGTTTCTTGAAGAAAGATTCGCTTTAGTTGAATCTGGTCTCGAATTAG
GTCCTTCAGTTTGTGTTGTTAGAAAACAGAGAAATGGATTTCATCTATGAAGAAGAAATTCGAAAGATTGTCGAAATCTGGTGTGCA
TTGGCCGGAATTATCTGTAGCTTTTTCAGAGAGAAAGTCCAACTAAGGAATACGTTCAACATAAGATGATGGATAAGGCATCCGACATATG
GAACATGAACAGTCAAGGTGCTTATTTGTACGTTTGGGTGACGCAAAAGGATGTCACATAGATCTTTGCACACAAATTG
CTCAAGAAACAAGGTTCCATGGATAGTACCAAAAGCTGAAGGTTTCGTAAAGAACTTACAAACTTCCGGTAGATACTTGAGAGATGTCCTCG
TGA

Stevia rebaudiana CPR7 (SEQ ID NO: 173; cloned from *S. rebaudiana* cDNA)

ATGCAATCGGAATCCGTTGAAGCATCGACGATTGATTTGATGACTGCTGTTTGAAGGACACAGT'GATCGATACAGCGAACGCATCTGA
TAACGGAGACTCAAAGATGCCCGCGGTGGCGATGATGTTCCGAAATTCGTGATCTGTTGCTGATTTTGACTACGTCAGTTGCTGTTT
TGGTCGGATGTTTCGTTGTTTGGTGTGGAAGAGATCGTCCGGGAAGATCCGGCAAGGAATTGGAGCCGCCGAAGATCGTTGTCGG
AAGAGCGGCTGGAGCAGGAGTTGATGATGTTAAGAAGGTTACGATTTCTTCGGAACACAAACTGGAACGGCTGAAGTTTCGC
TAAGGCACTTTTCGAAGAAGCGGATATGAAAAGGCAGCGTTTAAAGTGAATTGGATGATTTATGCTGCT'GATTTGGATG
AGTATGCAGAGAAGCTGAAGAAACAATATGCTTTCTTCTTGGCT'ACATA'ATGGAGATGGTAGCCAACTGATAATGCTGCCAAA
TTTTATAAATGGTTTACTGAGGAGACGAGAAAGCGTTTGGCTTCAAAAACCTTCAATATGGAGTATTTGGTCTTGGCAACAGACAATA
TCAACATTTCAACAAGATTGGAATAGTGGTTGATGGTCTCACCGAGCAGGGTGCAAAACGCATTGTTCCCGTTGGTCTTGGAGACG
ACGATCAATCAATTGAAGACGATTTTTCGGCATGGAAGAGTTAGTGTGCCCCGAAATTGGATCTATTGCTTCGCGATGAAGATGACAAA
GCTGCTGCAACTCCTTACACAGCTGCAATCCCTGAAATACCGCGTCGTATTTTCATGACAAACCCGATGCGTTTTCGTGATGATCACTCA
AACCAATGGTCAATGCTGTTTCAATGCTCAACATCCCATGCAGATCCCAATGTGGCTGTAAATAAGAGCTTCATCTCCTGAATCCGATC
GTTCAATGCACACATCTTGAATTTGACATTTCTCACACTGGATTATCTTATGAAACTGGGGATCATGTTGGTGATATCTGTGAAAACCTA
ATTGAAGTAGTGAAGAAGCTGGGAAATTTAGGATTATCAACAGATACTTATTTCTCGTTACATAATTGATAACGAAGATGGTTTCAAC
ACTTGGTGGACCTTCATTACAACCTCCTTTTCCCTCTGTACTTTAAGAAAAGCATTGACTAATTAATGCAGATCTGT'AAAGCTCTCCCA
AAAAGTCAACTTTGCTTGTCTAGCTGCTCATGCTTCCGATCCCAC'TGAAGCTGATCGTTTAAAGATTCTTGCATCTCGCGAGGCAAG
GATGAATATGCTGAATGGGTGTTGCAAAACCAAGAAGCTCTTGAAGTCAATGGAAGCTTTCCCGTCAGCTAGACCCCACTTGGTGT
TTTCTT'GCAGCGGTTGCACCGGTTTACAGCCTCGTTACTACTTATTTCTTCCCTCCCAAGATGGAACCAACAGGATTCATGTTA
CTTGGCGGTTGGTTATGAAAAAACTCCCGCAGGTCGTATCCACAAAGGAATCTGCTCAACCTGGATGAAGAACGCTGTACCTTTGACC
GAAAGTCAAGATTGCAGTTGGGCACCGATTTTGTGTAACAATCAAACTTCAGACTTCCAAATTGACCCGAAAGTCCCGGTTATCATGAT
TGGTCTCGAAACCGGGTTGGCTCCAATTAGGGGTTTCTTCAAGAAAGAT'GGCTCTTAAAGAAATCCGGAAACCGAACTCGGGTCATCTA
TTTTATTCTTCGGTTGTAGAAACCGCAAGTGGATTACATATATGAGAAATGAACCTCAACAACTTTGTTGAAAATGGTGGCTTTCTGAG
CT'GAT'GTTGCTTCTCCCGCATGGCCCGACGAAAGAAATACGTGCAACATAAAAATGACCCAAAAGGCTTCTGAAATATGGAATATGCT
TTC'TGAGGGAGCATATTTATATGATGTTGTTGATGCTAAAGGCATGGCTAAAGATGTACACCGTACACTTCACACCATGTGCAANGAAC
AGGGAAGTTTGGACTCGTCTAAAGCGGAGTTGTAATGTGAAGAATCTACAAATGTCAGGAAGATACCTCCGTGATGTTTGGTAA

Stevia rebaudiana CPR8 (SEQ ID NO: 174; CPR cloned from *S. rebaudiana* cDNA)
ATGCAATCTAACTCCGTGAAGATTTTCGCCGCTTGATCTGGTAACCTGCTGTTTAGCGGCAAGGTTTGGACACATCGAACGCATCGGA
ATCGGGAGAATCTGCTATGCTGCCGACTATAGCGATGATATGGAGAATCGTGAGCTGTTGATGATACTCACAACGTCGGTTGCTGTAT
TGATCGGATGCGTTGCTGTTTGGTGTGGCGGAGATCGTCTACCAAGAAAGTACGGTTTCTTCGGCACCCAAACTGGAACAGCTGAAGGCTTCGCTAAGGC
GTGCAAGAGGAGGAAGTTGATGATGTTAAGAAAGGCTGCTTTAAAGTAATTGATTGGATGATTATGCTGCTGATGACGATGAGTATG
ACTTGTGAGGAAGCTAAAGCTCGATATGAAAAGGCTGCTTTTGGCTTTTTCGCTACGTATGGAGATGGTGAGCCAAAGATAATGCTGCCACATTTAT
AGGAGAACTAAAGAAAGAACTTTTGGCTTTTTCGCTACGTATGGAGATCAATATGGAGTATTTGGTTTGGGTAAACAGACAATATGAACA
AAATGGTTTACTGAGGAGATGCGAAAGGAGAAATGGCTTAATAAGCTTCAATATGGAGTATTTGGTTTGGGTAAACAGACAATATGAACA
TTTTAACAAAGATCGCAAAAGTGGTTGATGCTTTGATGACAGAGGTGCAAGCGTCTTGTTCCTGTTGGACTTGGAGATGATGATC
AATGTATTGAAGATGACTTCACCGCATGGAAGAGTTAGTATGGCCGGAGTTGGATCAATTACTTTCGTGATGAGGATGACACAACTGTT
GCTACTCCATACACAGCTGCTGTTGCAGAAATATCGCGTTGTTTTTCATGAAAACCCAGACGCGCTTTTCTGAAGATTATAGTTATACAAA
TGGCCATGCTGTTTCATGATGCTCAACATCCATGCAGATCCAAACGTGGCTGTCAAAAAGGAACCTTCATAGTCTGAACTGACCGGTCCTT
GCACTCATCTTGAATTGACATCTCGAACACCGGACTATCATATGAAACTGGGACCATGTTGGAGTTTACTGTGAAAACCTTGAGTGAA
GTTGTGAATGATGCTGAAGATTAGTAGGATTACCACCAGACACTTACTCTCCATCCACACTGATAGTGAAGACGGGTCGCCACTTGG
CGGAGCCCTCATTTGCCGCTCCCTTCCCGCCATGCACCTTAAGGAAAGCATTGACGTGTTATGCTGATGTTTGGAGTTCTCCCAAGAGT
CGGCTTTGCTTGCACTAGCTGCTCATGCCACCGATCCCGATGAGCTGATAGATTGAAATTTCTTGCATCCCCCGCGGAAAGGATGAA
TATTCATCAATGGATGTTGCAAGCCAAAGAGTCTCTTGAAGTCATGGAAGCATTTCCCGTCAGCTAAGCCTTCACCTGGTGTGTTCTT
TGCATCTGTTGCCCGCGCTTACAAACCAAGATACTACTATTTCTTCTCCTCACCCAAAGATGGCACCGGATAGGATTCATGTTACATGTG
CATTAGTCTATGAGAAAACACCTGCAGGCCGCATCCCAACAAAGAGTTGTTCAACTTGGATGAAGAACGCAAGTGCCTATGACCGAGAGT
CAAGATTGCAGTTGGGCCCCCAATATACGTCCGAACATCCAAATTCAGACTACCATCTGACCCCTAAGTCCCGGTTATCATGATGGACC
TGGCACTGGTTTGGCTCCTTTTAGAGGTTTCCCTCAAGAGCGGTTAGCTTTAAAGGAAGCCGGAACCTGACCTCGGTTTATCCATTTAT
TCTTCGGATGTAGGAATCGAAAGTGGATTTCATATATGAAAACGAGCTTAACAACCTTTGTGGAGACTGGTGTCTCTTCTGAGCTTAT
GTTGCTTTCTCCCGTGAAGGCCCGACAAAGAAATATGTGCAACACAAGATGAGTGAGAAGGCTTCGGATATCTGGAACCTTGTCTG
AGGAGCATATTTATACGTATGTGGTGTGATGCCAAAGGCATGGCCAAAGATGTACATCGAAACCCCTCCACACAATTTGTCAAGAACACAGGGAT
CTCTTGACTCGTCAAAAGGCAGAACTCTACGTGAAGAATCTACAAATGTCAAGGAAGATACCTCCGCTGACGTTTGGTAA

FIGURE 14

A. *Zea mays* CDPS nucleotide (SEQ ID NO: 157)

atggttttgtg	cttcttcttg	tactacagta	ccacacttat	cttcattagc	tgtcgtgcaa	60
cttgggtcctt	ggagcagtag	gattaaaaag	aaaaccgata	ctgttgagc	accagccgct	120
<u>gcagggaaggt</u>	<u>ggagaagggc</u>	<u>cttgggctaga</u>	gcacagcaca	catcagaatc	cgcagctgtc	180
gcaaagggca	gcagtttgac	ccctatagt	agaactgacg	ctgagtcaag	gagaacaaga	240
tggccaaccg	atgacgatga	cgcggaaact	ttagtggatg	agatcagggc	aatgcttact	300
tccatgtctg	atggtgacat	ttccgtgagc	gcatacgata	cagcctgggt	cggattgggt	360
ccaagattag	acggcgggtga	aggctcctcaa	tttccagcag	ctgtgagatg	gataagaaat	420
aaccagttgc	ctgacgggaag	ttggggcgat	gccgcattat	ttcttgccta	tgacaggctt	480
atcaataccc	ttgccctgcgt	tgtaactttg	acaaggllgt	ccctagaacc	agagatgaga	540
ggtagaggac	tatcttlllt	gggtaggaaac	atgtggaaat	tagcaactga	agatgaagag	600
tcaatgccta	ttggcttcga	attagcattt	ccatctttga	tagagcttgc	taagagccta	660
ggtgtccatg	acttccctta	tgatccaccg	gccctacaag	gaatctactc	ttcaagagag	720
atcaaaaatga	agaggattcc	aaaagaagt	atgcataccg	ttccaacalc	aatattgcac	780
agtttggagg	gtatgcttgg	cctagallgg	gctaaactac	ttaaactaca	gagcagcgac	840
ggaagtthtt	tgcttcacc	agctgccact	gcataatgctt	taatgaatac	cggagatgac	900
aggtgtttta	gctacatcga	tagaacagta	aagaaattca	acggcggcgt	ccctaattgtt	960
tatccagtggt	atctatttga	acatatttgg	gccgttgata	gacttgaaaag	attagggaatc	1020
tccagggtact	tccaaaagga	gategaaca	tgcatggatt	atglaaacag	gcattggact	1080
gaggacggta	tttgttgggc	aaggaaactct	gatgtcaaaag	aggtggacga	cacagctatg	1140
gccttttagac	ttcttaggtt	gcacggctac	agcgtcagtc	ctgatgtgtt	taaaaaacttc	1200
gaaaaggacg	gtgaattttt	cgcatttgtc	ggacagtcta	atcaagctgt	taccgggtatg	1260
tacaacttaa	acagagcaag	ccagatatcc	ttcccaggcg	aggatgtgct	tcatagagct	1320
ggtgccttct	catatgagtt	cttgaggaga	aaagaagcag	agggagcttt	gaggggacaag	1380
tggatcattt	claaaagatct	acctggtgaa	gttgtgtata	ctttggattt	tccatggtag	1440
ggcaacttac	ctagagtctga	ggccagagac	tacctagagc	aatacggagg	tggtgatgac	1500
gtttggattg	gcaagacatt	gtataggatg	ccacttgtaa	acaatgatgt	atatttggaa	1560
ttgggcaagaa	tggatttcaa	ccactgccag	gctttgcata	agttagagtg	gcaaggacta	1620
aaaagatggt	atactgaaaa	laggttgatg	gactttgggtg	tcgccccaga	agatgcctt	1680

agagcttatt	ttcttgcagc	cgcattctgtt	taacgagcctt	gtagagctgc	cgagaggctt	1740
gcattgggcta	gagccgcaat	actagctaac	gccgtgagca	cccacttaag	aaatagccca	1800
tcatttcagag	aaagggttaga	gcatttctctt	aggtgtgagac	ctagtgaaga	gacagatggc	1860
tcctgggttta	actcctcaag	tggctctgat	gcagtttttag	taaaggctgt	cttaagactt	1920
actgattcat	tagccaggga	agcacagcca	atccatggag	gtgacccaga	agatattata	1980
cacaaagtgt	taagatctgc	ttgggccgag	tgggttaggg	aaaaggcaga	cgctgccgat	2040
agcgtgtgca	atggtagttc	tgcagtagaa	caagagggat	caagaatggt	ccatgataaa	2100
cagacctgtc	tattallggc	lagaalgatc	gaaatttctg	ccggtagggc	agctggtgaa	2160
gcagccagtg	aggacggcga	tagaagaata	attcaattaa	caggtcccat	ctgcgacagt	2220
cttaagcaaa	aaatgctagt	ttcacaggac	cctgaaaaaa	atgaagagat	gatgtctcac	2280
gtggatgacg	aattgaagtt	gaggattaga	gagttcgttc	aatatttgc	tagactaggt	2340
gaaaaaaaga	ctggatctag	cgaaccagg	caaacatttt	taagtatatg	gaaatcatgt	2400
tactatgctg	ctcattgcc	acctcatgtc	gttgatagac	acattagtag	agtgattttc	2460
gagccagtaa	gtgccgcaaa	gtaaccggg				2490

25/47

B. *Zea mays* CDPS polypeptide (SEQ ID NO: 158)

Met	Val	Leu	Ser	Ser	Cys	Thr	Thr	Val	Pro	His	Leu	Ser	Ser	Leu
1				5				10					15	
Ala	Val	Val	Gln	Leu	Gly	Pro	Trp	Ser	Ser	Arg	Ile	Lys	Lys	Thr
Asp	Thr	Val	Ala	Val	Pro	Ala	Ala	Ala	Gly	Arg	Trp	Arg	Arg	Ala
Ala	Arg	Ala	Gln	His	Thr	Ser	Glu	Ser	Ala	Ala	Val	Ala	Lys	Gly
Ser	Leu	Thr	Pro	Ile	Val	Arg	Thr	Asp	Ala	Glu	Ser	Arg	Arg	Thr
Trp	Pro	Thr	Asp	Asp	Asp	Asp	Ala	Glu	Pro	Leu	Val	Asp	Glu	Ile
Ala	Met	Leu	Thr	Ser	Met	Ser	Asp	Gly	Asp	Ile	Ser	Val	Ser	Ala
Asp	Thr	Ala	Trp	Val	Gly	Leu	Val	Pro	Arg	Leu	Asp	Gly	Glu	Gly

115	Pro	Gln	Phe	Pro	Ala	Ala	Val	Arg	Trp	Ile	Arg	Asn	Asn	Gln	Leu	Pro
130							135						140			
145	Asp	Gly	Ser	Trp	Gly	Asp	Ala	Ala	Leu	Phe	Ser	Ala	Tyr	Asp	Arg	Leu
						150					155					160
	Ile	Asn	Thr	Leu	Ala	Cys	Val	Val	Thr	Leu	Thr	Arg	Trp	Ser	Leu	Glu
						165				170					175	
	Pro	Glu	Met	Arg	Gly	Arg	Gly	Leu	Ser	Phe	Leu	Gly	Arg	Asn	Met	Trp
						180				185				190		
	Lys	Leu	Ala	Thr	Glu	Asp	Glu	Glu	Ser	Met	Pro	Ile	Gly	Phe	Glu	Leu
						195		200					205			
	Ala	Phe	Pro	Ser	Leu	Ile	Glu	Leu	Ala	Lys	Ser	Leu	Gly	Val	His	Asp
						210		215				220				
	Phe	Pro	Tyr	Asp	His	Gln	Ala	Leu	Gln	Gly	Ile	Tyr	Ser	Ser	Arg	Glu
225						230					235					240
	Ile	Lys	Met	Lys	Arg	Ile	Pro	Lys	Glu	Val	Met	His	Thr	Val	Pro	Thr
					245					250					255	
	Ser	Ile	Leu	His	Ser	Leu	Glu	Gly	Met	Pro	Gly	Leu	Asp	Trp	Ala	Lys
					260				265					270		
	Leu	Leu	Lys	Leu	Gln	Ser	Ser	Asp	Gly	Ser	Phe	Leu	Phe	Ser	Pro	Ala
					275			280			285					
	Ala	Thr	Ala	Tyr	Ala	Leu	Met	Asn	Thr	Gly	Asp	Asp	Arg	Cys	Phe	Ser
290							295					300				
	Tyr	Ile	Asp	Arg	Thr	Val	Lys	Lys	Phe	Asn	Gly	Gly	Val	Pro	Asn	Val
305						310					315					320
	Tyr	Pro	Val	Asp	Leu	Phe	Glu	His	Ile	Trp	Ala	Val	Asp	Arg	Leu	Glu
					325					330					335	
	Arg	Leu	Gly	Ile	Ser	Arg	Tyr	Phe	Gln	Lys	Glu	Ile	Glu	Gln	Cys	Met
					340				345					350		
	Asp	Tyr	Val	Asn	Arg	His	Trp	Thr	Glu	Asp	Gly	Ile	Cys	Trp	Ala	Arg
					355			360					365			

Asn	Ser	Asp	Val	Lys	Glu	Val	Asp	Asp	Thr	Ala	Met	Ala	Phe	Arg	Leu
370						375					380				
Leu	Arg	Leu	His	Gly	Tyr	Ser	Val	Ser	Pro	Asp	Val	Phe	Lys	Asn	Phe
385					390					395					400
Glu	Lys	Asp	Gly	Glu	Phe	Phe	Ala	Phe	Val	Gly	Gln	Ser	Asn	Gln	Ala
				405					410					415	
Val	Thr	Gly	Met	Tyr	Asn	Leu	Asn	Arg	Ala	Ser	Gln	Ile	Ser	Phe	Pro
			420					425					430		
Gly	Glu	Asp	Val	Leu	His	Arg	Ala	Gly	Ala	Phe	Ser	Tyr	Glu	Phe	Leu
		435					440					445			
Arg	Arg	Lys	Glu	Ala	Glu	Gly	Ala	Leu	Arg	Asp	Lys	Trp	Ile	Ile	Ser
450						455					460				
Lys	Asp	Leu	Pro	Gly	Glu	Val	Val	Tyr	Thr	Leu	Asp	Phe	Pro	Trp	Tyr
465					470					475					480
Gly	Asn	Leu	Pro	Arg	Val	Glu	Ala	Arg	Asp	Tyr	Leu	Glu	Gln	Tyr	Gly
				485					490					495	
Gly	Gly	Asp	Asp	Val	Trp	Ile	Gly	Lys	Thr	Leu	Tyr	Arg	Met	Pro	Leu
			500					505					510		
Val	Asn	Asn	Asp	Val	Tyr	Leu	Glu	Leu	Ala	Arg	Met	Asp	Phe	Asn	His
			515				520					525			
Cys	Gln	Ala	Leu	His	Gln	Leu	Glu	Trp	Gln	Gly	Leu	Lys	Arg	Trp	Tyr
530						535					540				
Thr	Glu	Asn	Arg	Leu	Met	Asp	Phe	Gly	Val	Ala	Gln	Glu	Asp	Ala	Leu
545					550					555					560
Arg	Ala	Tyr	Phe	Leu	Ala	Ala	Ala	Ser	Val	Tyr	Glu	Pro	Cys	Arg	Ala
				565					570					575	
Ala	Glu	Arg	Leu	Ala	Trp	Ala	Arg	Ala	Ala	Ile	Leu	Ala	Asn	Ala	Val
			580					585					590		
Ser	Thr	His	Leu	Arg	Asn	Ser	Pro	Ser	Phe	Arg	Glu	Arg	Leu	Glu	His
							600								
															605

Ser	Leu	Arg	Cys	Arg	Pro	Ser	Glu	Glu	Thr	Asp	Gly	Ser	Trp	Phe	Asn
610						615					620				
Ser	Ser	Ser	Gly	Ser	Asp	Ala	Val	Leu	Val	Lys	Ala	Val	Leu	Arg	Leu
625					630					635					640
Thr	Asp	Ser	Leu	Ala	Arg	Glu	Ala	Gln	Pro	Ile	His	Gly	Gly	Asp	Pro
				645					650					655	
Glu	Asp	Ile	Ile	His	Lys	Leu	Leu	Arg	Ser	Ala	Trp	Ala	Glu	Trp	Val
		660						665					670		
Arg	Glu	Lys	Ala	Asp	Ala	Ala	Asp	Ser	Val	Cys	Asn	Gly	Ser	Ser	Ala
		675					680					685			
Val	Glu	Gln	Glu	Gly	Ser	Arg	Met	Val	His	Asp	Lys	Gln	Thr	Cys	Leu
						695					700				
Leu	Leu	Ala	Arg	Met	Ile	Glu	Ile	Ser	Ala	Gly	Arg	Ala	Ala	Gly	Glu
705					710					715					720
Ala	Ala	Ser	Glu	Asp	Gly	Asp	Arg	Arg	Ile	Ile	Gln	Leu	Thr	Gly	Ser
				725					730					735	
Ile	Cys	Asp	Ser	Leu	Lys	Gln	Lys	Met	Leu	Val	Ser	Gln	Asp	Pro	Glu
			740					745					750		
Lys	Asn	Glu	Glu	Met	Met	Ser	His	Val	Asp	Asp	Glu	Leu	Lys	Leu	Arg
		755					760					765			
Ile	Arg	Glu	Phe	Val	Gln	Tyr	Leu	Leu	Arg	Leu	Gly	Glu	Lys	Lys	Thr
		770				775					780				
Gly	Ser	Ser	Glu	Thr	Arg	Gln	Thr	Phe	Leu	Ser	Ile	Val	Lys	Ser	Cys
785					790					795					800
Tyr	Tyr	Ala	Ala	His	Cys	Pro	Pro	His	Val	Val	Asp	Arg	His	Ile	Ser
				805					810					815	
Arg	Val	Ile	Phe	Glu	Pro	Val	Ser	Ala	Ala	Lys					
				820				825							

FIGURE 15

A. Codon-optimized nucleotide sequence for CDPS-KS (SEQ ID NO:161)


ATGCCTGGTAAATTTGAAATGGTACCCCAAGGACCTCAAGACTGGAAATCATTTTCTTCTGCTGAAGNGTTTACTAGATCGAGC
 TTTCAAAGTCATCATTCCTACTACGGATTATGCTCAACTTCATGTCAAGTTTATGATACAGCTTGGGTGCAATGATTCCAAAAAACAA
 GAGATAATGTAAACACAGTGGTTGTTCCAGAAATGTTCCATTACCTCTTAAAAACACAAGCCGAGATGGCTCATGGGGTTCATTGCCCT
 ACAACACAGACAGCGGGTATCCTAGATACAGCCTCAGCTGTGCTGGCATTATTGTGCCACGCACAGAGCCCTTACAAATATTGGATGT
 ATCTCCAGATGAAATGGGGTTGAGAAATAGAACACGGTGTACATCCTTGAAACGTCAATTAGCAGTTTGGAAATGATGTGGAGGACACCA
 ACCATATTGGCGTCGAGTTTATCATACAGCCTTACTTTCCATGCTAGAAAAAGGAATTAGATGTTCCTCATCTTTTGAATTTCCCATGTAGG
 TCCATCTTAGAGAGAAATGCACGGGGAGAAATTAGGTCAATTTCGACCTGGAACAAAGTTTACGGCAAGCCAAAGCTCAATTGTGCACTCAT
 GGAAGCATTTCTCGGTAAGCTAGATTTTGATCGACTATCACATCACCTATACCCACGGCAGTATGATGGCATCTCCATCTTCAACGGCTG
 CTTATCTTATTGGGGCTACAAAAATGGGATGACGAAGCCGAAAGATTACCTAAGACATGTAATGCGTAATGGTGCAGGACATGGGAATGGA
 GGTATTTCTGGTACATTTCCAACTACTCATTTTCGAATGTAGCTGGATTATAGCAACGTTGTTAAAGGTTGGCTTTTACTTTGAAGCAAAT
 TGACGGCGATGGCTTAAGAGGTTTATCAACCATCTTACTTGAGGCGCTTCGTGATGAGAATGGTGCATAGGCTTTGCCCTTAGAACAG
 CAGATGTAGATGACACAGCCAAAGCTCTATTGGCCTTGTCATTGGTAAACCAGCCAGTGCACCTGATATCATGATTAAGGTCTTTGAG
 GGCAAGACCATTTTACCACCTTTTGGTTCAGAAAGAGATCCATCATTGACTTCCAACCTGCACGCTCTTTTATCTTTTACTTAAACAAATC
 TAACTTGTCTCAATACCATCCTCAAAATCC"CAAAACAACATATTATTCACCTGTAGATGGTGGGGTCCGATCATTTGTGTCAAAGACA
 AATGGAAATTTGAGTCACCTATATCCAACTATGTTGTTGGTTGAAGCCTTCACCTGAAGTGTCTCCATCATTCACCTGCCTCAATTGTCT
 AGTCTGTTTGATGAATCCTTTAAGTGAAGATTGGTCTTAGCATCTTTCAAGCGGTACTTAGAATAATCCTCACCCCAAGACAAACGACGG
 CTCTTGGAGAGGATACAGAGAACAGACGTGTACGCAATATTGGCTTTAGTTCAAGCGGAGACATGTATGCTTTTTCACCTCACATGGTTG
 ACAGACTGCAATCATGTGTTGATCGAGGTTTCTCATGGTTGAAATCTTGTCTTTTTCATTTCTCAAGACCTGACTTGGACCTCTAAAACA
 GCTTATGAAGTGGGTTTCTGTAGCTGAAGCATATAAACTAGCTGCTTTACAAATCTGGCTTTCCCTGGAGGTTCCCTGTGCCACCATTTGGACA
 TTCTGTCAAGTCTGCCGTTCCATCAAGTGATCTTGAAAAATACATGAGATTGGTGAGAAAAAAGTGGCTTATCTCTCCACTGGATGAGT
 GGGGCTAAATGGCTTCTATCATCGAATCTTCAATTTTTCGTACCATTTACTGCAGGCACAAAGAGTTGAAATATACCTTAGAGATAATATC
 AAGGTGGACGAAGATAAGTACTTGTCTATTATCCCATTCACATGGGTGCGATGCAATAATAGGTCTAGAACTTTTCGCAAGTAACAGATG
 GCTATACGATATGATGTACCTTTTCACTAC"CGGCTATCAAAACCGACGAGTACATGGAAGCTGTAGCTGGGCCAGTGTGTTGGGATGTTT
 CCTTGTACATCAAAACAATTGATAAGGTGATTGATAATACAATGGTAACTTGGAGAGCCAAATGGAAACAGTACACACTGGTAATGGA
 CATCAGCACGAATCTCCTAATATAGGTCAAGTCGAGGACACCTTGACTCGTTTTCACAAATTCAGTCTTGAATCACAAAGACGTCCTTAA
 CTCAGCTCATCTGATCAAGATACCTTTGAGAAAGAGAGTTTAGAACATTCATGCACGCTCATATAACACAAATCGAAGATAACTCACGAT
 TCAGTAAGCAAGCCTCATCCGATGCGTTTTCCTCTCTCGTAACAAATCTTACTTTCAATGGGTGAACCTCAACTGGTGGCTCACATGTGCGCT
 TGGGCCATTATCATTTGCTTCTCTAATTGCCCTCATGTCTGCAAAATTTTGTTCAGGGTAAAGACGCAITTTCCAAAGCGGAACGCAAAAGTA

C'TTAATCTCCTCTGTTATGAGACATGCCACAAACATGTGTAGAAATGTATAACGACTTTTGGCTCTATTGCCAGAGACAAACGCTGAGAGAA
ATGTTAATAGTATTTCCTGAGTTTACTCTCTGTAAACGGAACCTCTCAAACCTAGATGAAAGGAAAGACTTCTCTGAAAATC
GCAACTTACGAACAAGGGTATTGATAGAGCACTAGAGGCCTTGAAAGACAGAGTAGAGATGATGCCGGAGACAGAGCTGGATCTAA
AGATATGAGAAAAGTTGAAAATCGTTAAGTTATTCTGTGATGTTACGGACTTATACGATCAGCTCTACGTTATCAAAGATTGTGTCATCCT
CTATGAAGTAA

B. *Gibberella fujikuroi* CDPS-KS polypeptide (SEQ ID NO:162)

MPGKIENGTPKDLKTGNDEFVSAAKSLIDRAFKSHHSYYGLCSTSCQVYDTAWVAMIPKTR
DNVKQWLFPECFHYLLKTKQAADGSWGS�PTTQTAGILDTASAVIALLLCHAQEPQLILDVS
PDEMGLRIEHGVTSLKRQLAVWNDVEDTNHIGVEFIIIPALLSMLEKELDVPSFEFFCRSI
LERMHGEKLGHFDELEQVYGKPSLLHSLEAFLGKLDLDFDRLSHHLYHGSMMA SPSSSTAAYL
IGATKWDDEAEDYLRHVMRNGAGHGNGGISGTFPTTHFEC SWI IATLLKVGFLLKQIDGD
GLRGLSTILLEALRDENGVI GFAPRTADVDDTAKALLALS LNQPVSPDIMIKVFEGKDH
FTTFGSE RDP SLT SNLHVLLSLLKQSNLSQYHPQLKTTLTCTCRWWGSDHCVKDKWNLS
HLYPTMLLVEAFTEVLHLIDGELSSLFDESEFKCKIGLSIFQAVLRIILTTQDNDG SWRGY
REQTCYAILALVQARHVCFFTHMVDRLQSCVDRGFSWLKSCFSHQDLTWTSTAYEVGF
VAEAYKLAALQASLEVPAAATIGHSVTS AVPSDDLEKYMRLVRKTA LFSPLD EWGLMASI
TESSEFFVPLLQAQRVEIYPRDNIKVDEDKYLSIIPFTWVG CNRSRTFASNRWLYDMMYL
SLLGYQTDEYMEAVAGPVFGDVSL LHQTIDKVIDNTMGNLARANGTVHSGNGHQHESPNI
GQVEDTLTRFTNSVLN HKDV LNSSSSDQDTLRREFRTFMHAHI TQIEDNSRFSKQASSDA
FSSPEQSYFQWVNSTGGSHVACAYSFAFSNCLMSANLLQ GKDAFP SGTKYLISSVMRHA
TNMCRMYNDFGSIARDNAFRNVNSIHFEFTLCNGTSQNLDERKERLLKIATYEQGYLDR
ALEALERQSRDDAGDRAGSKDMRKLKIVKLCFCDVTDLYDQLYVIKDLSSSMK

FIGURE 16



A. Native A. *thaliana* SUS1 nucleotide (SEQ ID NO: 175)

ATGGCAACCGCTGAACGTTATGATAACGCCCGTCCACAGCCAACGTTAGCGCTTGAACGAAACGCTTGTCTTGAGAGAAACGAAGTCCTTGCCCTTGCTTCCAGGGTTGAAGCCAAAGTAAGTATTTTACAACAAACACGATCAATGCTGAATTCGAAGCTTTGCCTGAACAAAAACCCGGAAGAAACCTTGAAGGTGCTCTTCTTGACCTTCTCAAATCCACTCAGGAAGCAATTGTGTGCCAACCATGGGTGCTCTAGCTGTGAGGCCAAGGCCTGGTGTTGGGAATACATTACGAGTCAATCTCCATGCTCTGTGTTGAAGAACTCCAACCTGCTGAGTTTCTTCAAGGAAGAACTCGTTGATGGAGTTAAGAAATGGTAATTTCACTCTTGAGCTTGATTTTCGAGCCATTCAATGCGTCTATCCCTCGTCCAACACTCCACAATAACATTGGAATAAGTGTGACTTCCTTAACCGTCAATTAACGGCTAAGCTCTTCCATGACAAGGAGAGTTTGCTTCCATTGCTTAAGTTCCTTCGTTCCAGGCCACAGGGCAAGAACCTGATGTTGAGCGAGAAGATTTCAGAACCTCAACACTCTGCAACAACACTTGAGGAAACGAGAAGAGTATCTAGCAGAGCTTAAGTCCGAAACACTGATGAAGAGTTTGAGGCCAAGTTTGACGAGATTTGGTCTTGAGAGGGGATGGGACACAAATGCAGAGCGTGCTTGACATGATACGCTCTCTTTTGGAACCTTTGAGGCGCCTGATCCTTGCACTCTTGAGACTTTCTTGGAAGAGTACCAATGGTGTTCAACGTTGTGATCCTCTCCACATGTTTACTTTTGCTCAGGACAAATGTTCTTTGGTTACCCCTGACACTGGTGGACAGGTTGTTTACATTTCTTGATCAAGTTCTGTCTCGAGATAGAGATGCTTCAACGTATTAAGCAACAAGGACTCAACATTAACCAAGGATTCATTTCACTGACTTCTACCTGATGCGGTAGGAACACTACATCGGTGAACGTTCTCGAGAGAGTTATGATTTCTGAGTACTGTGATATTTCTGTGTGCCCCCTCAGAACAGAGAAGGTATTTGTTCCGAAATGGATCTCAAGGTTCCGAAGTCTGGCATAATCTAGAGACTTACACCGGAGATGCTGCGGTTGAGCTATCGAAAGAAATGAAATGGCAAGCCTGACCTTATCATTTGGTAACTACAGTACGTATCAGAGACTTGTGTGCTTCTTAATGGCTCACAAACTTGGTGTCACTCAGTGTAACATTGCTCATGCTCTTGAGAAACAAAGATACCGGATTCAGATATCTACTGGAAGAAGCTTGACGACAAGTACCATTTCTCATGCCAGTTCACTGCGGATATTTTCGCAATGAACCCACACATGATTTTCATCATCTAGTACTTTCCAAAGAAATGCTGGAAGCAAGAAGAACTGTTGGCAGTATGAAAGCCACACAGCCTTTACTCTTCCGGATTGTATCGAGTTGTTCACGGGATTGATGTGTTTGATCCCAAGTTCAACATTTGCTCTCCTGCTGCTGATATGAGCATCTACTTCCCTTACACAGAGAGAAGGTAGATTGACTAAGTTCCACTCTGAGATCGAGGAGCTCCTCTACAGCGGATGTTGAGAACAAAGAGCACTTATGTGTGCTCAAGGACAAGCAAGCCGATTCTCTTCACAAATGCCGATTCTCTTCACAAATGGCTAGGTTGTTGAGTGGTACGGGAAGAACACCCGCTTGCGTGAGCTAGCTAACTTGGTTGTGTTGGAGGAGACAGGAGGAAGAATCAAGCTAAACGGTCAGTTCAAGCCTTTGGGTTAACTGTTGTGGGAACGAGAGATCTCATTTGAGGAATACAGCTAAACGGTCAGTTCAAGCCTTATGAAAGCTTTCAGACATTAAGTGTGAGCTTACCGGACTTTCGCACTTGCAAAAGGTGGTCCAGCTGAGATCATTTGTCAACGGTAAATCCGGTTTCCACATTAAGGCTATGACTTGTGATCTCTTGCTGATTTCTTGCTGATTTCTTCCACCAAGTGTAAAGGAGGATCCATCTCACTGGGATGAGATCTCGACCTTACCATTGGTATCAGGCTGCTGATCTCTTGCTGATTTCTTCCACCAAGTGTAAAGGAGGATCCATCTCACTGGGATGAGATCTCAAAAGGAGGCTTCAGAGGATTGAGGAGAAATACACTTGGCAAAATCTATTACAGAGGCTCTTGACATTTGACTGGTGTGATGGATTCTTGGAGCATGTTCTGAAATGTTCTATGCAATGAAGTATCGCCCATTTGGCTCAGGCTGTTCTCTTGCACAAGATGATGA

C. *Coffea arabica* sus1 nucleotide (SEQ ID NO: 177)

ATGGCCGAACGTGTTCTGACCCCGTGTTCACAGCCTCCGGAACGCCCTTGATGCTACTTTGGCTGCCACCGCAACGATGTTTTTGCTGTT
TATGTCGAGGCTTGAAACCCATGGGAAGGGATCCTGAAACCCCAACCACTTTTGGCTGAGTTTGAAGAAATTAACAAGGATGTTAAAC
AAAAATTCATGATCATGCCCTTGAAGAAGTCCCTGAAGTCCACACAGGAAGCAATTTGTGTGCCCCCTGGGTGCACCTGCTATTCTGT
CTCAGACCTGGTGTCTGGAGTATGTTCCAGTCAATGTCCATGCACCTGTTGAGGAGTTAACCGTGCCAGAGTACCTGCATTTCAA
GGAAGAACTCGTTGATGGAAGCAAAATGGGAATTTTGTGTTGAACTGGACTTCGAACCATTTACAGCCTCTTTTCCCAAGCCAACTC
TAACATAAGTACATAGGCGACGGAGTTGAGTTCCCTCAACAGGCACCTCTCTGCCAAAATGTTCCATGACAAGGAGCATGGCCCCCTCTC
CTTGATTTTCTCCGTGTTCAACCAATACAAGGGCAAGACAATGATGCTTAACGACAGGATCAAGGACCTTAACACTCTCCAAGCAGTTCT
GAGGAAGGCAGAGGAGTACCTAACAAACACTCTCTGCAGATACACCAATACCTCTGAAATTCGAGCACAAATTCCAAGAAAATTGGACTGGAGA
GAGGTTGGGTGATGCTGAGCGTGTCTTGAAATGATCTGCATGCTTCTGGATCTTCTGGGGCTCCTGACTCGTGCACTAGAG
AAATTCCTAGGGAGAAATCCCTATGGTATTCAAATGTTGTTATTTCTTCCCCCATGGATACTTTGCCAGGAAAACGTAATTGGGTTATCC
TGATACCGGTGGCCAGGTTGTTACATATTTGATCAAGTTCTGCTTGCCTTGAGCGCTGAGATGCTGAAGAGGATAAAGGAACAAGGACTTG
ATGTCAAGCCACGCATTCATATTAATACTAGGCTGCTTCTGATGCCCTGGAAACCACTTGTGGTCAACGGCTTGAGAAAATATATGGA
TCAGAGTACTCCCATATACTCAGAGTCCCCCTTCAGAACTGAGAAAGGGAGTTGTTGCAAAATGGATCTCTCGCTTTGAAAGTTTGGCCCTA
CATGGAACAATTTACTGAGGATGTTGCAAAAAGAACTCACAGCAATTAACAGCAAGCCAGATTTGGTTATTGGTAACACAGTGAGG
GTAACCTGTTGCTCCTGCTGCTCACAAAGTTAGGTGTAACACACAGTGACCAATTCCTCATGCTTTGGAAAAAACCAAGTATCCTGAT
TCTGATATTTATTTGAGCAAAATTTGATGAAAAGTACCCTTCTCATGTCACTGCGGATCTTATCGCAATGAACCATACAGATTT
CATATACACTAGCACTTTCCAAAGAAATAGCTGGAAGCAAGGACACTGTTGGGCAATATGAAAGCCATATGGCCTTCACAATGCCAGGAT
TATACAGAGTTGTACATGGCATTTGATGTTTGTGATCCAAAATTCAAACATTTGCTCACCTGGAGCTGATACAAACCTCTACTTCCCACAC
ACAGAGAAGGAAAAGAGATTGACATCTTTCCATCTCTGAAAATTGAGGAGTTGCTTTTCAGCGGATGTGGAGAAATGAGGAACACCTATGTGT
GCTAAAAGACAAAAGAGCAATGTTCAATCTTATTCACCATGGCAAGACTGGATCGCGTAAAGAAATTTGACAGGGCTTGTGAAATGTATGCTA
AGAACCCAAAACATAAGGGAATTTGTTCAATCTTGTCGTGGTTGGTGGAGACCCGAAAGGAAGGAAATCCAAAGATTTGGAAGAACAAAGCTGAG
ATGAAGAAAATGTATTCATTGATAGAAAATTCAAACTTGAACGGGCAATTCAGATGGATTTCTTCTCAGATGAACAGGTTAGAAAATGG
TGAACCTATCGGTACATTTGCTGACACCCAGGGAGCATTCGTGCAACCTGCATTTATGAGGCAATTTGGGTGACTGTGGTCGAGGCCA
TGACATGTGGTTTGCCAAACATTTGCAACCAACCATGGTGGTCTCTGCTGAGATCATTTATTCATGGGAAATCTGCTTCCACATTTGATCCA
TACCATGGTGAGCAGGTACGGAGCTCTTGCCAAATTTCTTTGAAAGGTGCAAGAAAGACCTTCTTACTGGGACACCATTTTCAGCCGG
TGGCTTGAAAGCGTATCCAGGAAAAGTACACCTGGCAAAATTTACTCAGATCGGTTGCTGACGCTGGCTGGAGTTTATGGATTTCTGAAAT
GTGTTTCCAAGCTTGATCGCCAGGAGATCCGCCGTTATCTGAAAATGTTTTATGCTCTCAAGTATCGCAAGTTGGCTGAAGCTGTT**CCA**
TTGGCTGTTGATCAGTAA

FIGURE 18




FIGURE 19

- A. *A. thaliana* UDP-glycosyltransferase UGT72E2 polypeptide (SEQ ID NO: 178)
 MHTTKPHAAMFSSPGMGHVIPVIELGKRLSANNGFHVTVFVLETDAAASAQSKFLNSTGVDIVKLPSPDIYGLVDPDDHVVTKIGVIMRA
 AVPALRSKIAAMHQKPTALIVDLFGTDALCLAKEFNLSYVFIPITNARFLGVSIIYYPNLDKDIKEEHTVQRNPLAIPGCEPVRFEEDTLD
 AYLVPDEPVYRDFVRHGLAYPKADGILVNTWEEMEPKSLKSLNPKLLGRVARVPVYPIGLCRPIQSSETDHPVLDWLNQEPNESVLY
 ISFGSGGCLSAKQLTELAWGLEQSQQRFFVWVRPPVDGSCCSEYVSANGGGTEDNTPEYLPPEGFVSRTSRDRGFVVPSPWAPQAEILSHRA
 VGGFLTHCGWSSTLESVVGGVPMIAWPLFAEQNMNAALLSDELGLAVRLDDPKEDISRWKIEALVRKVMTEKEGEAMRRKVKKKLRDSAE
 MSLSIDGGGLAHESLCRVTKECQRFLERVVDLSRGA
- B. *A. thaliana* sucrose transporter SUC1 from (SEQ ID NO: 179)
 MGAYETEKPTKDAAALETQSPEDFDQSPIRKIIISVASIAAGVQFGWALQLSLLTPYVQLLGIPHKWSSLIWLCGPVSGMIVQPIVGFH
 SDRCRSKFGRRRPFIAATGAALVAVAVFLIGYAADFGYKMGDKLEEKVKVRAIGIFALGFWILDVANNTLQGPCRAFLADLAAGDAKRTR
 VANAFSFFMAVGNVLGYAAGSYTNLHKMFPTM"KACDIYCANLKTCCFLSITLLLIIVTVTSLWVNDKQWSPPRNADDDDEKTSVPE
 LFGEIFGAFKVMKRPMWMLLIIVTALNWIAPFELLEDTDWMGREVFGGSDCGNERSKKLYSLGVQSGAMGLMFNSIVLGFMSIGVEWIG
 RKLGGAKRLWGIVNFILAAGLAMTVLVTKFAEDHRKTAGDLAGPSASVKAGALSLEFVLGIFLAITFTSTPPFALASIFSSSCSCAGQGCLSL
 GVLNLAIVIPQMIVSLGGGPFDAIFGGGNLPAFIVAAIAAASGVLAITVLPSPPPDPAPKATTMGGFH
- C. *Coffea arabica* sucrose synthase polypeptide (SEQ ID NO: 180)
 MAERVLTTRVHSLRERLDATLAHRNDVLLFMSRLETHGKGILKPHQLLAEEFEIINKDGKQKIHDAFEEVLKSTQFAIVLPPWVALAIR
 LRPGWVEYVRNVVHALVVEELTVPEYLHFKEELVDGSKNGNFVLELDFEPTASEFPKPTLTKYIGDGVFNLNRHLSAKMFHDKESMAPL
 LDFLRVHQYKGMTMLNDRIKDLNLTQLAVLRKAAEEYLTLSADTPYSEFEHKFQEIIGLERGWGDTAERVLEMICMLDLDLGGAPDSCTLE
 KFLGRIPMVENVVILSPHGYFAQENVIGYPTGGQVVYILDQVPALEREMLKRIKEQGLDVKPRILIIITRLLPDAAGTTCGQRLEKVVY
 SEYSHILRPVFRTEKGVVRKWKISRFEVWPYMETFTEDVAKEVTAELQAKPDLVIGNYSEGNLVALLAHKLGVTOCTIAHALEKTKYPD
 SDIYLSKFDEKYHFSQF"ADLIAMNHTDFIITSTFQEIAGSKDTVQGYESHMAFTMPGLYRVVHGIDVDFDPKFNIVSPGADTNLYFPH
 TEKEKRLTSFHPHPEIEELLFSDVENEELCVLKDKKKPIFTMARLDRVKNLTGLVELYAKNPKLRELNLVVVGGDRRKESKDLEEQAE
 MKKMYSLIETYNLNGQFRWISSQMNVRVNGELYRYIADTRGAFVQPAFYEAFFGLTVVEAMTCGLPTFATNHGGPAEIIHKGSGFHIDP
 YHGEQVSELLANFFERCKEPSYWDTISAGGLKRIQKYTWQIYSDRLLTLAGVYGFWKVCVSKLDRQEIIRRYLEMFYALKYRKLAEAVP
 LAVDQ

FIGURE 20

SEQ ID NO: 185 (*Saccharomyces cerevisiae* Cyc1 promoter)

gaggttggttggtgataaagccacagcggtaggcaatcctcgagcagatccgccaggcgtgtatatatatagcgtggatggccaggaactt
tagtgcgcacacatacaggcatatataatgtgtgcagcacatgatcatatggcatgtgctctgtatgtatatataaaactctt
ggtttctttcttctaataattctttcttatacattaggacclttgcagcataaattactatacttctatagacacacacacaa
tacacacactaaatttaata

SEQ ID NO: 186 (*Saccharomyces cerevisiae* Kex2 promoter)

gggtcagcagctctgatgtagatcacagctatctcgaatgttttatttttactatacatataaaagaaataaaaaatgataacgtgtgataattattattcataataatcaatgaggtcattttctgaacgcgaataacggttaattggaataagatagaaaaagaaaaaaacaaacaaaggaaggttagcatattaaataactgagctgatacttcaacagcatcgtgaagagaaacagtattgaaacgcgaacattttctataaaggcaaaacaaggtactccatatttgcggacgtgtttctctctcgtttccatagcataattctgtcataagcctgtttcttttctcgtgttaaacatcccgttttggtaaaagagaatatctatccacatatttccattcctggctaccataactaaggataaaactaatcccgttgtttttggcctcgtcacataattataaaactaaccattatcaga

FIGURE 22





FIGURE 23



SEQ ID NO: 187	#5-CACAAATACACACACTAAATTAATA-----atg	wt	100%
SEQ ID NO: 191	#4-CACAAATACACACACTAAATTAATATGAATTCGTTAACGAAATtTatg		75%
SEQ ID NO: 190	#3-CACAAATACACACACTAAATTAATATGAATTCGTTAACGAAAGTCatg		50%
SEQ ID NO: 189	#2-CACAAATACACACACTAAATTAATATGAATTCGTTAACGAACTCcatg		20%
SEQ ID NO: 188	#1-CACAAATACACACACTAAATTAATATGAATTCGTTAACGAAATTCcatg		5%

FIGURE 24




FIGURE 25

```

>sp|P29704|FDFT_YEAST Squalene synthase OS=Saccharomyces cerevisiae (strain ATCC 204508 /
S288c) GN=ERG9 PE=1 SV=2 (SEQ ID NO: 192)
MGKLLQLALHPVEMKAALKKFCRTPLFSYDQSTSPYLLHCFFELNLNLTSSFAAVIREL
HPELRNCVTLFYLLRALDITIEDDMSIEHDLKIDLLRHFHEKLLLTKWSFDGNAPDVKDR
AVLTDFESILIEFHKLKPEYQEVKEITEKMGNGMADYILDENYNLNGI,QTVHDYDVYCH
YVAGLVGDGLTRLIVIAKFANESLYSNEQLYESMGLFLQKTNIIRDYNEDLVDGRSFWPK
EWSQYAPQLKDFMKPENEQLGLDCINHLVINALSHVIDVLTLAGIHEQSTFQFCAIPQ
VMAIATLALVFNNNREVLHGNVKIRKGTTCYLLIKSRTLRCGVEIFDYILRDIKSKLAVQD
PNFLKLNIQISKIEQFMEEMYQDKLPNNVKPNETPIFLKVKERSRYDDELVPTQQEEFYK
FNMVLSIILSVLLGFYIYTLIRA

>sp|P36596|FDFT_SCHPO Squalene synthase OS=Schizosaccharomyces pombe (strain ATCC 38366 /
972) GN=erg9 PE=1 SV=1 (SEQ ID NO: 193)
MSLANRIEIRCLCQYKLWDLPSYGEDENVQPQNIIRRCYQLLDMTSRSFAVVIKELPNGI
REAVMIFYLVLRGLDVTEDDMTLPDKKLPILRDFYKTIEVEGTFNESGPNKDRQLLV
EFDVVIKEYLNLSEGYRNVISNITKEMGDGMAYYASLAEKNDGFSVETIEDFNKYCHYVA
GLVGIGLSRLFAQSKLEDPDLAHSQAISNSLGLFLQKVNIRDYREDFDDNRHFWPREIW
SKYTSSFGDCLCPDNSEKALECLSDMTANALTHATDALVYLSQLKTQEIFNFCAIPQVMA
IATLAAVFRNPDPVFQTNVKIRKGQAVQIILHSVNLKNVCDLFLRYTRDIHYKNTPKDPNF
LKISIECGKIEQVSESLFPRRFRFEMYEKAYVSKLSEQKKNGTGQKAILNDEQKELYRKDL
QKLGISILFVFFTLVCLAVIFYVFNIRIHWSDFKELNLF

>sp|Q9Y753|FDFT_YARLI Squalene synthase OS=Yarrowia lipolytica (strain CLIB 122 / E 150)
GN=SQS1 PE=3 SV=1 (SEQ ID NO: 194)
MGKLIELLHPSELAAIHVKLWRQPLHPRDLSKESTELRRCYELLDVCSRSFAAVIREL
HPEVRDAMLFYLLRALDITIEDDMTSLRDIKIPILRDFTKCMKTPGWKFTDSDPNERDR
VVLQEFVVMTEFNKLPKYQEVYDITDRMGNGMADVVIDDDFNNNGVDTIAAYDLYCH
HVAGIVGEGLTRITILAGFGIDVLHENPRLQESMGLFLQKVNIRDYREDIDVNRADFWR
EIWHKYAEEMRDFKDPKYSKKALHCTSDIVANAIGHATDCLDLDNVNTPDPSTFTFCAIPQ

```

VMAIATIDLVRNPDVFQKNVKLRKGTTSVLILEASNVSGVCDIFTRYARKVYKKSDDPND
 PNYFRVSVLCGKIEQHAALIKRQRPAPAKTIAQLEGERKEMALSLIVCLAVIFSMSGLMA
 YIAYVSGFRWSPREIFDSKMFPLRD

>sp|Q9HGZ6|FDFT_CANGA Squalene synthase OS=Candida glabrata (strain ATCC 2001 / CBS 138 / JCM 3761 / NBRC 0622 / NRRL Y-65) GN=ERG9 PE=3 SV=2 (SEQ ID NO: 195)
 MGKVLDLALHPLELRAALKLKFIRQPLFSTNDTRATPQLERCYELLNLTSSFAAVIMEL
 HPELRNVIMVFLILRALDVTVEDDMTIDPQLKVKVLRREFDSKLDTTDWSFDGNDLKEKDR
 VVLTEFPCLGEXHKLKPEYQKVIKRITGLMGNGMADYILDENFNLNGVQTVKYDYDKYCH
 YVAGLVGDGLTELIVLAGFGSDDLHYHGKNSFQLYESMGLFLQKTNIIIRDYAEDLDDGRSF
 WPKEIWSEYATKLTDFRDPKNTQKGVDCINHLVNLATHVIDVLT'YLSSIHEQSSFFQFCA
 IPQVMAIATLAKVFNNPEVLRKNVKIRKGTTCDDLILNSRTLKGCVDIFQYYLRDMKQRLP
 VEDPNYLKENIQVAKIEQFIEEMFQDNLPAQVEPRETMIYLVQERLKWDTQVIPRVQEE
 DYKFNMAHSVVCVLLSFYFFTK

>sp|Q752X9|FDFT_ASHGO Squalene synthase OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) GN=ERG9 PE=3 SV=1 (SEQ ID NO: 196)
 MCKVVQLFTHPLELKAALKLFLREPLYPADDTQGSSELKRCYQLLQRTSRSFAAVIMEL
 HPELRNAVMLFYLLRALDVTVEDDMTISPVKVPLLRREFDQKLKLDTSFDSGNAKTEKDR
 DVI.VEFSTILAEFHKLKPEYQQVIAADITHKMNGMADYILDEKFNLSGLETIQDYDRYCH
 YVAGLVGDGLTHLIMLAKFSSPGLYYDSPDLYESMGLFLQKTNIIIRDYAEDLADGRSFWP
 KEIWSHYADDLASFSPENATAGVYCINHLVNLALGHVQHVLTYLASLREQSSFFQFCAIP
 QVMAIATLALVFGNERVLQTSVKIRKGTTCYLILKSRTFQGCVEIFEHYLRDIRKRLTVA
 DPNYLKLNIEIAKLDKFIEMYQDKLPVGAKPQETEIYKKVRSAYDLEVLPREQEEEF
 KFNVLLSILFTVFGALYWYAK

>sp|O74165|FDFT_CYBJA Squalene synthase OS=Cyberlindnera jadinii GN=ERG9 PE=3 SV=1 (SEQ ID NO: 197)
 MGKLLQLALHPDELASIVQFKLFRKNENARNPATESAELIRCYELLNLTSSFAAVIEEL
 HPELRNVIMVFLVLRALDVTVEVDMSIENSVKLPVLRQFHEKLDTKDWTDFDGNSPNEKDR
 CVLVEFDRILGQYHELKPPQYQKVIKEITEKMNGMADYIENFNENFNSGLLTIEDYDLYCY

YVAGLVGDGLTQLIVLAKFGNSELSVKNQLFKSMGLFLQKTNIIIRDYEEDQVDGRAFWPK
ETWGYANELSDFMKPENQSQGLWCISELVCNALDHVIDVLQYLALVEEQTSFNFCaipQ
VMAIATLELVFQNPQVLtQHVKIRKGTtVSLILESRtLEGCArIFRRYLrKIHUKSHPSD
PNYLRLGITIGKIEQFLDGMYPHYVPKGITPQTTSIRtQVVKRLQLDEPMKRDIDEEILK
TRILLSLGVAVEGVVYGVRrII

>sp|P78589|FDFT_CANAL_Squalene synthase OS=Candida albicans GN=ERG9 PE=3 SV=1
(SEQ ID NO: 198)

MGKFLQLLSHPTelKAViQLFGFRQPLHPGKRdVNDKELGRcYELLNLtSRsFAAVIEEL
HPELRdAVMiFYLVLRALDtIEDDMtIKSSiKIPLLREFDtkINTKNTFDGyGPNekDR
TVLVEFDKiLNVYHRLKPQYQDIiKSITFKMGNGMADYiLDEEFNVyGVATVEDYNLYCH
YVAGLVGEGLTnLFVLANFGDKTLTENnFAKADSMGLFLQKTNiIRDIHEDLQDGRSFWP
REtWSKYTENLQDFHKVKTPAKEFAGVSCINELVnALGHVTDCLDYLsLVKDPSSFSFC
AiPQVMaVATLAEVYNNPKVLHGvVKIRKGTtCRLLILESRtLPGVVKIFKEYiQVINHKs
SVRDPNylKiGIKCGEIEQYCEMiYPNKQALPPSMKSLPENKFTKiVASRESIDLSVQRR
IEPGNFNCNVLEGiGALiLSLIYFVLy

>sp|P38604|ERG7_YEAST_Lanosterol synthase OS=Saccharomyces cerevisiae (strain ATCC 204508
/ S288c) GN=ERG7 PE=1 SV=6 (SEQ ID NO: 199)

MTEFYSDTiGLPKTDPrLWRLRtDELGResWEYLTpQQAANDPPStFTQWLLQDPKFPQp
HPErNKHSDFsAFDACHNGASFFKLLQEPDSGiFPcQYKGPMFMTiGYAVNYiAGIEi
PEHErIELIRYiVNTAHPVDGGWGLHSVDKStVFGTVLNYViLRLGLPKDHPVCAKARS
TLRLGGAIGSPHWGKiWLSALNLYKWEGVNPAPPETWLLPYSiLPMHPGRWWVHTRGVYi
PVSYLSLVKFSCPMTPLLLEEIRNEiYTKPFDKiNFSKNRNTVCgVDLYPHStTLNIAANS
LVVFYEKYLNRNFiYSLSKKkVYDLiKTELQNTDSLciAPVnQAFcALVtLIEEGVDSEA
FQRLQYRFKDALFHGPQGMtIMGtNGVQIWDCAFAiQYFFVAGLAERPEFYNTiVSAYKF
LCHAQFDTEcVPGSYRDKRKGAWGFStKTQGYtVADCTAEAiKAIIMVKNSPVfSEVHHM
ISSERLFEGiDVLNLQNiGSFEYGSFAiYEKiKAPLaMETLNPAEiVFGNiMVEYPYVEc
TDSSVLGLTYFHkYFDYRKEEiRtRiRiAEiFiKKSQLPDGSwYGSwGiCfTYAGMFALE
ALHTVGETYENSStVRKGCDFLVSKQMKDGGWGESMKSSeLHSYVDSEKSLVVQTAWALI
ALLFAEYPNKEViDRGiDLLKNRQEEsGEWKFESVEGVFNHSCAiEYPSYRFLFiKALGMYSRAYETHTL

```

>sp|P37268|FDFT_HUMAN Squalene synthase OS=Homo sapiens GN=Fdft1 PE=1 SV=1
(SEQ ID NO: 200)
MEFVKCLGHPEEFYNLVRFRIGGRKRVMPKMDQDSLSSSLKTCYKYLNQTSRSFAAVIQ
LDGEMRNAVCIFYLVLRALDTLEDDMTISVEKKVPLLNHNFHSFLYQPDWRFMESKEKDRQ
VLEDFPTISLEFRNLAEKYQTVIADICRRMGIGMAEFLLDKHVTSEQEWDKYCHYVAGLVG
IGLSRLFSASEFEDPLVGEDTERANSMGLFLQKTNIIIRDYLEDDQGGREFWPQFVWSRYV
KKLGDFAKPENIDLAVQCLNELITNALHHIPDVITYLSRLRNQSVNFCAIPQVMAIATL
AACYNNQQVFKGAVKIRKGQAVTLMMDATNMPAVKAIYQYIEEIIYHRIPNSDPSSSKTR
QIISTIRTQNLPCQLISRSHYSPIYLSFVMLLAALSWQYLTTLSQVTEYVQTEGH

>sp|P53798|FDFT_MOUSE Squalene synthase OS=Mus musculus GN=Fdft1 PE=2 SV=2
(SEQ ID NO: 201)
MEFVKCLGHPEEFYNLLRFRMGRRNFIPKMDQDSLSSSLKTCYKYLNQTSRSFAAVIQ
LDGDIRHAICVFYLVLRALDTVEDDMSISVEKKIPLLCNFHTFLYDPEWRFTESKEKDRQ
VLEDFPTISLEFRNLAEKYQTVIIDDICHRMGCGMAEFVDKDVTSKQDWDKYCHYVAGLVG
IGLSRLFSASEFEDPIVGEDIECANSMGLFLQKTNIIIRDYLEDDQEGRKFWPQEVWGRIY
KKLEDFAKPENVDVAVQCLNELITNTLQHIPDVITYLSRLRNQSVNFCAIPQVMAIATL
AACYNNQQVFKGVVKIRKGQAVTLMMDATNMPAVKAIYQYIEEIIYHRIPNSDPSSSKTK
QVISKIRTQNLPCQLISRSHYSPIYLSFIMLLAALSWQYLSTLSQVTEYVQREH

>sp|Q02769|FDFT_RAT Squalene synthase OS=Rattus norvegicus GN=Fdft1 PE=2 SV=1
(SEQ ID NO: 202)
MEFVKCLGHPEEFYNLLRFRMGRRNFIPKMDRNSLSLSLKTCYKYLDQTSRSFAAVIQ
LDGDIRHAVCVFYLIIRAMDTVEDDMAISVEKKIPLLRNFHTFLYEPWRFTESKEKHRV
VLEDFPTISLEFRNLAEKYQTVIADICHRMGCGMAEFLLNKDVTSKQDWDKYCHYVAGLVG
IGLSRLFSASEFEDPIVGEDTECANSMGLFLQKTNIIIRDYLEDDQEGRKFWPQEVWGRIY
KKLEDFVKPENVDVAVKCLNELITNALQHIPDVITYLSRLRNQSVNFCAIPQVMAIATL
AACYNNHQVEKGVVKIRKGQAVTLMMDATNMPAVKAIYQYIEEIIYHRVPNSDPSASKAK
QLISNIQTQSLPCQLISRSHYSPIYLSFIMLLAALSWQYLSTLSQVTEYVQREH

```

Aspergillus nidulans GPPS-2 polypeptide (SEQ ID NO: 203)
 MTSDSHFPHPAIPPRISSNRMSGASTRDKAALMGNEFKDWLSKCDKLQ'TNTDLSKRHTR
 NQSSLDGTYKYKDGKWSQENEEVIMGPYDYMQLQHPGKDLRRQMINAFNVWLKVPSESIAII
 TKVVAMLHTASLLIDDDVEDNSLLRRGIPVAHSIYGTATINSANYVYFLALQEVQKLKSP
 AAIDIVVQELLNLHRGQGMDFWRD'TLTCPSDEYLEMVGNKTGGLFRLAVKLMQAESST
 GKDCVALVNVGLVFQICDDYLNLSDTTYTQNKGLCEDLTEGKFSFPIIHSIRSNPGNHQ
 LINILRQRTKDEEVKRYALQYMESTGSFKHTQDVVRQLRARALQLIEEIEENSENGEQPEE
 HNDGTMVRAILLDKITESTLADTNTTTRDINGNCATR

Saccharomyces cerevisiae GPPS-3 polypeptide (SEQ ID NO: 167)
 MEAKIDELINNDPVWSSQNESLISKPYNHILLKPGKNFRNLIVQINRVMNLPKDQLAIV
 SQIVELLHNSLLIDDIEDNAPLRRGQTTSHLIFGVPTINTANYMYFRAMQLVSQLTTK
 EPLYHNLIITIFNEELINHRGQGLDIYWRDFLPEIIPTEMYLNMVMNKTGGFLRLTLRL
 MEALSPSSHGHGSLVPFINLLGIYQIRDDYLNLDQFQMSSEKGFADITEGKLSFPPIVH
 ALNFTKTGQTEQHNEILRILLRTSDKDIKLLIQILEFDTNSIAYTKNFINQLVNMIR
 NDNENKYLPLDASHSDTATNLHDELLYIIDHLSEL

FIGURE 26







FIGURE 27







Steviol




Steviolmonoside




Steviolbioside




Stevioside




Rebaudioside A




Rebaudioside B




Rebaudioside C




Rebaudioside D



Rebaudioside E



Rebaudioside F



Dulcoside A